Datasets:
bio-datasets
/
bigbio-ner-merged

Dataset card Data Studio Files
xet
Community
answer
stringlengths
1
16.1k
id
stringlengths
7
56
instruction
stringlengths
106
72.6k
ner_tags
list
text
stringlengths
5
72.4k
tokens
list
types
list
Kindes- is an umlsterm, Jugendlichenalter is an umlsterm, -Syndrom is an umlsterm, supraventrikulaere Tachykardien is an umlsterm, Synkope is an umlsterm, Herz - Kreislauf - Stillstand is an umlsterm, Reanimation is an umlsterm
MonatsschriftKinderheilkunde.71450020.ger.abstr_task1
Sentence: Im Kindes- und Jugendlichenalter manifestiert sich das Wolff-Parkinson-White ( WPW ) -Syndrom fast ausschliesslich durch paroxysmale supraventrikulaere Tachykardien . Ursache einer Synkope bei einem 15 Jahre alten , zuvor voellig asymptomatischen Jugendlichen war ein durch Kammerflattern bedingter Herz-Kreislauf-Stillstand . Nach erfolgreicher Reanimation zeigte sich im Elektrokardiogramm ein klassisches Praeexzitationsmuster . Bei der elektrophysiologischen Untersuchung fand sich eine linksposterior lokalisierte akzessorische Leitungsbahn , die dann durch Hochfrequenzapplikation erfolgreich abladiert wurde . Seither ist der Junge beschwerdefrei . Instructions: please typing these entity words according to sentence: Kindes-, Jugendlichenalter, -Syndrom, supraventrikulaere Tachykardien, Synkope, Herz - Kreislauf - Stillstand, Reanimation Options: umlsterm
[ "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Im Kindes- und Jugendlichenalter manifestiert sich das Wolff-Parkinson-White ( WPW ) -Syndrom fast ausschliesslich durch paroxysmale supraventrikulaere Tachykardien . Ursache einer Synkope bei einem 15 Jahre alten , zuvor voellig asymptomatischen Jugendlichen war ein durch Kammerflattern bedingter Herz-Kreislauf-Stillstand . Nach erfolgreicher Reanimation zeigte sich im Elektrokardiogramm ein klassisches Praeexzitationsmuster . Bei der elektrophysiologischen Untersuchung fand sich eine linksposterior lokalisierte akzessorische Leitungsbahn , die dann durch Hochfrequenzapplikation erfolgreich abladiert wurde . Seither ist der Junge beschwerdefrei .
[ "Im", "Kindes-", "und", "Jugendlichenalter", "manifestiert", "sich", "das", "Wolff", "-", "Parkinson", "-", "White", "(", "WPW", ")", "-Syndrom", "fast", "ausschliesslich", "durch", "paroxysmale", "supraventrikulaere", "Tachykardien", ".", "Ursache", "einer", "Synkope", "bei", "einem", "15", "Jahre", "alten", ",", "zuvor", "voellig", "asymptomatischen", "Jugendlichen", "war", "ein", "durch", "Kammerflattern", "bedingter", "Herz", "-", "Kreislauf", "-", "Stillstand", ".", "Nach", "erfolgreicher", "Reanimation", "zeigte", "sich", "im", "Elektrokardiogramm", "ein", "klassisches", "Praeexzitationsmuster", ".", "Bei", "der", "elektrophysiologischen", "Untersuchung", "fand", "sich", "eine", "linksposterior", "lokalisierte", "akzessorische", "Leitungsbahn", ",", "die", "dann", "durch", "Hochfrequenzapplikation", "erfolgreich", "abladiert", "wurde", ".", "Seither", "ist", "der", "Junge", "beschwerdefrei", "." ]
[ "umlsterm" ]
Kindes-, Jugendlichenalter, -Syndrom, supraventrikulaere Tachykardien, Synkope, Herz - Kreislauf - Stillstand, Reanimation
MonatsschriftKinderheilkunde.71450020.ger.abstr_task2
Sentence: Im Kindes- und Jugendlichenalter manifestiert sich das Wolff-Parkinson-White ( WPW ) -Syndrom fast ausschliesslich durch paroxysmale supraventrikulaere Tachykardien . Ursache einer Synkope bei einem 15 Jahre alten , zuvor voellig asymptomatischen Jugendlichen war ein durch Kammerflattern bedingter Herz-Kreislauf-Stillstand . Nach erfolgreicher Reanimation zeigte sich im Elektrokardiogramm ein klassisches Praeexzitationsmuster . Bei der elektrophysiologischen Untersuchung fand sich eine linksposterior lokalisierte akzessorische Leitungsbahn , die dann durch Hochfrequenzapplikation erfolgreich abladiert wurde . Seither ist der Junge beschwerdefrei . Instructions: please extract entity words from the input sentence
[ "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Im Kindes- und Jugendlichenalter manifestiert sich das Wolff-Parkinson-White ( WPW ) -Syndrom fast ausschliesslich durch paroxysmale supraventrikulaere Tachykardien . Ursache einer Synkope bei einem 15 Jahre alten , zuvor voellig asymptomatischen Jugendlichen war ein durch Kammerflattern bedingter Herz-Kreislauf-Stillstand . Nach erfolgreicher Reanimation zeigte sich im Elektrokardiogramm ein klassisches Praeexzitationsmuster . Bei der elektrophysiologischen Untersuchung fand sich eine linksposterior lokalisierte akzessorische Leitungsbahn , die dann durch Hochfrequenzapplikation erfolgreich abladiert wurde . Seither ist der Junge beschwerdefrei .
[ "Im", "Kindes-", "und", "Jugendlichenalter", "manifestiert", "sich", "das", "Wolff", "-", "Parkinson", "-", "White", "(", "WPW", ")", "-Syndrom", "fast", "ausschliesslich", "durch", "paroxysmale", "supraventrikulaere", "Tachykardien", ".", "Ursache", "einer", "Synkope", "bei", "einem", "15", "Jahre", "alten", ",", "zuvor", "voellig", "asymptomatischen", "Jugendlichen", "war", "ein", "durch", "Kammerflattern", "bedingter", "Herz", "-", "Kreislauf", "-", "Stillstand", ".", "Nach", "erfolgreicher", "Reanimation", "zeigte", "sich", "im", "Elektrokardiogramm", "ein", "klassisches", "Praeexzitationsmuster", ".", "Bei", "der", "elektrophysiologischen", "Untersuchung", "fand", "sich", "eine", "linksposterior", "lokalisierte", "akzessorische", "Leitungsbahn", ",", "die", "dann", "durch", "Hochfrequenzapplikation", "erfolgreich", "abladiert", "wurde", ".", "Seither", "ist", "der", "Junge", "beschwerdefrei", "." ]
[ "umlsterm" ]
Ornithine transcarbamylase is an umlsterm, deficiency is an umlsterm, disorder is an umlsterm, urea - cycle is an umlsterm, metabolism is an umlsterm, females is an umlsterm, protein is an umlsterm, nutrition is an umlsterm, protein is an umlsterm, catabolism is an umlsterm, lives is an umlsterm
MonatsschriftKinderheilkunde.01480997.eng.abstr_task0
Sentence: Background . Ornithine transcarbamylase deficiency is an x-linked disorder of the urea-cycle . With a prevalance of 1:14000 it is one of the most frequent inborn errors of metabolism . Heterozygous females exposed to high protein nutrition or protein catabolism , are faced with highly detrimental effects througout their lives . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm
[ "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O" ]
Background . Ornithine transcarbamylase deficiency is an x-linked disorder of the urea-cycle . With a prevalance of 1:14000 it is one of the most frequent inborn errors of metabolism . Heterozygous females exposed to high protein nutrition or protein catabolism , are faced with highly detrimental effects througout their lives .
[ "Background", ".", "Ornithine", "transcarbamylase", "deficiency", "is", "an", "x", "-", "linked", "disorder", "of", "the", "urea", "-", "cycle", ".", "With", "a", "prevalance", "of", "1:14000", "it", "is", "one", "of", "the", "most", "frequent", "inborn", "errors", "of", "metabolism", ".", "Heterozygous", "females", "exposed", "to", "high", "protein", "nutrition", "or", "protein", "catabolism", ",", "are", "faced", "with", "highly", "detrimental", "effects", "througout", "their", "lives", "." ]
[ "umlsterm" ]
Ornithine transcarbamylase is an umlsterm, deficiency is an umlsterm, disorder is an umlsterm, urea - cycle is an umlsterm, metabolism is an umlsterm, females is an umlsterm, protein is an umlsterm, nutrition is an umlsterm, protein is an umlsterm, catabolism is an umlsterm, lives is an umlsterm
MonatsschriftKinderheilkunde.01480997.eng.abstr_task1
Sentence: Background . Ornithine transcarbamylase deficiency is an x-linked disorder of the urea-cycle . With a prevalance of 1:14000 it is one of the most frequent inborn errors of metabolism . Heterozygous females exposed to high protein nutrition or protein catabolism , are faced with highly detrimental effects througout their lives . Instructions: please typing these entity words according to sentence: Ornithine transcarbamylase, deficiency, disorder, urea - cycle, metabolism, females, protein, nutrition, protein, catabolism, lives Options: umlsterm
[ "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O" ]
Background . Ornithine transcarbamylase deficiency is an x-linked disorder of the urea-cycle . With a prevalance of 1:14000 it is one of the most frequent inborn errors of metabolism . Heterozygous females exposed to high protein nutrition or protein catabolism , are faced with highly detrimental effects througout their lives .
[ "Background", ".", "Ornithine", "transcarbamylase", "deficiency", "is", "an", "x", "-", "linked", "disorder", "of", "the", "urea", "-", "cycle", ".", "With", "a", "prevalance", "of", "1:14000", "it", "is", "one", "of", "the", "most", "frequent", "inborn", "errors", "of", "metabolism", ".", "Heterozygous", "females", "exposed", "to", "high", "protein", "nutrition", "or", "protein", "catabolism", ",", "are", "faced", "with", "highly", "detrimental", "effects", "througout", "their", "lives", "." ]
[ "umlsterm" ]
Ornithine transcarbamylase, deficiency, disorder, urea - cycle, metabolism, females, protein, nutrition, protein, catabolism, lives
MonatsschriftKinderheilkunde.01480997.eng.abstr_task2
Sentence: Background . Ornithine transcarbamylase deficiency is an x-linked disorder of the urea-cycle . With a prevalance of 1:14000 it is one of the most frequent inborn errors of metabolism . Heterozygous females exposed to high protein nutrition or protein catabolism , are faced with highly detrimental effects througout their lives . Instructions: please extract entity words from the input sentence
[ "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O" ]
Background . Ornithine transcarbamylase deficiency is an x-linked disorder of the urea-cycle . With a prevalance of 1:14000 it is one of the most frequent inborn errors of metabolism . Heterozygous females exposed to high protein nutrition or protein catabolism , are faced with highly detrimental effects througout their lives .
[ "Background", ".", "Ornithine", "transcarbamylase", "deficiency", "is", "an", "x", "-", "linked", "disorder", "of", "the", "urea", "-", "cycle", ".", "With", "a", "prevalance", "of", "1:14000", "it", "is", "one", "of", "the", "most", "frequent", "inborn", "errors", "of", "metabolism", ".", "Heterozygous", "females", "exposed", "to", "high", "protein", "nutrition", "or", "protein", "catabolism", ",", "are", "faced", "with", "highly", "detrimental", "effects", "througout", "their", "lives", "." ]
[ "umlsterm" ]
lung function is a Outcome_Physical, cytokine production is a Outcome_Physical, system disruption is a Outcome_Physical, inflammatory markers is a Outcome_Physical, 16 is a Participant_Sample-size, 8 is a Participant_Sample-size, women is a Participant_Sex, adults is a Participant_Age, baseline and at 0 , 1 , and 3 hours after a 1-hour SHS exposure set at bar / restaurant SHS levels is a Intervention_Physical, Serum and urine cotinine is a Outcome_Physical, cytokines IL-4 , IL-5 , IL-6 is a Intervention_Pharmacological, tumor necrosis factor ( TNF ) -alpha is a Intervention_Pharmacological, IFN - gamma is a Intervention_Pharmacological, lung function parameters is a Outcome_Physical, FEV ( 1 ) is a Outcome_Physical, IL-4 and TNF - alpha is a Outcome_Physical, IL-5 , IL-6 , and IFN - gamma is a Outcome_Physical, FEV ( 1 ) /FVC ratio is a Outcome_Physical, serum cotinine is a Outcome_Physical, decrements on lung function is a Outcome_Physical, inflammatory cytokines is a Outcome_Physical, effects on lung function is a Outcome_Physical
39400_task0
Sentence: Acute and short-term effects of secondhand smoke on lung function and cytokine production . RATIONALE The acute effect of secondhand smoke ( SHS ) on lung function and the duration of system disruption remain unknown . OBJECTIVES To assess the SHS effects and their duration on lung function and inflammatory markers . METHODS In a randomized single-blind crossover experiment data were obtained from 16 ( 8 women ) nonsmoking adults at baseline and at 0 , 1 , and 3 hours after a 1-hour SHS exposure set at bar/restaurant SHS levels . MEASUREMENTS AND MAIN RESULTS Serum and urine cotinine , lung function , and cytokines IL-4 , IL-5 , IL-6 , tumor necrosis factor ( TNF ) -alpha , and IFN-gamma . At 0 hours most lung function parameters were significantly reduced ( indicative : FEV ( 1 ) , 4.3 +/- 0.4 vs. 3.8 +/- 0.3 L ; FEV ( 1 ) /FVC , 0.9 +/- 0.1 vs. 0.8 +/- 0.1 ; P < 0.05 ) but at 3 hours they were at baseline levels . In contrast , cotinine ( serum , 8.9 +/- 3.2 vs. 35.5 +/- 10.2 ng x ml ( -1 ) ) , IL-4 ( 41.3 +/- 5.8 vs. 44.2 +/- 4.5 pg x ml ( -1 ) ) , IL-5 ( 36.1 +/- 3.2 vs. 60.1 +/- 7.0 pg x ml ( -1 ) ) , IL-6 ( 2.5 +/- 0.3 vs. 7.6 +/- 1.4 pg x ml ( -1 ) ) and IFN-gamma ( 0.3 +/- 0.2 vs. 0.6 +/- 0.2 IU x ml ( -1 ) ) at 3 hours were higher than at baseline ( P < 0.05 ) . IL-4 and TNF-alpha increased only in men , whereas IL-5 , IL-6 , and IFN-gamma were different between sexes after exposure ( P < 0.05 ) . Regression analyses revealed inverse associations of FEV ( 1 ) and FEV ( 1 ) /FVC ratio with IL-5 ( P < 0.05 ) in men and with IL-5 ( P = 0.01 ) , IL-6 ( P < 0.001 ) , IFN-gamma ( P = 0.034 ) and serum cotinine ( P < 0.001 ) in women . CONCLUSIONS We conclude that 1 hour of SHS exposure at bar/restaurant levels is accompanied by significant decrements on lung function and marked increases in inflammatory cytokines , particularly in men . More importantly , whereas most smoke-induced effects on lung function appear to recede within 60 minutes , inflammatory cytokines remain elevated for at least 3 hours after exposure to SHS . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Intervention_Pharmacological, Intervention_Physical, Participant_Sex, Participant_Age, Outcome_Physical, Participant_Sample-size
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "B-Participant_Sample-size", "B-Participant_Sex", "O", "O", "B-Participant_Age", "O", "B-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Acute and short-term effects of secondhand smoke on lung function and cytokine production . RATIONALE The acute effect of secondhand smoke ( SHS ) on lung function and the duration of system disruption remain unknown . OBJECTIVES To assess the SHS effects and their duration on lung function and inflammatory markers . METHODS In a randomized single-blind crossover experiment data were obtained from 16 ( 8 women ) nonsmoking adults at baseline and at 0 , 1 , and 3 hours after a 1-hour SHS exposure set at bar/restaurant SHS levels . MEASUREMENTS AND MAIN RESULTS Serum and urine cotinine , lung function , and cytokines IL-4 , IL-5 , IL-6 , tumor necrosis factor ( TNF ) -alpha , and IFN-gamma . At 0 hours most lung function parameters were significantly reduced ( indicative : FEV ( 1 ) , 4.3 +/- 0.4 vs. 3.8 +/- 0.3 L ; FEV ( 1 ) /FVC , 0.9 +/- 0.1 vs. 0.8 +/- 0.1 ; P < 0.05 ) but at 3 hours they were at baseline levels . In contrast , cotinine ( serum , 8.9 +/- 3.2 vs. 35.5 +/- 10.2 ng x ml ( -1 ) ) , IL-4 ( 41.3 +/- 5.8 vs. 44.2 +/- 4.5 pg x ml ( -1 ) ) , IL-5 ( 36.1 +/- 3.2 vs. 60.1 +/- 7.0 pg x ml ( -1 ) ) , IL-6 ( 2.5 +/- 0.3 vs. 7.6 +/- 1.4 pg x ml ( -1 ) ) and IFN-gamma ( 0.3 +/- 0.2 vs. 0.6 +/- 0.2 IU x ml ( -1 ) ) at 3 hours were higher than at baseline ( P < 0.05 ) . IL-4 and TNF-alpha increased only in men , whereas IL-5 , IL-6 , and IFN-gamma were different between sexes after exposure ( P < 0.05 ) . Regression analyses revealed inverse associations of FEV ( 1 ) and FEV ( 1 ) /FVC ratio with IL-5 ( P < 0.05 ) in men and with IL-5 ( P = 0.01 ) , IL-6 ( P < 0.001 ) , IFN-gamma ( P = 0.034 ) and serum cotinine ( P < 0.001 ) in women . CONCLUSIONS We conclude that 1 hour of SHS exposure at bar/restaurant levels is accompanied by significant decrements on lung function and marked increases in inflammatory cytokines , particularly in men . More importantly , whereas most smoke-induced effects on lung function appear to recede within 60 minutes , inflammatory cytokines remain elevated for at least 3 hours after exposure to SHS .
[ "Acute", "and", "short", "-", "term", "effects", "of", "secondhand", "smoke", "on", "lung", "function", "and", "cytokine", "production", ".", "RATIONALE", "The", "acute", "effect", "of", "secondhand", "smoke", "(", "SHS", ")", "on", "lung", "function", "and", "the", "duration", "of", "system", "disruption", "remain", "unknown", ".", "OBJECTIVES", "To", "assess", "the", "SHS", "effects", "and", "their", "duration", "on", "lung", "function", "and", "inflammatory", "markers", ".", "METHODS", "In", "a", "randomized", "single", "-", "blind", "crossover", "experiment", "data", "were", "obtained", "from", "16", "(", "8", "women", ")", "nonsmoking", "adults", "at", "baseline", "and", "at", "0", ",", "1", ",", "and", "3", "hours", "after", "a", "1-hour", "SHS", "exposure", "set", "at", "bar", "/", "restaurant", "SHS", "levels", ".", "MEASUREMENTS", "AND", "MAIN", "RESULTS", "Serum", "and", "urine", "cotinine", ",", "lung", "function", ",", "and", "cytokines", "IL-4", ",", "IL-5", ",", "IL-6", ",", "tumor", "necrosis", "factor", "(", "TNF", ")", "-alpha", ",", "and", "IFN", "-", "gamma", ".", "At", "0", "hours", "most", "lung", "function", "parameters", "were", "significantly", "reduced", "(", "indicative", ":", "FEV", "(", "1", ")", ",", "4.3", "+", "/-", "0.4", "vs", ".", "3.8", "+", "/-", "0.3", "L", ";", "FEV", "(", "1", ")", "/FVC", ",", "0.9", "+", "/-", "0.1", "vs", ".", "0.8", "+", "/-", "0.1", ";", "P", "<", "0.05", ")", "but", "at", "3", "hours", "they", "were", "at", "baseline", "levels", ".", "In", "contrast", ",", "cotinine", "(", "serum", ",", "8.9", "+", "/-", "3.2", "vs", ".", "35.5", "+", "/-", "10.2", "ng", "x", "ml", "(", "-1", ")", ")", ",", "IL-4", "(", "41.3", "+", "/-", "5.8", "vs", ".", "44.2", "+", "/-", "4.5", "pg", "x", "ml", "(", "-1", ")", ")", ",", "IL-5", "(", "36.1", "+", "/-", "3.2", "vs", ".", "60.1", "+", "/-", "7.0", "pg", "x", "ml", "(", "-1", ")", ")", ",", "IL-6", "(", "2.5", "+", "/-", "0.3", "vs", ".", "7.6", "+", "/-", "1.4", "pg", "x", "ml", "(", "-1", ")", ")", "and", "IFN", "-", "gamma", "(", "0.3", "+", "/-", "0.2", "vs", ".", "0.6", "+", "/-", "0.2", "IU", "x", "ml", "(", "-1", ")", ")", "at", "3", "hours", "were", "higher", "than", "at", "baseline", "(", "P", "<", "0.05", ")", ".", "IL-4", "and", "TNF", "-", "alpha", "increased", "only", "in", "men", ",", "whereas", "IL-5", ",", "IL-6", ",", "and", "IFN", "-", "gamma", "were", "different", "between", "sexes", "after", "exposure", "(", "P", "<", "0.05", ")", ".", "Regression", "analyses", "revealed", "inverse", "associations", "of", "FEV", "(", "1", ")", "and", "FEV", "(", "1", ")", "/FVC", "ratio", "with", "IL-5", "(", "P", "<", "0.05", ")", "in", "men", "and", "with", "IL-5", "(", "P", "=", "0.01", ")", ",", "IL-6", "(", "P", "<", "0.001", ")", ",", "IFN", "-", "gamma", "(", "P", "=", "0.034", ")", "and", "serum", "cotinine", "(", "P", "<", "0.001", ")", "in", "women", ".", "CONCLUSIONS", "We", "conclude", "that", "1", "hour", "of", "SHS", "exposure", "at", "bar", "/", "restaurant", "levels", "is", "accompanied", "by", "significant", "decrements", "on", "lung", "function", "and", "marked", "increases", "in", "inflammatory", "cytokines", ",", "particularly", "in", "men", ".", "More", "importantly", ",", "whereas", "most", "smoke", "-", "induced", "effects", "on", "lung", "function", "appear", "to", "recede", "within", "60", "minutes", ",", "inflammatory", "cytokines", "remain", "elevated", "for", "at", "least", "3", "hours", "after", "exposure", "to", "SHS", "." ]
[ "Intervention_Physical", "Intervention_Pharmacological", "Outcome_Physical", "Participant_Age", "Participant_Sex", "Participant_Sample-size" ]
lung function is a Outcome_Physical, cytokine production is a Outcome_Physical, system disruption is a Outcome_Physical, inflammatory markers is a Outcome_Physical, 16 is a Participant_Sample-size, 8 is a Participant_Sample-size, women is a Participant_Sex, adults is a Participant_Age, baseline and at 0 , 1 , and 3 hours after a 1-hour SHS exposure set at bar / restaurant SHS levels is a Intervention_Physical, Serum and urine cotinine is a Outcome_Physical, cytokines IL-4 , IL-5 , IL-6 is a Intervention_Pharmacological, tumor necrosis factor ( TNF ) -alpha is a Intervention_Pharmacological, IFN - gamma is a Intervention_Pharmacological, lung function parameters is a Outcome_Physical, FEV ( 1 ) is a Outcome_Physical, IL-4 and TNF - alpha is a Outcome_Physical, IL-5 , IL-6 , and IFN - gamma is a Outcome_Physical, FEV ( 1 ) /FVC ratio is a Outcome_Physical, serum cotinine is a Outcome_Physical, decrements on lung function is a Outcome_Physical, inflammatory cytokines is a Outcome_Physical, effects on lung function is a Outcome_Physical
39400_task1
Sentence: Acute and short-term effects of secondhand smoke on lung function and cytokine production . RATIONALE The acute effect of secondhand smoke ( SHS ) on lung function and the duration of system disruption remain unknown . OBJECTIVES To assess the SHS effects and their duration on lung function and inflammatory markers . METHODS In a randomized single-blind crossover experiment data were obtained from 16 ( 8 women ) nonsmoking adults at baseline and at 0 , 1 , and 3 hours after a 1-hour SHS exposure set at bar/restaurant SHS levels . MEASUREMENTS AND MAIN RESULTS Serum and urine cotinine , lung function , and cytokines IL-4 , IL-5 , IL-6 , tumor necrosis factor ( TNF ) -alpha , and IFN-gamma . At 0 hours most lung function parameters were significantly reduced ( indicative : FEV ( 1 ) , 4.3 +/- 0.4 vs. 3.8 +/- 0.3 L ; FEV ( 1 ) /FVC , 0.9 +/- 0.1 vs. 0.8 +/- 0.1 ; P < 0.05 ) but at 3 hours they were at baseline levels . In contrast , cotinine ( serum , 8.9 +/- 3.2 vs. 35.5 +/- 10.2 ng x ml ( -1 ) ) , IL-4 ( 41.3 +/- 5.8 vs. 44.2 +/- 4.5 pg x ml ( -1 ) ) , IL-5 ( 36.1 +/- 3.2 vs. 60.1 +/- 7.0 pg x ml ( -1 ) ) , IL-6 ( 2.5 +/- 0.3 vs. 7.6 +/- 1.4 pg x ml ( -1 ) ) and IFN-gamma ( 0.3 +/- 0.2 vs. 0.6 +/- 0.2 IU x ml ( -1 ) ) at 3 hours were higher than at baseline ( P < 0.05 ) . IL-4 and TNF-alpha increased only in men , whereas IL-5 , IL-6 , and IFN-gamma were different between sexes after exposure ( P < 0.05 ) . Regression analyses revealed inverse associations of FEV ( 1 ) and FEV ( 1 ) /FVC ratio with IL-5 ( P < 0.05 ) in men and with IL-5 ( P = 0.01 ) , IL-6 ( P < 0.001 ) , IFN-gamma ( P = 0.034 ) and serum cotinine ( P < 0.001 ) in women . CONCLUSIONS We conclude that 1 hour of SHS exposure at bar/restaurant levels is accompanied by significant decrements on lung function and marked increases in inflammatory cytokines , particularly in men . More importantly , whereas most smoke-induced effects on lung function appear to recede within 60 minutes , inflammatory cytokines remain elevated for at least 3 hours after exposure to SHS . Instructions: please typing these entity words according to sentence: lung function, cytokine production, system disruption, inflammatory markers, 16, 8, women, adults, baseline and at 0 , 1 , and 3 hours after a 1-hour SHS exposure set at bar / restaurant SHS levels, Serum and urine cotinine, cytokines IL-4 , IL-5 , IL-6, tumor necrosis factor ( TNF ) -alpha, IFN - gamma, lung function parameters, FEV ( 1 ), IL-4 and TNF - alpha, IL-5 , IL-6 , and IFN - gamma, FEV ( 1 ) /FVC ratio, serum cotinine, decrements on lung function, inflammatory cytokines, effects on lung function Options: Intervention_Pharmacological, Intervention_Physical, Participant_Sex, Participant_Age, Outcome_Physical, Participant_Sample-size
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "B-Participant_Sample-size", "B-Participant_Sex", "O", "O", "B-Participant_Age", "O", "B-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Acute and short-term effects of secondhand smoke on lung function and cytokine production . RATIONALE The acute effect of secondhand smoke ( SHS ) on lung function and the duration of system disruption remain unknown . OBJECTIVES To assess the SHS effects and their duration on lung function and inflammatory markers . METHODS In a randomized single-blind crossover experiment data were obtained from 16 ( 8 women ) nonsmoking adults at baseline and at 0 , 1 , and 3 hours after a 1-hour SHS exposure set at bar/restaurant SHS levels . MEASUREMENTS AND MAIN RESULTS Serum and urine cotinine , lung function , and cytokines IL-4 , IL-5 , IL-6 , tumor necrosis factor ( TNF ) -alpha , and IFN-gamma . At 0 hours most lung function parameters were significantly reduced ( indicative : FEV ( 1 ) , 4.3 +/- 0.4 vs. 3.8 +/- 0.3 L ; FEV ( 1 ) /FVC , 0.9 +/- 0.1 vs. 0.8 +/- 0.1 ; P < 0.05 ) but at 3 hours they were at baseline levels . In contrast , cotinine ( serum , 8.9 +/- 3.2 vs. 35.5 +/- 10.2 ng x ml ( -1 ) ) , IL-4 ( 41.3 +/- 5.8 vs. 44.2 +/- 4.5 pg x ml ( -1 ) ) , IL-5 ( 36.1 +/- 3.2 vs. 60.1 +/- 7.0 pg x ml ( -1 ) ) , IL-6 ( 2.5 +/- 0.3 vs. 7.6 +/- 1.4 pg x ml ( -1 ) ) and IFN-gamma ( 0.3 +/- 0.2 vs. 0.6 +/- 0.2 IU x ml ( -1 ) ) at 3 hours were higher than at baseline ( P < 0.05 ) . IL-4 and TNF-alpha increased only in men , whereas IL-5 , IL-6 , and IFN-gamma were different between sexes after exposure ( P < 0.05 ) . Regression analyses revealed inverse associations of FEV ( 1 ) and FEV ( 1 ) /FVC ratio with IL-5 ( P < 0.05 ) in men and with IL-5 ( P = 0.01 ) , IL-6 ( P < 0.001 ) , IFN-gamma ( P = 0.034 ) and serum cotinine ( P < 0.001 ) in women . CONCLUSIONS We conclude that 1 hour of SHS exposure at bar/restaurant levels is accompanied by significant decrements on lung function and marked increases in inflammatory cytokines , particularly in men . More importantly , whereas most smoke-induced effects on lung function appear to recede within 60 minutes , inflammatory cytokines remain elevated for at least 3 hours after exposure to SHS .
[ "Acute", "and", "short", "-", "term", "effects", "of", "secondhand", "smoke", "on", "lung", "function", "and", "cytokine", "production", ".", "RATIONALE", "The", "acute", "effect", "of", "secondhand", "smoke", "(", "SHS", ")", "on", "lung", "function", "and", "the", "duration", "of", "system", "disruption", "remain", "unknown", ".", "OBJECTIVES", "To", "assess", "the", "SHS", "effects", "and", "their", "duration", "on", "lung", "function", "and", "inflammatory", "markers", ".", "METHODS", "In", "a", "randomized", "single", "-", "blind", "crossover", "experiment", "data", "were", "obtained", "from", "16", "(", "8", "women", ")", "nonsmoking", "adults", "at", "baseline", "and", "at", "0", ",", "1", ",", "and", "3", "hours", "after", "a", "1-hour", "SHS", "exposure", "set", "at", "bar", "/", "restaurant", "SHS", "levels", ".", "MEASUREMENTS", "AND", "MAIN", "RESULTS", "Serum", "and", "urine", "cotinine", ",", "lung", "function", ",", "and", "cytokines", "IL-4", ",", "IL-5", ",", "IL-6", ",", "tumor", "necrosis", "factor", "(", "TNF", ")", "-alpha", ",", "and", "IFN", "-", "gamma", ".", "At", "0", "hours", "most", "lung", "function", "parameters", "were", "significantly", "reduced", "(", "indicative", ":", "FEV", "(", "1", ")", ",", "4.3", "+", "/-", "0.4", "vs", ".", "3.8", "+", "/-", "0.3", "L", ";", "FEV", "(", "1", ")", "/FVC", ",", "0.9", "+", "/-", "0.1", "vs", ".", "0.8", "+", "/-", "0.1", ";", "P", "<", "0.05", ")", "but", "at", "3", "hours", "they", "were", "at", "baseline", "levels", ".", "In", "contrast", ",", "cotinine", "(", "serum", ",", "8.9", "+", "/-", "3.2", "vs", ".", "35.5", "+", "/-", "10.2", "ng", "x", "ml", "(", "-1", ")", ")", ",", "IL-4", "(", "41.3", "+", "/-", "5.8", "vs", ".", "44.2", "+", "/-", "4.5", "pg", "x", "ml", "(", "-1", ")", ")", ",", "IL-5", "(", "36.1", "+", "/-", "3.2", "vs", ".", "60.1", "+", "/-", "7.0", "pg", "x", "ml", "(", "-1", ")", ")", ",", "IL-6", "(", "2.5", "+", "/-", "0.3", "vs", ".", "7.6", "+", "/-", "1.4", "pg", "x", "ml", "(", "-1", ")", ")", "and", "IFN", "-", "gamma", "(", "0.3", "+", "/-", "0.2", "vs", ".", "0.6", "+", "/-", "0.2", "IU", "x", "ml", "(", "-1", ")", ")", "at", "3", "hours", "were", "higher", "than", "at", "baseline", "(", "P", "<", "0.05", ")", ".", "IL-4", "and", "TNF", "-", "alpha", "increased", "only", "in", "men", ",", "whereas", "IL-5", ",", "IL-6", ",", "and", "IFN", "-", "gamma", "were", "different", "between", "sexes", "after", "exposure", "(", "P", "<", "0.05", ")", ".", "Regression", "analyses", "revealed", "inverse", "associations", "of", "FEV", "(", "1", ")", "and", "FEV", "(", "1", ")", "/FVC", "ratio", "with", "IL-5", "(", "P", "<", "0.05", ")", "in", "men", "and", "with", "IL-5", "(", "P", "=", "0.01", ")", ",", "IL-6", "(", "P", "<", "0.001", ")", ",", "IFN", "-", "gamma", "(", "P", "=", "0.034", ")", "and", "serum", "cotinine", "(", "P", "<", "0.001", ")", "in", "women", ".", "CONCLUSIONS", "We", "conclude", "that", "1", "hour", "of", "SHS", "exposure", "at", "bar", "/", "restaurant", "levels", "is", "accompanied", "by", "significant", "decrements", "on", "lung", "function", "and", "marked", "increases", "in", "inflammatory", "cytokines", ",", "particularly", "in", "men", ".", "More", "importantly", ",", "whereas", "most", "smoke", "-", "induced", "effects", "on", "lung", "function", "appear", "to", "recede", "within", "60", "minutes", ",", "inflammatory", "cytokines", "remain", "elevated", "for", "at", "least", "3", "hours", "after", "exposure", "to", "SHS", "." ]
[ "Intervention_Physical", "Intervention_Pharmacological", "Outcome_Physical", "Participant_Age", "Participant_Sex", "Participant_Sample-size" ]
lung function, cytokine production, system disruption, inflammatory markers, 16, 8, women, adults, baseline and at 0 , 1 , and 3 hours after a 1-hour SHS exposure set at bar / restaurant SHS levels, Serum and urine cotinine, cytokines IL-4 , IL-5 , IL-6, tumor necrosis factor ( TNF ) -alpha, IFN - gamma, lung function parameters, FEV ( 1 ), IL-4 and TNF - alpha, IL-5 , IL-6 , and IFN - gamma, FEV ( 1 ) /FVC ratio, serum cotinine, decrements on lung function, inflammatory cytokines, effects on lung function
39400_task2
Sentence: Acute and short-term effects of secondhand smoke on lung function and cytokine production . RATIONALE The acute effect of secondhand smoke ( SHS ) on lung function and the duration of system disruption remain unknown . OBJECTIVES To assess the SHS effects and their duration on lung function and inflammatory markers . METHODS In a randomized single-blind crossover experiment data were obtained from 16 ( 8 women ) nonsmoking adults at baseline and at 0 , 1 , and 3 hours after a 1-hour SHS exposure set at bar/restaurant SHS levels . MEASUREMENTS AND MAIN RESULTS Serum and urine cotinine , lung function , and cytokines IL-4 , IL-5 , IL-6 , tumor necrosis factor ( TNF ) -alpha , and IFN-gamma . At 0 hours most lung function parameters were significantly reduced ( indicative : FEV ( 1 ) , 4.3 +/- 0.4 vs. 3.8 +/- 0.3 L ; FEV ( 1 ) /FVC , 0.9 +/- 0.1 vs. 0.8 +/- 0.1 ; P < 0.05 ) but at 3 hours they were at baseline levels . In contrast , cotinine ( serum , 8.9 +/- 3.2 vs. 35.5 +/- 10.2 ng x ml ( -1 ) ) , IL-4 ( 41.3 +/- 5.8 vs. 44.2 +/- 4.5 pg x ml ( -1 ) ) , IL-5 ( 36.1 +/- 3.2 vs. 60.1 +/- 7.0 pg x ml ( -1 ) ) , IL-6 ( 2.5 +/- 0.3 vs. 7.6 +/- 1.4 pg x ml ( -1 ) ) and IFN-gamma ( 0.3 +/- 0.2 vs. 0.6 +/- 0.2 IU x ml ( -1 ) ) at 3 hours were higher than at baseline ( P < 0.05 ) . IL-4 and TNF-alpha increased only in men , whereas IL-5 , IL-6 , and IFN-gamma were different between sexes after exposure ( P < 0.05 ) . Regression analyses revealed inverse associations of FEV ( 1 ) and FEV ( 1 ) /FVC ratio with IL-5 ( P < 0.05 ) in men and with IL-5 ( P = 0.01 ) , IL-6 ( P < 0.001 ) , IFN-gamma ( P = 0.034 ) and serum cotinine ( P < 0.001 ) in women . CONCLUSIONS We conclude that 1 hour of SHS exposure at bar/restaurant levels is accompanied by significant decrements on lung function and marked increases in inflammatory cytokines , particularly in men . More importantly , whereas most smoke-induced effects on lung function appear to recede within 60 minutes , inflammatory cytokines remain elevated for at least 3 hours after exposure to SHS . Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "B-Participant_Sample-size", "B-Participant_Sex", "O", "O", "B-Participant_Age", "O", "B-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Acute and short-term effects of secondhand smoke on lung function and cytokine production . RATIONALE The acute effect of secondhand smoke ( SHS ) on lung function and the duration of system disruption remain unknown . OBJECTIVES To assess the SHS effects and their duration on lung function and inflammatory markers . METHODS In a randomized single-blind crossover experiment data were obtained from 16 ( 8 women ) nonsmoking adults at baseline and at 0 , 1 , and 3 hours after a 1-hour SHS exposure set at bar/restaurant SHS levels . MEASUREMENTS AND MAIN RESULTS Serum and urine cotinine , lung function , and cytokines IL-4 , IL-5 , IL-6 , tumor necrosis factor ( TNF ) -alpha , and IFN-gamma . At 0 hours most lung function parameters were significantly reduced ( indicative : FEV ( 1 ) , 4.3 +/- 0.4 vs. 3.8 +/- 0.3 L ; FEV ( 1 ) /FVC , 0.9 +/- 0.1 vs. 0.8 +/- 0.1 ; P < 0.05 ) but at 3 hours they were at baseline levels . In contrast , cotinine ( serum , 8.9 +/- 3.2 vs. 35.5 +/- 10.2 ng x ml ( -1 ) ) , IL-4 ( 41.3 +/- 5.8 vs. 44.2 +/- 4.5 pg x ml ( -1 ) ) , IL-5 ( 36.1 +/- 3.2 vs. 60.1 +/- 7.0 pg x ml ( -1 ) ) , IL-6 ( 2.5 +/- 0.3 vs. 7.6 +/- 1.4 pg x ml ( -1 ) ) and IFN-gamma ( 0.3 +/- 0.2 vs. 0.6 +/- 0.2 IU x ml ( -1 ) ) at 3 hours were higher than at baseline ( P < 0.05 ) . IL-4 and TNF-alpha increased only in men , whereas IL-5 , IL-6 , and IFN-gamma were different between sexes after exposure ( P < 0.05 ) . Regression analyses revealed inverse associations of FEV ( 1 ) and FEV ( 1 ) /FVC ratio with IL-5 ( P < 0.05 ) in men and with IL-5 ( P = 0.01 ) , IL-6 ( P < 0.001 ) , IFN-gamma ( P = 0.034 ) and serum cotinine ( P < 0.001 ) in women . CONCLUSIONS We conclude that 1 hour of SHS exposure at bar/restaurant levels is accompanied by significant decrements on lung function and marked increases in inflammatory cytokines , particularly in men . More importantly , whereas most smoke-induced effects on lung function appear to recede within 60 minutes , inflammatory cytokines remain elevated for at least 3 hours after exposure to SHS .
[ "Acute", "and", "short", "-", "term", "effects", "of", "secondhand", "smoke", "on", "lung", "function", "and", "cytokine", "production", ".", "RATIONALE", "The", "acute", "effect", "of", "secondhand", "smoke", "(", "SHS", ")", "on", "lung", "function", "and", "the", "duration", "of", "system", "disruption", "remain", "unknown", ".", "OBJECTIVES", "To", "assess", "the", "SHS", "effects", "and", "their", "duration", "on", "lung", "function", "and", "inflammatory", "markers", ".", "METHODS", "In", "a", "randomized", "single", "-", "blind", "crossover", "experiment", "data", "were", "obtained", "from", "16", "(", "8", "women", ")", "nonsmoking", "adults", "at", "baseline", "and", "at", "0", ",", "1", ",", "and", "3", "hours", "after", "a", "1-hour", "SHS", "exposure", "set", "at", "bar", "/", "restaurant", "SHS", "levels", ".", "MEASUREMENTS", "AND", "MAIN", "RESULTS", "Serum", "and", "urine", "cotinine", ",", "lung", "function", ",", "and", "cytokines", "IL-4", ",", "IL-5", ",", "IL-6", ",", "tumor", "necrosis", "factor", "(", "TNF", ")", "-alpha", ",", "and", "IFN", "-", "gamma", ".", "At", "0", "hours", "most", "lung", "function", "parameters", "were", "significantly", "reduced", "(", "indicative", ":", "FEV", "(", "1", ")", ",", "4.3", "+", "/-", "0.4", "vs", ".", "3.8", "+", "/-", "0.3", "L", ";", "FEV", "(", "1", ")", "/FVC", ",", "0.9", "+", "/-", "0.1", "vs", ".", "0.8", "+", "/-", "0.1", ";", "P", "<", "0.05", ")", "but", "at", "3", "hours", "they", "were", "at", "baseline", "levels", ".", "In", "contrast", ",", "cotinine", "(", "serum", ",", "8.9", "+", "/-", "3.2", "vs", ".", "35.5", "+", "/-", "10.2", "ng", "x", "ml", "(", "-1", ")", ")", ",", "IL-4", "(", "41.3", "+", "/-", "5.8", "vs", ".", "44.2", "+", "/-", "4.5", "pg", "x", "ml", "(", "-1", ")", ")", ",", "IL-5", "(", "36.1", "+", "/-", "3.2", "vs", ".", "60.1", "+", "/-", "7.0", "pg", "x", "ml", "(", "-1", ")", ")", ",", "IL-6", "(", "2.5", "+", "/-", "0.3", "vs", ".", "7.6", "+", "/-", "1.4", "pg", "x", "ml", "(", "-1", ")", ")", "and", "IFN", "-", "gamma", "(", "0.3", "+", "/-", "0.2", "vs", ".", "0.6", "+", "/-", "0.2", "IU", "x", "ml", "(", "-1", ")", ")", "at", "3", "hours", "were", "higher", "than", "at", "baseline", "(", "P", "<", "0.05", ")", ".", "IL-4", "and", "TNF", "-", "alpha", "increased", "only", "in", "men", ",", "whereas", "IL-5", ",", "IL-6", ",", "and", "IFN", "-", "gamma", "were", "different", "between", "sexes", "after", "exposure", "(", "P", "<", "0.05", ")", ".", "Regression", "analyses", "revealed", "inverse", "associations", "of", "FEV", "(", "1", ")", "and", "FEV", "(", "1", ")", "/FVC", "ratio", "with", "IL-5", "(", "P", "<", "0.05", ")", "in", "men", "and", "with", "IL-5", "(", "P", "=", "0.01", ")", ",", "IL-6", "(", "P", "<", "0.001", ")", ",", "IFN", "-", "gamma", "(", "P", "=", "0.034", ")", "and", "serum", "cotinine", "(", "P", "<", "0.001", ")", "in", "women", ".", "CONCLUSIONS", "We", "conclude", "that", "1", "hour", "of", "SHS", "exposure", "at", "bar", "/", "restaurant", "levels", "is", "accompanied", "by", "significant", "decrements", "on", "lung", "function", "and", "marked", "increases", "in", "inflammatory", "cytokines", ",", "particularly", "in", "men", ".", "More", "importantly", ",", "whereas", "most", "smoke", "-", "induced", "effects", "on", "lung", "function", "appear", "to", "recede", "within", "60", "minutes", ",", "inflammatory", "cytokines", "remain", "elevated", "for", "at", "least", "3", "hours", "after", "exposure", "to", "SHS", "." ]
[ "Intervention_Physical", "Intervention_Pharmacological", "Outcome_Physical", "Participant_Age", "Participant_Sex", "Participant_Sample-size" ]
nuclear proteins is a protein_family_or_group, clinically sensitive chronic myelogenous leukemia patients is a multi_cell
97725_task0
Sentence: Interferon affects nuclear proteins in cells of clinically sensitive chronic myelogenous leukemia patients. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: protein_family_or_group, multi_cell
[ "O", "O", "B-protein_family_or_group", "I-protein_family_or_group", "O", "O", "O", "B-multi_cell", "I-multi_cell", "I-multi_cell", "I-multi_cell", "I-multi_cell", "I-multi_cell", "O" ]
Interferon affects nuclear proteins in cells of clinically sensitive chronic myelogenous leukemia patients.
[ "Interferon", "affects", "nuclear", "proteins", "in", "cells", "of", "clinically", "sensitive", "chronic", "myelogenous", "leukemia", "patients", "." ]
[ "multi_cell", "cell_type", "protein_complex", "other_name", "cell_component", "protein_family_or_group", "protein_molecule" ]
nuclear proteins is a protein_family_or_group, clinically sensitive chronic myelogenous leukemia patients is a multi_cell
97725_task1
Sentence: Interferon affects nuclear proteins in cells of clinically sensitive chronic myelogenous leukemia patients. Instructions: please typing these entity words according to sentence: nuclear proteins, clinically sensitive chronic myelogenous leukemia patients Options: protein_family_or_group, multi_cell
[ "O", "O", "B-protein_family_or_group", "I-protein_family_or_group", "O", "O", "O", "B-multi_cell", "I-multi_cell", "I-multi_cell", "I-multi_cell", "I-multi_cell", "I-multi_cell", "O" ]
Interferon affects nuclear proteins in cells of clinically sensitive chronic myelogenous leukemia patients.
[ "Interferon", "affects", "nuclear", "proteins", "in", "cells", "of", "clinically", "sensitive", "chronic", "myelogenous", "leukemia", "patients", "." ]
[ "multi_cell", "cell_type", "protein_complex", "other_name", "cell_component", "protein_family_or_group", "protein_molecule" ]
nuclear proteins, clinically sensitive chronic myelogenous leukemia patients
97725_task2
Sentence: Interferon affects nuclear proteins in cells of clinically sensitive chronic myelogenous leukemia patients. Instructions: please extract entity words from the input sentence
[ "O", "O", "B-protein_family_or_group", "I-protein_family_or_group", "O", "O", "O", "B-multi_cell", "I-multi_cell", "I-multi_cell", "I-multi_cell", "I-multi_cell", "I-multi_cell", "O" ]
Interferon affects nuclear proteins in cells of clinically sensitive chronic myelogenous leukemia patients.
[ "Interferon", "affects", "nuclear", "proteins", "in", "cells", "of", "clinically", "sensitive", "chronic", "myelogenous", "leukemia", "patients", "." ]
[ "multi_cell", "cell_type", "protein_complex", "other_name", "cell_component", "protein_family_or_group", "protein_molecule" ]
spine disorders is an umlsterm, occupational disease is an umlsterm, disorders is an umlsterm, spondylosis is an umlsterm, function is an umlsterm, pain is an umlsterm, disorders is an umlsterm, disorders is an umlsterm, scoliosis is an umlsterm, spondylolisthesis is an umlsterm, rejections is an umlsterm, consensus is an umlsterm, markers is an umlsterm, disorders is an umlsterm
DerUnfallchirurg.81010799.eng.abstr_task0
Sentence: Necessary precondition for acceptance of spine disorders as occupational disease is an excessive occupational exposition , its compatibility with and an explicit causal relation to this disorders . The latter may be assumed in case of multisegmental spondylosis of the column , combined with local impairment of function and pain , if the vertebral disorders of the occupationally exposed column-segment are significantly worse than those of other vertebral segments . Finally non-occupational , preexisting discrete vertebral disorders ( e . g . scoliosis , spondylolisthesis ) have to been excluded . So far there are no alternatives or rejections to this consensus , called " Hamburg formula " . It should be used as long as no other valid , positive markers of occupationally caused disorders can be defined on the basis of reliable epidemiological investigations . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm
[ "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Necessary precondition for acceptance of spine disorders as occupational disease is an excessive occupational exposition , its compatibility with and an explicit causal relation to this disorders . The latter may be assumed in case of multisegmental spondylosis of the column , combined with local impairment of function and pain , if the vertebral disorders of the occupationally exposed column-segment are significantly worse than those of other vertebral segments . Finally non-occupational , preexisting discrete vertebral disorders ( e . g . scoliosis , spondylolisthesis ) have to been excluded . So far there are no alternatives or rejections to this consensus , called " Hamburg formula " . It should be used as long as no other valid , positive markers of occupationally caused disorders can be defined on the basis of reliable epidemiological investigations .
[ "Necessary", "precondition", "for", "acceptance", "of", "spine", "disorders", "as", "occupational", "disease", "is", "an", "excessive", "occupational", "exposition", ",", "its", "compatibility", "with", "and", "an", "explicit", "causal", "relation", "to", "this", "disorders", ".", "The", "latter", "may", "be", "assumed", "in", "case", "of", "multisegmental", "spondylosis", "of", "the", "column", ",", "combined", "with", "local", "impairment", "of", "function", "and", "pain", ",", "if", "the", "vertebral", "disorders", "of", "the", "occupationally", "exposed", "column", "-", "segment", "are", "significantly", "worse", "than", "those", "of", "other", "vertebral", "segments", ".", "Finally", "non", "-", "occupational", ",", "preexisting", "discrete", "vertebral", "disorders", "(", "e", ".", "g", ".", "scoliosis", ",", "spondylolisthesis", ")", "have", "to", "been", "excluded", ".", "So", "far", "there", "are", "no", "alternatives", "or", "rejections", "to", "this", "consensus", ",", "called", "\"", "Hamburg", "formula", "\"", ".", "It", "should", "be", "used", "as", "long", "as", "no", "other", "valid", ",", "positive", "markers", "of", "occupationally", "caused", "disorders", "can", "be", "defined", "on", "the", "basis", "of", "reliable", "epidemiological", "investigations", "." ]
[ "umlsterm" ]
spine disorders is an umlsterm, occupational disease is an umlsterm, disorders is an umlsterm, spondylosis is an umlsterm, function is an umlsterm, pain is an umlsterm, disorders is an umlsterm, disorders is an umlsterm, scoliosis is an umlsterm, spondylolisthesis is an umlsterm, rejections is an umlsterm, consensus is an umlsterm, markers is an umlsterm, disorders is an umlsterm
DerUnfallchirurg.81010799.eng.abstr_task1
Sentence: Necessary precondition for acceptance of spine disorders as occupational disease is an excessive occupational exposition , its compatibility with and an explicit causal relation to this disorders . The latter may be assumed in case of multisegmental spondylosis of the column , combined with local impairment of function and pain , if the vertebral disorders of the occupationally exposed column-segment are significantly worse than those of other vertebral segments . Finally non-occupational , preexisting discrete vertebral disorders ( e . g . scoliosis , spondylolisthesis ) have to been excluded . So far there are no alternatives or rejections to this consensus , called " Hamburg formula " . It should be used as long as no other valid , positive markers of occupationally caused disorders can be defined on the basis of reliable epidemiological investigations . Instructions: please typing these entity words according to sentence: spine disorders, occupational disease, disorders, spondylosis, function, pain, disorders, disorders, scoliosis, spondylolisthesis, rejections, consensus, markers, disorders Options: umlsterm
[ "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Necessary precondition for acceptance of spine disorders as occupational disease is an excessive occupational exposition , its compatibility with and an explicit causal relation to this disorders . The latter may be assumed in case of multisegmental spondylosis of the column , combined with local impairment of function and pain , if the vertebral disorders of the occupationally exposed column-segment are significantly worse than those of other vertebral segments . Finally non-occupational , preexisting discrete vertebral disorders ( e . g . scoliosis , spondylolisthesis ) have to been excluded . So far there are no alternatives or rejections to this consensus , called " Hamburg formula " . It should be used as long as no other valid , positive markers of occupationally caused disorders can be defined on the basis of reliable epidemiological investigations .
[ "Necessary", "precondition", "for", "acceptance", "of", "spine", "disorders", "as", "occupational", "disease", "is", "an", "excessive", "occupational", "exposition", ",", "its", "compatibility", "with", "and", "an", "explicit", "causal", "relation", "to", "this", "disorders", ".", "The", "latter", "may", "be", "assumed", "in", "case", "of", "multisegmental", "spondylosis", "of", "the", "column", ",", "combined", "with", "local", "impairment", "of", "function", "and", "pain", ",", "if", "the", "vertebral", "disorders", "of", "the", "occupationally", "exposed", "column", "-", "segment", "are", "significantly", "worse", "than", "those", "of", "other", "vertebral", "segments", ".", "Finally", "non", "-", "occupational", ",", "preexisting", "discrete", "vertebral", "disorders", "(", "e", ".", "g", ".", "scoliosis", ",", "spondylolisthesis", ")", "have", "to", "been", "excluded", ".", "So", "far", "there", "are", "no", "alternatives", "or", "rejections", "to", "this", "consensus", ",", "called", "\"", "Hamburg", "formula", "\"", ".", "It", "should", "be", "used", "as", "long", "as", "no", "other", "valid", ",", "positive", "markers", "of", "occupationally", "caused", "disorders", "can", "be", "defined", "on", "the", "basis", "of", "reliable", "epidemiological", "investigations", "." ]
[ "umlsterm" ]
spine disorders, occupational disease, disorders, spondylosis, function, pain, disorders, disorders, scoliosis, spondylolisthesis, rejections, consensus, markers, disorders
DerUnfallchirurg.81010799.eng.abstr_task2
Sentence: Necessary precondition for acceptance of spine disorders as occupational disease is an excessive occupational exposition , its compatibility with and an explicit causal relation to this disorders . The latter may be assumed in case of multisegmental spondylosis of the column , combined with local impairment of function and pain , if the vertebral disorders of the occupationally exposed column-segment are significantly worse than those of other vertebral segments . Finally non-occupational , preexisting discrete vertebral disorders ( e . g . scoliosis , spondylolisthesis ) have to been excluded . So far there are no alternatives or rejections to this consensus , called " Hamburg formula " . It should be used as long as no other valid , positive markers of occupationally caused disorders can be defined on the basis of reliable epidemiological investigations . Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Necessary precondition for acceptance of spine disorders as occupational disease is an excessive occupational exposition , its compatibility with and an explicit causal relation to this disorders . The latter may be assumed in case of multisegmental spondylosis of the column , combined with local impairment of function and pain , if the vertebral disorders of the occupationally exposed column-segment are significantly worse than those of other vertebral segments . Finally non-occupational , preexisting discrete vertebral disorders ( e . g . scoliosis , spondylolisthesis ) have to been excluded . So far there are no alternatives or rejections to this consensus , called " Hamburg formula " . It should be used as long as no other valid , positive markers of occupationally caused disorders can be defined on the basis of reliable epidemiological investigations .
[ "Necessary", "precondition", "for", "acceptance", "of", "spine", "disorders", "as", "occupational", "disease", "is", "an", "excessive", "occupational", "exposition", ",", "its", "compatibility", "with", "and", "an", "explicit", "causal", "relation", "to", "this", "disorders", ".", "The", "latter", "may", "be", "assumed", "in", "case", "of", "multisegmental", "spondylosis", "of", "the", "column", ",", "combined", "with", "local", "impairment", "of", "function", "and", "pain", ",", "if", "the", "vertebral", "disorders", "of", "the", "occupationally", "exposed", "column", "-", "segment", "are", "significantly", "worse", "than", "those", "of", "other", "vertebral", "segments", ".", "Finally", "non", "-", "occupational", ",", "preexisting", "discrete", "vertebral", "disorders", "(", "e", ".", "g", ".", "scoliosis", ",", "spondylolisthesis", ")", "have", "to", "been", "excluded", ".", "So", "far", "there", "are", "no", "alternatives", "or", "rejections", "to", "this", "consensus", ",", "called", "\"", "Hamburg", "formula", "\"", ".", "It", "should", "be", "used", "as", "long", "as", "no", "other", "valid", ",", "positive", "markers", "of", "occupationally", "caused", "disorders", "can", "be", "defined", "on", "the", "basis", "of", "reliable", "epidemiological", "investigations", "." ]
[ "umlsterm" ]
transcripts is a RNA_family_or_group, alternative transcript encoding is an other_name, autoantigen La / SS - B is a protein_molecule, cDNA library is a DNA_family_or_group, patient is a multi_cell, primary Sjogrens ' syndrome is an other_name
9501_task0
Sentence: One gene, two transcripts: isolation of an alternative transcript encoding for the autoantigen La/SS-B from a cDNA library of a patient with primary Sjogrens' syndrome. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: DNA_family_or_group, multi_cell, other_name, RNA_family_or_group, protein_molecule
[ "O", "O", "O", "O", "B-RNA_family_or_group", "O", "O", "O", "O", "B-other_name", "I-other_name", "I-other_name", "O", "O", "B-protein_molecule", "I-protein_molecule", "I-protein_molecule", "I-protein_molecule", "I-protein_molecule", "I-protein_molecule", "O", "O", "B-DNA_family_or_group", "I-DNA_family_or_group", "O", "O", "B-multi_cell", "O", "B-other_name", "I-other_name", "I-other_name", "I-other_name", "O" ]
One gene, two transcripts: isolation of an alternative transcript encoding for the autoantigen La/SS-B from a cDNA library of a patient with primary Sjogrens' syndrome.
[ "One", "gene", ",", "two", "transcripts", ":", "isolation", "of", "an", "alternative", "transcript", "encoding", "for", "the", "autoantigen", "La", "/", "SS", "-", "B", "from", "a", "cDNA", "library", "of", "a", "patient", "with", "primary", "Sjogrens", "'", "syndrome", "." ]
[ "other_name", "protein_molecule", "DNA_domain_or_region", "protein_family_or_group", "RNA_molecule", "(AND DNA_domain_or_region DNA_domain_or_region)", "DNA_family_or_group", "RNA_family_or_group", "cell_type", "multi_cell", "" ]
transcripts is a RNA_family_or_group, alternative transcript encoding is an other_name, autoantigen La / SS - B is a protein_molecule, cDNA library is a DNA_family_or_group, patient is a multi_cell, primary Sjogrens ' syndrome is an other_name
9501_task1
Sentence: One gene, two transcripts: isolation of an alternative transcript encoding for the autoantigen La/SS-B from a cDNA library of a patient with primary Sjogrens' syndrome. Instructions: please typing these entity words according to sentence: transcripts, alternative transcript encoding, autoantigen La / SS - B, cDNA library, patient, primary Sjogrens ' syndrome Options: DNA_family_or_group, multi_cell, other_name, RNA_family_or_group, protein_molecule
[ "O", "O", "O", "O", "B-RNA_family_or_group", "O", "O", "O", "O", "B-other_name", "I-other_name", "I-other_name", "O", "O", "B-protein_molecule", "I-protein_molecule", "I-protein_molecule", "I-protein_molecule", "I-protein_molecule", "I-protein_molecule", "O", "O", "B-DNA_family_or_group", "I-DNA_family_or_group", "O", "O", "B-multi_cell", "O", "B-other_name", "I-other_name", "I-other_name", "I-other_name", "O" ]
One gene, two transcripts: isolation of an alternative transcript encoding for the autoantigen La/SS-B from a cDNA library of a patient with primary Sjogrens' syndrome.
[ "One", "gene", ",", "two", "transcripts", ":", "isolation", "of", "an", "alternative", "transcript", "encoding", "for", "the", "autoantigen", "La", "/", "SS", "-", "B", "from", "a", "cDNA", "library", "of", "a", "patient", "with", "primary", "Sjogrens", "'", "syndrome", "." ]
[ "other_name", "protein_molecule", "DNA_domain_or_region", "protein_family_or_group", "RNA_molecule", "(AND DNA_domain_or_region DNA_domain_or_region)", "DNA_family_or_group", "RNA_family_or_group", "cell_type", "multi_cell", "" ]
transcripts, alternative transcript encoding, autoantigen La / SS - B, cDNA library, patient, primary Sjogrens ' syndrome
9501_task2
Sentence: One gene, two transcripts: isolation of an alternative transcript encoding for the autoantigen La/SS-B from a cDNA library of a patient with primary Sjogrens' syndrome. Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "B-RNA_family_or_group", "O", "O", "O", "O", "B-other_name", "I-other_name", "I-other_name", "O", "O", "B-protein_molecule", "I-protein_molecule", "I-protein_molecule", "I-protein_molecule", "I-protein_molecule", "I-protein_molecule", "O", "O", "B-DNA_family_or_group", "I-DNA_family_or_group", "O", "O", "B-multi_cell", "O", "B-other_name", "I-other_name", "I-other_name", "I-other_name", "O" ]
One gene, two transcripts: isolation of an alternative transcript encoding for the autoantigen La/SS-B from a cDNA library of a patient with primary Sjogrens' syndrome.
[ "One", "gene", ",", "two", "transcripts", ":", "isolation", "of", "an", "alternative", "transcript", "encoding", "for", "the", "autoantigen", "La", "/", "SS", "-", "B", "from", "a", "cDNA", "library", "of", "a", "patient", "with", "primary", "Sjogrens", "'", "syndrome", "." ]
[ "other_name", "protein_molecule", "DNA_domain_or_region", "protein_family_or_group", "RNA_molecule", "(AND DNA_domain_or_region DNA_domain_or_region)", "DNA_family_or_group", "RNA_family_or_group", "cell_type", "multi_cell", "" ]
risk factors is an umlsterm, coronary artery disease is an umlsterm, CAD is an umlsterm, patients is an umlsterm, knowledge is an umlsterm, patients is an umlsterm, CAD is an umlsterm, myocardial infarction is an umlsterm, secondary is an umlsterm, prevention is an umlsterm, guidelines is an umlsterm, secondary is an umlsterm, prevention is an umlsterm, patients is an umlsterm, Marburg is an umlsterm, CAD is an umlsterm, Prevention is an umlsterm, computer is an umlsterm, data base is an umlsterm, CAD is an umlsterm, laboratory is an umlsterm, computer program is an umlsterm, risk factors is an umlsterm, findings is an umlsterm, Patients is an umlsterm, physicians is an umlsterm, need is an umlsterm, risk factors is an umlsterm, all is an umlsterm, patients is an umlsterm, CAD is an umlsterm, recommendations is an umlsterm, treatment is an umlsterm
Herz.00250113.eng.abstr_task0
Sentence: In recent years we identified numerous cardiovascular risk factors and had been able to reduce cardiovascular events by a variety of different interventions . There is no question that we can improve the course of coronary artery disease ( CAD ) in patients with a high-risk profile by modifying these factors . Despite this knowledge , many patients with known CAD or myocardial infarction are not treated for secondary prevention as recommended by well established guidelines . In order to improve secondary prevention in our patients we started a project , the so called " Marburg CAD Prevention Project " . By this we combine our computer data base of the CAD preventional routine laboratory with the computer program CARDDAS . Individual risk factors and the angiographic findings were analyzed . Patients as well as local physicians were informed on the need to treat the important risk factors . This approach ensures that at least all of out patients with documented CAD receive the appropriate preventional recommendations and treatment . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm
[ "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O" ]
In recent years we identified numerous cardiovascular risk factors and had been able to reduce cardiovascular events by a variety of different interventions . There is no question that we can improve the course of coronary artery disease ( CAD ) in patients with a high-risk profile by modifying these factors . Despite this knowledge , many patients with known CAD or myocardial infarction are not treated for secondary prevention as recommended by well established guidelines . In order to improve secondary prevention in our patients we started a project , the so called " Marburg CAD Prevention Project " . By this we combine our computer data base of the CAD preventional routine laboratory with the computer program CARDDAS . Individual risk factors and the angiographic findings were analyzed . Patients as well as local physicians were informed on the need to treat the important risk factors . This approach ensures that at least all of out patients with documented CAD receive the appropriate preventional recommendations and treatment .
[ "In", "recent", "years", "we", "identified", "numerous", "cardiovascular", "risk", "factors", "and", "had", "been", "able", "to", "reduce", "cardiovascular", "events", "by", "a", "variety", "of", "different", "interventions", ".", "There", "is", "no", "question", "that", "we", "can", "improve", "the", "course", "of", "coronary", "artery", "disease", "(", "CAD", ")", "in", "patients", "with", "a", "high", "-", "risk", "profile", "by", "modifying", "these", "factors", ".", "Despite", "this", "knowledge", ",", "many", "patients", "with", "known", "CAD", "or", "myocardial", "infarction", "are", "not", "treated", "for", "secondary", "prevention", "as", "recommended", "by", "well", "established", "guidelines", ".", "In", "order", "to", "improve", "secondary", "prevention", "in", "our", "patients", "we", "started", "a", "project", ",", "the", "so", "called", "\"", "Marburg", "CAD", "Prevention", "Project", "\"", ".", "By", "this", "we", "combine", "our", "computer", "data", "base", "of", "the", "CAD", "preventional", "routine", "laboratory", "with", "the", "computer", "program", "CARDDAS", ".", "Individual", "risk", "factors", "and", "the", "angiographic", "findings", "were", "analyzed", ".", "Patients", "as", "well", "as", "local", "physicians", "were", "informed", "on", "the", "need", "to", "treat", "the", "important", "risk", "factors", ".", "This", "approach", "ensures", "that", "at", "least", "all", "of", "out", "patients", "with", "documented", "CAD", "receive", "the", "appropriate", "preventional", "recommendations", "and", "treatment", "." ]
[ "umlsterm" ]
risk factors is an umlsterm, coronary artery disease is an umlsterm, CAD is an umlsterm, patients is an umlsterm, knowledge is an umlsterm, patients is an umlsterm, CAD is an umlsterm, myocardial infarction is an umlsterm, secondary is an umlsterm, prevention is an umlsterm, guidelines is an umlsterm, secondary is an umlsterm, prevention is an umlsterm, patients is an umlsterm, Marburg is an umlsterm, CAD is an umlsterm, Prevention is an umlsterm, computer is an umlsterm, data base is an umlsterm, CAD is an umlsterm, laboratory is an umlsterm, computer program is an umlsterm, risk factors is an umlsterm, findings is an umlsterm, Patients is an umlsterm, physicians is an umlsterm, need is an umlsterm, risk factors is an umlsterm, all is an umlsterm, patients is an umlsterm, CAD is an umlsterm, recommendations is an umlsterm, treatment is an umlsterm
Herz.00250113.eng.abstr_task1
Sentence: In recent years we identified numerous cardiovascular risk factors and had been able to reduce cardiovascular events by a variety of different interventions . There is no question that we can improve the course of coronary artery disease ( CAD ) in patients with a high-risk profile by modifying these factors . Despite this knowledge , many patients with known CAD or myocardial infarction are not treated for secondary prevention as recommended by well established guidelines . In order to improve secondary prevention in our patients we started a project , the so called " Marburg CAD Prevention Project " . By this we combine our computer data base of the CAD preventional routine laboratory with the computer program CARDDAS . Individual risk factors and the angiographic findings were analyzed . Patients as well as local physicians were informed on the need to treat the important risk factors . This approach ensures that at least all of out patients with documented CAD receive the appropriate preventional recommendations and treatment . Instructions: please typing these entity words according to sentence: risk factors, coronary artery disease, CAD, patients, knowledge, patients, CAD, myocardial infarction, secondary, prevention, guidelines, secondary, prevention, patients, Marburg, CAD, Prevention, computer, data base, CAD, laboratory, computer program, risk factors, findings, Patients, physicians, need, risk factors, all, patients, CAD, recommendations, treatment Options: umlsterm
[ "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O" ]
In recent years we identified numerous cardiovascular risk factors and had been able to reduce cardiovascular events by a variety of different interventions . There is no question that we can improve the course of coronary artery disease ( CAD ) in patients with a high-risk profile by modifying these factors . Despite this knowledge , many patients with known CAD or myocardial infarction are not treated for secondary prevention as recommended by well established guidelines . In order to improve secondary prevention in our patients we started a project , the so called " Marburg CAD Prevention Project " . By this we combine our computer data base of the CAD preventional routine laboratory with the computer program CARDDAS . Individual risk factors and the angiographic findings were analyzed . Patients as well as local physicians were informed on the need to treat the important risk factors . This approach ensures that at least all of out patients with documented CAD receive the appropriate preventional recommendations and treatment .
[ "In", "recent", "years", "we", "identified", "numerous", "cardiovascular", "risk", "factors", "and", "had", "been", "able", "to", "reduce", "cardiovascular", "events", "by", "a", "variety", "of", "different", "interventions", ".", "There", "is", "no", "question", "that", "we", "can", "improve", "the", "course", "of", "coronary", "artery", "disease", "(", "CAD", ")", "in", "patients", "with", "a", "high", "-", "risk", "profile", "by", "modifying", "these", "factors", ".", "Despite", "this", "knowledge", ",", "many", "patients", "with", "known", "CAD", "or", "myocardial", "infarction", "are", "not", "treated", "for", "secondary", "prevention", "as", "recommended", "by", "well", "established", "guidelines", ".", "In", "order", "to", "improve", "secondary", "prevention", "in", "our", "patients", "we", "started", "a", "project", ",", "the", "so", "called", "\"", "Marburg", "CAD", "Prevention", "Project", "\"", ".", "By", "this", "we", "combine", "our", "computer", "data", "base", "of", "the", "CAD", "preventional", "routine", "laboratory", "with", "the", "computer", "program", "CARDDAS", ".", "Individual", "risk", "factors", "and", "the", "angiographic", "findings", "were", "analyzed", ".", "Patients", "as", "well", "as", "local", "physicians", "were", "informed", "on", "the", "need", "to", "treat", "the", "important", "risk", "factors", ".", "This", "approach", "ensures", "that", "at", "least", "all", "of", "out", "patients", "with", "documented", "CAD", "receive", "the", "appropriate", "preventional", "recommendations", "and", "treatment", "." ]
[ "umlsterm" ]
risk factors, coronary artery disease, CAD, patients, knowledge, patients, CAD, myocardial infarction, secondary, prevention, guidelines, secondary, prevention, patients, Marburg, CAD, Prevention, computer, data base, CAD, laboratory, computer program, risk factors, findings, Patients, physicians, need, risk factors, all, patients, CAD, recommendations, treatment
Herz.00250113.eng.abstr_task2
Sentence: In recent years we identified numerous cardiovascular risk factors and had been able to reduce cardiovascular events by a variety of different interventions . There is no question that we can improve the course of coronary artery disease ( CAD ) in patients with a high-risk profile by modifying these factors . Despite this knowledge , many patients with known CAD or myocardial infarction are not treated for secondary prevention as recommended by well established guidelines . In order to improve secondary prevention in our patients we started a project , the so called " Marburg CAD Prevention Project " . By this we combine our computer data base of the CAD preventional routine laboratory with the computer program CARDDAS . Individual risk factors and the angiographic findings were analyzed . Patients as well as local physicians were informed on the need to treat the important risk factors . This approach ensures that at least all of out patients with documented CAD receive the appropriate preventional recommendations and treatment . Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O" ]
In recent years we identified numerous cardiovascular risk factors and had been able to reduce cardiovascular events by a variety of different interventions . There is no question that we can improve the course of coronary artery disease ( CAD ) in patients with a high-risk profile by modifying these factors . Despite this knowledge , many patients with known CAD or myocardial infarction are not treated for secondary prevention as recommended by well established guidelines . In order to improve secondary prevention in our patients we started a project , the so called " Marburg CAD Prevention Project " . By this we combine our computer data base of the CAD preventional routine laboratory with the computer program CARDDAS . Individual risk factors and the angiographic findings were analyzed . Patients as well as local physicians were informed on the need to treat the important risk factors . This approach ensures that at least all of out patients with documented CAD receive the appropriate preventional recommendations and treatment .
[ "In", "recent", "years", "we", "identified", "numerous", "cardiovascular", "risk", "factors", "and", "had", "been", "able", "to", "reduce", "cardiovascular", "events", "by", "a", "variety", "of", "different", "interventions", ".", "There", "is", "no", "question", "that", "we", "can", "improve", "the", "course", "of", "coronary", "artery", "disease", "(", "CAD", ")", "in", "patients", "with", "a", "high", "-", "risk", "profile", "by", "modifying", "these", "factors", ".", "Despite", "this", "knowledge", ",", "many", "patients", "with", "known", "CAD", "or", "myocardial", "infarction", "are", "not", "treated", "for", "secondary", "prevention", "as", "recommended", "by", "well", "established", "guidelines", ".", "In", "order", "to", "improve", "secondary", "prevention", "in", "our", "patients", "we", "started", "a", "project", ",", "the", "so", "called", "\"", "Marburg", "CAD", "Prevention", "Project", "\"", ".", "By", "this", "we", "combine", "our", "computer", "data", "base", "of", "the", "CAD", "preventional", "routine", "laboratory", "with", "the", "computer", "program", "CARDDAS", ".", "Individual", "risk", "factors", "and", "the", "angiographic", "findings", "were", "analyzed", ".", "Patients", "as", "well", "as", "local", "physicians", "were", "informed", "on", "the", "need", "to", "treat", "the", "important", "risk", "factors", ".", "This", "approach", "ensures", "that", "at", "least", "all", "of", "out", "patients", "with", "documented", "CAD", "receive", "the", "appropriate", "preventional", "recommendations", "and", "treatment", "." ]
[ "umlsterm" ]
Cook is an umlsterm, patients is an umlsterm, patent ductus arteriosus is an umlsterm
ZfuerKardiologie.90881006.eng.abstr_task0
Sentence: Purpose : To describe the radiographic appearance of the Gianturco and the Cook detachable coils and present the clinical results in patients who underwent transcatheter closure of patent ductus arteriosus . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O" ]
Purpose : To describe the radiographic appearance of the Gianturco and the Cook detachable coils and present the clinical results in patients who underwent transcatheter closure of patent ductus arteriosus .
[ "Purpose", ":", "To", "describe", "the", "radiographic", "appearance", "of", "the", "Gianturco", "and", "the", "Cook", "detachable", "coils", "and", "present", "the", "clinical", "results", "in", "patients", "who", "underwent", "transcatheter", "closure", "of", "patent", "ductus", "arteriosus", "." ]
[ "umlsterm" ]
Cook is an umlsterm, patients is an umlsterm, patent ductus arteriosus is an umlsterm
ZfuerKardiologie.90881006.eng.abstr_task1
Sentence: Purpose : To describe the radiographic appearance of the Gianturco and the Cook detachable coils and present the clinical results in patients who underwent transcatheter closure of patent ductus arteriosus . Instructions: please typing these entity words according to sentence: Cook, patients, patent ductus arteriosus Options: umlsterm
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O" ]
Purpose : To describe the radiographic appearance of the Gianturco and the Cook detachable coils and present the clinical results in patients who underwent transcatheter closure of patent ductus arteriosus .
[ "Purpose", ":", "To", "describe", "the", "radiographic", "appearance", "of", "the", "Gianturco", "and", "the", "Cook", "detachable", "coils", "and", "present", "the", "clinical", "results", "in", "patients", "who", "underwent", "transcatheter", "closure", "of", "patent", "ductus", "arteriosus", "." ]
[ "umlsterm" ]
Cook, patients, patent ductus arteriosus
ZfuerKardiologie.90881006.eng.abstr_task2
Sentence: Purpose : To describe the radiographic appearance of the Gianturco and the Cook detachable coils and present the clinical results in patients who underwent transcatheter closure of patent ductus arteriosus . Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O" ]
Purpose : To describe the radiographic appearance of the Gianturco and the Cook detachable coils and present the clinical results in patients who underwent transcatheter closure of patent ductus arteriosus .
[ "Purpose", ":", "To", "describe", "the", "radiographic", "appearance", "of", "the", "Gianturco", "and", "the", "Cook", "detachable", "coils", "and", "present", "the", "clinical", "results", "in", "patients", "who", "underwent", "transcatheter", "closure", "of", "patent", "ductus", "arteriosus", "." ]
[ "umlsterm" ]
injuries is an umlsterm, shoulder is an umlsterm, relative is an umlsterm, standard is an umlsterm, diagnostic is an umlsterm, therapeutic is an umlsterm, measures is an umlsterm, rehabilitation is an umlsterm, Diagnostic is an umlsterm, therapeutic is an umlsterm, injuries is an umlsterm, humerus is an umlsterm, dislocation is an umlsterm, fractures is an umlsterm, dislocation is an umlsterm, fractures is an umlsterm, rotator cuff is an umlsterm, posterior is an umlsterm, dislocation is an umlsterm, fractures is an umlsterm, fractures is an umlsterm, fractures is an umlsterm, dislocations is an umlsterm, awareness is an umlsterm, diagnostic is an umlsterm, therapeutic aspects is an umlsterm, treatment protocols is an umlsterm
DerOrthopaede.80270002.eng.abstr_task0
Sentence: Complex injuries of the shoulder require differentiated management . Interestingly there is a relative lag of warranted information on this subject . Generally the different lesions are discussed separately . However it is not acceptable to simply add the standard diagnostic and therapeutic measures , because major tactic , strategic and rehabilitation incompatibilities could occur . Diagnostic and therapeutic difficulties are frequent for the following injuries : complex proximal humerus dislocation fractures , dislocation fractures with associated lesions of the rotator cuff , posterior dislocation fractures , peri- and intraarticular segmental fractures and fractures or dislocations associated with major neurovascular lesions . Increased awareness of the most relevant diagnostic and therapeutic aspects should contribute to optimize treatment protocols . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm
[ "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O" ]
Complex injuries of the shoulder require differentiated management . Interestingly there is a relative lag of warranted information on this subject . Generally the different lesions are discussed separately . However it is not acceptable to simply add the standard diagnostic and therapeutic measures , because major tactic , strategic and rehabilitation incompatibilities could occur . Diagnostic and therapeutic difficulties are frequent for the following injuries : complex proximal humerus dislocation fractures , dislocation fractures with associated lesions of the rotator cuff , posterior dislocation fractures , peri- and intraarticular segmental fractures and fractures or dislocations associated with major neurovascular lesions . Increased awareness of the most relevant diagnostic and therapeutic aspects should contribute to optimize treatment protocols .
[ "Complex", "injuries", "of", "the", "shoulder", "require", "differentiated", "management", ".", "Interestingly", "there", "is", "a", "relative", "lag", "of", "warranted", "information", "on", "this", "subject", ".", "Generally", "the", "different", "lesions", "are", "discussed", "separately", ".", "However", "it", "is", "not", "acceptable", "to", "simply", "add", "the", "standard", "diagnostic", "and", "therapeutic", "measures", ",", "because", "major", "tactic", ",", "strategic", "and", "rehabilitation", "incompatibilities", "could", "occur", ".", "Diagnostic", "and", "therapeutic", "difficulties", "are", "frequent", "for", "the", "following", "injuries", ":", "complex", "proximal", "humerus", "dislocation", "fractures", ",", "dislocation", "fractures", "with", "associated", "lesions", "of", "the", "rotator", "cuff", ",", "posterior", "dislocation", "fractures", ",", "peri-", "and", "intraarticular", "segmental", "fractures", "and", "fractures", "or", "dislocations", "associated", "with", "major", "neurovascular", "lesions", ".", "Increased", "awareness", "of", "the", "most", "relevant", "diagnostic", "and", "therapeutic", "aspects", "should", "contribute", "to", "optimize", "treatment", "protocols", "." ]
[ "umlsterm" ]
injuries is an umlsterm, shoulder is an umlsterm, relative is an umlsterm, standard is an umlsterm, diagnostic is an umlsterm, therapeutic is an umlsterm, measures is an umlsterm, rehabilitation is an umlsterm, Diagnostic is an umlsterm, therapeutic is an umlsterm, injuries is an umlsterm, humerus is an umlsterm, dislocation is an umlsterm, fractures is an umlsterm, dislocation is an umlsterm, fractures is an umlsterm, rotator cuff is an umlsterm, posterior is an umlsterm, dislocation is an umlsterm, fractures is an umlsterm, fractures is an umlsterm, fractures is an umlsterm, dislocations is an umlsterm, awareness is an umlsterm, diagnostic is an umlsterm, therapeutic aspects is an umlsterm, treatment protocols is an umlsterm
DerOrthopaede.80270002.eng.abstr_task1
Sentence: Complex injuries of the shoulder require differentiated management . Interestingly there is a relative lag of warranted information on this subject . Generally the different lesions are discussed separately . However it is not acceptable to simply add the standard diagnostic and therapeutic measures , because major tactic , strategic and rehabilitation incompatibilities could occur . Diagnostic and therapeutic difficulties are frequent for the following injuries : complex proximal humerus dislocation fractures , dislocation fractures with associated lesions of the rotator cuff , posterior dislocation fractures , peri- and intraarticular segmental fractures and fractures or dislocations associated with major neurovascular lesions . Increased awareness of the most relevant diagnostic and therapeutic aspects should contribute to optimize treatment protocols . Instructions: please typing these entity words according to sentence: injuries, shoulder, relative, standard, diagnostic, therapeutic, measures, rehabilitation, Diagnostic, therapeutic, injuries, humerus, dislocation, fractures, dislocation, fractures, rotator cuff, posterior, dislocation, fractures, fractures, fractures, dislocations, awareness, diagnostic, therapeutic aspects, treatment protocols Options: umlsterm
[ "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O" ]
Complex injuries of the shoulder require differentiated management . Interestingly there is a relative lag of warranted information on this subject . Generally the different lesions are discussed separately . However it is not acceptable to simply add the standard diagnostic and therapeutic measures , because major tactic , strategic and rehabilitation incompatibilities could occur . Diagnostic and therapeutic difficulties are frequent for the following injuries : complex proximal humerus dislocation fractures , dislocation fractures with associated lesions of the rotator cuff , posterior dislocation fractures , peri- and intraarticular segmental fractures and fractures or dislocations associated with major neurovascular lesions . Increased awareness of the most relevant diagnostic and therapeutic aspects should contribute to optimize treatment protocols .
[ "Complex", "injuries", "of", "the", "shoulder", "require", "differentiated", "management", ".", "Interestingly", "there", "is", "a", "relative", "lag", "of", "warranted", "information", "on", "this", "subject", ".", "Generally", "the", "different", "lesions", "are", "discussed", "separately", ".", "However", "it", "is", "not", "acceptable", "to", "simply", "add", "the", "standard", "diagnostic", "and", "therapeutic", "measures", ",", "because", "major", "tactic", ",", "strategic", "and", "rehabilitation", "incompatibilities", "could", "occur", ".", "Diagnostic", "and", "therapeutic", "difficulties", "are", "frequent", "for", "the", "following", "injuries", ":", "complex", "proximal", "humerus", "dislocation", "fractures", ",", "dislocation", "fractures", "with", "associated", "lesions", "of", "the", "rotator", "cuff", ",", "posterior", "dislocation", "fractures", ",", "peri-", "and", "intraarticular", "segmental", "fractures", "and", "fractures", "or", "dislocations", "associated", "with", "major", "neurovascular", "lesions", ".", "Increased", "awareness", "of", "the", "most", "relevant", "diagnostic", "and", "therapeutic", "aspects", "should", "contribute", "to", "optimize", "treatment", "protocols", "." ]
[ "umlsterm" ]
injuries, shoulder, relative, standard, diagnostic, therapeutic, measures, rehabilitation, Diagnostic, therapeutic, injuries, humerus, dislocation, fractures, dislocation, fractures, rotator cuff, posterior, dislocation, fractures, fractures, fractures, dislocations, awareness, diagnostic, therapeutic aspects, treatment protocols
DerOrthopaede.80270002.eng.abstr_task2
Sentence: Complex injuries of the shoulder require differentiated management . Interestingly there is a relative lag of warranted information on this subject . Generally the different lesions are discussed separately . However it is not acceptable to simply add the standard diagnostic and therapeutic measures , because major tactic , strategic and rehabilitation incompatibilities could occur . Diagnostic and therapeutic difficulties are frequent for the following injuries : complex proximal humerus dislocation fractures , dislocation fractures with associated lesions of the rotator cuff , posterior dislocation fractures , peri- and intraarticular segmental fractures and fractures or dislocations associated with major neurovascular lesions . Increased awareness of the most relevant diagnostic and therapeutic aspects should contribute to optimize treatment protocols . Instructions: please extract entity words from the input sentence
[ "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O" ]
Complex injuries of the shoulder require differentiated management . Interestingly there is a relative lag of warranted information on this subject . Generally the different lesions are discussed separately . However it is not acceptable to simply add the standard diagnostic and therapeutic measures , because major tactic , strategic and rehabilitation incompatibilities could occur . Diagnostic and therapeutic difficulties are frequent for the following injuries : complex proximal humerus dislocation fractures , dislocation fractures with associated lesions of the rotator cuff , posterior dislocation fractures , peri- and intraarticular segmental fractures and fractures or dislocations associated with major neurovascular lesions . Increased awareness of the most relevant diagnostic and therapeutic aspects should contribute to optimize treatment protocols .
[ "Complex", "injuries", "of", "the", "shoulder", "require", "differentiated", "management", ".", "Interestingly", "there", "is", "a", "relative", "lag", "of", "warranted", "information", "on", "this", "subject", ".", "Generally", "the", "different", "lesions", "are", "discussed", "separately", ".", "However", "it", "is", "not", "acceptable", "to", "simply", "add", "the", "standard", "diagnostic", "and", "therapeutic", "measures", ",", "because", "major", "tactic", ",", "strategic", "and", "rehabilitation", "incompatibilities", "could", "occur", ".", "Diagnostic", "and", "therapeutic", "difficulties", "are", "frequent", "for", "the", "following", "injuries", ":", "complex", "proximal", "humerus", "dislocation", "fractures", ",", "dislocation", "fractures", "with", "associated", "lesions", "of", "the", "rotator", "cuff", ",", "posterior", "dislocation", "fractures", ",", "peri-", "and", "intraarticular", "segmental", "fractures", "and", "fractures", "or", "dislocations", "associated", "with", "major", "neurovascular", "lesions", ".", "Increased", "awareness", "of", "the", "most", "relevant", "diagnostic", "and", "therapeutic", "aspects", "should", "contribute", "to", "optimize", "treatment", "protocols", "." ]
[ "umlsterm" ]
knowledge is an umlsterm, community is an umlsterm, aim is an umlsterm, education is an umlsterm, World Wide Web is an umlsterm, WWW is an umlsterm, education is an umlsterm, use is an umlsterm, cultural is an umlsterm, knowledge is an umlsterm, Adaptation is an umlsterm, technology - based is an umlsterm, technology is an umlsterm, students is an umlsterm, architecture is an umlsterm, programs is an umlsterm, role is an umlsterm, costs is an umlsterm
DerRadiologe.00400388.eng.abstr_task0
Sentence: A world wide homogenous level of knowledge for all members of an expert community is the proposed aim of academic education . The potential of the World Wide Web ( WWW ) with respect to under- and postgraduate education maybe accomplished if its use will become a definite part of cultural skills . Additionally , the process of simple collection of information should be added by the process of gaining knowledge and experience . Adaptation to the target group and a high degree of interactivity are the two main characteristics of high-quality technology-based learning materials . Considering both most of the web-ressources show deficits . Instructional design as well as information technology have means to overcome these deficits . With respect to the didactic principles of materials for beginners and advanced students , the architecture of computerised learning programs plays a significant role . However , costs to develop high-level learning materials is extremely high . Therefore it is necessary , to use synergetic effects with other digitized clinical and scientific materials . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm
[ "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
A world wide homogenous level of knowledge for all members of an expert community is the proposed aim of academic education . The potential of the World Wide Web ( WWW ) with respect to under- and postgraduate education maybe accomplished if its use will become a definite part of cultural skills . Additionally , the process of simple collection of information should be added by the process of gaining knowledge and experience . Adaptation to the target group and a high degree of interactivity are the two main characteristics of high-quality technology-based learning materials . Considering both most of the web-ressources show deficits . Instructional design as well as information technology have means to overcome these deficits . With respect to the didactic principles of materials for beginners and advanced students , the architecture of computerised learning programs plays a significant role . However , costs to develop high-level learning materials is extremely high . Therefore it is necessary , to use synergetic effects with other digitized clinical and scientific materials .
[ "A", "world", "wide", "homogenous", "level", "of", "knowledge", "for", "all", "members", "of", "an", "expert", "community", "is", "the", "proposed", "aim", "of", "academic", "education", ".", "The", "potential", "of", "the", "World", "Wide", "Web", "(", "WWW", ")", "with", "respect", "to", "under-", "and", "postgraduate", "education", "maybe", "accomplished", "if", "its", "use", "will", "become", "a", "definite", "part", "of", "cultural", "skills", ".", "Additionally", ",", "the", "process", "of", "simple", "collection", "of", "information", "should", "be", "added", "by", "the", "process", "of", "gaining", "knowledge", "and", "experience", ".", "Adaptation", "to", "the", "target", "group", "and", "a", "high", "degree", "of", "interactivity", "are", "the", "two", "main", "characteristics", "of", "high", "-", "quality", "technology", "-", "based", "learning", "materials", ".", "Considering", "both", "most", "of", "the", "web", "-", "ressources", "show", "deficits", ".", "Instructional", "design", "as", "well", "as", "information", "technology", "have", "means", "to", "overcome", "these", "deficits", ".", "With", "respect", "to", "the", "didactic", "principles", "of", "materials", "for", "beginners", "and", "advanced", "students", ",", "the", "architecture", "of", "computerised", "learning", "programs", "plays", "a", "significant", "role", ".", "However", ",", "costs", "to", "develop", "high", "-", "level", "learning", "materials", "is", "extremely", "high", ".", "Therefore", "it", "is", "necessary", ",", "to", "use", "synergetic", "effects", "with", "other", "digitized", "clinical", "and", "scientific", "materials", "." ]
[ "umlsterm" ]
knowledge is an umlsterm, community is an umlsterm, aim is an umlsterm, education is an umlsterm, World Wide Web is an umlsterm, WWW is an umlsterm, education is an umlsterm, use is an umlsterm, cultural is an umlsterm, knowledge is an umlsterm, Adaptation is an umlsterm, technology - based is an umlsterm, technology is an umlsterm, students is an umlsterm, architecture is an umlsterm, programs is an umlsterm, role is an umlsterm, costs is an umlsterm
DerRadiologe.00400388.eng.abstr_task1
Sentence: A world wide homogenous level of knowledge for all members of an expert community is the proposed aim of academic education . The potential of the World Wide Web ( WWW ) with respect to under- and postgraduate education maybe accomplished if its use will become a definite part of cultural skills . Additionally , the process of simple collection of information should be added by the process of gaining knowledge and experience . Adaptation to the target group and a high degree of interactivity are the two main characteristics of high-quality technology-based learning materials . Considering both most of the web-ressources show deficits . Instructional design as well as information technology have means to overcome these deficits . With respect to the didactic principles of materials for beginners and advanced students , the architecture of computerised learning programs plays a significant role . However , costs to develop high-level learning materials is extremely high . Therefore it is necessary , to use synergetic effects with other digitized clinical and scientific materials . Instructions: please typing these entity words according to sentence: knowledge, community, aim, education, World Wide Web, WWW, education, use, cultural, knowledge, Adaptation, technology - based, technology, students, architecture, programs, role, costs Options: umlsterm
[ "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
A world wide homogenous level of knowledge for all members of an expert community is the proposed aim of academic education . The potential of the World Wide Web ( WWW ) with respect to under- and postgraduate education maybe accomplished if its use will become a definite part of cultural skills . Additionally , the process of simple collection of information should be added by the process of gaining knowledge and experience . Adaptation to the target group and a high degree of interactivity are the two main characteristics of high-quality technology-based learning materials . Considering both most of the web-ressources show deficits . Instructional design as well as information technology have means to overcome these deficits . With respect to the didactic principles of materials for beginners and advanced students , the architecture of computerised learning programs plays a significant role . However , costs to develop high-level learning materials is extremely high . Therefore it is necessary , to use synergetic effects with other digitized clinical and scientific materials .
[ "A", "world", "wide", "homogenous", "level", "of", "knowledge", "for", "all", "members", "of", "an", "expert", "community", "is", "the", "proposed", "aim", "of", "academic", "education", ".", "The", "potential", "of", "the", "World", "Wide", "Web", "(", "WWW", ")", "with", "respect", "to", "under-", "and", "postgraduate", "education", "maybe", "accomplished", "if", "its", "use", "will", "become", "a", "definite", "part", "of", "cultural", "skills", ".", "Additionally", ",", "the", "process", "of", "simple", "collection", "of", "information", "should", "be", "added", "by", "the", "process", "of", "gaining", "knowledge", "and", "experience", ".", "Adaptation", "to", "the", "target", "group", "and", "a", "high", "degree", "of", "interactivity", "are", "the", "two", "main", "characteristics", "of", "high", "-", "quality", "technology", "-", "based", "learning", "materials", ".", "Considering", "both", "most", "of", "the", "web", "-", "ressources", "show", "deficits", ".", "Instructional", "design", "as", "well", "as", "information", "technology", "have", "means", "to", "overcome", "these", "deficits", ".", "With", "respect", "to", "the", "didactic", "principles", "of", "materials", "for", "beginners", "and", "advanced", "students", ",", "the", "architecture", "of", "computerised", "learning", "programs", "plays", "a", "significant", "role", ".", "However", ",", "costs", "to", "develop", "high", "-", "level", "learning", "materials", "is", "extremely", "high", ".", "Therefore", "it", "is", "necessary", ",", "to", "use", "synergetic", "effects", "with", "other", "digitized", "clinical", "and", "scientific", "materials", "." ]
[ "umlsterm" ]
knowledge, community, aim, education, World Wide Web, WWW, education, use, cultural, knowledge, Adaptation, technology - based, technology, students, architecture, programs, role, costs
DerRadiologe.00400388.eng.abstr_task2
Sentence: A world wide homogenous level of knowledge for all members of an expert community is the proposed aim of academic education . The potential of the World Wide Web ( WWW ) with respect to under- and postgraduate education maybe accomplished if its use will become a definite part of cultural skills . Additionally , the process of simple collection of information should be added by the process of gaining knowledge and experience . Adaptation to the target group and a high degree of interactivity are the two main characteristics of high-quality technology-based learning materials . Considering both most of the web-ressources show deficits . Instructional design as well as information technology have means to overcome these deficits . With respect to the didactic principles of materials for beginners and advanced students , the architecture of computerised learning programs plays a significant role . However , costs to develop high-level learning materials is extremely high . Therefore it is necessary , to use synergetic effects with other digitized clinical and scientific materials . Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
A world wide homogenous level of knowledge for all members of an expert community is the proposed aim of academic education . The potential of the World Wide Web ( WWW ) with respect to under- and postgraduate education maybe accomplished if its use will become a definite part of cultural skills . Additionally , the process of simple collection of information should be added by the process of gaining knowledge and experience . Adaptation to the target group and a high degree of interactivity are the two main characteristics of high-quality technology-based learning materials . Considering both most of the web-ressources show deficits . Instructional design as well as information technology have means to overcome these deficits . With respect to the didactic principles of materials for beginners and advanced students , the architecture of computerised learning programs plays a significant role . However , costs to develop high-level learning materials is extremely high . Therefore it is necessary , to use synergetic effects with other digitized clinical and scientific materials .
[ "A", "world", "wide", "homogenous", "level", "of", "knowledge", "for", "all", "members", "of", "an", "expert", "community", "is", "the", "proposed", "aim", "of", "academic", "education", ".", "The", "potential", "of", "the", "World", "Wide", "Web", "(", "WWW", ")", "with", "respect", "to", "under-", "and", "postgraduate", "education", "maybe", "accomplished", "if", "its", "use", "will", "become", "a", "definite", "part", "of", "cultural", "skills", ".", "Additionally", ",", "the", "process", "of", "simple", "collection", "of", "information", "should", "be", "added", "by", "the", "process", "of", "gaining", "knowledge", "and", "experience", ".", "Adaptation", "to", "the", "target", "group", "and", "a", "high", "degree", "of", "interactivity", "are", "the", "two", "main", "characteristics", "of", "high", "-", "quality", "technology", "-", "based", "learning", "materials", ".", "Considering", "both", "most", "of", "the", "web", "-", "ressources", "show", "deficits", ".", "Instructional", "design", "as", "well", "as", "information", "technology", "have", "means", "to", "overcome", "these", "deficits", ".", "With", "respect", "to", "the", "didactic", "principles", "of", "materials", "for", "beginners", "and", "advanced", "students", ",", "the", "architecture", "of", "computerised", "learning", "programs", "plays", "a", "significant", "role", ".", "However", ",", "costs", "to", "develop", "high", "-", "level", "learning", "materials", "is", "extremely", "high", ".", "Therefore", "it", "is", "necessary", ",", "to", "use", "synergetic", "effects", "with", "other", "digitized", "clinical", "and", "scientific", "materials", "." ]
[ "umlsterm" ]
MEN1 is a Gene, MEN1 is a Gene, MEN1 is a Gene, MEN1 is a Gene, MEN1 is a Gene, MEN1 is a Gene, MEN1 is a Gene
376_task0
Sentence: Homozygotes for the autosomal dominant neoplasia syndrome (MEN1). Families in which both parents are heterozygotes for the same autosomal dominant neoplasia syndrome are extremely unusual. Recently, we had the unique opportunity to evaluate three symptomatic siblings from the union between two unrelated individuals affected by multiple endocrine neoplasia type 1 (MEN1). When the three siblings and their parents and relatives were genotyped for 12 markers tightly linked to the MEN1 locus, at 11q13, two of the siblings were found to be homozygotes, and one a heterozygote, for MEN1. With regard to the MEN1 syndrome, no phenotypic differences were observed between the two homozygotes and the heterozygotes. However, the two homozygotes showed unexplained infertility, which was not the case for any of the heterozygotes. Thus, MEN1 appears to be a disease with complete dominance, and the presence of two MEN1 alleles with mutations of the type that occur constitutionally may be insufficient for tumor development. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Gene
[ "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "O", "O", "O", "O", "O", "B-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Homozygotes for the autosomal dominant neoplasia syndrome (MEN1). Families in which both parents are heterozygotes for the same autosomal dominant neoplasia syndrome are extremely unusual. Recently, we had the unique opportunity to evaluate three symptomatic siblings from the union between two unrelated individuals affected by multiple endocrine neoplasia type 1 (MEN1). When the three siblings and their parents and relatives were genotyped for 12 markers tightly linked to the MEN1 locus, at 11q13, two of the siblings were found to be homozygotes, and one a heterozygote, for MEN1. With regard to the MEN1 syndrome, no phenotypic differences were observed between the two homozygotes and the heterozygotes. However, the two homozygotes showed unexplained infertility, which was not the case for any of the heterozygotes. Thus, MEN1 appears to be a disease with complete dominance, and the presence of two MEN1 alleles with mutations of the type that occur constitutionally may be insufficient for tumor development.
[ "Homozygotes", "for", "the", "autosomal", "dominant", "neoplasia", "syndrome", "(", "MEN1", ")", ".", "Families", "in", "which", "both", "parents", "are", "heterozygotes", "for", "the", "same", "autosomal", "dominant", "neoplasia", "syndrome", "are", "extremely", "unusual", ".", "Recently", ",", "we", "had", "the", "unique", "opportunity", "to", "evaluate", "three", "symptomatic", "siblings", "from", "the", "union", "between", "two", "unrelated", "individuals", "affected", "by", "multiple", "endocrine", "neoplasia", "type", "1", "(", "MEN1", ")", ".", "When", "the", "three", "siblings", "and", "their", "parents", "and", "relatives", "were", "genotyped", "for", "12", "markers", "tightly", "linked", "to", "the", "MEN1", "locus", ",", "at", "11q13", ",", "two", "of", "the", "siblings", "were", "found", "to", "be", "homozygotes", ",", "and", "one", "a", "heterozygote", ",", "for", "MEN1", ".", "With", "regard", "to", "the", "MEN1", "syndrome", ",", "no", "phenotypic", "differences", "were", "observed", "between", "the", "two", "homozygotes", "and", "the", "heterozygotes", ".", "However", ",", "the", "two", "homozygotes", "showed", "unexplained", "infertility", ",", "which", "was", "not", "the", "case", "for", "any", "of", "the", "heterozygotes", ".", "Thus", ",", "MEN1", "appears", "to", "be", "a", "disease", "with", "complete", "dominance", ",", "and", "the", "presence", "of", "two", "MEN1", "alleles", "with", "mutations", "of", "the", "type", "that", "occur", "constitutionally", "may", "be", "insufficient", "for", "tumor", "development", ".", "\n" ]
[ "Gene" ]
MEN1 is a Gene, MEN1 is a Gene, MEN1 is a Gene, MEN1 is a Gene, MEN1 is a Gene, MEN1 is a Gene, MEN1 is a Gene
376_task1
Sentence: Homozygotes for the autosomal dominant neoplasia syndrome (MEN1). Families in which both parents are heterozygotes for the same autosomal dominant neoplasia syndrome are extremely unusual. Recently, we had the unique opportunity to evaluate three symptomatic siblings from the union between two unrelated individuals affected by multiple endocrine neoplasia type 1 (MEN1). When the three siblings and their parents and relatives were genotyped for 12 markers tightly linked to the MEN1 locus, at 11q13, two of the siblings were found to be homozygotes, and one a heterozygote, for MEN1. With regard to the MEN1 syndrome, no phenotypic differences were observed between the two homozygotes and the heterozygotes. However, the two homozygotes showed unexplained infertility, which was not the case for any of the heterozygotes. Thus, MEN1 appears to be a disease with complete dominance, and the presence of two MEN1 alleles with mutations of the type that occur constitutionally may be insufficient for tumor development. Instructions: please typing these entity words according to sentence: MEN1, MEN1, MEN1, MEN1, MEN1, MEN1, MEN1 Options: Gene
[ "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "O", "O", "O", "O", "O", "B-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Homozygotes for the autosomal dominant neoplasia syndrome (MEN1). Families in which both parents are heterozygotes for the same autosomal dominant neoplasia syndrome are extremely unusual. Recently, we had the unique opportunity to evaluate three symptomatic siblings from the union between two unrelated individuals affected by multiple endocrine neoplasia type 1 (MEN1). When the three siblings and their parents and relatives were genotyped for 12 markers tightly linked to the MEN1 locus, at 11q13, two of the siblings were found to be homozygotes, and one a heterozygote, for MEN1. With regard to the MEN1 syndrome, no phenotypic differences were observed between the two homozygotes and the heterozygotes. However, the two homozygotes showed unexplained infertility, which was not the case for any of the heterozygotes. Thus, MEN1 appears to be a disease with complete dominance, and the presence of two MEN1 alleles with mutations of the type that occur constitutionally may be insufficient for tumor development.
[ "Homozygotes", "for", "the", "autosomal", "dominant", "neoplasia", "syndrome", "(", "MEN1", ")", ".", "Families", "in", "which", "both", "parents", "are", "heterozygotes", "for", "the", "same", "autosomal", "dominant", "neoplasia", "syndrome", "are", "extremely", "unusual", ".", "Recently", ",", "we", "had", "the", "unique", "opportunity", "to", "evaluate", "three", "symptomatic", "siblings", "from", "the", "union", "between", "two", "unrelated", "individuals", "affected", "by", "multiple", "endocrine", "neoplasia", "type", "1", "(", "MEN1", ")", ".", "When", "the", "three", "siblings", "and", "their", "parents", "and", "relatives", "were", "genotyped", "for", "12", "markers", "tightly", "linked", "to", "the", "MEN1", "locus", ",", "at", "11q13", ",", "two", "of", "the", "siblings", "were", "found", "to", "be", "homozygotes", ",", "and", "one", "a", "heterozygote", ",", "for", "MEN1", ".", "With", "regard", "to", "the", "MEN1", "syndrome", ",", "no", "phenotypic", "differences", "were", "observed", "between", "the", "two", "homozygotes", "and", "the", "heterozygotes", ".", "However", ",", "the", "two", "homozygotes", "showed", "unexplained", "infertility", ",", "which", "was", "not", "the", "case", "for", "any", "of", "the", "heterozygotes", ".", "Thus", ",", "MEN1", "appears", "to", "be", "a", "disease", "with", "complete", "dominance", ",", "and", "the", "presence", "of", "two", "MEN1", "alleles", "with", "mutations", "of", "the", "type", "that", "occur", "constitutionally", "may", "be", "insufficient", "for", "tumor", "development", ".", "\n" ]
[ "Gene" ]
MEN1, MEN1, MEN1, MEN1, MEN1, MEN1, MEN1
376_task2
Sentence: Homozygotes for the autosomal dominant neoplasia syndrome (MEN1). Families in which both parents are heterozygotes for the same autosomal dominant neoplasia syndrome are extremely unusual. Recently, we had the unique opportunity to evaluate three symptomatic siblings from the union between two unrelated individuals affected by multiple endocrine neoplasia type 1 (MEN1). When the three siblings and their parents and relatives were genotyped for 12 markers tightly linked to the MEN1 locus, at 11q13, two of the siblings were found to be homozygotes, and one a heterozygote, for MEN1. With regard to the MEN1 syndrome, no phenotypic differences were observed between the two homozygotes and the heterozygotes. However, the two homozygotes showed unexplained infertility, which was not the case for any of the heterozygotes. Thus, MEN1 appears to be a disease with complete dominance, and the presence of two MEN1 alleles with mutations of the type that occur constitutionally may be insufficient for tumor development. Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "O", "O", "O", "O", "O", "B-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Homozygotes for the autosomal dominant neoplasia syndrome (MEN1). Families in which both parents are heterozygotes for the same autosomal dominant neoplasia syndrome are extremely unusual. Recently, we had the unique opportunity to evaluate three symptomatic siblings from the union between two unrelated individuals affected by multiple endocrine neoplasia type 1 (MEN1). When the three siblings and their parents and relatives were genotyped for 12 markers tightly linked to the MEN1 locus, at 11q13, two of the siblings were found to be homozygotes, and one a heterozygote, for MEN1. With regard to the MEN1 syndrome, no phenotypic differences were observed between the two homozygotes and the heterozygotes. However, the two homozygotes showed unexplained infertility, which was not the case for any of the heterozygotes. Thus, MEN1 appears to be a disease with complete dominance, and the presence of two MEN1 alleles with mutations of the type that occur constitutionally may be insufficient for tumor development.
[ "Homozygotes", "for", "the", "autosomal", "dominant", "neoplasia", "syndrome", "(", "MEN1", ")", ".", "Families", "in", "which", "both", "parents", "are", "heterozygotes", "for", "the", "same", "autosomal", "dominant", "neoplasia", "syndrome", "are", "extremely", "unusual", ".", "Recently", ",", "we", "had", "the", "unique", "opportunity", "to", "evaluate", "three", "symptomatic", "siblings", "from", "the", "union", "between", "two", "unrelated", "individuals", "affected", "by", "multiple", "endocrine", "neoplasia", "type", "1", "(", "MEN1", ")", ".", "When", "the", "three", "siblings", "and", "their", "parents", "and", "relatives", "were", "genotyped", "for", "12", "markers", "tightly", "linked", "to", "the", "MEN1", "locus", ",", "at", "11q13", ",", "two", "of", "the", "siblings", "were", "found", "to", "be", "homozygotes", ",", "and", "one", "a", "heterozygote", ",", "for", "MEN1", ".", "With", "regard", "to", "the", "MEN1", "syndrome", ",", "no", "phenotypic", "differences", "were", "observed", "between", "the", "two", "homozygotes", "and", "the", "heterozygotes", ".", "However", ",", "the", "two", "homozygotes", "showed", "unexplained", "infertility", ",", "which", "was", "not", "the", "case", "for", "any", "of", "the", "heterozygotes", ".", "Thus", ",", "MEN1", "appears", "to", "be", "a", "disease", "with", "complete", "dominance", ",", "and", "the", "presence", "of", "two", "MEN1", "alleles", "with", "mutations", "of", "the", "type", "that", "occur", "constitutionally", "may", "be", "insufficient", "for", "tumor", "development", ".", "\n" ]
[ "Gene" ]
Therapiemoeglichkeiten is an umlsterm, Praxis is an umlsterm, Rehabilitation is an umlsterm, Balneotherapie is an umlsterm, Physiotherapie is an umlsterm, Frauenheilkunde is an umlsterm, Naturheilverfahren is an umlsterm, Schmerzverminderung is an umlsterm, Gewebebeeinflussung is an umlsterm
DerGynaekologe.00330018.ger.abstr_task0
Sentence: Als weitere Therapiemoeglichkeiten bieten sich dem Frauenarzt in Praxis , Klinik und in der Rehabilitation die Balneotherapie und die Physiotherapie als primaer oder ergaenzende Behandlungsmassnahmen an . In der Frauenheilkunde ist die Balneogynaekologie als ein Naturheilverfahren fester Bestandteil der therapeutischen Strategien geworden . Balneogynaekologische und physiotherapeutische Massnahmen sind indikationsbezogen vorwiegend als ergaenzende Massnahmen anzuwenden . Lediglich bei chronischen Zustaenden sowie akuten muskulaeren Verspannungen eignen sie sich vor allem zur Schmerzverminderung und positiven Gewebebeeinflussung als primaere Massnahmen . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm
[ "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O" ]
Als weitere Therapiemoeglichkeiten bieten sich dem Frauenarzt in Praxis , Klinik und in der Rehabilitation die Balneotherapie und die Physiotherapie als primaer oder ergaenzende Behandlungsmassnahmen an . In der Frauenheilkunde ist die Balneogynaekologie als ein Naturheilverfahren fester Bestandteil der therapeutischen Strategien geworden . Balneogynaekologische und physiotherapeutische Massnahmen sind indikationsbezogen vorwiegend als ergaenzende Massnahmen anzuwenden . Lediglich bei chronischen Zustaenden sowie akuten muskulaeren Verspannungen eignen sie sich vor allem zur Schmerzverminderung und positiven Gewebebeeinflussung als primaere Massnahmen .
[ "Als", "weitere", "Therapiemoeglichkeiten", "bieten", "sich", "dem", "Frauenarzt", "in", "Praxis", ",", "Klinik", "und", "in", "der", "Rehabilitation", "die", "Balneotherapie", "und", "die", "Physiotherapie", "als", "primaer", "oder", "ergaenzende", "Behandlungsmassnahmen", "an", ".", "In", "der", "Frauenheilkunde", "ist", "die", "Balneogynaekologie", "als", "ein", "Naturheilverfahren", "fester", "Bestandteil", "der", "therapeutischen", "Strategien", "geworden", ".", "Balneogynaekologische", "und", "physiotherapeutische", "Massnahmen", "sind", "indikationsbezogen", "vorwiegend", "als", "ergaenzende", "Massnahmen", "anzuwenden", ".", "Lediglich", "bei", "chronischen", "Zustaenden", "sowie", "akuten", "muskulaeren", "Verspannungen", "eignen", "sie", "sich", "vor", "allem", "zur", "Schmerzverminderung", "und", "positiven", "Gewebebeeinflussung", "als", "primaere", "Massnahmen", "." ]
[ "umlsterm" ]
Therapiemoeglichkeiten is an umlsterm, Praxis is an umlsterm, Rehabilitation is an umlsterm, Balneotherapie is an umlsterm, Physiotherapie is an umlsterm, Frauenheilkunde is an umlsterm, Naturheilverfahren is an umlsterm, Schmerzverminderung is an umlsterm, Gewebebeeinflussung is an umlsterm
DerGynaekologe.00330018.ger.abstr_task1
Sentence: Als weitere Therapiemoeglichkeiten bieten sich dem Frauenarzt in Praxis , Klinik und in der Rehabilitation die Balneotherapie und die Physiotherapie als primaer oder ergaenzende Behandlungsmassnahmen an . In der Frauenheilkunde ist die Balneogynaekologie als ein Naturheilverfahren fester Bestandteil der therapeutischen Strategien geworden . Balneogynaekologische und physiotherapeutische Massnahmen sind indikationsbezogen vorwiegend als ergaenzende Massnahmen anzuwenden . Lediglich bei chronischen Zustaenden sowie akuten muskulaeren Verspannungen eignen sie sich vor allem zur Schmerzverminderung und positiven Gewebebeeinflussung als primaere Massnahmen . Instructions: please typing these entity words according to sentence: Therapiemoeglichkeiten, Praxis, Rehabilitation, Balneotherapie, Physiotherapie, Frauenheilkunde, Naturheilverfahren, Schmerzverminderung, Gewebebeeinflussung Options: umlsterm
[ "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O" ]
Als weitere Therapiemoeglichkeiten bieten sich dem Frauenarzt in Praxis , Klinik und in der Rehabilitation die Balneotherapie und die Physiotherapie als primaer oder ergaenzende Behandlungsmassnahmen an . In der Frauenheilkunde ist die Balneogynaekologie als ein Naturheilverfahren fester Bestandteil der therapeutischen Strategien geworden . Balneogynaekologische und physiotherapeutische Massnahmen sind indikationsbezogen vorwiegend als ergaenzende Massnahmen anzuwenden . Lediglich bei chronischen Zustaenden sowie akuten muskulaeren Verspannungen eignen sie sich vor allem zur Schmerzverminderung und positiven Gewebebeeinflussung als primaere Massnahmen .
[ "Als", "weitere", "Therapiemoeglichkeiten", "bieten", "sich", "dem", "Frauenarzt", "in", "Praxis", ",", "Klinik", "und", "in", "der", "Rehabilitation", "die", "Balneotherapie", "und", "die", "Physiotherapie", "als", "primaer", "oder", "ergaenzende", "Behandlungsmassnahmen", "an", ".", "In", "der", "Frauenheilkunde", "ist", "die", "Balneogynaekologie", "als", "ein", "Naturheilverfahren", "fester", "Bestandteil", "der", "therapeutischen", "Strategien", "geworden", ".", "Balneogynaekologische", "und", "physiotherapeutische", "Massnahmen", "sind", "indikationsbezogen", "vorwiegend", "als", "ergaenzende", "Massnahmen", "anzuwenden", ".", "Lediglich", "bei", "chronischen", "Zustaenden", "sowie", "akuten", "muskulaeren", "Verspannungen", "eignen", "sie", "sich", "vor", "allem", "zur", "Schmerzverminderung", "und", "positiven", "Gewebebeeinflussung", "als", "primaere", "Massnahmen", "." ]
[ "umlsterm" ]
Therapiemoeglichkeiten, Praxis, Rehabilitation, Balneotherapie, Physiotherapie, Frauenheilkunde, Naturheilverfahren, Schmerzverminderung, Gewebebeeinflussung
DerGynaekologe.00330018.ger.abstr_task2
Sentence: Als weitere Therapiemoeglichkeiten bieten sich dem Frauenarzt in Praxis , Klinik und in der Rehabilitation die Balneotherapie und die Physiotherapie als primaer oder ergaenzende Behandlungsmassnahmen an . In der Frauenheilkunde ist die Balneogynaekologie als ein Naturheilverfahren fester Bestandteil der therapeutischen Strategien geworden . Balneogynaekologische und physiotherapeutische Massnahmen sind indikationsbezogen vorwiegend als ergaenzende Massnahmen anzuwenden . Lediglich bei chronischen Zustaenden sowie akuten muskulaeren Verspannungen eignen sie sich vor allem zur Schmerzverminderung und positiven Gewebebeeinflussung als primaere Massnahmen . Instructions: please extract entity words from the input sentence
[ "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O" ]
Als weitere Therapiemoeglichkeiten bieten sich dem Frauenarzt in Praxis , Klinik und in der Rehabilitation die Balneotherapie und die Physiotherapie als primaer oder ergaenzende Behandlungsmassnahmen an . In der Frauenheilkunde ist die Balneogynaekologie als ein Naturheilverfahren fester Bestandteil der therapeutischen Strategien geworden . Balneogynaekologische und physiotherapeutische Massnahmen sind indikationsbezogen vorwiegend als ergaenzende Massnahmen anzuwenden . Lediglich bei chronischen Zustaenden sowie akuten muskulaeren Verspannungen eignen sie sich vor allem zur Schmerzverminderung und positiven Gewebebeeinflussung als primaere Massnahmen .
[ "Als", "weitere", "Therapiemoeglichkeiten", "bieten", "sich", "dem", "Frauenarzt", "in", "Praxis", ",", "Klinik", "und", "in", "der", "Rehabilitation", "die", "Balneotherapie", "und", "die", "Physiotherapie", "als", "primaer", "oder", "ergaenzende", "Behandlungsmassnahmen", "an", ".", "In", "der", "Frauenheilkunde", "ist", "die", "Balneogynaekologie", "als", "ein", "Naturheilverfahren", "fester", "Bestandteil", "der", "therapeutischen", "Strategien", "geworden", ".", "Balneogynaekologische", "und", "physiotherapeutische", "Massnahmen", "sind", "indikationsbezogen", "vorwiegend", "als", "ergaenzende", "Massnahmen", "anzuwenden", ".", "Lediglich", "bei", "chronischen", "Zustaenden", "sowie", "akuten", "muskulaeren", "Verspannungen", "eignen", "sie", "sich", "vor", "allem", "zur", "Schmerzverminderung", "und", "positiven", "Gewebebeeinflussung", "als", "primaere", "Massnahmen", "." ]
[ "umlsterm" ]
Hautveraenderungen is an umlsterm, Rhinophym is an umlsterm, Beschaeftigung is an umlsterm, plastischen Chirurgie is an umlsterm, Nasenbereich is an umlsterm, Gesellschaft is an umlsterm
DerHautarzt.00510101.ger.abstr_task0
Sentence: Wegen Hautveraenderungen , die aufgrund des vorliegenden biographischen Materials als beginnendes Rhinophym gewertet werden muessen , unterzog sich Andy Warhol 1957 einer Dermabrasio . Ueber seine gesamte kuenstlerische Schaffensphase hinweg kann eine Beschaeftigung des Kuenstlers mit Aspekten der plastischen Chirurgie insbesondere im Nasenbereich nachgewiesen werden . Als ein Begruender der Pop-Art hat Warhol mit seinem Gesamtwerk die moderne Gesellschaft wesentlich mitgepraegt und dabei auch unsere Ansprueche an aesthetische Formen beeinflusst . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm
[ "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Wegen Hautveraenderungen , die aufgrund des vorliegenden biographischen Materials als beginnendes Rhinophym gewertet werden muessen , unterzog sich Andy Warhol 1957 einer Dermabrasio . Ueber seine gesamte kuenstlerische Schaffensphase hinweg kann eine Beschaeftigung des Kuenstlers mit Aspekten der plastischen Chirurgie insbesondere im Nasenbereich nachgewiesen werden . Als ein Begruender der Pop-Art hat Warhol mit seinem Gesamtwerk die moderne Gesellschaft wesentlich mitgepraegt und dabei auch unsere Ansprueche an aesthetische Formen beeinflusst .
[ "Wegen", "Hautveraenderungen", ",", "die", "aufgrund", "des", "vorliegenden", "biographischen", "Materials", "als", "beginnendes", "Rhinophym", "gewertet", "werden", "muessen", ",", "unterzog", "sich", "Andy", "Warhol", "1957", "einer", "Dermabrasio", ".", "Ueber", "seine", "gesamte", "kuenstlerische", "Schaffensphase", "hinweg", "kann", "eine", "Beschaeftigung", "des", "Kuenstlers", "mit", "Aspekten", "der", "plastischen", "Chirurgie", "insbesondere", "im", "Nasenbereich", "nachgewiesen", "werden", ".", "Als", "ein", "Begruender", "der", "Pop", "-", "Art", "hat", "Warhol", "mit", "seinem", "Gesamtwerk", "die", "moderne", "Gesellschaft", "wesentlich", "mitgepraegt", "und", "dabei", "auch", "unsere", "Ansprueche", "an", "aesthetische", "Formen", "beeinflusst", "." ]
[ "umlsterm" ]
Hautveraenderungen is an umlsterm, Rhinophym is an umlsterm, Beschaeftigung is an umlsterm, plastischen Chirurgie is an umlsterm, Nasenbereich is an umlsterm, Gesellschaft is an umlsterm
DerHautarzt.00510101.ger.abstr_task1
Sentence: Wegen Hautveraenderungen , die aufgrund des vorliegenden biographischen Materials als beginnendes Rhinophym gewertet werden muessen , unterzog sich Andy Warhol 1957 einer Dermabrasio . Ueber seine gesamte kuenstlerische Schaffensphase hinweg kann eine Beschaeftigung des Kuenstlers mit Aspekten der plastischen Chirurgie insbesondere im Nasenbereich nachgewiesen werden . Als ein Begruender der Pop-Art hat Warhol mit seinem Gesamtwerk die moderne Gesellschaft wesentlich mitgepraegt und dabei auch unsere Ansprueche an aesthetische Formen beeinflusst . Instructions: please typing these entity words according to sentence: Hautveraenderungen, Rhinophym, Beschaeftigung, plastischen Chirurgie, Nasenbereich, Gesellschaft Options: umlsterm
[ "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Wegen Hautveraenderungen , die aufgrund des vorliegenden biographischen Materials als beginnendes Rhinophym gewertet werden muessen , unterzog sich Andy Warhol 1957 einer Dermabrasio . Ueber seine gesamte kuenstlerische Schaffensphase hinweg kann eine Beschaeftigung des Kuenstlers mit Aspekten der plastischen Chirurgie insbesondere im Nasenbereich nachgewiesen werden . Als ein Begruender der Pop-Art hat Warhol mit seinem Gesamtwerk die moderne Gesellschaft wesentlich mitgepraegt und dabei auch unsere Ansprueche an aesthetische Formen beeinflusst .
[ "Wegen", "Hautveraenderungen", ",", "die", "aufgrund", "des", "vorliegenden", "biographischen", "Materials", "als", "beginnendes", "Rhinophym", "gewertet", "werden", "muessen", ",", "unterzog", "sich", "Andy", "Warhol", "1957", "einer", "Dermabrasio", ".", "Ueber", "seine", "gesamte", "kuenstlerische", "Schaffensphase", "hinweg", "kann", "eine", "Beschaeftigung", "des", "Kuenstlers", "mit", "Aspekten", "der", "plastischen", "Chirurgie", "insbesondere", "im", "Nasenbereich", "nachgewiesen", "werden", ".", "Als", "ein", "Begruender", "der", "Pop", "-", "Art", "hat", "Warhol", "mit", "seinem", "Gesamtwerk", "die", "moderne", "Gesellschaft", "wesentlich", "mitgepraegt", "und", "dabei", "auch", "unsere", "Ansprueche", "an", "aesthetische", "Formen", "beeinflusst", "." ]
[ "umlsterm" ]
Hautveraenderungen, Rhinophym, Beschaeftigung, plastischen Chirurgie, Nasenbereich, Gesellschaft
DerHautarzt.00510101.ger.abstr_task2
Sentence: Wegen Hautveraenderungen , die aufgrund des vorliegenden biographischen Materials als beginnendes Rhinophym gewertet werden muessen , unterzog sich Andy Warhol 1957 einer Dermabrasio . Ueber seine gesamte kuenstlerische Schaffensphase hinweg kann eine Beschaeftigung des Kuenstlers mit Aspekten der plastischen Chirurgie insbesondere im Nasenbereich nachgewiesen werden . Als ein Begruender der Pop-Art hat Warhol mit seinem Gesamtwerk die moderne Gesellschaft wesentlich mitgepraegt und dabei auch unsere Ansprueche an aesthetische Formen beeinflusst . Instructions: please extract entity words from the input sentence
[ "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Wegen Hautveraenderungen , die aufgrund des vorliegenden biographischen Materials als beginnendes Rhinophym gewertet werden muessen , unterzog sich Andy Warhol 1957 einer Dermabrasio . Ueber seine gesamte kuenstlerische Schaffensphase hinweg kann eine Beschaeftigung des Kuenstlers mit Aspekten der plastischen Chirurgie insbesondere im Nasenbereich nachgewiesen werden . Als ein Begruender der Pop-Art hat Warhol mit seinem Gesamtwerk die moderne Gesellschaft wesentlich mitgepraegt und dabei auch unsere Ansprueche an aesthetische Formen beeinflusst .
[ "Wegen", "Hautveraenderungen", ",", "die", "aufgrund", "des", "vorliegenden", "biographischen", "Materials", "als", "beginnendes", "Rhinophym", "gewertet", "werden", "muessen", ",", "unterzog", "sich", "Andy", "Warhol", "1957", "einer", "Dermabrasio", ".", "Ueber", "seine", "gesamte", "kuenstlerische", "Schaffensphase", "hinweg", "kann", "eine", "Beschaeftigung", "des", "Kuenstlers", "mit", "Aspekten", "der", "plastischen", "Chirurgie", "insbesondere", "im", "Nasenbereich", "nachgewiesen", "werden", ".", "Als", "ein", "Begruender", "der", "Pop", "-", "Art", "hat", "Warhol", "mit", "seinem", "Gesamtwerk", "die", "moderne", "Gesellschaft", "wesentlich", "mitgepraegt", "und", "dabei", "auch", "unsere", "Ansprueche", "an", "aesthetische", "Formen", "beeinflusst", "." ]
[ "umlsterm" ]
1,25-dihydroxyvitamin D3 is a lipid, calcitriol is a lipid, lymphocytes is a cell_type, children is a multi_cell, rickets is an other_name, rickets - like diseases is an other_name
97632_task0
Sentence: [Differential diagnostic value of receptors of 1,25-dihydroxyvitamin D3 (calcitriol) determination in lymphocytes of children with rickets and rickets-like diseases] Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: cell_type, multi_cell, lipid, other_name
[ "O", "O", "O", "O", "O", "O", "O", "B-lipid", "I-lipid", "O", "B-lipid", "O", "O", "O", "B-cell_type", "O", "B-multi_cell", "O", "B-other_name", "O", "B-other_name", "I-other_name", "I-other_name", "I-other_name", "O" ]
[Differential diagnostic value of receptors of 1,25-dihydroxyvitamin D3 (calcitriol) determination in lymphocytes of children with rickets and rickets-like diseases]
[ "[", "Differential", "diagnostic", "value", "of", "receptors", "of", "1,25-dihydroxyvitamin", "D3", "(", "calcitriol", ")", "determination", "in", "lymphocytes", "of", "children", "with", "rickets", "and", "rickets", "-", "like", "diseases", "]" ]
[ "other_name", "lipid", "cell_type", "multi_cell" ]
1,25-dihydroxyvitamin D3 is a lipid, calcitriol is a lipid, lymphocytes is a cell_type, children is a multi_cell, rickets is an other_name, rickets - like diseases is an other_name
97632_task1
Sentence: [Differential diagnostic value of receptors of 1,25-dihydroxyvitamin D3 (calcitriol) determination in lymphocytes of children with rickets and rickets-like diseases] Instructions: please typing these entity words according to sentence: 1,25-dihydroxyvitamin D3, calcitriol, lymphocytes, children, rickets, rickets - like diseases Options: cell_type, multi_cell, lipid, other_name
[ "O", "O", "O", "O", "O", "O", "O", "B-lipid", "I-lipid", "O", "B-lipid", "O", "O", "O", "B-cell_type", "O", "B-multi_cell", "O", "B-other_name", "O", "B-other_name", "I-other_name", "I-other_name", "I-other_name", "O" ]
[Differential diagnostic value of receptors of 1,25-dihydroxyvitamin D3 (calcitriol) determination in lymphocytes of children with rickets and rickets-like diseases]
[ "[", "Differential", "diagnostic", "value", "of", "receptors", "of", "1,25-dihydroxyvitamin", "D3", "(", "calcitriol", ")", "determination", "in", "lymphocytes", "of", "children", "with", "rickets", "and", "rickets", "-", "like", "diseases", "]" ]
[ "other_name", "lipid", "cell_type", "multi_cell" ]
1,25-dihydroxyvitamin D3, calcitriol, lymphocytes, children, rickets, rickets - like diseases
97632_task2
Sentence: [Differential diagnostic value of receptors of 1,25-dihydroxyvitamin D3 (calcitriol) determination in lymphocytes of children with rickets and rickets-like diseases] Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "O", "O", "O", "B-lipid", "I-lipid", "O", "B-lipid", "O", "O", "O", "B-cell_type", "O", "B-multi_cell", "O", "B-other_name", "O", "B-other_name", "I-other_name", "I-other_name", "I-other_name", "O" ]
[Differential diagnostic value of receptors of 1,25-dihydroxyvitamin D3 (calcitriol) determination in lymphocytes of children with rickets and rickets-like diseases]
[ "[", "Differential", "diagnostic", "value", "of", "receptors", "of", "1,25-dihydroxyvitamin", "D3", "(", "calcitriol", ")", "determination", "in", "lymphocytes", "of", "children", "with", "rickets", "and", "rickets", "-", "like", "diseases", "]" ]
[ "other_name", "lipid", "cell_type", "multi_cell" ]
holmium is an umlsterm, lasers is an umlsterm, hyperopia is an umlsterm, laser is an umlsterm, laser is an umlsterm, pulses is an umlsterm, collagen is an umlsterm, temperature is an umlsterm, laser is an umlsterm, minipigs is an umlsterm, temperature is an umlsterm, aim is an umlsterm, safety is an umlsterm, blind is an umlsterm, human is an umlsterm, eyes is an umlsterm
DerOpthalmologe.90960306.eng.abstr_task0
Sentence: Purpose : Pulsed holmium lasers are currently used to correct hyperopia by means of laser thermokeratoplasty ( LTK ) . Series of µs laser pulses are applied with a high repetition rate to induce shrinkage of corneal collagen fibers . The pulsed energy application results in intrastromal temperature peaks of up to 200 °C. A continuously emitting laser diode can - as we demonstrated recently in an invivo study on minipigs - be used for LTK and may be of advantage because the temperature rise is more steady . The aim of this study was to examine the safety , amount , and stability of hyperopic correction of diode LTK on blind human eyes . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm
[ "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "B-umlsterm", "O" ]
Purpose : Pulsed holmium lasers are currently used to correct hyperopia by means of laser thermokeratoplasty ( LTK ) . Series of µs laser pulses are applied with a high repetition rate to induce shrinkage of corneal collagen fibers . The pulsed energy application results in intrastromal temperature peaks of up to 200 °C. A continuously emitting laser diode can - as we demonstrated recently in an invivo study on minipigs - be used for LTK and may be of advantage because the temperature rise is more steady . The aim of this study was to examine the safety , amount , and stability of hyperopic correction of diode LTK on blind human eyes .
[ "Purpose", ":", "Pulsed", "holmium", "lasers", "are", "currently", "used", "to", "correct", "hyperopia", "by", "means", "of", "laser", "thermokeratoplasty", "(", "LTK", ")", ".", "Series", "of", "µs", "laser", "pulses", "are", "applied", "with", "a", "high", "repetition", "rate", "to", "induce", "shrinkage", "of", "corneal", "collagen", "fibers", ".", "The", "pulsed", "energy", "application", "results", "in", "intrastromal", "temperature", "peaks", "of", "up", "to", "200", "°", "C", ".", "A", "continuously", "emitting", "laser", "diode", "can", "-", "as", "we", "demonstrated", "recently", "in", "an", "invivo", "study", "on", "minipigs", "-", "be", "used", "for", "LTK", "and", "may", "be", "of", "advantage", "because", "the", "temperature", "rise", "is", "more", "steady", ".", "The", "aim", "of", "this", "study", "was", "to", "examine", "the", "safety", ",", "amount", ",", "and", "stability", "of", "hyperopic", "correction", "of", "diode", "LTK", "on", "blind", "human", "eyes", "." ]
[ "umlsterm" ]
holmium is an umlsterm, lasers is an umlsterm, hyperopia is an umlsterm, laser is an umlsterm, laser is an umlsterm, pulses is an umlsterm, collagen is an umlsterm, temperature is an umlsterm, laser is an umlsterm, minipigs is an umlsterm, temperature is an umlsterm, aim is an umlsterm, safety is an umlsterm, blind is an umlsterm, human is an umlsterm, eyes is an umlsterm
DerOpthalmologe.90960306.eng.abstr_task1
Sentence: Purpose : Pulsed holmium lasers are currently used to correct hyperopia by means of laser thermokeratoplasty ( LTK ) . Series of µs laser pulses are applied with a high repetition rate to induce shrinkage of corneal collagen fibers . The pulsed energy application results in intrastromal temperature peaks of up to 200 °C. A continuously emitting laser diode can - as we demonstrated recently in an invivo study on minipigs - be used for LTK and may be of advantage because the temperature rise is more steady . The aim of this study was to examine the safety , amount , and stability of hyperopic correction of diode LTK on blind human eyes . Instructions: please typing these entity words according to sentence: holmium, lasers, hyperopia, laser, laser, pulses, collagen, temperature, laser, minipigs, temperature, aim, safety, blind, human, eyes Options: umlsterm
[ "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "B-umlsterm", "O" ]
Purpose : Pulsed holmium lasers are currently used to correct hyperopia by means of laser thermokeratoplasty ( LTK ) . Series of µs laser pulses are applied with a high repetition rate to induce shrinkage of corneal collagen fibers . The pulsed energy application results in intrastromal temperature peaks of up to 200 °C. A continuously emitting laser diode can - as we demonstrated recently in an invivo study on minipigs - be used for LTK and may be of advantage because the temperature rise is more steady . The aim of this study was to examine the safety , amount , and stability of hyperopic correction of diode LTK on blind human eyes .
[ "Purpose", ":", "Pulsed", "holmium", "lasers", "are", "currently", "used", "to", "correct", "hyperopia", "by", "means", "of", "laser", "thermokeratoplasty", "(", "LTK", ")", ".", "Series", "of", "µs", "laser", "pulses", "are", "applied", "with", "a", "high", "repetition", "rate", "to", "induce", "shrinkage", "of", "corneal", "collagen", "fibers", ".", "The", "pulsed", "energy", "application", "results", "in", "intrastromal", "temperature", "peaks", "of", "up", "to", "200", "°", "C", ".", "A", "continuously", "emitting", "laser", "diode", "can", "-", "as", "we", "demonstrated", "recently", "in", "an", "invivo", "study", "on", "minipigs", "-", "be", "used", "for", "LTK", "and", "may", "be", "of", "advantage", "because", "the", "temperature", "rise", "is", "more", "steady", ".", "The", "aim", "of", "this", "study", "was", "to", "examine", "the", "safety", ",", "amount", ",", "and", "stability", "of", "hyperopic", "correction", "of", "diode", "LTK", "on", "blind", "human", "eyes", "." ]
[ "umlsterm" ]
holmium, lasers, hyperopia, laser, laser, pulses, collagen, temperature, laser, minipigs, temperature, aim, safety, blind, human, eyes
DerOpthalmologe.90960306.eng.abstr_task2
Sentence: Purpose : Pulsed holmium lasers are currently used to correct hyperopia by means of laser thermokeratoplasty ( LTK ) . Series of µs laser pulses are applied with a high repetition rate to induce shrinkage of corneal collagen fibers . The pulsed energy application results in intrastromal temperature peaks of up to 200 °C. A continuously emitting laser diode can - as we demonstrated recently in an invivo study on minipigs - be used for LTK and may be of advantage because the temperature rise is more steady . The aim of this study was to examine the safety , amount , and stability of hyperopic correction of diode LTK on blind human eyes . Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "B-umlsterm", "O" ]
Purpose : Pulsed holmium lasers are currently used to correct hyperopia by means of laser thermokeratoplasty ( LTK ) . Series of µs laser pulses are applied with a high repetition rate to induce shrinkage of corneal collagen fibers . The pulsed energy application results in intrastromal temperature peaks of up to 200 °C. A continuously emitting laser diode can - as we demonstrated recently in an invivo study on minipigs - be used for LTK and may be of advantage because the temperature rise is more steady . The aim of this study was to examine the safety , amount , and stability of hyperopic correction of diode LTK on blind human eyes .
[ "Purpose", ":", "Pulsed", "holmium", "lasers", "are", "currently", "used", "to", "correct", "hyperopia", "by", "means", "of", "laser", "thermokeratoplasty", "(", "LTK", ")", ".", "Series", "of", "µs", "laser", "pulses", "are", "applied", "with", "a", "high", "repetition", "rate", "to", "induce", "shrinkage", "of", "corneal", "collagen", "fibers", ".", "The", "pulsed", "energy", "application", "results", "in", "intrastromal", "temperature", "peaks", "of", "up", "to", "200", "°", "C", ".", "A", "continuously", "emitting", "laser", "diode", "can", "-", "as", "we", "demonstrated", "recently", "in", "an", "invivo", "study", "on", "minipigs", "-", "be", "used", "for", "LTK", "and", "may", "be", "of", "advantage", "because", "the", "temperature", "rise", "is", "more", "steady", ".", "The", "aim", "of", "this", "study", "was", "to", "examine", "the", "safety", ",", "amount", ",", "and", "stability", "of", "hyperopic", "correction", "of", "diode", "LTK", "on", "blind", "human", "eyes", "." ]
[ "umlsterm" ]
metástasis de tumor neuroendocrino ( TNE ) moderadamente diferenciado is a MORFOLOGIA_NEOPLASIA, metástasis de tumor neuroendocrino is a MORFOLOGIA_NEOPLASIA, colangiocarcinoma is a MORFOLOGIA_NEOPLASIA, pT3N1Mx is a MORFOLOGIA_NEOPLASIA, tumorales is a MORFOLOGIA_NEOPLASIA, TNE is a MORFOLOGIA_NEOPLASIA, metastásicos is a MORFOLOGIA_NEOPLASIA, metastásica is a MORFOLOGIA_NEOPLASIA, TNE is a MORFOLOGIA_NEOPLASIA, colangiocarcinoma is a MORFOLOGIA_NEOPLASIA, nódulos pulmonares is a MORFOLOGIA_NEOPLASIA, lesiones pulmonares is a MORFOLOGIA_NEOPLASIA, TNE is a MORFOLOGIA_NEOPLASIA, tumor heterogéneo is a MORFOLOGIA_NEOPLASIA, adenocarcinoma is a MORFOLOGIA_NEOPLASIA, carcinoma mixto ( adeno - neuroendocrino ) is a MORFOLOGIA_NEOPLASIA, metástasis is a MORFOLOGIA_NEOPLASIA, maligna is a MORFOLOGIA_NEOPLASIA, infiltración medular is a MORFOLOGIA_NEOPLASIA
153_task0
Sentence: Anamnesis Hombre de 32 años de nacionalidad española, informático de profesión y sin antecedentes patológicos personales o familiares de interés. No reacciones alérgicas medicamentas conocidas. Fumador de 10 cigarrillos al día y toma esporádica de alcohol como únicos hábitos tóxicos. No toma medicación habitual. El paciente, en diciembre de 2014, consulta en el servicio de urgencias de su hospital de referencia por un cuadro de un mes de evolución de dolor en hipocondrio derecho asociado a subictericia desde los días previos. Salvo náuseas ocasionales y una ligera astenia, no refiere otra sintomatología. En la exploración física tan sólo destaca la subictericia, sin otros hallazgos de interés. Tras realización de ecografía abdominal se detecta una lesión ocupante de espacio en el lóbulo hepático derecho e ingresa para completar estudio. En el TAC realizado se describe una lesión dependiente de lóbulo hepático derecho, hipovascular. Tras biopsia de la lesión, se llega finalmente al diagnóstico histológico de una metástasis de tumor neuroendocrino (TNE) moderadamente diferenciado con primario no localizado: gammagrafía con octeótride sin captación fuera del territorio hepático. Resto de estudio de extensión, en principio negativo. Como centro terciario, el paciente es derivado a nuestro centro para realización de cirugía hepática. La cirugía se lleva a cabo en febrero de 2015, realizándose transección parenquimatosa con cavitador-aspirador quirúrgico ultrasónico (CUSA), en forma de hepatectomía derecha. A pesar del diagnóstico inicial de metástasis de tumor neuroendocrino, el estudio histológico definitivo de la pieza quirúrgica es de un colangiocarcinoma intrahepático. Márgenes no afectos (R0): pT3N1Mx. Es en este momento cuando el paciente es derivado a la consulta de Oncología Médica (marzo 2015). Exploración física Durante la primera valoración por Oncología, el paciente presenta excelente estado general, con un Performance Status de 1. Exploración abdominal sin hallazgos patológicos, cicatriz de laparotomía en buen estado, sin dehiscencias ni signos inflamatorios cicundantes. Pruebas complementarias Analíticamente destaca una discreta elevación de las enzimas hepáticas, resto anodino. Revisando el TAC abdominal, además de la masa hepática, en los cortes inferiores del tórax se describen unos pequeños nódulos bilaterales, inespecíficos, que en el contexto de un paciente joven y fumador, en principio no se consideran como tumorales. Debido al diagnóstico histológico definitivo, tras discusión en comité multidisciplinar, se opta por administrar tratamiento pseudoadyuvante con cisplatino-gemcitabina durante seis meses, según tolerancia y respuesta. No obstante, previo al inicio de tratamiento se solicita un TAC torácico para mejor caracterización de los dudosos nódulos observados en estudio radiológico previo. Además, de igual modo pedimos la revisión del estudio histológico para descartar definitivamente la sospecha inicial de TNE. En el TAC torácico, se describen múltiples nódulos bilaterales milimétricos, metastásicos, además de unas dilataciones arteriales bilaterales segmentarias y periféricas, asociadas a nódulos adyacentes de distribución "en árbol en brote": características de microangiopatía trombótica metastásica. El paciente no presenta estigmas de sangrado y la hemostasia y el hemograma están dentro de la normalidad. Diagnóstico Tras nueva valoración de las muestras de la pieza quirúrgica por parte del servicio de anatomía patológica, en principio se descarta que se trate de un TNE: en la inmunohistoquímica todos los marcadores neuroendocrinos son negativos. Se mantiene, por lo tanto, el diagnóstico de colangiocarcinoma intrahepático. Tratamiento Tras estos hallazgos, además de proceder al tratamiento con enoxaparina a dosis plenas, se modifica el planteamiento terapéutico: dada la irresecabilidad de las lesiones y el excelente estado general del paciente, se planifica una quimioterapia paliativa basada en 7 ciclos de cisplatino-gemcitabina, con posible mantenimento posterior de gemcitabina en monoterapia. Evolución El paciente inicia el tratamiento en abril de 2015. Primer TAC de evaluación en junio de 2015 (hasta entonces se han administrado 4 ciclos, sin toxicidad de interés). En dicha evaluación se objetiva respuesta heterogénea, con disminución del tamaño o desaparición de los nódulos presentes previamente pero con aparición de dos nuevos nódulos pulmonares en lóbulo superior izquierdo, no presentes en estudio previo. Se continúa con el plan establecido y se administran 3 ciclos más, con excelente tolerancia, finalizando en septiembre de 2015. El paciente permanece asintomático, con una analítica anodina y en la evaluación destaca la estabilidad de las lesiones pulmonares. Ante la heterogeneidad y lo atípico de la evolución, junto al diagnóstico histológico inicial de TNE, se solicitan las muestras del diagnóstico inicial realizadas en el hospital de referencia del paciente para nueva valoración por el servicio de Anatomía Patológica de nuestro centro. En dicha valoración, se llega a la conclusión de que se trata de un tumor heterogéneo, con dos zonas morfológicamente diferentes: un área más glandular con estructuras cribiformes y secreción de mucina (zona de adenocarcinoma) y otra zona más cordonal, de patrón organoide. Dicha zona, al análisis inmunohistoquímico se presenta como positiva débil y difusa para la enolasa y focal para la sinaptrofisina, siendo la cromogranina y CD 56 negativas. Estos hallazgos histológicos y clínicos sugieren el diagnóstico definitivo de un carcinoma mixto (adeno-neuroendocrino), sin claro predominio de uno de los dos componentes. Tras esto, se decide administrar dos ciclos más de cisplatino-gemcitabina y sunitinib posterior como tratamiento de mantenimiento. Mantenimiento que inicia en octubre de 2015. En diciembre de 2015, tras aparición de dolor óseo a nivel de columna dorsal y masa de rápido crecimiento en región axilar derecha, se diagnostica de metástasis óseas en varios cuerpos vertebrales y costal derecha, tratadas mediante radioterapia antiálgica. Además, el paciente presentaba una úlcera gingival de dos meses de evolución: maligna, tras estudio histológico. El paciente inicia un progresivo deterioro con aparición de pancitopenia mantenida por infiltración medular, falleciendo, desgraciadamente, en febrero de 2016. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: MORFOLOGIA_NEOPLASIA
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Anamnesis Hombre de 32 años de nacionalidad española, informático de profesión y sin antecedentes patológicos personales o familiares de interés. No reacciones alérgicas medicamentas conocidas. Fumador de 10 cigarrillos al día y toma esporádica de alcohol como únicos hábitos tóxicos. No toma medicación habitual. El paciente, en diciembre de 2014, consulta en el servicio de urgencias de su hospital de referencia por un cuadro de un mes de evolución de dolor en hipocondrio derecho asociado a subictericia desde los días previos. Salvo náuseas ocasionales y una ligera astenia, no refiere otra sintomatología. En la exploración física tan sólo destaca la subictericia, sin otros hallazgos de interés. Tras realización de ecografía abdominal se detecta una lesión ocupante de espacio en el lóbulo hepático derecho e ingresa para completar estudio. En el TAC realizado se describe una lesión dependiente de lóbulo hepático derecho, hipovascular. Tras biopsia de la lesión, se llega finalmente al diagnóstico histológico de una metástasis de tumor neuroendocrino (TNE) moderadamente diferenciado con primario no localizado: gammagrafía con octeótride sin captación fuera del territorio hepático. Resto de estudio de extensión, en principio negativo. Como centro terciario, el paciente es derivado a nuestro centro para realización de cirugía hepática. La cirugía se lleva a cabo en febrero de 2015, realizándose transección parenquimatosa con cavitador-aspirador quirúrgico ultrasónico (CUSA), en forma de hepatectomía derecha. A pesar del diagnóstico inicial de metástasis de tumor neuroendocrino, el estudio histológico definitivo de la pieza quirúrgica es de un colangiocarcinoma intrahepático. Márgenes no afectos (R0): pT3N1Mx. Es en este momento cuando el paciente es derivado a la consulta de Oncología Médica (marzo 2015). Exploración física Durante la primera valoración por Oncología, el paciente presenta excelente estado general, con un Performance Status de 1. Exploración abdominal sin hallazgos patológicos, cicatriz de laparotomía en buen estado, sin dehiscencias ni signos inflamatorios cicundantes. Pruebas complementarias Analíticamente destaca una discreta elevación de las enzimas hepáticas, resto anodino. Revisando el TAC abdominal, además de la masa hepática, en los cortes inferiores del tórax se describen unos pequeños nódulos bilaterales, inespecíficos, que en el contexto de un paciente joven y fumador, en principio no se consideran como tumorales. Debido al diagnóstico histológico definitivo, tras discusión en comité multidisciplinar, se opta por administrar tratamiento pseudoadyuvante con cisplatino-gemcitabina durante seis meses, según tolerancia y respuesta. No obstante, previo al inicio de tratamiento se solicita un TAC torácico para mejor caracterización de los dudosos nódulos observados en estudio radiológico previo. Además, de igual modo pedimos la revisión del estudio histológico para descartar definitivamente la sospecha inicial de TNE. En el TAC torácico, se describen múltiples nódulos bilaterales milimétricos, metastásicos, además de unas dilataciones arteriales bilaterales segmentarias y periféricas, asociadas a nódulos adyacentes de distribución "en árbol en brote": características de microangiopatía trombótica metastásica. El paciente no presenta estigmas de sangrado y la hemostasia y el hemograma están dentro de la normalidad. Diagnóstico Tras nueva valoración de las muestras de la pieza quirúrgica por parte del servicio de anatomía patológica, en principio se descarta que se trate de un TNE: en la inmunohistoquímica todos los marcadores neuroendocrinos son negativos. Se mantiene, por lo tanto, el diagnóstico de colangiocarcinoma intrahepático. Tratamiento Tras estos hallazgos, además de proceder al tratamiento con enoxaparina a dosis plenas, se modifica el planteamiento terapéutico: dada la irresecabilidad de las lesiones y el excelente estado general del paciente, se planifica una quimioterapia paliativa basada en 7 ciclos de cisplatino-gemcitabina, con posible mantenimento posterior de gemcitabina en monoterapia. Evolución El paciente inicia el tratamiento en abril de 2015. Primer TAC de evaluación en junio de 2015 (hasta entonces se han administrado 4 ciclos, sin toxicidad de interés). En dicha evaluación se objetiva respuesta heterogénea, con disminución del tamaño o desaparición de los nódulos presentes previamente pero con aparición de dos nuevos nódulos pulmonares en lóbulo superior izquierdo, no presentes en estudio previo. Se continúa con el plan establecido y se administran 3 ciclos más, con excelente tolerancia, finalizando en septiembre de 2015. El paciente permanece asintomático, con una analítica anodina y en la evaluación destaca la estabilidad de las lesiones pulmonares. Ante la heterogeneidad y lo atípico de la evolución, junto al diagnóstico histológico inicial de TNE, se solicitan las muestras del diagnóstico inicial realizadas en el hospital de referencia del paciente para nueva valoración por el servicio de Anatomía Patológica de nuestro centro. En dicha valoración, se llega a la conclusión de que se trata de un tumor heterogéneo, con dos zonas morfológicamente diferentes: un área más glandular con estructuras cribiformes y secreción de mucina (zona de adenocarcinoma) y otra zona más cordonal, de patrón organoide. Dicha zona, al análisis inmunohistoquímico se presenta como positiva débil y difusa para la enolasa y focal para la sinaptrofisina, siendo la cromogranina y CD 56 negativas. Estos hallazgos histológicos y clínicos sugieren el diagnóstico definitivo de un carcinoma mixto (adeno-neuroendocrino), sin claro predominio de uno de los dos componentes. Tras esto, se decide administrar dos ciclos más de cisplatino-gemcitabina y sunitinib posterior como tratamiento de mantenimiento. Mantenimiento que inicia en octubre de 2015. En diciembre de 2015, tras aparición de dolor óseo a nivel de columna dorsal y masa de rápido crecimiento en región axilar derecha, se diagnostica de metástasis óseas en varios cuerpos vertebrales y costal derecha, tratadas mediante radioterapia antiálgica. Además, el paciente presentaba una úlcera gingival de dos meses de evolución: maligna, tras estudio histológico. El paciente inicia un progresivo deterioro con aparición de pancitopenia mantenida por infiltración medular, falleciendo, desgraciadamente, en febrero de 2016.
[ "Anamnesis", "\n", "Hombre", "de", "32", "años", "de", "nacionalidad", "española", ",", "informático", "de", "profesión", "y", "sin", "antecedentes", "patológicos", "personales", "o", "familiares", "de", "interés", ".", "No", "reacciones", "alérgicas", "medicamentas", "conocidas", ".", "Fumador", "de", "10", "cigarrillos", "al", "día", "y", "toma", "esporádica", "de", "alcohol", "como", "únicos", "hábitos", "tóxicos", ".", "No", "toma", "medicación", "habitual", ".", "\n", "El", "paciente", ",", "en", "diciembre", "de", "2014", ",", "consulta", "en", "el", "servicio", "de", "urgencias", "de", "su", "hospital", "de", "referencia", "por", "un", "cuadro", "de", "un", "mes", "de", "evolución", "de", "dolor", "en", "hipocondrio", "derecho", "asociado", "a", "subictericia", "desde", "los", "días", "previos", ".", "Salvo", "náuseas", "ocasionales", "y", "una", "ligera", "astenia", ",", "no", "refiere", "otra", "sintomatología", ".", "En", "la", "exploración", "física", "tan", "sólo", "destaca", "la", "subictericia", ",", "sin", "otros", "hallazgos", "de", "interés", ".", "\n\n", "Tras", "realización", "de", "ecografía", "abdominal", "se", "detecta", "una", "lesión", "ocupante", "de", "espacio", "en", "el", "lóbulo", "hepático", "derecho", "e", "ingresa", "para", "completar", "estudio", ".", "En", "el", "TAC", "realizado", "se", "describe", "una", "lesión", "dependiente", "de", "lóbulo", "hepático", "derecho", ",", "hipovascular", ".", "Tras", "biopsia", "de", "la", "lesión", ",", "se", "llega", "finalmente", "al", "diagnóstico", "histológico", "de", "una", "metástasis", "de", "tumor", "neuroendocrino", "(", "TNE", ")", "moderadamente", "diferenciado", "con", "primario", "no", "localizado", ":", "gammagrafía", "con", "octeótride", "sin", "captación", "fuera", "del", "territorio", "hepático", ".", "Resto", "de", "estudio", "de", "extensión", ",", "en", "principio", "negativo", ".", "Como", "centro", "terciario", ",", "el", "paciente", "es", "derivado", "a", "nuestro", "centro", "para", "realización", "de", "cirugía", "hepática", ".", "\n\n", "La", "cirugía", "se", "lleva", "a", "cabo", "en", "febrero", "de", "2015", ",", "realizándose", "transección", "parenquimatosa", "con", "cavitador", "-", "aspirador", "quirúrgico", "ultrasónico", "(", "CUSA", ")", ",", "en", "forma", "de", "hepatectomía", "derecha", ".", "A", "pesar", "del", "diagnóstico", "inicial", "de", "metástasis", "de", "tumor", "neuroendocrino", ",", "el", "estudio", "histológico", "definitivo", "de", "la", "pieza", "quirúrgica", "es", "de", "un", "colangiocarcinoma", "intrahepático", ".", "Márgenes", "no", "afectos", "(", "R0", "):", "pT3N1Mx", ".", "\n", "Es", "en", "este", "momento", "cuando", "el", "paciente", "es", "derivado", "a", "la", "consulta", "de", "Oncología", "Médica", "(", "marzo", "2015", ")", ".", "\n \n", "Exploración", "física", "\n", "Durante", "la", "primera", "valoración", "por", "Oncología", ",", "el", "paciente", "presenta", "excelente", "estado", "general", ",", "con", "un", "Performance", "Status", "de", "1", ".", "Exploración", "abdominal", "sin", "hallazgos", "patológicos", ",", "cicatriz", "de", "laparotomía", "en", "buen", "estado", ",", "sin", "dehiscencias", "ni", "signos", "inflamatorios", "cicundantes", ".", "\n\n", "Pruebas", "complementarias", "\n", "Analíticamente", "destaca", "una", "discreta", "elevación", "de", "las", "enzimas", "hepáticas", ",", "resto", "anodino", ".", "Revisando", "el", "TAC", "abdominal", ",", "además", "de", "la", "masa", "hepática", ",", "en", "los", "cortes", "inferiores", "del", "tórax", "se", "describen", "unos", "pequeños", "nódulos", "bilaterales", ",", "inespecíficos", ",", "que", "en", "el", "contexto", "de", "un", "paciente", "joven", "y", "fumador", ",", "en", "principio", "no", "se", "consideran", "como", "tumorales", ".", "\n\n", "Debido", "al", "diagnóstico", "histológico", "definitivo", ",", "tras", "discusión", "en", "comité", "multidisciplinar", ",", "se", "opta", "por", "administrar", "tratamiento", "pseudoadyuvante", "con", "cisplatino", "-", "gemcitabina", "durante", "seis", "meses", ",", "según", "tolerancia", "y", "respuesta", ".", "\n", "No", "obstante", ",", "previo", "al", "inicio", "de", "tratamiento", "se", "solicita", "un", "TAC", "torácico", "para", "mejor", "caracterización", "de", "los", "dudosos", "nódulos", "observados", "en", "estudio", "radiológico", "previo", ".", "Además", ",", "de", "igual", "modo", "pedimos", "la", "revisión", "del", "estudio", "histológico", "para", "descartar", "definitivamente", "la", "sospecha", "inicial", "de", "TNE", ".", "\n\n", "En", "el", "TAC", "torácico", ",", "se", "describen", "múltiples", "nódulos", "bilaterales", "milimétricos", ",", "metastásicos", ",", "además", "de", "unas", "dilataciones", "arteriales", "bilaterales", "segmentarias", "y", "periféricas", ",", "asociadas", "a", "nódulos", "adyacentes", "de", "distribución", "\"", "en", "árbol", "en", "brote", "\"", ":", "características", "de", "microangiopatía", "trombótica", "metastásica", ".", "El", "paciente", "no", "presenta", "estigmas", "de", "sangrado", "y", "la", "hemostasia", "y", "el", "hemograma", "están", "dentro", "de", "la", "normalidad", ".", "\n\n", "Diagnóstico", "\n", "Tras", "nueva", "valoración", "de", "las", "muestras", "de", "la", "pieza", "quirúrgica", "por", "parte", "del", "servicio", "de", "anatomía", "patológica", ",", "en", "principio", "se", "descarta", "que", "se", "trate", "de", "un", "TNE", ":", "en", "la", "inmunohistoquímica", "todos", "los", "marcadores", "neuroendocrinos", "son", "negativos", ".", "Se", "mantiene", ",", "por", "lo", "tanto", ",", "el", "diagnóstico", "de", "colangiocarcinoma", "intrahepático", ".", "\n\n", "Tratamiento", "\n", "Tras", "estos", "hallazgos", ",", "además", "de", "proceder", "al", "tratamiento", "con", "enoxaparina", "a", "dosis", "plenas", ",", "se", "modifica", "el", "planteamiento", "terapéutico", ":", "dada", "la", "irresecabilidad", "de", "las", "lesiones", "y", "el", "excelente", "estado", "general", "del", "paciente", ",", "se", "planifica", "una", "quimioterapia", "paliativa", "basada", "en", "7", "ciclos", "de", "cisplatino", "-", "gemcitabina", ",", "con", "posible", "mantenimento", "posterior", "de", "gemcitabina", "en", "monoterapia", ".", "\n\n", "Evolución", "\n", "El", "paciente", "inicia", "el", "tratamiento", "en", "abril", "de", "2015", ".", "Primer", "TAC", "de", "evaluación", "en", "junio", "de", "2015", "(", "hasta", "entonces", "se", "han", "administrado", "4", "ciclos", ",", "sin", "toxicidad", "de", "interés", ")", ".", "En", "dicha", "evaluación", "se", "objetiva", "respuesta", "heterogénea", ",", "con", "disminución", "del", "tamaño", "o", "desaparición", "de", "los", "nódulos", "presentes", "previamente", "pero", "con", "aparición", "de", "dos", "nuevos", "nódulos", "pulmonares", "en", "lóbulo", "superior", "izquierdo", ",", "no", "presentes", "en", "estudio", "previo", ".", "Se", "continúa", "con", "el", "plan", "establecido", "y", "se", "administran", "3", "ciclos", "más", ",", "con", "excelente", "tolerancia", ",", "finalizando", "en", "septiembre", "de", "2015", ".", "El", "paciente", "permanece", "asintomático", ",", "con", "una", "analítica", "anodina", "y", "en", "la", "evaluación", "destaca", "la", "estabilidad", "de", "las", "lesiones", "pulmonares", ".", "\n\n", "Ante", "la", "heterogeneidad", "y", "lo", "atípico", "de", "la", "evolución", ",", "junto", "al", "diagnóstico", "histológico", "inicial", "de", "TNE", ",", "se", "solicitan", "las", "muestras", "del", "diagnóstico", "inicial", "realizadas", "en", "el", "hospital", "de", "referencia", "del", "paciente", "para", "nueva", "valoración", "por", "el", "servicio", "de", "Anatomía", "Patológica", "de", "nuestro", "centro", ".", "En", "dicha", "valoración", ",", "se", "llega", "a", "la", "conclusión", "de", "que", "se", "trata", "de", "un", "tumor", "heterogéneo", ",", "con", "dos", "zonas", "morfológicamente", "diferentes", ":", "un", "área", "más", "glandular", "con", "estructuras", "cribiformes", "y", "secreción", "de", "mucina", "(", "zona", "de", "adenocarcinoma", ")", "y", "otra", "zona", "más", "cordonal", ",", "de", "patrón", "organoide", ".", "Dicha", "zona", ",", "al", "análisis", "inmunohistoquímico", "se", "presenta", "como", "positiva", "débil", "y", "difusa", "para", "la", "enolasa", "y", "focal", "para", "la", "sinaptrofisina", ",", "siendo", "la", "cromogranina", "y", "CD", "56", "negativas", ".", "Estos", "hallazgos", "histológicos", "y", "clínicos", "sugieren", "el", "diagnóstico", "definitivo", "de", "un", "carcinoma", "mixto", "(", "adeno", "-", "neuroendocrino", ")", ",", "sin", "claro", "predominio", "de", "uno", "de", "los", "dos", "componentes", ".", "Tras", "esto", ",", "se", "decide", "administrar", "dos", "ciclos", "más", "de", "cisplatino", "-", "gemcitabina", "y", "sunitinib", "posterior", "como", "tratamiento", "de", "mantenimiento", ".", "Mantenimiento", "que", "inicia", "en", "octubre", "de", "2015", ".", "\n\n", "En", "diciembre", "de", "2015", ",", "tras", "aparición", "de", "dolor", "óseo", "a", "nivel", "de", "columna", "dorsal", "y", "masa", "de", "rápido", "crecimiento", "en", "región", "axilar", "derecha", ",", "se", "diagnostica", "de", "metástasis", "óseas", "en", "varios", "cuerpos", "vertebrales", "y", "costal", "derecha", ",", "tratadas", "mediante", "radioterapia", "antiálgica", ".", "Además", ",", "el", "paciente", "presentaba", "una", "úlcera", "gingival", "de", "dos", "meses", "de", "evolución", ":", "maligna", ",", "tras", "estudio", "histológico", ".", "El", "paciente", "inicia", "un", "progresivo", "deterioro", "con", "aparición", "de", "pancitopenia", "mantenida", "por", "infiltración", "medular", ",", "falleciendo", ",", "desgraciadamente", ",", "en", "febrero", "de", "2016", "." ]
[ "MORFOLOGIA_NEOPLASIA" ]
metástasis de tumor neuroendocrino ( TNE ) moderadamente diferenciado is a MORFOLOGIA_NEOPLASIA, metástasis de tumor neuroendocrino is a MORFOLOGIA_NEOPLASIA, colangiocarcinoma is a MORFOLOGIA_NEOPLASIA, pT3N1Mx is a MORFOLOGIA_NEOPLASIA, tumorales is a MORFOLOGIA_NEOPLASIA, TNE is a MORFOLOGIA_NEOPLASIA, metastásicos is a MORFOLOGIA_NEOPLASIA, metastásica is a MORFOLOGIA_NEOPLASIA, TNE is a MORFOLOGIA_NEOPLASIA, colangiocarcinoma is a MORFOLOGIA_NEOPLASIA, nódulos pulmonares is a MORFOLOGIA_NEOPLASIA, lesiones pulmonares is a MORFOLOGIA_NEOPLASIA, TNE is a MORFOLOGIA_NEOPLASIA, tumor heterogéneo is a MORFOLOGIA_NEOPLASIA, adenocarcinoma is a MORFOLOGIA_NEOPLASIA, carcinoma mixto ( adeno - neuroendocrino ) is a MORFOLOGIA_NEOPLASIA, metástasis is a MORFOLOGIA_NEOPLASIA, maligna is a MORFOLOGIA_NEOPLASIA, infiltración medular is a MORFOLOGIA_NEOPLASIA
153_task1
Sentence: Anamnesis Hombre de 32 años de nacionalidad española, informático de profesión y sin antecedentes patológicos personales o familiares de interés. No reacciones alérgicas medicamentas conocidas. Fumador de 10 cigarrillos al día y toma esporádica de alcohol como únicos hábitos tóxicos. No toma medicación habitual. El paciente, en diciembre de 2014, consulta en el servicio de urgencias de su hospital de referencia por un cuadro de un mes de evolución de dolor en hipocondrio derecho asociado a subictericia desde los días previos. Salvo náuseas ocasionales y una ligera astenia, no refiere otra sintomatología. En la exploración física tan sólo destaca la subictericia, sin otros hallazgos de interés. Tras realización de ecografía abdominal se detecta una lesión ocupante de espacio en el lóbulo hepático derecho e ingresa para completar estudio. En el TAC realizado se describe una lesión dependiente de lóbulo hepático derecho, hipovascular. Tras biopsia de la lesión, se llega finalmente al diagnóstico histológico de una metástasis de tumor neuroendocrino (TNE) moderadamente diferenciado con primario no localizado: gammagrafía con octeótride sin captación fuera del territorio hepático. Resto de estudio de extensión, en principio negativo. Como centro terciario, el paciente es derivado a nuestro centro para realización de cirugía hepática. La cirugía se lleva a cabo en febrero de 2015, realizándose transección parenquimatosa con cavitador-aspirador quirúrgico ultrasónico (CUSA), en forma de hepatectomía derecha. A pesar del diagnóstico inicial de metástasis de tumor neuroendocrino, el estudio histológico definitivo de la pieza quirúrgica es de un colangiocarcinoma intrahepático. Márgenes no afectos (R0): pT3N1Mx. Es en este momento cuando el paciente es derivado a la consulta de Oncología Médica (marzo 2015). Exploración física Durante la primera valoración por Oncología, el paciente presenta excelente estado general, con un Performance Status de 1. Exploración abdominal sin hallazgos patológicos, cicatriz de laparotomía en buen estado, sin dehiscencias ni signos inflamatorios cicundantes. Pruebas complementarias Analíticamente destaca una discreta elevación de las enzimas hepáticas, resto anodino. Revisando el TAC abdominal, además de la masa hepática, en los cortes inferiores del tórax se describen unos pequeños nódulos bilaterales, inespecíficos, que en el contexto de un paciente joven y fumador, en principio no se consideran como tumorales. Debido al diagnóstico histológico definitivo, tras discusión en comité multidisciplinar, se opta por administrar tratamiento pseudoadyuvante con cisplatino-gemcitabina durante seis meses, según tolerancia y respuesta. No obstante, previo al inicio de tratamiento se solicita un TAC torácico para mejor caracterización de los dudosos nódulos observados en estudio radiológico previo. Además, de igual modo pedimos la revisión del estudio histológico para descartar definitivamente la sospecha inicial de TNE. En el TAC torácico, se describen múltiples nódulos bilaterales milimétricos, metastásicos, además de unas dilataciones arteriales bilaterales segmentarias y periféricas, asociadas a nódulos adyacentes de distribución "en árbol en brote": características de microangiopatía trombótica metastásica. El paciente no presenta estigmas de sangrado y la hemostasia y el hemograma están dentro de la normalidad. Diagnóstico Tras nueva valoración de las muestras de la pieza quirúrgica por parte del servicio de anatomía patológica, en principio se descarta que se trate de un TNE: en la inmunohistoquímica todos los marcadores neuroendocrinos son negativos. Se mantiene, por lo tanto, el diagnóstico de colangiocarcinoma intrahepático. Tratamiento Tras estos hallazgos, además de proceder al tratamiento con enoxaparina a dosis plenas, se modifica el planteamiento terapéutico: dada la irresecabilidad de las lesiones y el excelente estado general del paciente, se planifica una quimioterapia paliativa basada en 7 ciclos de cisplatino-gemcitabina, con posible mantenimento posterior de gemcitabina en monoterapia. Evolución El paciente inicia el tratamiento en abril de 2015. Primer TAC de evaluación en junio de 2015 (hasta entonces se han administrado 4 ciclos, sin toxicidad de interés). En dicha evaluación se objetiva respuesta heterogénea, con disminución del tamaño o desaparición de los nódulos presentes previamente pero con aparición de dos nuevos nódulos pulmonares en lóbulo superior izquierdo, no presentes en estudio previo. Se continúa con el plan establecido y se administran 3 ciclos más, con excelente tolerancia, finalizando en septiembre de 2015. El paciente permanece asintomático, con una analítica anodina y en la evaluación destaca la estabilidad de las lesiones pulmonares. Ante la heterogeneidad y lo atípico de la evolución, junto al diagnóstico histológico inicial de TNE, se solicitan las muestras del diagnóstico inicial realizadas en el hospital de referencia del paciente para nueva valoración por el servicio de Anatomía Patológica de nuestro centro. En dicha valoración, se llega a la conclusión de que se trata de un tumor heterogéneo, con dos zonas morfológicamente diferentes: un área más glandular con estructuras cribiformes y secreción de mucina (zona de adenocarcinoma) y otra zona más cordonal, de patrón organoide. Dicha zona, al análisis inmunohistoquímico se presenta como positiva débil y difusa para la enolasa y focal para la sinaptrofisina, siendo la cromogranina y CD 56 negativas. Estos hallazgos histológicos y clínicos sugieren el diagnóstico definitivo de un carcinoma mixto (adeno-neuroendocrino), sin claro predominio de uno de los dos componentes. Tras esto, se decide administrar dos ciclos más de cisplatino-gemcitabina y sunitinib posterior como tratamiento de mantenimiento. Mantenimiento que inicia en octubre de 2015. En diciembre de 2015, tras aparición de dolor óseo a nivel de columna dorsal y masa de rápido crecimiento en región axilar derecha, se diagnostica de metástasis óseas en varios cuerpos vertebrales y costal derecha, tratadas mediante radioterapia antiálgica. Además, el paciente presentaba una úlcera gingival de dos meses de evolución: maligna, tras estudio histológico. El paciente inicia un progresivo deterioro con aparición de pancitopenia mantenida por infiltración medular, falleciendo, desgraciadamente, en febrero de 2016. Instructions: please typing these entity words according to sentence: metástasis de tumor neuroendocrino ( TNE ) moderadamente diferenciado, metástasis de tumor neuroendocrino, colangiocarcinoma, pT3N1Mx, tumorales, TNE, metastásicos, metastásica, TNE, colangiocarcinoma, nódulos pulmonares, lesiones pulmonares, TNE, tumor heterogéneo, adenocarcinoma, carcinoma mixto ( adeno - neuroendocrino ), metástasis, maligna, infiltración medular Options: MORFOLOGIA_NEOPLASIA
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Anamnesis Hombre de 32 años de nacionalidad española, informático de profesión y sin antecedentes patológicos personales o familiares de interés. No reacciones alérgicas medicamentas conocidas. Fumador de 10 cigarrillos al día y toma esporádica de alcohol como únicos hábitos tóxicos. No toma medicación habitual. El paciente, en diciembre de 2014, consulta en el servicio de urgencias de su hospital de referencia por un cuadro de un mes de evolución de dolor en hipocondrio derecho asociado a subictericia desde los días previos. Salvo náuseas ocasionales y una ligera astenia, no refiere otra sintomatología. En la exploración física tan sólo destaca la subictericia, sin otros hallazgos de interés. Tras realización de ecografía abdominal se detecta una lesión ocupante de espacio en el lóbulo hepático derecho e ingresa para completar estudio. En el TAC realizado se describe una lesión dependiente de lóbulo hepático derecho, hipovascular. Tras biopsia de la lesión, se llega finalmente al diagnóstico histológico de una metástasis de tumor neuroendocrino (TNE) moderadamente diferenciado con primario no localizado: gammagrafía con octeótride sin captación fuera del territorio hepático. Resto de estudio de extensión, en principio negativo. Como centro terciario, el paciente es derivado a nuestro centro para realización de cirugía hepática. La cirugía se lleva a cabo en febrero de 2015, realizándose transección parenquimatosa con cavitador-aspirador quirúrgico ultrasónico (CUSA), en forma de hepatectomía derecha. A pesar del diagnóstico inicial de metástasis de tumor neuroendocrino, el estudio histológico definitivo de la pieza quirúrgica es de un colangiocarcinoma intrahepático. Márgenes no afectos (R0): pT3N1Mx. Es en este momento cuando el paciente es derivado a la consulta de Oncología Médica (marzo 2015). Exploración física Durante la primera valoración por Oncología, el paciente presenta excelente estado general, con un Performance Status de 1. Exploración abdominal sin hallazgos patológicos, cicatriz de laparotomía en buen estado, sin dehiscencias ni signos inflamatorios cicundantes. Pruebas complementarias Analíticamente destaca una discreta elevación de las enzimas hepáticas, resto anodino. Revisando el TAC abdominal, además de la masa hepática, en los cortes inferiores del tórax se describen unos pequeños nódulos bilaterales, inespecíficos, que en el contexto de un paciente joven y fumador, en principio no se consideran como tumorales. Debido al diagnóstico histológico definitivo, tras discusión en comité multidisciplinar, se opta por administrar tratamiento pseudoadyuvante con cisplatino-gemcitabina durante seis meses, según tolerancia y respuesta. No obstante, previo al inicio de tratamiento se solicita un TAC torácico para mejor caracterización de los dudosos nódulos observados en estudio radiológico previo. Además, de igual modo pedimos la revisión del estudio histológico para descartar definitivamente la sospecha inicial de TNE. En el TAC torácico, se describen múltiples nódulos bilaterales milimétricos, metastásicos, además de unas dilataciones arteriales bilaterales segmentarias y periféricas, asociadas a nódulos adyacentes de distribución "en árbol en brote": características de microangiopatía trombótica metastásica. El paciente no presenta estigmas de sangrado y la hemostasia y el hemograma están dentro de la normalidad. Diagnóstico Tras nueva valoración de las muestras de la pieza quirúrgica por parte del servicio de anatomía patológica, en principio se descarta que se trate de un TNE: en la inmunohistoquímica todos los marcadores neuroendocrinos son negativos. Se mantiene, por lo tanto, el diagnóstico de colangiocarcinoma intrahepático. Tratamiento Tras estos hallazgos, además de proceder al tratamiento con enoxaparina a dosis plenas, se modifica el planteamiento terapéutico: dada la irresecabilidad de las lesiones y el excelente estado general del paciente, se planifica una quimioterapia paliativa basada en 7 ciclos de cisplatino-gemcitabina, con posible mantenimento posterior de gemcitabina en monoterapia. Evolución El paciente inicia el tratamiento en abril de 2015. Primer TAC de evaluación en junio de 2015 (hasta entonces se han administrado 4 ciclos, sin toxicidad de interés). En dicha evaluación se objetiva respuesta heterogénea, con disminución del tamaño o desaparición de los nódulos presentes previamente pero con aparición de dos nuevos nódulos pulmonares en lóbulo superior izquierdo, no presentes en estudio previo. Se continúa con el plan establecido y se administran 3 ciclos más, con excelente tolerancia, finalizando en septiembre de 2015. El paciente permanece asintomático, con una analítica anodina y en la evaluación destaca la estabilidad de las lesiones pulmonares. Ante la heterogeneidad y lo atípico de la evolución, junto al diagnóstico histológico inicial de TNE, se solicitan las muestras del diagnóstico inicial realizadas en el hospital de referencia del paciente para nueva valoración por el servicio de Anatomía Patológica de nuestro centro. En dicha valoración, se llega a la conclusión de que se trata de un tumor heterogéneo, con dos zonas morfológicamente diferentes: un área más glandular con estructuras cribiformes y secreción de mucina (zona de adenocarcinoma) y otra zona más cordonal, de patrón organoide. Dicha zona, al análisis inmunohistoquímico se presenta como positiva débil y difusa para la enolasa y focal para la sinaptrofisina, siendo la cromogranina y CD 56 negativas. Estos hallazgos histológicos y clínicos sugieren el diagnóstico definitivo de un carcinoma mixto (adeno-neuroendocrino), sin claro predominio de uno de los dos componentes. Tras esto, se decide administrar dos ciclos más de cisplatino-gemcitabina y sunitinib posterior como tratamiento de mantenimiento. Mantenimiento que inicia en octubre de 2015. En diciembre de 2015, tras aparición de dolor óseo a nivel de columna dorsal y masa de rápido crecimiento en región axilar derecha, se diagnostica de metástasis óseas en varios cuerpos vertebrales y costal derecha, tratadas mediante radioterapia antiálgica. Además, el paciente presentaba una úlcera gingival de dos meses de evolución: maligna, tras estudio histológico. El paciente inicia un progresivo deterioro con aparición de pancitopenia mantenida por infiltración medular, falleciendo, desgraciadamente, en febrero de 2016.
[ "Anamnesis", "\n", "Hombre", "de", "32", "años", "de", "nacionalidad", "española", ",", "informático", "de", "profesión", "y", "sin", "antecedentes", "patológicos", "personales", "o", "familiares", "de", "interés", ".", "No", "reacciones", "alérgicas", "medicamentas", "conocidas", ".", "Fumador", "de", "10", "cigarrillos", "al", "día", "y", "toma", "esporádica", "de", "alcohol", "como", "únicos", "hábitos", "tóxicos", ".", "No", "toma", "medicación", "habitual", ".", "\n", "El", "paciente", ",", "en", "diciembre", "de", "2014", ",", "consulta", "en", "el", "servicio", "de", "urgencias", "de", "su", "hospital", "de", "referencia", "por", "un", "cuadro", "de", "un", "mes", "de", "evolución", "de", "dolor", "en", "hipocondrio", "derecho", "asociado", "a", "subictericia", "desde", "los", "días", "previos", ".", "Salvo", "náuseas", "ocasionales", "y", "una", "ligera", "astenia", ",", "no", "refiere", "otra", "sintomatología", ".", "En", "la", "exploración", "física", "tan", "sólo", "destaca", "la", "subictericia", ",", "sin", "otros", "hallazgos", "de", "interés", ".", "\n\n", "Tras", "realización", "de", "ecografía", "abdominal", "se", "detecta", "una", "lesión", "ocupante", "de", "espacio", "en", "el", "lóbulo", "hepático", "derecho", "e", "ingresa", "para", "completar", "estudio", ".", "En", "el", "TAC", "realizado", "se", "describe", "una", "lesión", "dependiente", "de", "lóbulo", "hepático", "derecho", ",", "hipovascular", ".", "Tras", "biopsia", "de", "la", "lesión", ",", "se", "llega", "finalmente", "al", "diagnóstico", "histológico", "de", "una", "metástasis", "de", "tumor", "neuroendocrino", "(", "TNE", ")", "moderadamente", "diferenciado", "con", "primario", "no", "localizado", ":", "gammagrafía", "con", "octeótride", "sin", "captación", "fuera", "del", "territorio", "hepático", ".", "Resto", "de", "estudio", "de", "extensión", ",", "en", "principio", "negativo", ".", "Como", "centro", "terciario", ",", "el", "paciente", "es", "derivado", "a", "nuestro", "centro", "para", "realización", "de", "cirugía", "hepática", ".", "\n\n", "La", "cirugía", "se", "lleva", "a", "cabo", "en", "febrero", "de", "2015", ",", "realizándose", "transección", "parenquimatosa", "con", "cavitador", "-", "aspirador", "quirúrgico", "ultrasónico", "(", "CUSA", ")", ",", "en", "forma", "de", "hepatectomía", "derecha", ".", "A", "pesar", "del", "diagnóstico", "inicial", "de", "metástasis", "de", "tumor", "neuroendocrino", ",", "el", "estudio", "histológico", "definitivo", "de", "la", "pieza", "quirúrgica", "es", "de", "un", "colangiocarcinoma", "intrahepático", ".", "Márgenes", "no", "afectos", "(", "R0", "):", "pT3N1Mx", ".", "\n", "Es", "en", "este", "momento", "cuando", "el", "paciente", "es", "derivado", "a", "la", "consulta", "de", "Oncología", "Médica", "(", "marzo", "2015", ")", ".", "\n \n", "Exploración", "física", "\n", "Durante", "la", "primera", "valoración", "por", "Oncología", ",", "el", "paciente", "presenta", "excelente", "estado", "general", ",", "con", "un", "Performance", "Status", "de", "1", ".", "Exploración", "abdominal", "sin", "hallazgos", "patológicos", ",", "cicatriz", "de", "laparotomía", "en", "buen", "estado", ",", "sin", "dehiscencias", "ni", "signos", "inflamatorios", "cicundantes", ".", "\n\n", "Pruebas", "complementarias", "\n", "Analíticamente", "destaca", "una", "discreta", "elevación", "de", "las", "enzimas", "hepáticas", ",", "resto", "anodino", ".", "Revisando", "el", "TAC", "abdominal", ",", "además", "de", "la", "masa", "hepática", ",", "en", "los", "cortes", "inferiores", "del", "tórax", "se", "describen", "unos", "pequeños", "nódulos", "bilaterales", ",", "inespecíficos", ",", "que", "en", "el", "contexto", "de", "un", "paciente", "joven", "y", "fumador", ",", "en", "principio", "no", "se", "consideran", "como", "tumorales", ".", "\n\n", "Debido", "al", "diagnóstico", "histológico", "definitivo", ",", "tras", "discusión", "en", "comité", "multidisciplinar", ",", "se", "opta", "por", "administrar", "tratamiento", "pseudoadyuvante", "con", "cisplatino", "-", "gemcitabina", "durante", "seis", "meses", ",", "según", "tolerancia", "y", "respuesta", ".", "\n", "No", "obstante", ",", "previo", "al", "inicio", "de", "tratamiento", "se", "solicita", "un", "TAC", "torácico", "para", "mejor", "caracterización", "de", "los", "dudosos", "nódulos", "observados", "en", "estudio", "radiológico", "previo", ".", "Además", ",", "de", "igual", "modo", "pedimos", "la", "revisión", "del", "estudio", "histológico", "para", "descartar", "definitivamente", "la", "sospecha", "inicial", "de", "TNE", ".", "\n\n", "En", "el", "TAC", "torácico", ",", "se", "describen", "múltiples", "nódulos", "bilaterales", "milimétricos", ",", "metastásicos", ",", "además", "de", "unas", "dilataciones", "arteriales", "bilaterales", "segmentarias", "y", "periféricas", ",", "asociadas", "a", "nódulos", "adyacentes", "de", "distribución", "\"", "en", "árbol", "en", "brote", "\"", ":", "características", "de", "microangiopatía", "trombótica", "metastásica", ".", "El", "paciente", "no", "presenta", "estigmas", "de", "sangrado", "y", "la", "hemostasia", "y", "el", "hemograma", "están", "dentro", "de", "la", "normalidad", ".", "\n\n", "Diagnóstico", "\n", "Tras", "nueva", "valoración", "de", "las", "muestras", "de", "la", "pieza", "quirúrgica", "por", "parte", "del", "servicio", "de", "anatomía", "patológica", ",", "en", "principio", "se", "descarta", "que", "se", "trate", "de", "un", "TNE", ":", "en", "la", "inmunohistoquímica", "todos", "los", "marcadores", "neuroendocrinos", "son", "negativos", ".", "Se", "mantiene", ",", "por", "lo", "tanto", ",", "el", "diagnóstico", "de", "colangiocarcinoma", "intrahepático", ".", "\n\n", "Tratamiento", "\n", "Tras", "estos", "hallazgos", ",", "además", "de", "proceder", "al", "tratamiento", "con", "enoxaparina", "a", "dosis", "plenas", ",", "se", "modifica", "el", "planteamiento", "terapéutico", ":", "dada", "la", "irresecabilidad", "de", "las", "lesiones", "y", "el", "excelente", "estado", "general", "del", "paciente", ",", "se", "planifica", "una", "quimioterapia", "paliativa", "basada", "en", "7", "ciclos", "de", "cisplatino", "-", "gemcitabina", ",", "con", "posible", "mantenimento", "posterior", "de", "gemcitabina", "en", "monoterapia", ".", "\n\n", "Evolución", "\n", "El", "paciente", "inicia", "el", "tratamiento", "en", "abril", "de", "2015", ".", "Primer", "TAC", "de", "evaluación", "en", "junio", "de", "2015", "(", "hasta", "entonces", "se", "han", "administrado", "4", "ciclos", ",", "sin", "toxicidad", "de", "interés", ")", ".", "En", "dicha", "evaluación", "se", "objetiva", "respuesta", "heterogénea", ",", "con", "disminución", "del", "tamaño", "o", "desaparición", "de", "los", "nódulos", "presentes", "previamente", "pero", "con", "aparición", "de", "dos", "nuevos", "nódulos", "pulmonares", "en", "lóbulo", "superior", "izquierdo", ",", "no", "presentes", "en", "estudio", "previo", ".", "Se", "continúa", "con", "el", "plan", "establecido", "y", "se", "administran", "3", "ciclos", "más", ",", "con", "excelente", "tolerancia", ",", "finalizando", "en", "septiembre", "de", "2015", ".", "El", "paciente", "permanece", "asintomático", ",", "con", "una", "analítica", "anodina", "y", "en", "la", "evaluación", "destaca", "la", "estabilidad", "de", "las", "lesiones", "pulmonares", ".", "\n\n", "Ante", "la", "heterogeneidad", "y", "lo", "atípico", "de", "la", "evolución", ",", "junto", "al", "diagnóstico", "histológico", "inicial", "de", "TNE", ",", "se", "solicitan", "las", "muestras", "del", "diagnóstico", "inicial", "realizadas", "en", "el", "hospital", "de", "referencia", "del", "paciente", "para", "nueva", "valoración", "por", "el", "servicio", "de", "Anatomía", "Patológica", "de", "nuestro", "centro", ".", "En", "dicha", "valoración", ",", "se", "llega", "a", "la", "conclusión", "de", "que", "se", "trata", "de", "un", "tumor", "heterogéneo", ",", "con", "dos", "zonas", "morfológicamente", "diferentes", ":", "un", "área", "más", "glandular", "con", "estructuras", "cribiformes", "y", "secreción", "de", "mucina", "(", "zona", "de", "adenocarcinoma", ")", "y", "otra", "zona", "más", "cordonal", ",", "de", "patrón", "organoide", ".", "Dicha", "zona", ",", "al", "análisis", "inmunohistoquímico", "se", "presenta", "como", "positiva", "débil", "y", "difusa", "para", "la", "enolasa", "y", "focal", "para", "la", "sinaptrofisina", ",", "siendo", "la", "cromogranina", "y", "CD", "56", "negativas", ".", "Estos", "hallazgos", "histológicos", "y", "clínicos", "sugieren", "el", "diagnóstico", "definitivo", "de", "un", "carcinoma", "mixto", "(", "adeno", "-", "neuroendocrino", ")", ",", "sin", "claro", "predominio", "de", "uno", "de", "los", "dos", "componentes", ".", "Tras", "esto", ",", "se", "decide", "administrar", "dos", "ciclos", "más", "de", "cisplatino", "-", "gemcitabina", "y", "sunitinib", "posterior", "como", "tratamiento", "de", "mantenimiento", ".", "Mantenimiento", "que", "inicia", "en", "octubre", "de", "2015", ".", "\n\n", "En", "diciembre", "de", "2015", ",", "tras", "aparición", "de", "dolor", "óseo", "a", "nivel", "de", "columna", "dorsal", "y", "masa", "de", "rápido", "crecimiento", "en", "región", "axilar", "derecha", ",", "se", "diagnostica", "de", "metástasis", "óseas", "en", "varios", "cuerpos", "vertebrales", "y", "costal", "derecha", ",", "tratadas", "mediante", "radioterapia", "antiálgica", ".", "Además", ",", "el", "paciente", "presentaba", "una", "úlcera", "gingival", "de", "dos", "meses", "de", "evolución", ":", "maligna", ",", "tras", "estudio", "histológico", ".", "El", "paciente", "inicia", "un", "progresivo", "deterioro", "con", "aparición", "de", "pancitopenia", "mantenida", "por", "infiltración", "medular", ",", "falleciendo", ",", "desgraciadamente", ",", "en", "febrero", "de", "2016", "." ]
[ "MORFOLOGIA_NEOPLASIA" ]
metástasis de tumor neuroendocrino ( TNE ) moderadamente diferenciado, metástasis de tumor neuroendocrino, colangiocarcinoma, pT3N1Mx, tumorales, TNE, metastásicos, metastásica, TNE, colangiocarcinoma, nódulos pulmonares, lesiones pulmonares, TNE, tumor heterogéneo, adenocarcinoma, carcinoma mixto ( adeno - neuroendocrino ), metástasis, maligna, infiltración medular
153_task2
Sentence: Anamnesis Hombre de 32 años de nacionalidad española, informático de profesión y sin antecedentes patológicos personales o familiares de interés. No reacciones alérgicas medicamentas conocidas. Fumador de 10 cigarrillos al día y toma esporádica de alcohol como únicos hábitos tóxicos. No toma medicación habitual. El paciente, en diciembre de 2014, consulta en el servicio de urgencias de su hospital de referencia por un cuadro de un mes de evolución de dolor en hipocondrio derecho asociado a subictericia desde los días previos. Salvo náuseas ocasionales y una ligera astenia, no refiere otra sintomatología. En la exploración física tan sólo destaca la subictericia, sin otros hallazgos de interés. Tras realización de ecografía abdominal se detecta una lesión ocupante de espacio en el lóbulo hepático derecho e ingresa para completar estudio. En el TAC realizado se describe una lesión dependiente de lóbulo hepático derecho, hipovascular. Tras biopsia de la lesión, se llega finalmente al diagnóstico histológico de una metástasis de tumor neuroendocrino (TNE) moderadamente diferenciado con primario no localizado: gammagrafía con octeótride sin captación fuera del territorio hepático. Resto de estudio de extensión, en principio negativo. Como centro terciario, el paciente es derivado a nuestro centro para realización de cirugía hepática. La cirugía se lleva a cabo en febrero de 2015, realizándose transección parenquimatosa con cavitador-aspirador quirúrgico ultrasónico (CUSA), en forma de hepatectomía derecha. A pesar del diagnóstico inicial de metástasis de tumor neuroendocrino, el estudio histológico definitivo de la pieza quirúrgica es de un colangiocarcinoma intrahepático. Márgenes no afectos (R0): pT3N1Mx. Es en este momento cuando el paciente es derivado a la consulta de Oncología Médica (marzo 2015). Exploración física Durante la primera valoración por Oncología, el paciente presenta excelente estado general, con un Performance Status de 1. Exploración abdominal sin hallazgos patológicos, cicatriz de laparotomía en buen estado, sin dehiscencias ni signos inflamatorios cicundantes. Pruebas complementarias Analíticamente destaca una discreta elevación de las enzimas hepáticas, resto anodino. Revisando el TAC abdominal, además de la masa hepática, en los cortes inferiores del tórax se describen unos pequeños nódulos bilaterales, inespecíficos, que en el contexto de un paciente joven y fumador, en principio no se consideran como tumorales. Debido al diagnóstico histológico definitivo, tras discusión en comité multidisciplinar, se opta por administrar tratamiento pseudoadyuvante con cisplatino-gemcitabina durante seis meses, según tolerancia y respuesta. No obstante, previo al inicio de tratamiento se solicita un TAC torácico para mejor caracterización de los dudosos nódulos observados en estudio radiológico previo. Además, de igual modo pedimos la revisión del estudio histológico para descartar definitivamente la sospecha inicial de TNE. En el TAC torácico, se describen múltiples nódulos bilaterales milimétricos, metastásicos, además de unas dilataciones arteriales bilaterales segmentarias y periféricas, asociadas a nódulos adyacentes de distribución "en árbol en brote": características de microangiopatía trombótica metastásica. El paciente no presenta estigmas de sangrado y la hemostasia y el hemograma están dentro de la normalidad. Diagnóstico Tras nueva valoración de las muestras de la pieza quirúrgica por parte del servicio de anatomía patológica, en principio se descarta que se trate de un TNE: en la inmunohistoquímica todos los marcadores neuroendocrinos son negativos. Se mantiene, por lo tanto, el diagnóstico de colangiocarcinoma intrahepático. Tratamiento Tras estos hallazgos, además de proceder al tratamiento con enoxaparina a dosis plenas, se modifica el planteamiento terapéutico: dada la irresecabilidad de las lesiones y el excelente estado general del paciente, se planifica una quimioterapia paliativa basada en 7 ciclos de cisplatino-gemcitabina, con posible mantenimento posterior de gemcitabina en monoterapia. Evolución El paciente inicia el tratamiento en abril de 2015. Primer TAC de evaluación en junio de 2015 (hasta entonces se han administrado 4 ciclos, sin toxicidad de interés). En dicha evaluación se objetiva respuesta heterogénea, con disminución del tamaño o desaparición de los nódulos presentes previamente pero con aparición de dos nuevos nódulos pulmonares en lóbulo superior izquierdo, no presentes en estudio previo. Se continúa con el plan establecido y se administran 3 ciclos más, con excelente tolerancia, finalizando en septiembre de 2015. El paciente permanece asintomático, con una analítica anodina y en la evaluación destaca la estabilidad de las lesiones pulmonares. Ante la heterogeneidad y lo atípico de la evolución, junto al diagnóstico histológico inicial de TNE, se solicitan las muestras del diagnóstico inicial realizadas en el hospital de referencia del paciente para nueva valoración por el servicio de Anatomía Patológica de nuestro centro. En dicha valoración, se llega a la conclusión de que se trata de un tumor heterogéneo, con dos zonas morfológicamente diferentes: un área más glandular con estructuras cribiformes y secreción de mucina (zona de adenocarcinoma) y otra zona más cordonal, de patrón organoide. Dicha zona, al análisis inmunohistoquímico se presenta como positiva débil y difusa para la enolasa y focal para la sinaptrofisina, siendo la cromogranina y CD 56 negativas. Estos hallazgos histológicos y clínicos sugieren el diagnóstico definitivo de un carcinoma mixto (adeno-neuroendocrino), sin claro predominio de uno de los dos componentes. Tras esto, se decide administrar dos ciclos más de cisplatino-gemcitabina y sunitinib posterior como tratamiento de mantenimiento. Mantenimiento que inicia en octubre de 2015. En diciembre de 2015, tras aparición de dolor óseo a nivel de columna dorsal y masa de rápido crecimiento en región axilar derecha, se diagnostica de metástasis óseas en varios cuerpos vertebrales y costal derecha, tratadas mediante radioterapia antiálgica. Además, el paciente presentaba una úlcera gingival de dos meses de evolución: maligna, tras estudio histológico. El paciente inicia un progresivo deterioro con aparición de pancitopenia mantenida por infiltración medular, falleciendo, desgraciadamente, en febrero de 2016. Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Anamnesis Hombre de 32 años de nacionalidad española, informático de profesión y sin antecedentes patológicos personales o familiares de interés. No reacciones alérgicas medicamentas conocidas. Fumador de 10 cigarrillos al día y toma esporádica de alcohol como únicos hábitos tóxicos. No toma medicación habitual. El paciente, en diciembre de 2014, consulta en el servicio de urgencias de su hospital de referencia por un cuadro de un mes de evolución de dolor en hipocondrio derecho asociado a subictericia desde los días previos. Salvo náuseas ocasionales y una ligera astenia, no refiere otra sintomatología. En la exploración física tan sólo destaca la subictericia, sin otros hallazgos de interés. Tras realización de ecografía abdominal se detecta una lesión ocupante de espacio en el lóbulo hepático derecho e ingresa para completar estudio. En el TAC realizado se describe una lesión dependiente de lóbulo hepático derecho, hipovascular. Tras biopsia de la lesión, se llega finalmente al diagnóstico histológico de una metástasis de tumor neuroendocrino (TNE) moderadamente diferenciado con primario no localizado: gammagrafía con octeótride sin captación fuera del territorio hepático. Resto de estudio de extensión, en principio negativo. Como centro terciario, el paciente es derivado a nuestro centro para realización de cirugía hepática. La cirugía se lleva a cabo en febrero de 2015, realizándose transección parenquimatosa con cavitador-aspirador quirúrgico ultrasónico (CUSA), en forma de hepatectomía derecha. A pesar del diagnóstico inicial de metástasis de tumor neuroendocrino, el estudio histológico definitivo de la pieza quirúrgica es de un colangiocarcinoma intrahepático. Márgenes no afectos (R0): pT3N1Mx. Es en este momento cuando el paciente es derivado a la consulta de Oncología Médica (marzo 2015). Exploración física Durante la primera valoración por Oncología, el paciente presenta excelente estado general, con un Performance Status de 1. Exploración abdominal sin hallazgos patológicos, cicatriz de laparotomía en buen estado, sin dehiscencias ni signos inflamatorios cicundantes. Pruebas complementarias Analíticamente destaca una discreta elevación de las enzimas hepáticas, resto anodino. Revisando el TAC abdominal, además de la masa hepática, en los cortes inferiores del tórax se describen unos pequeños nódulos bilaterales, inespecíficos, que en el contexto de un paciente joven y fumador, en principio no se consideran como tumorales. Debido al diagnóstico histológico definitivo, tras discusión en comité multidisciplinar, se opta por administrar tratamiento pseudoadyuvante con cisplatino-gemcitabina durante seis meses, según tolerancia y respuesta. No obstante, previo al inicio de tratamiento se solicita un TAC torácico para mejor caracterización de los dudosos nódulos observados en estudio radiológico previo. Además, de igual modo pedimos la revisión del estudio histológico para descartar definitivamente la sospecha inicial de TNE. En el TAC torácico, se describen múltiples nódulos bilaterales milimétricos, metastásicos, además de unas dilataciones arteriales bilaterales segmentarias y periféricas, asociadas a nódulos adyacentes de distribución "en árbol en brote": características de microangiopatía trombótica metastásica. El paciente no presenta estigmas de sangrado y la hemostasia y el hemograma están dentro de la normalidad. Diagnóstico Tras nueva valoración de las muestras de la pieza quirúrgica por parte del servicio de anatomía patológica, en principio se descarta que se trate de un TNE: en la inmunohistoquímica todos los marcadores neuroendocrinos son negativos. Se mantiene, por lo tanto, el diagnóstico de colangiocarcinoma intrahepático. Tratamiento Tras estos hallazgos, además de proceder al tratamiento con enoxaparina a dosis plenas, se modifica el planteamiento terapéutico: dada la irresecabilidad de las lesiones y el excelente estado general del paciente, se planifica una quimioterapia paliativa basada en 7 ciclos de cisplatino-gemcitabina, con posible mantenimento posterior de gemcitabina en monoterapia. Evolución El paciente inicia el tratamiento en abril de 2015. Primer TAC de evaluación en junio de 2015 (hasta entonces se han administrado 4 ciclos, sin toxicidad de interés). En dicha evaluación se objetiva respuesta heterogénea, con disminución del tamaño o desaparición de los nódulos presentes previamente pero con aparición de dos nuevos nódulos pulmonares en lóbulo superior izquierdo, no presentes en estudio previo. Se continúa con el plan establecido y se administran 3 ciclos más, con excelente tolerancia, finalizando en septiembre de 2015. El paciente permanece asintomático, con una analítica anodina y en la evaluación destaca la estabilidad de las lesiones pulmonares. Ante la heterogeneidad y lo atípico de la evolución, junto al diagnóstico histológico inicial de TNE, se solicitan las muestras del diagnóstico inicial realizadas en el hospital de referencia del paciente para nueva valoración por el servicio de Anatomía Patológica de nuestro centro. En dicha valoración, se llega a la conclusión de que se trata de un tumor heterogéneo, con dos zonas morfológicamente diferentes: un área más glandular con estructuras cribiformes y secreción de mucina (zona de adenocarcinoma) y otra zona más cordonal, de patrón organoide. Dicha zona, al análisis inmunohistoquímico se presenta como positiva débil y difusa para la enolasa y focal para la sinaptrofisina, siendo la cromogranina y CD 56 negativas. Estos hallazgos histológicos y clínicos sugieren el diagnóstico definitivo de un carcinoma mixto (adeno-neuroendocrino), sin claro predominio de uno de los dos componentes. Tras esto, se decide administrar dos ciclos más de cisplatino-gemcitabina y sunitinib posterior como tratamiento de mantenimiento. Mantenimiento que inicia en octubre de 2015. En diciembre de 2015, tras aparición de dolor óseo a nivel de columna dorsal y masa de rápido crecimiento en región axilar derecha, se diagnostica de metástasis óseas en varios cuerpos vertebrales y costal derecha, tratadas mediante radioterapia antiálgica. Además, el paciente presentaba una úlcera gingival de dos meses de evolución: maligna, tras estudio histológico. El paciente inicia un progresivo deterioro con aparición de pancitopenia mantenida por infiltración medular, falleciendo, desgraciadamente, en febrero de 2016.
[ "Anamnesis", "\n", "Hombre", "de", "32", "años", "de", "nacionalidad", "española", ",", "informático", "de", "profesión", "y", "sin", "antecedentes", "patológicos", "personales", "o", "familiares", "de", "interés", ".", "No", "reacciones", "alérgicas", "medicamentas", "conocidas", ".", "Fumador", "de", "10", "cigarrillos", "al", "día", "y", "toma", "esporádica", "de", "alcohol", "como", "únicos", "hábitos", "tóxicos", ".", "No", "toma", "medicación", "habitual", ".", "\n", "El", "paciente", ",", "en", "diciembre", "de", "2014", ",", "consulta", "en", "el", "servicio", "de", "urgencias", "de", "su", "hospital", "de", "referencia", "por", "un", "cuadro", "de", "un", "mes", "de", "evolución", "de", "dolor", "en", "hipocondrio", "derecho", "asociado", "a", "subictericia", "desde", "los", "días", "previos", ".", "Salvo", "náuseas", "ocasionales", "y", "una", "ligera", "astenia", ",", "no", "refiere", "otra", "sintomatología", ".", "En", "la", "exploración", "física", "tan", "sólo", "destaca", "la", "subictericia", ",", "sin", "otros", "hallazgos", "de", "interés", ".", "\n\n", "Tras", "realización", "de", "ecografía", "abdominal", "se", "detecta", "una", "lesión", "ocupante", "de", "espacio", "en", "el", "lóbulo", "hepático", "derecho", "e", "ingresa", "para", "completar", "estudio", ".", "En", "el", "TAC", "realizado", "se", "describe", "una", "lesión", "dependiente", "de", "lóbulo", "hepático", "derecho", ",", "hipovascular", ".", "Tras", "biopsia", "de", "la", "lesión", ",", "se", "llega", "finalmente", "al", "diagnóstico", "histológico", "de", "una", "metástasis", "de", "tumor", "neuroendocrino", "(", "TNE", ")", "moderadamente", "diferenciado", "con", "primario", "no", "localizado", ":", "gammagrafía", "con", "octeótride", "sin", "captación", "fuera", "del", "territorio", "hepático", ".", "Resto", "de", "estudio", "de", "extensión", ",", "en", "principio", "negativo", ".", "Como", "centro", "terciario", ",", "el", "paciente", "es", "derivado", "a", "nuestro", "centro", "para", "realización", "de", "cirugía", "hepática", ".", "\n\n", "La", "cirugía", "se", "lleva", "a", "cabo", "en", "febrero", "de", "2015", ",", "realizándose", "transección", "parenquimatosa", "con", "cavitador", "-", "aspirador", "quirúrgico", "ultrasónico", "(", "CUSA", ")", ",", "en", "forma", "de", "hepatectomía", "derecha", ".", "A", "pesar", "del", "diagnóstico", "inicial", "de", "metástasis", "de", "tumor", "neuroendocrino", ",", "el", "estudio", "histológico", "definitivo", "de", "la", "pieza", "quirúrgica", "es", "de", "un", "colangiocarcinoma", "intrahepático", ".", "Márgenes", "no", "afectos", "(", "R0", "):", "pT3N1Mx", ".", "\n", "Es", "en", "este", "momento", "cuando", "el", "paciente", "es", "derivado", "a", "la", "consulta", "de", "Oncología", "Médica", "(", "marzo", "2015", ")", ".", "\n \n", "Exploración", "física", "\n", "Durante", "la", "primera", "valoración", "por", "Oncología", ",", "el", "paciente", "presenta", "excelente", "estado", "general", ",", "con", "un", "Performance", "Status", "de", "1", ".", "Exploración", "abdominal", "sin", "hallazgos", "patológicos", ",", "cicatriz", "de", "laparotomía", "en", "buen", "estado", ",", "sin", "dehiscencias", "ni", "signos", "inflamatorios", "cicundantes", ".", "\n\n", "Pruebas", "complementarias", "\n", "Analíticamente", "destaca", "una", "discreta", "elevación", "de", "las", "enzimas", "hepáticas", ",", "resto", "anodino", ".", "Revisando", "el", "TAC", "abdominal", ",", "además", "de", "la", "masa", "hepática", ",", "en", "los", "cortes", "inferiores", "del", "tórax", "se", "describen", "unos", "pequeños", "nódulos", "bilaterales", ",", "inespecíficos", ",", "que", "en", "el", "contexto", "de", "un", "paciente", "joven", "y", "fumador", ",", "en", "principio", "no", "se", "consideran", "como", "tumorales", ".", "\n\n", "Debido", "al", "diagnóstico", "histológico", "definitivo", ",", "tras", "discusión", "en", "comité", "multidisciplinar", ",", "se", "opta", "por", "administrar", "tratamiento", "pseudoadyuvante", "con", "cisplatino", "-", "gemcitabina", "durante", "seis", "meses", ",", "según", "tolerancia", "y", "respuesta", ".", "\n", "No", "obstante", ",", "previo", "al", "inicio", "de", "tratamiento", "se", "solicita", "un", "TAC", "torácico", "para", "mejor", "caracterización", "de", "los", "dudosos", "nódulos", "observados", "en", "estudio", "radiológico", "previo", ".", "Además", ",", "de", "igual", "modo", "pedimos", "la", "revisión", "del", "estudio", "histológico", "para", "descartar", "definitivamente", "la", "sospecha", "inicial", "de", "TNE", ".", "\n\n", "En", "el", "TAC", "torácico", ",", "se", "describen", "múltiples", "nódulos", "bilaterales", "milimétricos", ",", "metastásicos", ",", "además", "de", "unas", "dilataciones", "arteriales", "bilaterales", "segmentarias", "y", "periféricas", ",", "asociadas", "a", "nódulos", "adyacentes", "de", "distribución", "\"", "en", "árbol", "en", "brote", "\"", ":", "características", "de", "microangiopatía", "trombótica", "metastásica", ".", "El", "paciente", "no", "presenta", "estigmas", "de", "sangrado", "y", "la", "hemostasia", "y", "el", "hemograma", "están", "dentro", "de", "la", "normalidad", ".", "\n\n", "Diagnóstico", "\n", "Tras", "nueva", "valoración", "de", "las", "muestras", "de", "la", "pieza", "quirúrgica", "por", "parte", "del", "servicio", "de", "anatomía", "patológica", ",", "en", "principio", "se", "descarta", "que", "se", "trate", "de", "un", "TNE", ":", "en", "la", "inmunohistoquímica", "todos", "los", "marcadores", "neuroendocrinos", "son", "negativos", ".", "Se", "mantiene", ",", "por", "lo", "tanto", ",", "el", "diagnóstico", "de", "colangiocarcinoma", "intrahepático", ".", "\n\n", "Tratamiento", "\n", "Tras", "estos", "hallazgos", ",", "además", "de", "proceder", "al", "tratamiento", "con", "enoxaparina", "a", "dosis", "plenas", ",", "se", "modifica", "el", "planteamiento", "terapéutico", ":", "dada", "la", "irresecabilidad", "de", "las", "lesiones", "y", "el", "excelente", "estado", "general", "del", "paciente", ",", "se", "planifica", "una", "quimioterapia", "paliativa", "basada", "en", "7", "ciclos", "de", "cisplatino", "-", "gemcitabina", ",", "con", "posible", "mantenimento", "posterior", "de", "gemcitabina", "en", "monoterapia", ".", "\n\n", "Evolución", "\n", "El", "paciente", "inicia", "el", "tratamiento", "en", "abril", "de", "2015", ".", "Primer", "TAC", "de", "evaluación", "en", "junio", "de", "2015", "(", "hasta", "entonces", "se", "han", "administrado", "4", "ciclos", ",", "sin", "toxicidad", "de", "interés", ")", ".", "En", "dicha", "evaluación", "se", "objetiva", "respuesta", "heterogénea", ",", "con", "disminución", "del", "tamaño", "o", "desaparición", "de", "los", "nódulos", "presentes", "previamente", "pero", "con", "aparición", "de", "dos", "nuevos", "nódulos", "pulmonares", "en", "lóbulo", "superior", "izquierdo", ",", "no", "presentes", "en", "estudio", "previo", ".", "Se", "continúa", "con", "el", "plan", "establecido", "y", "se", "administran", "3", "ciclos", "más", ",", "con", "excelente", "tolerancia", ",", "finalizando", "en", "septiembre", "de", "2015", ".", "El", "paciente", "permanece", "asintomático", ",", "con", "una", "analítica", "anodina", "y", "en", "la", "evaluación", "destaca", "la", "estabilidad", "de", "las", "lesiones", "pulmonares", ".", "\n\n", "Ante", "la", "heterogeneidad", "y", "lo", "atípico", "de", "la", "evolución", ",", "junto", "al", "diagnóstico", "histológico", "inicial", "de", "TNE", ",", "se", "solicitan", "las", "muestras", "del", "diagnóstico", "inicial", "realizadas", "en", "el", "hospital", "de", "referencia", "del", "paciente", "para", "nueva", "valoración", "por", "el", "servicio", "de", "Anatomía", "Patológica", "de", "nuestro", "centro", ".", "En", "dicha", "valoración", ",", "se", "llega", "a", "la", "conclusión", "de", "que", "se", "trata", "de", "un", "tumor", "heterogéneo", ",", "con", "dos", "zonas", "morfológicamente", "diferentes", ":", "un", "área", "más", "glandular", "con", "estructuras", "cribiformes", "y", "secreción", "de", "mucina", "(", "zona", "de", "adenocarcinoma", ")", "y", "otra", "zona", "más", "cordonal", ",", "de", "patrón", "organoide", ".", "Dicha", "zona", ",", "al", "análisis", "inmunohistoquímico", "se", "presenta", "como", "positiva", "débil", "y", "difusa", "para", "la", "enolasa", "y", "focal", "para", "la", "sinaptrofisina", ",", "siendo", "la", "cromogranina", "y", "CD", "56", "negativas", ".", "Estos", "hallazgos", "histológicos", "y", "clínicos", "sugieren", "el", "diagnóstico", "definitivo", "de", "un", "carcinoma", "mixto", "(", "adeno", "-", "neuroendocrino", ")", ",", "sin", "claro", "predominio", "de", "uno", "de", "los", "dos", "componentes", ".", "Tras", "esto", ",", "se", "decide", "administrar", "dos", "ciclos", "más", "de", "cisplatino", "-", "gemcitabina", "y", "sunitinib", "posterior", "como", "tratamiento", "de", "mantenimiento", ".", "Mantenimiento", "que", "inicia", "en", "octubre", "de", "2015", ".", "\n\n", "En", "diciembre", "de", "2015", ",", "tras", "aparición", "de", "dolor", "óseo", "a", "nivel", "de", "columna", "dorsal", "y", "masa", "de", "rápido", "crecimiento", "en", "región", "axilar", "derecha", ",", "se", "diagnostica", "de", "metástasis", "óseas", "en", "varios", "cuerpos", "vertebrales", "y", "costal", "derecha", ",", "tratadas", "mediante", "radioterapia", "antiálgica", ".", "Además", ",", "el", "paciente", "presentaba", "una", "úlcera", "gingival", "de", "dos", "meses", "de", "evolución", ":", "maligna", ",", "tras", "estudio", "histológico", ".", "El", "paciente", "inicia", "un", "progresivo", "deterioro", "con", "aparición", "de", "pancitopenia", "mantenida", "por", "infiltración", "medular", ",", "falleciendo", ",", "desgraciadamente", ",", "en", "febrero", "de", "2016", "." ]
[ "MORFOLOGIA_NEOPLASIA" ]
Intelligenzentwicklung is an umlsterm, Intelligenz is an umlsterm, Arbeit is an umlsterm, Verwendung is an umlsterm, Intelligenz is an umlsterm, Frauen is an umlsterm, Hauptfaktorenanalyse is an umlsterm, Leistungen is an umlsterm, Mosaiktest is an umlsterm, Intelligenz is an umlsterm, Intelligenz is an umlsterm, Intelligenz is an umlsterm
ZfuerGerontologie+Geriatrie.80310089.ger.abstr_task0
Sentence: Die Speed " " -Hypothese der Intelligenzentwicklung postuliert , dass die im Alter zurueckgehende Geschwindigkeit der Informationsverarbeitung die zentrale kritische Ressource fuer psychometrische Intelligenz darstellt . Die vorliegende Arbeit unternimmt den Versuch , die Speed " " -Hypothese unter Verwendung von Latent Growth Curve Models " " auf ihre individuelle Gueltigkeit fuer die Entwicklung der fluiden Intelligenz hin zu ueberpruefen . Dazu wird auf 4 Messzeitpunkte des Datenmaterials der Bonner Laengsschnittstudie zurueckgegriffen ( N=128, mittleres Alter 67,2 Jahre , 53% Frauen ) . Basierend auf einer Hauptfaktorenanalyse werden der HAWIE-Zahlen-Symbol-Test sowie die Leistungen bei einer einfachen psychomotorischen Geschwindigkeitsaufgabe als Indikatoren fuer Informationsverarbeitungsgeschwindigkeit und die HAWIE-Subtests Figurenlegen und Mosaiktest als Indikatoren fuer fluide Intelligenz herangezogen . Nach dem getrennten Anpassen zweier " Latent Growth Curve Models " fuer speed " " und fluide Intelligenz kann in einem kombinierten Modell die Uebereinstimmung mit dem Datenmaterial durch eine freie Schaetzung der Kovarianz zwischen den beiden " Slope " -Faktoren nicht verbessert werden . Dieses Ergebnis spricht gegen die " Speed " -Hypothese , da die intraindividuellen Veraenderungen von fluider Intelligenz nicht mit den entsprechenden Veraenderungen der Informationsverarbeitungsgeschwindigkeit zusammenhaengen . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm
[ "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Die Speed " " -Hypothese der Intelligenzentwicklung postuliert , dass die im Alter zurueckgehende Geschwindigkeit der Informationsverarbeitung die zentrale kritische Ressource fuer psychometrische Intelligenz darstellt . Die vorliegende Arbeit unternimmt den Versuch , die Speed " " -Hypothese unter Verwendung von Latent Growth Curve Models " " auf ihre individuelle Gueltigkeit fuer die Entwicklung der fluiden Intelligenz hin zu ueberpruefen . Dazu wird auf 4 Messzeitpunkte des Datenmaterials der Bonner Laengsschnittstudie zurueckgegriffen ( N=128, mittleres Alter 67,2 Jahre , 53% Frauen ) . Basierend auf einer Hauptfaktorenanalyse werden der HAWIE-Zahlen-Symbol-Test sowie die Leistungen bei einer einfachen psychomotorischen Geschwindigkeitsaufgabe als Indikatoren fuer Informationsverarbeitungsgeschwindigkeit und die HAWIE-Subtests Figurenlegen und Mosaiktest als Indikatoren fuer fluide Intelligenz herangezogen . Nach dem getrennten Anpassen zweier " Latent Growth Curve Models " fuer speed " " und fluide Intelligenz kann in einem kombinierten Modell die Uebereinstimmung mit dem Datenmaterial durch eine freie Schaetzung der Kovarianz zwischen den beiden " Slope " -Faktoren nicht verbessert werden . Dieses Ergebnis spricht gegen die " Speed " -Hypothese , da die intraindividuellen Veraenderungen von fluider Intelligenz nicht mit den entsprechenden Veraenderungen der Informationsverarbeitungsgeschwindigkeit zusammenhaengen .
[ "Die", "Speed", "\"", "\"", "-Hypothese", "der", "Intelligenzentwicklung", "postuliert", ",", "dass", "die", "im", "Alter", "zurueckgehende", "Geschwindigkeit", "der", "Informationsverarbeitung", "die", "zentrale", "kritische", "Ressource", "fuer", "psychometrische", "Intelligenz", "darstellt", ".", "Die", "vorliegende", "Arbeit", "unternimmt", "den", "Versuch", ",", "die", "Speed", "\"", "\"", "-Hypothese", "unter", "Verwendung", "von", "Latent", "Growth", "Curve", "Models", "\"", "\"", "auf", "ihre", "individuelle", "Gueltigkeit", "fuer", "die", "Entwicklung", "der", "fluiden", "Intelligenz", "hin", "zu", "ueberpruefen", ".", "Dazu", "wird", "auf", "4", "Messzeitpunkte", "des", "Datenmaterials", "der", "Bonner", "Laengsschnittstudie", "zurueckgegriffen", "(", "N=128", ",", "mittleres", "Alter", "67,2", "Jahre", ",", "53", "%", "Frauen", ")", ".", "Basierend", "auf", "einer", "Hauptfaktorenanalyse", "werden", "der", "HAWIE", "-", "Zahlen", "-", "Symbol", "-", "Test", "sowie", "die", "Leistungen", "bei", "einer", "einfachen", "psychomotorischen", "Geschwindigkeitsaufgabe", "als", "Indikatoren", "fuer", "Informationsverarbeitungsgeschwindigkeit", "und", "die", "HAWIE", "-", "Subtests", "Figurenlegen", "und", "Mosaiktest", "als", "Indikatoren", "fuer", "fluide", "Intelligenz", "herangezogen", ".", "Nach", "dem", "getrennten", "Anpassen", "zweier", "\"", "Latent", "Growth", "Curve", "Models", "\"", "fuer", "speed", "\"", "\"", "und", "fluide", "Intelligenz", "kann", "in", "einem", "kombinierten", "Modell", "die", "Uebereinstimmung", "mit", "dem", "Datenmaterial", "durch", "eine", "freie", "Schaetzung", "der", "Kovarianz", "zwischen", "den", "beiden", "\"", "Slope", "\"", "-Faktoren", "nicht", "verbessert", "werden", ".", "Dieses", "Ergebnis", "spricht", "gegen", "die", "\"", "Speed", "\"", "-Hypothese", ",", "da", "die", "intraindividuellen", "Veraenderungen", "von", "fluider", "Intelligenz", "nicht", "mit", "den", "entsprechenden", "Veraenderungen", "der", "Informationsverarbeitungsgeschwindigkeit", "zusammenhaengen", "." ]
[ "umlsterm" ]
Intelligenzentwicklung is an umlsterm, Intelligenz is an umlsterm, Arbeit is an umlsterm, Verwendung is an umlsterm, Intelligenz is an umlsterm, Frauen is an umlsterm, Hauptfaktorenanalyse is an umlsterm, Leistungen is an umlsterm, Mosaiktest is an umlsterm, Intelligenz is an umlsterm, Intelligenz is an umlsterm, Intelligenz is an umlsterm
ZfuerGerontologie+Geriatrie.80310089.ger.abstr_task1
Sentence: Die Speed " " -Hypothese der Intelligenzentwicklung postuliert , dass die im Alter zurueckgehende Geschwindigkeit der Informationsverarbeitung die zentrale kritische Ressource fuer psychometrische Intelligenz darstellt . Die vorliegende Arbeit unternimmt den Versuch , die Speed " " -Hypothese unter Verwendung von Latent Growth Curve Models " " auf ihre individuelle Gueltigkeit fuer die Entwicklung der fluiden Intelligenz hin zu ueberpruefen . Dazu wird auf 4 Messzeitpunkte des Datenmaterials der Bonner Laengsschnittstudie zurueckgegriffen ( N=128, mittleres Alter 67,2 Jahre , 53% Frauen ) . Basierend auf einer Hauptfaktorenanalyse werden der HAWIE-Zahlen-Symbol-Test sowie die Leistungen bei einer einfachen psychomotorischen Geschwindigkeitsaufgabe als Indikatoren fuer Informationsverarbeitungsgeschwindigkeit und die HAWIE-Subtests Figurenlegen und Mosaiktest als Indikatoren fuer fluide Intelligenz herangezogen . Nach dem getrennten Anpassen zweier " Latent Growth Curve Models " fuer speed " " und fluide Intelligenz kann in einem kombinierten Modell die Uebereinstimmung mit dem Datenmaterial durch eine freie Schaetzung der Kovarianz zwischen den beiden " Slope " -Faktoren nicht verbessert werden . Dieses Ergebnis spricht gegen die " Speed " -Hypothese , da die intraindividuellen Veraenderungen von fluider Intelligenz nicht mit den entsprechenden Veraenderungen der Informationsverarbeitungsgeschwindigkeit zusammenhaengen . Instructions: please typing these entity words according to sentence: Intelligenzentwicklung, Intelligenz, Arbeit, Verwendung, Intelligenz, Frauen, Hauptfaktorenanalyse, Leistungen, Mosaiktest, Intelligenz, Intelligenz, Intelligenz Options: umlsterm
[ "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Die Speed " " -Hypothese der Intelligenzentwicklung postuliert , dass die im Alter zurueckgehende Geschwindigkeit der Informationsverarbeitung die zentrale kritische Ressource fuer psychometrische Intelligenz darstellt . Die vorliegende Arbeit unternimmt den Versuch , die Speed " " -Hypothese unter Verwendung von Latent Growth Curve Models " " auf ihre individuelle Gueltigkeit fuer die Entwicklung der fluiden Intelligenz hin zu ueberpruefen . Dazu wird auf 4 Messzeitpunkte des Datenmaterials der Bonner Laengsschnittstudie zurueckgegriffen ( N=128, mittleres Alter 67,2 Jahre , 53% Frauen ) . Basierend auf einer Hauptfaktorenanalyse werden der HAWIE-Zahlen-Symbol-Test sowie die Leistungen bei einer einfachen psychomotorischen Geschwindigkeitsaufgabe als Indikatoren fuer Informationsverarbeitungsgeschwindigkeit und die HAWIE-Subtests Figurenlegen und Mosaiktest als Indikatoren fuer fluide Intelligenz herangezogen . Nach dem getrennten Anpassen zweier " Latent Growth Curve Models " fuer speed " " und fluide Intelligenz kann in einem kombinierten Modell die Uebereinstimmung mit dem Datenmaterial durch eine freie Schaetzung der Kovarianz zwischen den beiden " Slope " -Faktoren nicht verbessert werden . Dieses Ergebnis spricht gegen die " Speed " -Hypothese , da die intraindividuellen Veraenderungen von fluider Intelligenz nicht mit den entsprechenden Veraenderungen der Informationsverarbeitungsgeschwindigkeit zusammenhaengen .
[ "Die", "Speed", "\"", "\"", "-Hypothese", "der", "Intelligenzentwicklung", "postuliert", ",", "dass", "die", "im", "Alter", "zurueckgehende", "Geschwindigkeit", "der", "Informationsverarbeitung", "die", "zentrale", "kritische", "Ressource", "fuer", "psychometrische", "Intelligenz", "darstellt", ".", "Die", "vorliegende", "Arbeit", "unternimmt", "den", "Versuch", ",", "die", "Speed", "\"", "\"", "-Hypothese", "unter", "Verwendung", "von", "Latent", "Growth", "Curve", "Models", "\"", "\"", "auf", "ihre", "individuelle", "Gueltigkeit", "fuer", "die", "Entwicklung", "der", "fluiden", "Intelligenz", "hin", "zu", "ueberpruefen", ".", "Dazu", "wird", "auf", "4", "Messzeitpunkte", "des", "Datenmaterials", "der", "Bonner", "Laengsschnittstudie", "zurueckgegriffen", "(", "N=128", ",", "mittleres", "Alter", "67,2", "Jahre", ",", "53", "%", "Frauen", ")", ".", "Basierend", "auf", "einer", "Hauptfaktorenanalyse", "werden", "der", "HAWIE", "-", "Zahlen", "-", "Symbol", "-", "Test", "sowie", "die", "Leistungen", "bei", "einer", "einfachen", "psychomotorischen", "Geschwindigkeitsaufgabe", "als", "Indikatoren", "fuer", "Informationsverarbeitungsgeschwindigkeit", "und", "die", "HAWIE", "-", "Subtests", "Figurenlegen", "und", "Mosaiktest", "als", "Indikatoren", "fuer", "fluide", "Intelligenz", "herangezogen", ".", "Nach", "dem", "getrennten", "Anpassen", "zweier", "\"", "Latent", "Growth", "Curve", "Models", "\"", "fuer", "speed", "\"", "\"", "und", "fluide", "Intelligenz", "kann", "in", "einem", "kombinierten", "Modell", "die", "Uebereinstimmung", "mit", "dem", "Datenmaterial", "durch", "eine", "freie", "Schaetzung", "der", "Kovarianz", "zwischen", "den", "beiden", "\"", "Slope", "\"", "-Faktoren", "nicht", "verbessert", "werden", ".", "Dieses", "Ergebnis", "spricht", "gegen", "die", "\"", "Speed", "\"", "-Hypothese", ",", "da", "die", "intraindividuellen", "Veraenderungen", "von", "fluider", "Intelligenz", "nicht", "mit", "den", "entsprechenden", "Veraenderungen", "der", "Informationsverarbeitungsgeschwindigkeit", "zusammenhaengen", "." ]
[ "umlsterm" ]
Intelligenzentwicklung, Intelligenz, Arbeit, Verwendung, Intelligenz, Frauen, Hauptfaktorenanalyse, Leistungen, Mosaiktest, Intelligenz, Intelligenz, Intelligenz
ZfuerGerontologie+Geriatrie.80310089.ger.abstr_task2
Sentence: Die Speed " " -Hypothese der Intelligenzentwicklung postuliert , dass die im Alter zurueckgehende Geschwindigkeit der Informationsverarbeitung die zentrale kritische Ressource fuer psychometrische Intelligenz darstellt . Die vorliegende Arbeit unternimmt den Versuch , die Speed " " -Hypothese unter Verwendung von Latent Growth Curve Models " " auf ihre individuelle Gueltigkeit fuer die Entwicklung der fluiden Intelligenz hin zu ueberpruefen . Dazu wird auf 4 Messzeitpunkte des Datenmaterials der Bonner Laengsschnittstudie zurueckgegriffen ( N=128, mittleres Alter 67,2 Jahre , 53% Frauen ) . Basierend auf einer Hauptfaktorenanalyse werden der HAWIE-Zahlen-Symbol-Test sowie die Leistungen bei einer einfachen psychomotorischen Geschwindigkeitsaufgabe als Indikatoren fuer Informationsverarbeitungsgeschwindigkeit und die HAWIE-Subtests Figurenlegen und Mosaiktest als Indikatoren fuer fluide Intelligenz herangezogen . Nach dem getrennten Anpassen zweier " Latent Growth Curve Models " fuer speed " " und fluide Intelligenz kann in einem kombinierten Modell die Uebereinstimmung mit dem Datenmaterial durch eine freie Schaetzung der Kovarianz zwischen den beiden " Slope " -Faktoren nicht verbessert werden . Dieses Ergebnis spricht gegen die " Speed " -Hypothese , da die intraindividuellen Veraenderungen von fluider Intelligenz nicht mit den entsprechenden Veraenderungen der Informationsverarbeitungsgeschwindigkeit zusammenhaengen . Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Die Speed " " -Hypothese der Intelligenzentwicklung postuliert , dass die im Alter zurueckgehende Geschwindigkeit der Informationsverarbeitung die zentrale kritische Ressource fuer psychometrische Intelligenz darstellt . Die vorliegende Arbeit unternimmt den Versuch , die Speed " " -Hypothese unter Verwendung von Latent Growth Curve Models " " auf ihre individuelle Gueltigkeit fuer die Entwicklung der fluiden Intelligenz hin zu ueberpruefen . Dazu wird auf 4 Messzeitpunkte des Datenmaterials der Bonner Laengsschnittstudie zurueckgegriffen ( N=128, mittleres Alter 67,2 Jahre , 53% Frauen ) . Basierend auf einer Hauptfaktorenanalyse werden der HAWIE-Zahlen-Symbol-Test sowie die Leistungen bei einer einfachen psychomotorischen Geschwindigkeitsaufgabe als Indikatoren fuer Informationsverarbeitungsgeschwindigkeit und die HAWIE-Subtests Figurenlegen und Mosaiktest als Indikatoren fuer fluide Intelligenz herangezogen . Nach dem getrennten Anpassen zweier " Latent Growth Curve Models " fuer speed " " und fluide Intelligenz kann in einem kombinierten Modell die Uebereinstimmung mit dem Datenmaterial durch eine freie Schaetzung der Kovarianz zwischen den beiden " Slope " -Faktoren nicht verbessert werden . Dieses Ergebnis spricht gegen die " Speed " -Hypothese , da die intraindividuellen Veraenderungen von fluider Intelligenz nicht mit den entsprechenden Veraenderungen der Informationsverarbeitungsgeschwindigkeit zusammenhaengen .
[ "Die", "Speed", "\"", "\"", "-Hypothese", "der", "Intelligenzentwicklung", "postuliert", ",", "dass", "die", "im", "Alter", "zurueckgehende", "Geschwindigkeit", "der", "Informationsverarbeitung", "die", "zentrale", "kritische", "Ressource", "fuer", "psychometrische", "Intelligenz", "darstellt", ".", "Die", "vorliegende", "Arbeit", "unternimmt", "den", "Versuch", ",", "die", "Speed", "\"", "\"", "-Hypothese", "unter", "Verwendung", "von", "Latent", "Growth", "Curve", "Models", "\"", "\"", "auf", "ihre", "individuelle", "Gueltigkeit", "fuer", "die", "Entwicklung", "der", "fluiden", "Intelligenz", "hin", "zu", "ueberpruefen", ".", "Dazu", "wird", "auf", "4", "Messzeitpunkte", "des", "Datenmaterials", "der", "Bonner", "Laengsschnittstudie", "zurueckgegriffen", "(", "N=128", ",", "mittleres", "Alter", "67,2", "Jahre", ",", "53", "%", "Frauen", ")", ".", "Basierend", "auf", "einer", "Hauptfaktorenanalyse", "werden", "der", "HAWIE", "-", "Zahlen", "-", "Symbol", "-", "Test", "sowie", "die", "Leistungen", "bei", "einer", "einfachen", "psychomotorischen", "Geschwindigkeitsaufgabe", "als", "Indikatoren", "fuer", "Informationsverarbeitungsgeschwindigkeit", "und", "die", "HAWIE", "-", "Subtests", "Figurenlegen", "und", "Mosaiktest", "als", "Indikatoren", "fuer", "fluide", "Intelligenz", "herangezogen", ".", "Nach", "dem", "getrennten", "Anpassen", "zweier", "\"", "Latent", "Growth", "Curve", "Models", "\"", "fuer", "speed", "\"", "\"", "und", "fluide", "Intelligenz", "kann", "in", "einem", "kombinierten", "Modell", "die", "Uebereinstimmung", "mit", "dem", "Datenmaterial", "durch", "eine", "freie", "Schaetzung", "der", "Kovarianz", "zwischen", "den", "beiden", "\"", "Slope", "\"", "-Faktoren", "nicht", "verbessert", "werden", ".", "Dieses", "Ergebnis", "spricht", "gegen", "die", "\"", "Speed", "\"", "-Hypothese", ",", "da", "die", "intraindividuellen", "Veraenderungen", "von", "fluider", "Intelligenz", "nicht", "mit", "den", "entsprechenden", "Veraenderungen", "der", "Informationsverarbeitungsgeschwindigkeit", "zusammenhaengen", "." ]
[ "umlsterm" ]
abdominoplasty is a Procedure, TRAM flap breast reconstruction is a Procedure
NCT02542956_inc_task0
Sentence: Undergoing abdominoplasty or TRAM flap breast reconstruction Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Procedure
[ "O", "B-Procedure", "O", "B-Procedure", "I-Procedure", "I-Procedure", "I-Procedure", "O" ]
Undergoing abdominoplasty or TRAM flap breast reconstruction
[ "Undergoing", "abdominoplasty", "or", "TRAM", "flap", "breast", "reconstruction", "\n" ]
[ "Procedure" ]
abdominoplasty is a Procedure, TRAM flap breast reconstruction is a Procedure
NCT02542956_inc_task1
Sentence: Undergoing abdominoplasty or TRAM flap breast reconstruction Instructions: please typing these entity words according to sentence: abdominoplasty, TRAM flap breast reconstruction Options: Procedure
[ "O", "B-Procedure", "O", "B-Procedure", "I-Procedure", "I-Procedure", "I-Procedure", "O" ]
Undergoing abdominoplasty or TRAM flap breast reconstruction
[ "Undergoing", "abdominoplasty", "or", "TRAM", "flap", "breast", "reconstruction", "\n" ]
[ "Procedure" ]
abdominoplasty, TRAM flap breast reconstruction
NCT02542956_inc_task2
Sentence: Undergoing abdominoplasty or TRAM flap breast reconstruction Instructions: please extract entity words from the input sentence
[ "O", "B-Procedure", "O", "B-Procedure", "I-Procedure", "I-Procedure", "I-Procedure", "O" ]
Undergoing abdominoplasty or TRAM flap breast reconstruction
[ "Undergoing", "abdominoplasty", "or", "TRAM", "flap", "breast", "reconstruction", "\n" ]
[ "Procedure" ]
Effects is a Outcome_Other, oral brovincamine is a Intervention_Pharmacological, normal - tension glaucoma is a Participant_Condition, low - normal intraocular pressure is a Participant_Condition, effect is a Outcome_Other, cerebral vasodilator is a Intervention_Physical, normal - tension glaucoma ( NTG ) is a Participant_Condition, Fifty - two is a Participant_Sample-size, 57.7 is a Participant_Age, untreated control group . is a Intervention_Control, visual field examinations is a Intervention_Control, Changes in mean deviation ( MD ) is a Outcome_Other, corrected pattern standard deviation ( CPSD ) is a Outcome_Other, total deviation ( TD ) is a Outcome_Other, refraction is a Outcome_Physical, blood pressure is a Outcome_Physical, baseline IOP is a Outcome_Physical, Changes in MD is a Outcome_Other, Change in CPSD ( SE ) is a Outcome_Other, Change in TD is a Outcome_Other, average IOP is a Outcome_Physical, Oral brovincamine is a Intervention_Pharmacological
676_task0
Sentence: Effects of oral brovincamine on visual field damage in patients with normal-tension glaucoma with low-normal intraocular pressure . PURPOSE To prospectively study the effect of oral brovincamine , a relatively selective cerebral vasodilator , on further deterioration of visual field in patients with normal-tension glaucoma ( NTG ) with low-normal intraocular pressure ( IOP ) . METHODS Fifty-two patients with NTG ( average age 57.7 years ) with an IOP that was consistently less than 15 mmHg were randomly assigned to receive oral brovincamine ( 20 mg three times daily ) or to an untreated control group . The groups were prospectively followed for 2 years with visual field examinations every 4 months , using the 30-2 Humphrey perimeter program . Changes in mean deviation ( MD ) , corrected pattern standard deviation ( CPSD ) , and total deviation ( TD ) at 74 test points were analyzed using regression analysis with linear mixed model . Data from one eye without media opacity of each subject were analyzed . RESULTS There were no differences between groups in age ; sex distribution ; refraction ; blood pressure ; baseline IOP ; MD , CPSD , or TD at each point . Changes in MD ( standard error [ SE ] ) during the study period were -0.778 ( 0.178 ) and -0.071 ( 0.195 ) dB/year in the control and brovincamine groups , respectively ; change in the control group was significantly more negative than in the brovincamine group . Change in CPSD ( SE ) was 0.032 ( 0.015 ) and 0.004 ( 0.016 ) dB/year in the control and brovincamine groups , respectively . Change in the control group was significantly positive , but the intergroup difference was not significant . Change in TD was significantly negative at six test points in the control group , whereas no points showed a significant trend in the brovincamine group ; the intergroup difference was significant . The average IOP was 13.2 mmHg and 13.1 mmHg in the control and brovincamine groups , respectively , and there was no significant intergroup difference . CONCLUSION Oral brovincamine may retard further visual field deterioration in patients with NTG who have low-normal IOP . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Intervention_Pharmacological, Intervention_Physical, Participant_Condition, Intervention_Control, Participant_Age, Outcome_Physical, Participant_Sample-size, Outcome_Other
[ "B-Outcome_Other", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Physical", "I-Intervention_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "B-Participant_Age", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Effects of oral brovincamine on visual field damage in patients with normal-tension glaucoma with low-normal intraocular pressure . PURPOSE To prospectively study the effect of oral brovincamine , a relatively selective cerebral vasodilator , on further deterioration of visual field in patients with normal-tension glaucoma ( NTG ) with low-normal intraocular pressure ( IOP ) . METHODS Fifty-two patients with NTG ( average age 57.7 years ) with an IOP that was consistently less than 15 mmHg were randomly assigned to receive oral brovincamine ( 20 mg three times daily ) or to an untreated control group . The groups were prospectively followed for 2 years with visual field examinations every 4 months , using the 30-2 Humphrey perimeter program . Changes in mean deviation ( MD ) , corrected pattern standard deviation ( CPSD ) , and total deviation ( TD ) at 74 test points were analyzed using regression analysis with linear mixed model . Data from one eye without media opacity of each subject were analyzed . RESULTS There were no differences between groups in age ; sex distribution ; refraction ; blood pressure ; baseline IOP ; MD , CPSD , or TD at each point . Changes in MD ( standard error [ SE ] ) during the study period were -0.778 ( 0.178 ) and -0.071 ( 0.195 ) dB/year in the control and brovincamine groups , respectively ; change in the control group was significantly more negative than in the brovincamine group . Change in CPSD ( SE ) was 0.032 ( 0.015 ) and 0.004 ( 0.016 ) dB/year in the control and brovincamine groups , respectively . Change in the control group was significantly positive , but the intergroup difference was not significant . Change in TD was significantly negative at six test points in the control group , whereas no points showed a significant trend in the brovincamine group ; the intergroup difference was significant . The average IOP was 13.2 mmHg and 13.1 mmHg in the control and brovincamine groups , respectively , and there was no significant intergroup difference . CONCLUSION Oral brovincamine may retard further visual field deterioration in patients with NTG who have low-normal IOP .
[ "Effects", "of", "oral", "brovincamine", "on", "visual", "field", "damage", "in", "patients", "with", "normal", "-", "tension", "glaucoma", "with", "low", "-", "normal", "intraocular", "pressure", ".", "PURPOSE", "To", "prospectively", "study", "the", "effect", "of", "oral", "brovincamine", ",", "a", "relatively", "selective", "cerebral", "vasodilator", ",", "on", "further", "deterioration", "of", "visual", "field", "in", "patients", "with", "normal", "-", "tension", "glaucoma", "(", "NTG", ")", "with", "low", "-", "normal", "intraocular", "pressure", "(", "IOP", ")", ".", "METHODS", "Fifty", "-", "two", "patients", "with", "NTG", "(", "average", "age", "57.7", "years", ")", "with", "an", "IOP", "that", "was", "consistently", "less", "than", "15", "mmHg", "were", "randomly", "assigned", "to", "receive", "oral", "brovincamine", "(", "20", "mg", "three", "times", "daily", ")", "or", "to", "an", "untreated", "control", "group", ".", "The", "groups", "were", "prospectively", "followed", "for", "2", "years", "with", "visual", "field", "examinations", "every", "4", "months", ",", "using", "the", "30", "-", "2", "Humphrey", "perimeter", "program", ".", "Changes", "in", "mean", "deviation", "(", "MD", ")", ",", "corrected", "pattern", "standard", "deviation", "(", "CPSD", ")", ",", "and", "total", "deviation", "(", "TD", ")", "at", "74", "test", "points", "were", "analyzed", "using", "regression", "analysis", "with", "linear", "mixed", "model", ".", "Data", "from", "one", "eye", "without", "media", "opacity", "of", "each", "subject", "were", "analyzed", ".", "RESULTS", "There", "were", "no", "differences", "between", "groups", "in", "age", ";", "sex", "distribution", ";", "refraction", ";", "blood", "pressure", ";", "baseline", "IOP", ";", "MD", ",", "CPSD", ",", "or", "TD", "at", "each", "point", ".", "Changes", "in", "MD", "(", "standard", "error", "[", "SE", "]", ")", "during", "the", "study", "period", "were", "-0.778", "(", "0.178", ")", "and", "-0.071", "(", "0.195", ")", "dB", "/", "year", "in", "the", "control", "and", "brovincamine", "groups", ",", "respectively", ";", "change", "in", "the", "control", "group", "was", "significantly", "more", "negative", "than", "in", "the", "brovincamine", "group", ".", "Change", "in", "CPSD", "(", "SE", ")", "was", "0.032", "(", "0.015", ")", "and", "0.004", "(", "0.016", ")", "dB", "/", "year", "in", "the", "control", "and", "brovincamine", "groups", ",", "respectively", ".", "Change", "in", "the", "control", "group", "was", "significantly", "positive", ",", "but", "the", "intergroup", "difference", "was", "not", "significant", ".", "Change", "in", "TD", "was", "significantly", "negative", "at", "six", "test", "points", "in", "the", "control", "group", ",", "whereas", "no", "points", "showed", "a", "significant", "trend", "in", "the", "brovincamine", "group", ";", "the", "intergroup", "difference", "was", "significant", ".", "The", "average", "IOP", "was", "13.2", "mmHg", "and", "13.1", "mmHg", "in", "the", "control", "and", "brovincamine", "groups", ",", "respectively", ",", "and", "there", "was", "no", "significant", "intergroup", "difference", ".", "CONCLUSION", "Oral", "brovincamine", "may", "retard", "further", "visual", "field", "deterioration", "in", "patients", "with", "NTG", "who", "have", "low", "-", "normal", "IOP", "." ]
[ "Outcome_Other", "Participant_Condition", "Intervention_Control", "Intervention_Physical", "Intervention_Pharmacological", "Outcome_Physical", "Participant_Sample-size", "Participant_Age" ]
Effects is a Outcome_Other, oral brovincamine is a Intervention_Pharmacological, normal - tension glaucoma is a Participant_Condition, low - normal intraocular pressure is a Participant_Condition, effect is a Outcome_Other, cerebral vasodilator is a Intervention_Physical, normal - tension glaucoma ( NTG ) is a Participant_Condition, Fifty - two is a Participant_Sample-size, 57.7 is a Participant_Age, untreated control group . is a Intervention_Control, visual field examinations is a Intervention_Control, Changes in mean deviation ( MD ) is a Outcome_Other, corrected pattern standard deviation ( CPSD ) is a Outcome_Other, total deviation ( TD ) is a Outcome_Other, refraction is a Outcome_Physical, blood pressure is a Outcome_Physical, baseline IOP is a Outcome_Physical, Changes in MD is a Outcome_Other, Change in CPSD ( SE ) is a Outcome_Other, Change in TD is a Outcome_Other, average IOP is a Outcome_Physical, Oral brovincamine is a Intervention_Pharmacological
676_task1
Sentence: Effects of oral brovincamine on visual field damage in patients with normal-tension glaucoma with low-normal intraocular pressure . PURPOSE To prospectively study the effect of oral brovincamine , a relatively selective cerebral vasodilator , on further deterioration of visual field in patients with normal-tension glaucoma ( NTG ) with low-normal intraocular pressure ( IOP ) . METHODS Fifty-two patients with NTG ( average age 57.7 years ) with an IOP that was consistently less than 15 mmHg were randomly assigned to receive oral brovincamine ( 20 mg three times daily ) or to an untreated control group . The groups were prospectively followed for 2 years with visual field examinations every 4 months , using the 30-2 Humphrey perimeter program . Changes in mean deviation ( MD ) , corrected pattern standard deviation ( CPSD ) , and total deviation ( TD ) at 74 test points were analyzed using regression analysis with linear mixed model . Data from one eye without media opacity of each subject were analyzed . RESULTS There were no differences between groups in age ; sex distribution ; refraction ; blood pressure ; baseline IOP ; MD , CPSD , or TD at each point . Changes in MD ( standard error [ SE ] ) during the study period were -0.778 ( 0.178 ) and -0.071 ( 0.195 ) dB/year in the control and brovincamine groups , respectively ; change in the control group was significantly more negative than in the brovincamine group . Change in CPSD ( SE ) was 0.032 ( 0.015 ) and 0.004 ( 0.016 ) dB/year in the control and brovincamine groups , respectively . Change in the control group was significantly positive , but the intergroup difference was not significant . Change in TD was significantly negative at six test points in the control group , whereas no points showed a significant trend in the brovincamine group ; the intergroup difference was significant . The average IOP was 13.2 mmHg and 13.1 mmHg in the control and brovincamine groups , respectively , and there was no significant intergroup difference . CONCLUSION Oral brovincamine may retard further visual field deterioration in patients with NTG who have low-normal IOP . Instructions: please typing these entity words according to sentence: Effects, oral brovincamine, normal - tension glaucoma, low - normal intraocular pressure, effect, cerebral vasodilator, normal - tension glaucoma ( NTG ), Fifty - two, 57.7, untreated control group ., visual field examinations, Changes in mean deviation ( MD ), corrected pattern standard deviation ( CPSD ), total deviation ( TD ), refraction, blood pressure, baseline IOP, Changes in MD, Change in CPSD ( SE ), Change in TD, average IOP, Oral brovincamine Options: Intervention_Pharmacological, Intervention_Physical, Participant_Condition, Intervention_Control, Participant_Age, Outcome_Physical, Participant_Sample-size, Outcome_Other
[ "B-Outcome_Other", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Physical", "I-Intervention_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "B-Participant_Age", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Effects of oral brovincamine on visual field damage in patients with normal-tension glaucoma with low-normal intraocular pressure . PURPOSE To prospectively study the effect of oral brovincamine , a relatively selective cerebral vasodilator , on further deterioration of visual field in patients with normal-tension glaucoma ( NTG ) with low-normal intraocular pressure ( IOP ) . METHODS Fifty-two patients with NTG ( average age 57.7 years ) with an IOP that was consistently less than 15 mmHg were randomly assigned to receive oral brovincamine ( 20 mg three times daily ) or to an untreated control group . The groups were prospectively followed for 2 years with visual field examinations every 4 months , using the 30-2 Humphrey perimeter program . Changes in mean deviation ( MD ) , corrected pattern standard deviation ( CPSD ) , and total deviation ( TD ) at 74 test points were analyzed using regression analysis with linear mixed model . Data from one eye without media opacity of each subject were analyzed . RESULTS There were no differences between groups in age ; sex distribution ; refraction ; blood pressure ; baseline IOP ; MD , CPSD , or TD at each point . Changes in MD ( standard error [ SE ] ) during the study period were -0.778 ( 0.178 ) and -0.071 ( 0.195 ) dB/year in the control and brovincamine groups , respectively ; change in the control group was significantly more negative than in the brovincamine group . Change in CPSD ( SE ) was 0.032 ( 0.015 ) and 0.004 ( 0.016 ) dB/year in the control and brovincamine groups , respectively . Change in the control group was significantly positive , but the intergroup difference was not significant . Change in TD was significantly negative at six test points in the control group , whereas no points showed a significant trend in the brovincamine group ; the intergroup difference was significant . The average IOP was 13.2 mmHg and 13.1 mmHg in the control and brovincamine groups , respectively , and there was no significant intergroup difference . CONCLUSION Oral brovincamine may retard further visual field deterioration in patients with NTG who have low-normal IOP .
[ "Effects", "of", "oral", "brovincamine", "on", "visual", "field", "damage", "in", "patients", "with", "normal", "-", "tension", "glaucoma", "with", "low", "-", "normal", "intraocular", "pressure", ".", "PURPOSE", "To", "prospectively", "study", "the", "effect", "of", "oral", "brovincamine", ",", "a", "relatively", "selective", "cerebral", "vasodilator", ",", "on", "further", "deterioration", "of", "visual", "field", "in", "patients", "with", "normal", "-", "tension", "glaucoma", "(", "NTG", ")", "with", "low", "-", "normal", "intraocular", "pressure", "(", "IOP", ")", ".", "METHODS", "Fifty", "-", "two", "patients", "with", "NTG", "(", "average", "age", "57.7", "years", ")", "with", "an", "IOP", "that", "was", "consistently", "less", "than", "15", "mmHg", "were", "randomly", "assigned", "to", "receive", "oral", "brovincamine", "(", "20", "mg", "three", "times", "daily", ")", "or", "to", "an", "untreated", "control", "group", ".", "The", "groups", "were", "prospectively", "followed", "for", "2", "years", "with", "visual", "field", "examinations", "every", "4", "months", ",", "using", "the", "30", "-", "2", "Humphrey", "perimeter", "program", ".", "Changes", "in", "mean", "deviation", "(", "MD", ")", ",", "corrected", "pattern", "standard", "deviation", "(", "CPSD", ")", ",", "and", "total", "deviation", "(", "TD", ")", "at", "74", "test", "points", "were", "analyzed", "using", "regression", "analysis", "with", "linear", "mixed", "model", ".", "Data", "from", "one", "eye", "without", "media", "opacity", "of", "each", "subject", "were", "analyzed", ".", "RESULTS", "There", "were", "no", "differences", "between", "groups", "in", "age", ";", "sex", "distribution", ";", "refraction", ";", "blood", "pressure", ";", "baseline", "IOP", ";", "MD", ",", "CPSD", ",", "or", "TD", "at", "each", "point", ".", "Changes", "in", "MD", "(", "standard", "error", "[", "SE", "]", ")", "during", "the", "study", "period", "were", "-0.778", "(", "0.178", ")", "and", "-0.071", "(", "0.195", ")", "dB", "/", "year", "in", "the", "control", "and", "brovincamine", "groups", ",", "respectively", ";", "change", "in", "the", "control", "group", "was", "significantly", "more", "negative", "than", "in", "the", "brovincamine", "group", ".", "Change", "in", "CPSD", "(", "SE", ")", "was", "0.032", "(", "0.015", ")", "and", "0.004", "(", "0.016", ")", "dB", "/", "year", "in", "the", "control", "and", "brovincamine", "groups", ",", "respectively", ".", "Change", "in", "the", "control", "group", "was", "significantly", "positive", ",", "but", "the", "intergroup", "difference", "was", "not", "significant", ".", "Change", "in", "TD", "was", "significantly", "negative", "at", "six", "test", "points", "in", "the", "control", "group", ",", "whereas", "no", "points", "showed", "a", "significant", "trend", "in", "the", "brovincamine", "group", ";", "the", "intergroup", "difference", "was", "significant", ".", "The", "average", "IOP", "was", "13.2", "mmHg", "and", "13.1", "mmHg", "in", "the", "control", "and", "brovincamine", "groups", ",", "respectively", ",", "and", "there", "was", "no", "significant", "intergroup", "difference", ".", "CONCLUSION", "Oral", "brovincamine", "may", "retard", "further", "visual", "field", "deterioration", "in", "patients", "with", "NTG", "who", "have", "low", "-", "normal", "IOP", "." ]
[ "Outcome_Other", "Participant_Condition", "Intervention_Control", "Intervention_Physical", "Intervention_Pharmacological", "Outcome_Physical", "Participant_Sample-size", "Participant_Age" ]
Effects, oral brovincamine, normal - tension glaucoma, low - normal intraocular pressure, effect, cerebral vasodilator, normal - tension glaucoma ( NTG ), Fifty - two, 57.7, untreated control group ., visual field examinations, Changes in mean deviation ( MD ), corrected pattern standard deviation ( CPSD ), total deviation ( TD ), refraction, blood pressure, baseline IOP, Changes in MD, Change in CPSD ( SE ), Change in TD, average IOP, Oral brovincamine
676_task2
Sentence: Effects of oral brovincamine on visual field damage in patients with normal-tension glaucoma with low-normal intraocular pressure . PURPOSE To prospectively study the effect of oral brovincamine , a relatively selective cerebral vasodilator , on further deterioration of visual field in patients with normal-tension glaucoma ( NTG ) with low-normal intraocular pressure ( IOP ) . METHODS Fifty-two patients with NTG ( average age 57.7 years ) with an IOP that was consistently less than 15 mmHg were randomly assigned to receive oral brovincamine ( 20 mg three times daily ) or to an untreated control group . The groups were prospectively followed for 2 years with visual field examinations every 4 months , using the 30-2 Humphrey perimeter program . Changes in mean deviation ( MD ) , corrected pattern standard deviation ( CPSD ) , and total deviation ( TD ) at 74 test points were analyzed using regression analysis with linear mixed model . Data from one eye without media opacity of each subject were analyzed . RESULTS There were no differences between groups in age ; sex distribution ; refraction ; blood pressure ; baseline IOP ; MD , CPSD , or TD at each point . Changes in MD ( standard error [ SE ] ) during the study period were -0.778 ( 0.178 ) and -0.071 ( 0.195 ) dB/year in the control and brovincamine groups , respectively ; change in the control group was significantly more negative than in the brovincamine group . Change in CPSD ( SE ) was 0.032 ( 0.015 ) and 0.004 ( 0.016 ) dB/year in the control and brovincamine groups , respectively . Change in the control group was significantly positive , but the intergroup difference was not significant . Change in TD was significantly negative at six test points in the control group , whereas no points showed a significant trend in the brovincamine group ; the intergroup difference was significant . The average IOP was 13.2 mmHg and 13.1 mmHg in the control and brovincamine groups , respectively , and there was no significant intergroup difference . CONCLUSION Oral brovincamine may retard further visual field deterioration in patients with NTG who have low-normal IOP . Instructions: please extract entity words from the input sentence
[ "B-Outcome_Other", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Physical", "I-Intervention_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "B-Participant_Age", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Effects of oral brovincamine on visual field damage in patients with normal-tension glaucoma with low-normal intraocular pressure . PURPOSE To prospectively study the effect of oral brovincamine , a relatively selective cerebral vasodilator , on further deterioration of visual field in patients with normal-tension glaucoma ( NTG ) with low-normal intraocular pressure ( IOP ) . METHODS Fifty-two patients with NTG ( average age 57.7 years ) with an IOP that was consistently less than 15 mmHg were randomly assigned to receive oral brovincamine ( 20 mg three times daily ) or to an untreated control group . The groups were prospectively followed for 2 years with visual field examinations every 4 months , using the 30-2 Humphrey perimeter program . Changes in mean deviation ( MD ) , corrected pattern standard deviation ( CPSD ) , and total deviation ( TD ) at 74 test points were analyzed using regression analysis with linear mixed model . Data from one eye without media opacity of each subject were analyzed . RESULTS There were no differences between groups in age ; sex distribution ; refraction ; blood pressure ; baseline IOP ; MD , CPSD , or TD at each point . Changes in MD ( standard error [ SE ] ) during the study period were -0.778 ( 0.178 ) and -0.071 ( 0.195 ) dB/year in the control and brovincamine groups , respectively ; change in the control group was significantly more negative than in the brovincamine group . Change in CPSD ( SE ) was 0.032 ( 0.015 ) and 0.004 ( 0.016 ) dB/year in the control and brovincamine groups , respectively . Change in the control group was significantly positive , but the intergroup difference was not significant . Change in TD was significantly negative at six test points in the control group , whereas no points showed a significant trend in the brovincamine group ; the intergroup difference was significant . The average IOP was 13.2 mmHg and 13.1 mmHg in the control and brovincamine groups , respectively , and there was no significant intergroup difference . CONCLUSION Oral brovincamine may retard further visual field deterioration in patients with NTG who have low-normal IOP .
[ "Effects", "of", "oral", "brovincamine", "on", "visual", "field", "damage", "in", "patients", "with", "normal", "-", "tension", "glaucoma", "with", "low", "-", "normal", "intraocular", "pressure", ".", "PURPOSE", "To", "prospectively", "study", "the", "effect", "of", "oral", "brovincamine", ",", "a", "relatively", "selective", "cerebral", "vasodilator", ",", "on", "further", "deterioration", "of", "visual", "field", "in", "patients", "with", "normal", "-", "tension", "glaucoma", "(", "NTG", ")", "with", "low", "-", "normal", "intraocular", "pressure", "(", "IOP", ")", ".", "METHODS", "Fifty", "-", "two", "patients", "with", "NTG", "(", "average", "age", "57.7", "years", ")", "with", "an", "IOP", "that", "was", "consistently", "less", "than", "15", "mmHg", "were", "randomly", "assigned", "to", "receive", "oral", "brovincamine", "(", "20", "mg", "three", "times", "daily", ")", "or", "to", "an", "untreated", "control", "group", ".", "The", "groups", "were", "prospectively", "followed", "for", "2", "years", "with", "visual", "field", "examinations", "every", "4", "months", ",", "using", "the", "30", "-", "2", "Humphrey", "perimeter", "program", ".", "Changes", "in", "mean", "deviation", "(", "MD", ")", ",", "corrected", "pattern", "standard", "deviation", "(", "CPSD", ")", ",", "and", "total", "deviation", "(", "TD", ")", "at", "74", "test", "points", "were", "analyzed", "using", "regression", "analysis", "with", "linear", "mixed", "model", ".", "Data", "from", "one", "eye", "without", "media", "opacity", "of", "each", "subject", "were", "analyzed", ".", "RESULTS", "There", "were", "no", "differences", "between", "groups", "in", "age", ";", "sex", "distribution", ";", "refraction", ";", "blood", "pressure", ";", "baseline", "IOP", ";", "MD", ",", "CPSD", ",", "or", "TD", "at", "each", "point", ".", "Changes", "in", "MD", "(", "standard", "error", "[", "SE", "]", ")", "during", "the", "study", "period", "were", "-0.778", "(", "0.178", ")", "and", "-0.071", "(", "0.195", ")", "dB", "/", "year", "in", "the", "control", "and", "brovincamine", "groups", ",", "respectively", ";", "change", "in", "the", "control", "group", "was", "significantly", "more", "negative", "than", "in", "the", "brovincamine", "group", ".", "Change", "in", "CPSD", "(", "SE", ")", "was", "0.032", "(", "0.015", ")", "and", "0.004", "(", "0.016", ")", "dB", "/", "year", "in", "the", "control", "and", "brovincamine", "groups", ",", "respectively", ".", "Change", "in", "the", "control", "group", "was", "significantly", "positive", ",", "but", "the", "intergroup", "difference", "was", "not", "significant", ".", "Change", "in", "TD", "was", "significantly", "negative", "at", "six", "test", "points", "in", "the", "control", "group", ",", "whereas", "no", "points", "showed", "a", "significant", "trend", "in", "the", "brovincamine", "group", ";", "the", "intergroup", "difference", "was", "significant", ".", "The", "average", "IOP", "was", "13.2", "mmHg", "and", "13.1", "mmHg", "in", "the", "control", "and", "brovincamine", "groups", ",", "respectively", ",", "and", "there", "was", "no", "significant", "intergroup", "difference", ".", "CONCLUSION", "Oral", "brovincamine", "may", "retard", "further", "visual", "field", "deterioration", "in", "patients", "with", "NTG", "who", "have", "low", "-", "normal", "IOP", "." ]
[ "Outcome_Other", "Participant_Condition", "Intervention_Control", "Intervention_Physical", "Intervention_Pharmacological", "Outcome_Physical", "Participant_Sample-size", "Participant_Age" ]
Triton X-100 is a chemical, GST is an experiment-tag, GST - GBR1 is an experimental-construct, glutathione is a chemical
1.0alpha7.train.86_task0
Sentence: Triton X-100 extracts from a crude rat brain nuclear fraction was incubated with GST or GST-GBR1, and protein binding to the fusion proteins was recovered by adding glutathione beads. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: chemical, experiment-tag, experimental-construct
[ "B-chemical", "I-chemical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-experiment-tag", "O", "B-experimental-construct", "I-experimental-construct", "I-experimental-construct", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-chemical", "O", "O" ]
Triton X-100 extracts from a crude rat brain nuclear fraction was incubated with GST or GST-GBR1, and protein binding to the fusion proteins was recovered by adding glutathione beads.
[ "Triton", "X-100", "extracts", "from", "a", "crude", "rat", "brain", "nuclear", "fraction", "was", "incubated", "with", "GST", "or", "GST", "-", "GBR1", ",", "and", "protein", "binding", "to", "the", "fusion", "proteins", "was", "recovered", "by", "adding", "glutathione", "beads", "." ]
[ "chemical", "experimental-construct", "protein", "experiment-tag" ]
Triton X-100 is a chemical, GST is an experiment-tag, GST - GBR1 is an experimental-construct, glutathione is a chemical
1.0alpha7.train.86_task1
Sentence: Triton X-100 extracts from a crude rat brain nuclear fraction was incubated with GST or GST-GBR1, and protein binding to the fusion proteins was recovered by adding glutathione beads. Instructions: please typing these entity words according to sentence: Triton X-100, GST, GST - GBR1, glutathione Options: chemical, experiment-tag, experimental-construct
[ "B-chemical", "I-chemical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-experiment-tag", "O", "B-experimental-construct", "I-experimental-construct", "I-experimental-construct", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-chemical", "O", "O" ]
Triton X-100 extracts from a crude rat brain nuclear fraction was incubated with GST or GST-GBR1, and protein binding to the fusion proteins was recovered by adding glutathione beads.
[ "Triton", "X-100", "extracts", "from", "a", "crude", "rat", "brain", "nuclear", "fraction", "was", "incubated", "with", "GST", "or", "GST", "-", "GBR1", ",", "and", "protein", "binding", "to", "the", "fusion", "proteins", "was", "recovered", "by", "adding", "glutathione", "beads", "." ]
[ "chemical", "experimental-construct", "protein", "experiment-tag" ]
Triton X-100, GST, GST - GBR1, glutathione
1.0alpha7.train.86_task2
Sentence: Triton X-100 extracts from a crude rat brain nuclear fraction was incubated with GST or GST-GBR1, and protein binding to the fusion proteins was recovered by adding glutathione beads. Instructions: please extract entity words from the input sentence
[ "B-chemical", "I-chemical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-experiment-tag", "O", "B-experimental-construct", "I-experimental-construct", "I-experimental-construct", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-chemical", "O", "O" ]
Triton X-100 extracts from a crude rat brain nuclear fraction was incubated with GST or GST-GBR1, and protein binding to the fusion proteins was recovered by adding glutathione beads.
[ "Triton", "X-100", "extracts", "from", "a", "crude", "rat", "brain", "nuclear", "fraction", "was", "incubated", "with", "GST", "or", "GST", "-", "GBR1", ",", "and", "protein", "binding", "to", "the", "fusion", "proteins", "was", "recovered", "by", "adding", "glutathione", "beads", "." ]
[ "chemical", "experimental-construct", "protein", "experiment-tag" ]
Vitex is an umlsterm, Moenchspfeffers is an umlsterm, Hypophyse is an umlsterm, Prolaktinsekretion is an umlsterm, Frauen is an umlsterm, Hyperprolaktinaemie is an umlsterm, stress- is an umlsterm, tiefschlafphaseninduzierte is an umlsterm, Prolaktinsekretion is an umlsterm, Vitex is an umlsterm
DerGynaekologe.00330036.ger.abstr_task0
Sentence: Waessrig aethanolische Extrakte aus Vitex agnus-castus , der Frucht des Moenchspfeffers , enthalten wohlcharakterisierte dopaminerge Wirkprinzipien , die an der Hypophyse die Prolaktinsekretion blockieren . Dadurch wird bei Frauen mit latenter Hyperprolaktinaemie die stress- und tiefschlafphaseninduzierte ueberschiessende Prolaktinsekretion gebremst , so dass ein guenstiger Einfluss auf die praemenstruelle Mastodynie registriert wird . Moeglicherweise bewirken die dopaminergen Wirkprinzipien in Vitex agnus-castus auch durch eine Wirkung am nigrostriatalen oder mesolimbischen dopaminergen Gebieten eine Verbesserung psychischer und anderer vegetativer praemenstrueller Symptome . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm
[ "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Waessrig aethanolische Extrakte aus Vitex agnus-castus , der Frucht des Moenchspfeffers , enthalten wohlcharakterisierte dopaminerge Wirkprinzipien , die an der Hypophyse die Prolaktinsekretion blockieren . Dadurch wird bei Frauen mit latenter Hyperprolaktinaemie die stress- und tiefschlafphaseninduzierte ueberschiessende Prolaktinsekretion gebremst , so dass ein guenstiger Einfluss auf die praemenstruelle Mastodynie registriert wird . Moeglicherweise bewirken die dopaminergen Wirkprinzipien in Vitex agnus-castus auch durch eine Wirkung am nigrostriatalen oder mesolimbischen dopaminergen Gebieten eine Verbesserung psychischer und anderer vegetativer praemenstrueller Symptome .
[ "Waessrig", "aethanolische", "Extrakte", "aus", "Vitex", "agnus", "-", "castus", ",", "der", "Frucht", "des", "Moenchspfeffers", ",", "enthalten", "wohlcharakterisierte", "dopaminerge", "Wirkprinzipien", ",", "die", "an", "der", "Hypophyse", "die", "Prolaktinsekretion", "blockieren", ".", "Dadurch", "wird", "bei", "Frauen", "mit", "latenter", "Hyperprolaktinaemie", "die", "stress-", "und", "tiefschlafphaseninduzierte", "ueberschiessende", "Prolaktinsekretion", "gebremst", ",", "so", "dass", "ein", "guenstiger", "Einfluss", "auf", "die", "praemenstruelle", "Mastodynie", "registriert", "wird", ".", "Moeglicherweise", "bewirken", "die", "dopaminergen", "Wirkprinzipien", "in", "Vitex", "agnus", "-", "castus", "auch", "durch", "eine", "Wirkung", "am", "nigrostriatalen", "oder", "mesolimbischen", "dopaminergen", "Gebieten", "eine", "Verbesserung", "psychischer", "und", "anderer", "vegetativer", "praemenstrueller", "Symptome", "." ]
[ "umlsterm" ]
Vitex is an umlsterm, Moenchspfeffers is an umlsterm, Hypophyse is an umlsterm, Prolaktinsekretion is an umlsterm, Frauen is an umlsterm, Hyperprolaktinaemie is an umlsterm, stress- is an umlsterm, tiefschlafphaseninduzierte is an umlsterm, Prolaktinsekretion is an umlsterm, Vitex is an umlsterm
DerGynaekologe.00330036.ger.abstr_task1
Sentence: Waessrig aethanolische Extrakte aus Vitex agnus-castus , der Frucht des Moenchspfeffers , enthalten wohlcharakterisierte dopaminerge Wirkprinzipien , die an der Hypophyse die Prolaktinsekretion blockieren . Dadurch wird bei Frauen mit latenter Hyperprolaktinaemie die stress- und tiefschlafphaseninduzierte ueberschiessende Prolaktinsekretion gebremst , so dass ein guenstiger Einfluss auf die praemenstruelle Mastodynie registriert wird . Moeglicherweise bewirken die dopaminergen Wirkprinzipien in Vitex agnus-castus auch durch eine Wirkung am nigrostriatalen oder mesolimbischen dopaminergen Gebieten eine Verbesserung psychischer und anderer vegetativer praemenstrueller Symptome . Instructions: please typing these entity words according to sentence: Vitex, Moenchspfeffers, Hypophyse, Prolaktinsekretion, Frauen, Hyperprolaktinaemie, stress-, tiefschlafphaseninduzierte, Prolaktinsekretion, Vitex Options: umlsterm
[ "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Waessrig aethanolische Extrakte aus Vitex agnus-castus , der Frucht des Moenchspfeffers , enthalten wohlcharakterisierte dopaminerge Wirkprinzipien , die an der Hypophyse die Prolaktinsekretion blockieren . Dadurch wird bei Frauen mit latenter Hyperprolaktinaemie die stress- und tiefschlafphaseninduzierte ueberschiessende Prolaktinsekretion gebremst , so dass ein guenstiger Einfluss auf die praemenstruelle Mastodynie registriert wird . Moeglicherweise bewirken die dopaminergen Wirkprinzipien in Vitex agnus-castus auch durch eine Wirkung am nigrostriatalen oder mesolimbischen dopaminergen Gebieten eine Verbesserung psychischer und anderer vegetativer praemenstrueller Symptome .
[ "Waessrig", "aethanolische", "Extrakte", "aus", "Vitex", "agnus", "-", "castus", ",", "der", "Frucht", "des", "Moenchspfeffers", ",", "enthalten", "wohlcharakterisierte", "dopaminerge", "Wirkprinzipien", ",", "die", "an", "der", "Hypophyse", "die", "Prolaktinsekretion", "blockieren", ".", "Dadurch", "wird", "bei", "Frauen", "mit", "latenter", "Hyperprolaktinaemie", "die", "stress-", "und", "tiefschlafphaseninduzierte", "ueberschiessende", "Prolaktinsekretion", "gebremst", ",", "so", "dass", "ein", "guenstiger", "Einfluss", "auf", "die", "praemenstruelle", "Mastodynie", "registriert", "wird", ".", "Moeglicherweise", "bewirken", "die", "dopaminergen", "Wirkprinzipien", "in", "Vitex", "agnus", "-", "castus", "auch", "durch", "eine", "Wirkung", "am", "nigrostriatalen", "oder", "mesolimbischen", "dopaminergen", "Gebieten", "eine", "Verbesserung", "psychischer", "und", "anderer", "vegetativer", "praemenstrueller", "Symptome", "." ]
[ "umlsterm" ]
Vitex, Moenchspfeffers, Hypophyse, Prolaktinsekretion, Frauen, Hyperprolaktinaemie, stress-, tiefschlafphaseninduzierte, Prolaktinsekretion, Vitex
DerGynaekologe.00330036.ger.abstr_task2
Sentence: Waessrig aethanolische Extrakte aus Vitex agnus-castus , der Frucht des Moenchspfeffers , enthalten wohlcharakterisierte dopaminerge Wirkprinzipien , die an der Hypophyse die Prolaktinsekretion blockieren . Dadurch wird bei Frauen mit latenter Hyperprolaktinaemie die stress- und tiefschlafphaseninduzierte ueberschiessende Prolaktinsekretion gebremst , so dass ein guenstiger Einfluss auf die praemenstruelle Mastodynie registriert wird . Moeglicherweise bewirken die dopaminergen Wirkprinzipien in Vitex agnus-castus auch durch eine Wirkung am nigrostriatalen oder mesolimbischen dopaminergen Gebieten eine Verbesserung psychischer und anderer vegetativer praemenstrueller Symptome . Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Waessrig aethanolische Extrakte aus Vitex agnus-castus , der Frucht des Moenchspfeffers , enthalten wohlcharakterisierte dopaminerge Wirkprinzipien , die an der Hypophyse die Prolaktinsekretion blockieren . Dadurch wird bei Frauen mit latenter Hyperprolaktinaemie die stress- und tiefschlafphaseninduzierte ueberschiessende Prolaktinsekretion gebremst , so dass ein guenstiger Einfluss auf die praemenstruelle Mastodynie registriert wird . Moeglicherweise bewirken die dopaminergen Wirkprinzipien in Vitex agnus-castus auch durch eine Wirkung am nigrostriatalen oder mesolimbischen dopaminergen Gebieten eine Verbesserung psychischer und anderer vegetativer praemenstrueller Symptome .
[ "Waessrig", "aethanolische", "Extrakte", "aus", "Vitex", "agnus", "-", "castus", ",", "der", "Frucht", "des", "Moenchspfeffers", ",", "enthalten", "wohlcharakterisierte", "dopaminerge", "Wirkprinzipien", ",", "die", "an", "der", "Hypophyse", "die", "Prolaktinsekretion", "blockieren", ".", "Dadurch", "wird", "bei", "Frauen", "mit", "latenter", "Hyperprolaktinaemie", "die", "stress-", "und", "tiefschlafphaseninduzierte", "ueberschiessende", "Prolaktinsekretion", "gebremst", ",", "so", "dass", "ein", "guenstiger", "Einfluss", "auf", "die", "praemenstruelle", "Mastodynie", "registriert", "wird", ".", "Moeglicherweise", "bewirken", "die", "dopaminergen", "Wirkprinzipien", "in", "Vitex", "agnus", "-", "castus", "auch", "durch", "eine", "Wirkung", "am", "nigrostriatalen", "oder", "mesolimbischen", "dopaminergen", "Gebieten", "eine", "Verbesserung", "psychischer", "und", "anderer", "vegetativer", "praemenstrueller", "Symptome", "." ]
[ "umlsterm" ]
Vitamin D3- and retinoic acid - induced monocytic differentiation is a (AND other_name other_name), endogenous vitamin D3 receptor is a protein_family_or_group, retinoic acid receptors is a protein_family_or_group, retinoid X receptors is a protein_family_or_group, U-937 cells is a cell_line
25738_task0
Sentence: Vitamin D3- and retinoic acid-induced monocytic differentiation: interactions between the endogenous vitamin D3 receptor, retinoic acid receptors, and retinoid X receptors in U-937 cells. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: protein_family_or_group, cell_line, (AND other_name other_name)
[ "B-(AND other_name other_name)", "I-(AND other_name other_name)", "I-(AND other_name other_name)", "I-(AND other_name other_name)", "I-(AND other_name other_name)", "I-(AND other_name other_name)", "I-(AND other_name other_name)", "I-(AND other_name other_name)", "I-(AND other_name other_name)", "O", "O", "O", "O", "B-protein_family_or_group", "I-protein_family_or_group", "I-protein_family_or_group", "I-protein_family_or_group", "O", "B-protein_family_or_group", "I-protein_family_or_group", "I-protein_family_or_group", "O", "O", "B-protein_family_or_group", "I-protein_family_or_group", "I-protein_family_or_group", "O", "B-cell_line", "I-cell_line", "O" ]
Vitamin D3- and retinoic acid-induced monocytic differentiation: interactions between the endogenous vitamin D3 receptor, retinoic acid receptors, and retinoid X receptors in U-937 cells.
[ "Vitamin", "D3-", "and", "retinoic", "acid", "-", "induced", "monocytic", "differentiation", ":", "interactions", "between", "the", "endogenous", "vitamin", "D3", "receptor", ",", "retinoic", "acid", "receptors", ",", "and", "retinoid", "X", "receptors", "in", "U-937", "cells", "." ]
[ "(AND other_name other_name)", "DNA_molecule", "other_name", "lipid", "", "protein_family_or_group", "(AND protein_family_or_group protein_family_or_group)", "protein_complex", "DNA_domain_or_region", "cell_type", "DNA_family_or_group", "tissue", "cell_line", "other_organic_compound", "protein_molecule" ]
Vitamin D3- and retinoic acid - induced monocytic differentiation is a (AND other_name other_name), endogenous vitamin D3 receptor is a protein_family_or_group, retinoic acid receptors is a protein_family_or_group, retinoid X receptors is a protein_family_or_group, U-937 cells is a cell_line
25738_task1
Sentence: Vitamin D3- and retinoic acid-induced monocytic differentiation: interactions between the endogenous vitamin D3 receptor, retinoic acid receptors, and retinoid X receptors in U-937 cells. Instructions: please typing these entity words according to sentence: Vitamin D3- and retinoic acid - induced monocytic differentiation, endogenous vitamin D3 receptor, retinoic acid receptors, retinoid X receptors, U-937 cells Options: protein_family_or_group, cell_line, (AND other_name other_name)
[ "B-(AND other_name other_name)", "I-(AND other_name other_name)", "I-(AND other_name other_name)", "I-(AND other_name other_name)", "I-(AND other_name other_name)", "I-(AND other_name other_name)", "I-(AND other_name other_name)", "I-(AND other_name other_name)", "I-(AND other_name other_name)", "O", "O", "O", "O", "B-protein_family_or_group", "I-protein_family_or_group", "I-protein_family_or_group", "I-protein_family_or_group", "O", "B-protein_family_or_group", "I-protein_family_or_group", "I-protein_family_or_group", "O", "O", "B-protein_family_or_group", "I-protein_family_or_group", "I-protein_family_or_group", "O", "B-cell_line", "I-cell_line", "O" ]
Vitamin D3- and retinoic acid-induced monocytic differentiation: interactions between the endogenous vitamin D3 receptor, retinoic acid receptors, and retinoid X receptors in U-937 cells.
[ "Vitamin", "D3-", "and", "retinoic", "acid", "-", "induced", "monocytic", "differentiation", ":", "interactions", "between", "the", "endogenous", "vitamin", "D3", "receptor", ",", "retinoic", "acid", "receptors", ",", "and", "retinoid", "X", "receptors", "in", "U-937", "cells", "." ]
[ "(AND other_name other_name)", "DNA_molecule", "other_name", "lipid", "", "protein_family_or_group", "(AND protein_family_or_group protein_family_or_group)", "protein_complex", "DNA_domain_or_region", "cell_type", "DNA_family_or_group", "tissue", "cell_line", "other_organic_compound", "protein_molecule" ]
Vitamin D3- and retinoic acid - induced monocytic differentiation, endogenous vitamin D3 receptor, retinoic acid receptors, retinoid X receptors, U-937 cells
25738_task2
Sentence: Vitamin D3- and retinoic acid-induced monocytic differentiation: interactions between the endogenous vitamin D3 receptor, retinoic acid receptors, and retinoid X receptors in U-937 cells. Instructions: please extract entity words from the input sentence
[ "B-(AND other_name other_name)", "I-(AND other_name other_name)", "I-(AND other_name other_name)", "I-(AND other_name other_name)", "I-(AND other_name other_name)", "I-(AND other_name other_name)", "I-(AND other_name other_name)", "I-(AND other_name other_name)", "I-(AND other_name other_name)", "O", "O", "O", "O", "B-protein_family_or_group", "I-protein_family_or_group", "I-protein_family_or_group", "I-protein_family_or_group", "O", "B-protein_family_or_group", "I-protein_family_or_group", "I-protein_family_or_group", "O", "O", "B-protein_family_or_group", "I-protein_family_or_group", "I-protein_family_or_group", "O", "B-cell_line", "I-cell_line", "O" ]
Vitamin D3- and retinoic acid-induced monocytic differentiation: interactions between the endogenous vitamin D3 receptor, retinoic acid receptors, and retinoid X receptors in U-937 cells.
[ "Vitamin", "D3-", "and", "retinoic", "acid", "-", "induced", "monocytic", "differentiation", ":", "interactions", "between", "the", "endogenous", "vitamin", "D3", "receptor", ",", "retinoic", "acid", "receptors", ",", "and", "retinoid", "X", "receptors", "in", "U-937", "cells", "." ]
[ "(AND other_name other_name)", "DNA_molecule", "other_name", "lipid", "", "protein_family_or_group", "(AND protein_family_or_group protein_family_or_group)", "protein_complex", "DNA_domain_or_region", "cell_type", "DNA_family_or_group", "tissue", "cell_line", "other_organic_compound", "protein_molecule" ]
creatine phosphate is a Intervention_Pharmacological, aortic valve surgery -- a is a Participant_Condition, drop in high - energy phosphates is a Outcome_Physical, plain cardioplegic solutions is a Intervention_Control, control is a Intervention_Control, hemodynamic evaluation is a Outcome_Physical, stroke - work index is a Outcome_Physical, needing inotropic support is a Outcome_Physical, myocardial content of ATP and creatine phosphate is a Outcome_Physical, myocardial ATP and creatine phosphate is a Outcome_Physical
24691_task0
Sentence: Biochemical and functional effects of creatine phosphate in cardioplegic solution during aortic valve surgery -- a clinical study . During myocardial ischemia there is a drop in high-energy phosphates in the myocardium . Cold potassium cardioplegia decreases but does not altogether prevent this reduction . Supplementation of cardioplegic solutions with the high-energy compound creatine phosphate ( 10 mmol/L ) compared to plain cardioplegic solutions was investigated in this study . Thirty patients scheduled for aortic valve replacement were included . The patients were randomized to group I ( creatine phosphate ) or group II ( control ) . Postoperative hemodynamic evaluation revealed no significant differences between the groups . However , group I exhibited a tendency toward a better stroke-work index ( 135 +/- 18 % vs. 102 +/- 5 % recovery 15 minutes after bypass and 145 +/- 16 % vs. 119 +/- 11 % recovery 105 min after bypass ) . There were fewer patients in group I ( 5/15 ) needing inotropic support compared to group II ( 9/14 ) . The myocardial content of ATP and creatine phosphate showed no significant differences during ischemia and reperfusion . It is concluded that the myocardial protection during ischemia was sufficient to prevent significant reductions of myocardial ATP and creatine phosphate irrespective of supplementation with CP . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Intervention_Control, Intervention_Pharmacological, Outcome_Physical, Participant_Condition
[ "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Control", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O" ]
Biochemical and functional effects of creatine phosphate in cardioplegic solution during aortic valve surgery -- a clinical study . During myocardial ischemia there is a drop in high-energy phosphates in the myocardium . Cold potassium cardioplegia decreases but does not altogether prevent this reduction . Supplementation of cardioplegic solutions with the high-energy compound creatine phosphate ( 10 mmol/L ) compared to plain cardioplegic solutions was investigated in this study . Thirty patients scheduled for aortic valve replacement were included . The patients were randomized to group I ( creatine phosphate ) or group II ( control ) . Postoperative hemodynamic evaluation revealed no significant differences between the groups . However , group I exhibited a tendency toward a better stroke-work index ( 135 +/- 18 % vs. 102 +/- 5 % recovery 15 minutes after bypass and 145 +/- 16 % vs. 119 +/- 11 % recovery 105 min after bypass ) . There were fewer patients in group I ( 5/15 ) needing inotropic support compared to group II ( 9/14 ) . The myocardial content of ATP and creatine phosphate showed no significant differences during ischemia and reperfusion . It is concluded that the myocardial protection during ischemia was sufficient to prevent significant reductions of myocardial ATP and creatine phosphate irrespective of supplementation with CP .
[ "Biochemical", "and", "functional", "effects", "of", "creatine", "phosphate", "in", "cardioplegic", "solution", "during", "aortic", "valve", "surgery", "--", "a", "clinical", "study", ".", "During", "myocardial", "ischemia", "there", "is", "a", "drop", "in", "high", "-", "energy", "phosphates", "in", "the", "myocardium", ".", "Cold", "potassium", "cardioplegia", "decreases", "but", "does", "not", "altogether", "prevent", "this", "reduction", ".", "Supplementation", "of", "cardioplegic", "solutions", "with", "the", "high", "-", "energy", "compound", "creatine", "phosphate", "(", "10", "mmol", "/", "L", ")", "compared", "to", "plain", "cardioplegic", "solutions", "was", "investigated", "in", "this", "study", ".", "Thirty", "patients", "scheduled", "for", "aortic", "valve", "replacement", "were", "included", ".", "The", "patients", "were", "randomized", "to", "group", "I", "(", "creatine", "phosphate", ")", "or", "group", "II", "(", "control", ")", ".", "Postoperative", "hemodynamic", "evaluation", "revealed", "no", "significant", "differences", "between", "the", "groups", ".", "However", ",", "group", "I", "exhibited", "a", "tendency", "toward", "a", "better", "stroke", "-", "work", "index", "(", "135", "+", "/-", "18", "%", "vs", ".", "102", "+", "/-", "5", "%", "recovery", "15", "minutes", "after", "bypass", "and", "145", "+", "/-", "16", "%", "vs", ".", "119", "+", "/-", "11", "%", "recovery", "105", "min", "after", "bypass", ")", ".", "There", "were", "fewer", "patients", "in", "group", "I", "(", "5/15", ")", "needing", "inotropic", "support", "compared", "to", "group", "II", "(", "9/14", ")", ".", "The", "myocardial", "content", "of", "ATP", "and", "creatine", "phosphate", "showed", "no", "significant", "differences", "during", "ischemia", "and", "reperfusion", ".", "It", "is", "concluded", "that", "the", "myocardial", "protection", "during", "ischemia", "was", "sufficient", "to", "prevent", "significant", "reductions", "of", "myocardial", "ATP", "and", "creatine", "phosphate", "irrespective", "of", "supplementation", "with", "CP", "." ]
[ "Outcome_Physical", "Intervention_Control", "Participant_Condition", "Intervention_Pharmacological" ]
creatine phosphate is a Intervention_Pharmacological, aortic valve surgery -- a is a Participant_Condition, drop in high - energy phosphates is a Outcome_Physical, plain cardioplegic solutions is a Intervention_Control, control is a Intervention_Control, hemodynamic evaluation is a Outcome_Physical, stroke - work index is a Outcome_Physical, needing inotropic support is a Outcome_Physical, myocardial content of ATP and creatine phosphate is a Outcome_Physical, myocardial ATP and creatine phosphate is a Outcome_Physical
24691_task1
Sentence: Biochemical and functional effects of creatine phosphate in cardioplegic solution during aortic valve surgery -- a clinical study . During myocardial ischemia there is a drop in high-energy phosphates in the myocardium . Cold potassium cardioplegia decreases but does not altogether prevent this reduction . Supplementation of cardioplegic solutions with the high-energy compound creatine phosphate ( 10 mmol/L ) compared to plain cardioplegic solutions was investigated in this study . Thirty patients scheduled for aortic valve replacement were included . The patients were randomized to group I ( creatine phosphate ) or group II ( control ) . Postoperative hemodynamic evaluation revealed no significant differences between the groups . However , group I exhibited a tendency toward a better stroke-work index ( 135 +/- 18 % vs. 102 +/- 5 % recovery 15 minutes after bypass and 145 +/- 16 % vs. 119 +/- 11 % recovery 105 min after bypass ) . There were fewer patients in group I ( 5/15 ) needing inotropic support compared to group II ( 9/14 ) . The myocardial content of ATP and creatine phosphate showed no significant differences during ischemia and reperfusion . It is concluded that the myocardial protection during ischemia was sufficient to prevent significant reductions of myocardial ATP and creatine phosphate irrespective of supplementation with CP . Instructions: please typing these entity words according to sentence: creatine phosphate, aortic valve surgery -- a, drop in high - energy phosphates, plain cardioplegic solutions, control, hemodynamic evaluation, stroke - work index, needing inotropic support, myocardial content of ATP and creatine phosphate, myocardial ATP and creatine phosphate Options: Intervention_Control, Intervention_Pharmacological, Outcome_Physical, Participant_Condition
[ "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Control", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O" ]
Biochemical and functional effects of creatine phosphate in cardioplegic solution during aortic valve surgery -- a clinical study . During myocardial ischemia there is a drop in high-energy phosphates in the myocardium . Cold potassium cardioplegia decreases but does not altogether prevent this reduction . Supplementation of cardioplegic solutions with the high-energy compound creatine phosphate ( 10 mmol/L ) compared to plain cardioplegic solutions was investigated in this study . Thirty patients scheduled for aortic valve replacement were included . The patients were randomized to group I ( creatine phosphate ) or group II ( control ) . Postoperative hemodynamic evaluation revealed no significant differences between the groups . However , group I exhibited a tendency toward a better stroke-work index ( 135 +/- 18 % vs. 102 +/- 5 % recovery 15 minutes after bypass and 145 +/- 16 % vs. 119 +/- 11 % recovery 105 min after bypass ) . There were fewer patients in group I ( 5/15 ) needing inotropic support compared to group II ( 9/14 ) . The myocardial content of ATP and creatine phosphate showed no significant differences during ischemia and reperfusion . It is concluded that the myocardial protection during ischemia was sufficient to prevent significant reductions of myocardial ATP and creatine phosphate irrespective of supplementation with CP .
[ "Biochemical", "and", "functional", "effects", "of", "creatine", "phosphate", "in", "cardioplegic", "solution", "during", "aortic", "valve", "surgery", "--", "a", "clinical", "study", ".", "During", "myocardial", "ischemia", "there", "is", "a", "drop", "in", "high", "-", "energy", "phosphates", "in", "the", "myocardium", ".", "Cold", "potassium", "cardioplegia", "decreases", "but", "does", "not", "altogether", "prevent", "this", "reduction", ".", "Supplementation", "of", "cardioplegic", "solutions", "with", "the", "high", "-", "energy", "compound", "creatine", "phosphate", "(", "10", "mmol", "/", "L", ")", "compared", "to", "plain", "cardioplegic", "solutions", "was", "investigated", "in", "this", "study", ".", "Thirty", "patients", "scheduled", "for", "aortic", "valve", "replacement", "were", "included", ".", "The", "patients", "were", "randomized", "to", "group", "I", "(", "creatine", "phosphate", ")", "or", "group", "II", "(", "control", ")", ".", "Postoperative", "hemodynamic", "evaluation", "revealed", "no", "significant", "differences", "between", "the", "groups", ".", "However", ",", "group", "I", "exhibited", "a", "tendency", "toward", "a", "better", "stroke", "-", "work", "index", "(", "135", "+", "/-", "18", "%", "vs", ".", "102", "+", "/-", "5", "%", "recovery", "15", "minutes", "after", "bypass", "and", "145", "+", "/-", "16", "%", "vs", ".", "119", "+", "/-", "11", "%", "recovery", "105", "min", "after", "bypass", ")", ".", "There", "were", "fewer", "patients", "in", "group", "I", "(", "5/15", ")", "needing", "inotropic", "support", "compared", "to", "group", "II", "(", "9/14", ")", ".", "The", "myocardial", "content", "of", "ATP", "and", "creatine", "phosphate", "showed", "no", "significant", "differences", "during", "ischemia", "and", "reperfusion", ".", "It", "is", "concluded", "that", "the", "myocardial", "protection", "during", "ischemia", "was", "sufficient", "to", "prevent", "significant", "reductions", "of", "myocardial", "ATP", "and", "creatine", "phosphate", "irrespective", "of", "supplementation", "with", "CP", "." ]
[ "Outcome_Physical", "Intervention_Control", "Participant_Condition", "Intervention_Pharmacological" ]
creatine phosphate, aortic valve surgery -- a, drop in high - energy phosphates, plain cardioplegic solutions, control, hemodynamic evaluation, stroke - work index, needing inotropic support, myocardial content of ATP and creatine phosphate, myocardial ATP and creatine phosphate
24691_task2
Sentence: Biochemical and functional effects of creatine phosphate in cardioplegic solution during aortic valve surgery -- a clinical study . During myocardial ischemia there is a drop in high-energy phosphates in the myocardium . Cold potassium cardioplegia decreases but does not altogether prevent this reduction . Supplementation of cardioplegic solutions with the high-energy compound creatine phosphate ( 10 mmol/L ) compared to plain cardioplegic solutions was investigated in this study . Thirty patients scheduled for aortic valve replacement were included . The patients were randomized to group I ( creatine phosphate ) or group II ( control ) . Postoperative hemodynamic evaluation revealed no significant differences between the groups . However , group I exhibited a tendency toward a better stroke-work index ( 135 +/- 18 % vs. 102 +/- 5 % recovery 15 minutes after bypass and 145 +/- 16 % vs. 119 +/- 11 % recovery 105 min after bypass ) . There were fewer patients in group I ( 5/15 ) needing inotropic support compared to group II ( 9/14 ) . The myocardial content of ATP and creatine phosphate showed no significant differences during ischemia and reperfusion . It is concluded that the myocardial protection during ischemia was sufficient to prevent significant reductions of myocardial ATP and creatine phosphate irrespective of supplementation with CP . Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Control", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O" ]
Biochemical and functional effects of creatine phosphate in cardioplegic solution during aortic valve surgery -- a clinical study . During myocardial ischemia there is a drop in high-energy phosphates in the myocardium . Cold potassium cardioplegia decreases but does not altogether prevent this reduction . Supplementation of cardioplegic solutions with the high-energy compound creatine phosphate ( 10 mmol/L ) compared to plain cardioplegic solutions was investigated in this study . Thirty patients scheduled for aortic valve replacement were included . The patients were randomized to group I ( creatine phosphate ) or group II ( control ) . Postoperative hemodynamic evaluation revealed no significant differences between the groups . However , group I exhibited a tendency toward a better stroke-work index ( 135 +/- 18 % vs. 102 +/- 5 % recovery 15 minutes after bypass and 145 +/- 16 % vs. 119 +/- 11 % recovery 105 min after bypass ) . There were fewer patients in group I ( 5/15 ) needing inotropic support compared to group II ( 9/14 ) . The myocardial content of ATP and creatine phosphate showed no significant differences during ischemia and reperfusion . It is concluded that the myocardial protection during ischemia was sufficient to prevent significant reductions of myocardial ATP and creatine phosphate irrespective of supplementation with CP .
[ "Biochemical", "and", "functional", "effects", "of", "creatine", "phosphate", "in", "cardioplegic", "solution", "during", "aortic", "valve", "surgery", "--", "a", "clinical", "study", ".", "During", "myocardial", "ischemia", "there", "is", "a", "drop", "in", "high", "-", "energy", "phosphates", "in", "the", "myocardium", ".", "Cold", "potassium", "cardioplegia", "decreases", "but", "does", "not", "altogether", "prevent", "this", "reduction", ".", "Supplementation", "of", "cardioplegic", "solutions", "with", "the", "high", "-", "energy", "compound", "creatine", "phosphate", "(", "10", "mmol", "/", "L", ")", "compared", "to", "plain", "cardioplegic", "solutions", "was", "investigated", "in", "this", "study", ".", "Thirty", "patients", "scheduled", "for", "aortic", "valve", "replacement", "were", "included", ".", "The", "patients", "were", "randomized", "to", "group", "I", "(", "creatine", "phosphate", ")", "or", "group", "II", "(", "control", ")", ".", "Postoperative", "hemodynamic", "evaluation", "revealed", "no", "significant", "differences", "between", "the", "groups", ".", "However", ",", "group", "I", "exhibited", "a", "tendency", "toward", "a", "better", "stroke", "-", "work", "index", "(", "135", "+", "/-", "18", "%", "vs", ".", "102", "+", "/-", "5", "%", "recovery", "15", "minutes", "after", "bypass", "and", "145", "+", "/-", "16", "%", "vs", ".", "119", "+", "/-", "11", "%", "recovery", "105", "min", "after", "bypass", ")", ".", "There", "were", "fewer", "patients", "in", "group", "I", "(", "5/15", ")", "needing", "inotropic", "support", "compared", "to", "group", "II", "(", "9/14", ")", ".", "The", "myocardial", "content", "of", "ATP", "and", "creatine", "phosphate", "showed", "no", "significant", "differences", "during", "ischemia", "and", "reperfusion", ".", "It", "is", "concluded", "that", "the", "myocardial", "protection", "during", "ischemia", "was", "sufficient", "to", "prevent", "significant", "reductions", "of", "myocardial", "ATP", "and", "creatine", "phosphate", "irrespective", "of", "supplementation", "with", "CP", "." ]
[ "Outcome_Physical", "Intervention_Control", "Participant_Condition", "Intervention_Pharmacological" ]
blood is a Organism_substance, serum is a Organism_substance
PMC-2782986-sec-02_task0
Sentence: RESEARCH DESIGN AND METHODS For this study, 20 individuals (mean age 39.5 +/- 11.1 years) with long-standing type 1 diabetes (21.3 +/- 10.7 years) were enrolled in this prospective open-label crossover trial. After achieving optimal blood glucose control, 16 subjects were randomized to exenatide with or without daclizumab. Endogenous insulin production was determined by repeatedly measuring serum C-peptide. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Organism_substance
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism_substance", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism_substance", "O", "O", "O", "O", "O" ]
RESEARCH DESIGN AND METHODS For this study, 20 individuals (mean age 39.5 +/- 11.1 years) with long-standing type 1 diabetes (21.3 +/- 10.7 years) were enrolled in this prospective open-label crossover trial. After achieving optimal blood glucose control, 16 subjects were randomized to exenatide with or without daclizumab. Endogenous insulin production was determined by repeatedly measuring serum C-peptide.
[ "RESEARCH", "DESIGN", "AND", "METHODS", "\n", "For", "this", "study", ",", "20", "individuals", "(", "mean", "age", "39.5", "+", "/-", "11.1", "years", ")", "with", "long", "-", "standing", "type", "1", "diabetes", "(", "21.3", "+", "/-", "10.7", "years", ")", "were", "enrolled", "in", "this", "prospective", "open", "-", "label", "crossover", "trial", ".", "After", "achieving", "optimal", "blood", "glucose", "control", ",", "16", "subjects", "were", "randomized", "to", "exenatide", "with", "or", "without", "daclizumab", ".", "Endogenous", "insulin", "production", "was", "determined", "by", "repeatedly", "measuring", "serum", "C", "-", "peptide", ".", "\n" ]
[ "Organism_substance" ]
blood is a Organism_substance, serum is a Organism_substance
PMC-2782986-sec-02_task1
Sentence: RESEARCH DESIGN AND METHODS For this study, 20 individuals (mean age 39.5 +/- 11.1 years) with long-standing type 1 diabetes (21.3 +/- 10.7 years) were enrolled in this prospective open-label crossover trial. After achieving optimal blood glucose control, 16 subjects were randomized to exenatide with or without daclizumab. Endogenous insulin production was determined by repeatedly measuring serum C-peptide. Instructions: please typing these entity words according to sentence: blood, serum Options: Organism_substance
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism_substance", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism_substance", "O", "O", "O", "O", "O" ]
RESEARCH DESIGN AND METHODS For this study, 20 individuals (mean age 39.5 +/- 11.1 years) with long-standing type 1 diabetes (21.3 +/- 10.7 years) were enrolled in this prospective open-label crossover trial. After achieving optimal blood glucose control, 16 subjects were randomized to exenatide with or without daclizumab. Endogenous insulin production was determined by repeatedly measuring serum C-peptide.
[ "RESEARCH", "DESIGN", "AND", "METHODS", "\n", "For", "this", "study", ",", "20", "individuals", "(", "mean", "age", "39.5", "+", "/-", "11.1", "years", ")", "with", "long", "-", "standing", "type", "1", "diabetes", "(", "21.3", "+", "/-", "10.7", "years", ")", "were", "enrolled", "in", "this", "prospective", "open", "-", "label", "crossover", "trial", ".", "After", "achieving", "optimal", "blood", "glucose", "control", ",", "16", "subjects", "were", "randomized", "to", "exenatide", "with", "or", "without", "daclizumab", ".", "Endogenous", "insulin", "production", "was", "determined", "by", "repeatedly", "measuring", "serum", "C", "-", "peptide", ".", "\n" ]
[ "Organism_substance" ]
blood, serum
PMC-2782986-sec-02_task2
Sentence: RESEARCH DESIGN AND METHODS For this study, 20 individuals (mean age 39.5 +/- 11.1 years) with long-standing type 1 diabetes (21.3 +/- 10.7 years) were enrolled in this prospective open-label crossover trial. After achieving optimal blood glucose control, 16 subjects were randomized to exenatide with or without daclizumab. Endogenous insulin production was determined by repeatedly measuring serum C-peptide. Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism_substance", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism_substance", "O", "O", "O", "O", "O" ]
RESEARCH DESIGN AND METHODS For this study, 20 individuals (mean age 39.5 +/- 11.1 years) with long-standing type 1 diabetes (21.3 +/- 10.7 years) were enrolled in this prospective open-label crossover trial. After achieving optimal blood glucose control, 16 subjects were randomized to exenatide with or without daclizumab. Endogenous insulin production was determined by repeatedly measuring serum C-peptide.
[ "RESEARCH", "DESIGN", "AND", "METHODS", "\n", "For", "this", "study", ",", "20", "individuals", "(", "mean", "age", "39.5", "+", "/-", "11.1", "years", ")", "with", "long", "-", "standing", "type", "1", "diabetes", "(", "21.3", "+", "/-", "10.7", "years", ")", "were", "enrolled", "in", "this", "prospective", "open", "-", "label", "crossover", "trial", ".", "After", "achieving", "optimal", "blood", "glucose", "control", ",", "16", "subjects", "were", "randomized", "to", "exenatide", "with", "or", "without", "daclizumab", ".", "Endogenous", "insulin", "production", "was", "determined", "by", "repeatedly", "measuring", "serum", "C", "-", "peptide", ".", "\n" ]
[ "Organism_substance" ]
cAMP is a compound
DS.d1162_task0
Sentence: This initiates a cAMP signalling cascade resulting in the translocation of AQP2-bearing vesicles to the apical membrane. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: compound
[ "O", "O", "O", "B-compound", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
This initiates a cAMP signalling cascade resulting in the translocation of AQP2-bearing vesicles to the apical membrane.
[ "This", "initiates", "a", "cAMP", "signalling", "cascade", "resulting", "in", "the", "translocation", "of", "AQP2-bearing", "vesicles", "to", "the", "apical", "membrane", "." ]
[ "compound", "protein" ]
cAMP is a compound
DS.d1162_task1
Sentence: This initiates a cAMP signalling cascade resulting in the translocation of AQP2-bearing vesicles to the apical membrane. Instructions: please typing these entity words according to sentence: cAMP Options: compound
[ "O", "O", "O", "B-compound", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
This initiates a cAMP signalling cascade resulting in the translocation of AQP2-bearing vesicles to the apical membrane.
[ "This", "initiates", "a", "cAMP", "signalling", "cascade", "resulting", "in", "the", "translocation", "of", "AQP2-bearing", "vesicles", "to", "the", "apical", "membrane", "." ]
[ "compound", "protein" ]
cAMP
DS.d1162_task2
Sentence: This initiates a cAMP signalling cascade resulting in the translocation of AQP2-bearing vesicles to the apical membrane. Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "B-compound", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
This initiates a cAMP signalling cascade resulting in the translocation of AQP2-bearing vesicles to the apical membrane.
[ "This", "initiates", "a", "cAMP", "signalling", "cascade", "resulting", "in", "the", "translocation", "of", "AQP2-bearing", "vesicles", "to", "the", "apical", "membrane", "." ]
[ "compound", "protein" ]
Clobazam is a Intervention_Pharmacological, catamenial epilepsy is a Participant_Condition, benzodiazepine , clobazam . is a Intervention_Pharmacological, placebo is a Intervention_Control, 14 is a Participant_Sample-size, 18 is a Participant_Sample-size, seizures is a Outcome_Physical, frequency and severity is a Outcome_Other
78175_task0
Sentence: Clobazam in catamenial epilepsy . A model for evaluating anticonvulsants . The cyclical exacerbations of epilepsy ( catamenial epilepsy ) were used to assess the antiepileptic effect of a benzodiazepine , clobazam . Doses of 20 mg , and in some cases 30 mg , per day were compared with placebo over predetermined ten-day periods in a double-blind cross-over study . The results were evaluated by preference in a sequential procedure . In 14 of 18 patients who received both treatments clobazam was superior to placebo , and in 4 patients no preference was established . Clobazam completely prevented seizures in most of the patients , and toxic effects were of low frequency and severity . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Intervention_Pharmacological, Intervention_Control, Participant_Condition, Outcome_Physical, Participant_Sample-size, Outcome_Other
[ "B-Intervention_Pharmacological", "O", "B-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Control", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O" ]
Clobazam in catamenial epilepsy . A model for evaluating anticonvulsants . The cyclical exacerbations of epilepsy ( catamenial epilepsy ) were used to assess the antiepileptic effect of a benzodiazepine , clobazam . Doses of 20 mg , and in some cases 30 mg , per day were compared with placebo over predetermined ten-day periods in a double-blind cross-over study . The results were evaluated by preference in a sequential procedure . In 14 of 18 patients who received both treatments clobazam was superior to placebo , and in 4 patients no preference was established . Clobazam completely prevented seizures in most of the patients , and toxic effects were of low frequency and severity .
[ "Clobazam", "in", "catamenial", "epilepsy", ".", "A", "model", "for", "evaluating", "anticonvulsants", ".", "The", "cyclical", "exacerbations", "of", "epilepsy", "(", "catamenial", "epilepsy", ")", "were", "used", "to", "assess", "the", "antiepileptic", "effect", "of", "a", "benzodiazepine", ",", "clobazam", ".", "Doses", "of", "20", "mg", ",", "and", "in", "some", "cases", "30", "mg", ",", "per", "day", "were", "compared", "with", "placebo", "over", "predetermined", "ten", "-", "day", "periods", "in", "a", "double", "-", "blind", "cross", "-", "over", "study", ".", "The", "results", "were", "evaluated", "by", "preference", "in", "a", "sequential", "procedure", ".", "In", "14", "of", "18", "patients", "who", "received", "both", "treatments", "clobazam", "was", "superior", "to", "placebo", ",", "and", "in", "4", "patients", "no", "preference", "was", "established", ".", "Clobazam", "completely", "prevented", "seizures", "in", "most", "of", "the", "patients", ",", "and", "toxic", "effects", "were", "of", "low", "frequency", "and", "severity", "." ]
[ "Intervention_Pharmacological", "Outcome_Other", "Participant_Condition", "Outcome_Physical", "Intervention_Control", "Participant_Sample-size" ]
Clobazam is a Intervention_Pharmacological, catamenial epilepsy is a Participant_Condition, benzodiazepine , clobazam . is a Intervention_Pharmacological, placebo is a Intervention_Control, 14 is a Participant_Sample-size, 18 is a Participant_Sample-size, seizures is a Outcome_Physical, frequency and severity is a Outcome_Other
78175_task1
Sentence: Clobazam in catamenial epilepsy . A model for evaluating anticonvulsants . The cyclical exacerbations of epilepsy ( catamenial epilepsy ) were used to assess the antiepileptic effect of a benzodiazepine , clobazam . Doses of 20 mg , and in some cases 30 mg , per day were compared with placebo over predetermined ten-day periods in a double-blind cross-over study . The results were evaluated by preference in a sequential procedure . In 14 of 18 patients who received both treatments clobazam was superior to placebo , and in 4 patients no preference was established . Clobazam completely prevented seizures in most of the patients , and toxic effects were of low frequency and severity . Instructions: please typing these entity words according to sentence: Clobazam, catamenial epilepsy, benzodiazepine , clobazam ., placebo, 14, 18, seizures, frequency and severity Options: Intervention_Pharmacological, Intervention_Control, Participant_Condition, Outcome_Physical, Participant_Sample-size, Outcome_Other
[ "B-Intervention_Pharmacological", "O", "B-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Control", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O" ]
Clobazam in catamenial epilepsy . A model for evaluating anticonvulsants . The cyclical exacerbations of epilepsy ( catamenial epilepsy ) were used to assess the antiepileptic effect of a benzodiazepine , clobazam . Doses of 20 mg , and in some cases 30 mg , per day were compared with placebo over predetermined ten-day periods in a double-blind cross-over study . The results were evaluated by preference in a sequential procedure . In 14 of 18 patients who received both treatments clobazam was superior to placebo , and in 4 patients no preference was established . Clobazam completely prevented seizures in most of the patients , and toxic effects were of low frequency and severity .
[ "Clobazam", "in", "catamenial", "epilepsy", ".", "A", "model", "for", "evaluating", "anticonvulsants", ".", "The", "cyclical", "exacerbations", "of", "epilepsy", "(", "catamenial", "epilepsy", ")", "were", "used", "to", "assess", "the", "antiepileptic", "effect", "of", "a", "benzodiazepine", ",", "clobazam", ".", "Doses", "of", "20", "mg", ",", "and", "in", "some", "cases", "30", "mg", ",", "per", "day", "were", "compared", "with", "placebo", "over", "predetermined", "ten", "-", "day", "periods", "in", "a", "double", "-", "blind", "cross", "-", "over", "study", ".", "The", "results", "were", "evaluated", "by", "preference", "in", "a", "sequential", "procedure", ".", "In", "14", "of", "18", "patients", "who", "received", "both", "treatments", "clobazam", "was", "superior", "to", "placebo", ",", "and", "in", "4", "patients", "no", "preference", "was", "established", ".", "Clobazam", "completely", "prevented", "seizures", "in", "most", "of", "the", "patients", ",", "and", "toxic", "effects", "were", "of", "low", "frequency", "and", "severity", "." ]
[ "Intervention_Pharmacological", "Outcome_Other", "Participant_Condition", "Outcome_Physical", "Intervention_Control", "Participant_Sample-size" ]
Clobazam, catamenial epilepsy, benzodiazepine , clobazam ., placebo, 14, 18, seizures, frequency and severity
78175_task2
Sentence: Clobazam in catamenial epilepsy . A model for evaluating anticonvulsants . The cyclical exacerbations of epilepsy ( catamenial epilepsy ) were used to assess the antiepileptic effect of a benzodiazepine , clobazam . Doses of 20 mg , and in some cases 30 mg , per day were compared with placebo over predetermined ten-day periods in a double-blind cross-over study . The results were evaluated by preference in a sequential procedure . In 14 of 18 patients who received both treatments clobazam was superior to placebo , and in 4 patients no preference was established . Clobazam completely prevented seizures in most of the patients , and toxic effects were of low frequency and severity . Instructions: please extract entity words from the input sentence
[ "B-Intervention_Pharmacological", "O", "B-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Control", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O" ]
Clobazam in catamenial epilepsy . A model for evaluating anticonvulsants . The cyclical exacerbations of epilepsy ( catamenial epilepsy ) were used to assess the antiepileptic effect of a benzodiazepine , clobazam . Doses of 20 mg , and in some cases 30 mg , per day were compared with placebo over predetermined ten-day periods in a double-blind cross-over study . The results were evaluated by preference in a sequential procedure . In 14 of 18 patients who received both treatments clobazam was superior to placebo , and in 4 patients no preference was established . Clobazam completely prevented seizures in most of the patients , and toxic effects were of low frequency and severity .
[ "Clobazam", "in", "catamenial", "epilepsy", ".", "A", "model", "for", "evaluating", "anticonvulsants", ".", "The", "cyclical", "exacerbations", "of", "epilepsy", "(", "catamenial", "epilepsy", ")", "were", "used", "to", "assess", "the", "antiepileptic", "effect", "of", "a", "benzodiazepine", ",", "clobazam", ".", "Doses", "of", "20", "mg", ",", "and", "in", "some", "cases", "30", "mg", ",", "per", "day", "were", "compared", "with", "placebo", "over", "predetermined", "ten", "-", "day", "periods", "in", "a", "double", "-", "blind", "cross", "-", "over", "study", ".", "The", "results", "were", "evaluated", "by", "preference", "in", "a", "sequential", "procedure", ".", "In", "14", "of", "18", "patients", "who", "received", "both", "treatments", "clobazam", "was", "superior", "to", "placebo", ",", "and", "in", "4", "patients", "no", "preference", "was", "established", ".", "Clobazam", "completely", "prevented", "seizures", "in", "most", "of", "the", "patients", ",", "and", "toxic", "effects", "were", "of", "low", "frequency", "and", "severity", "." ]
[ "Intervention_Pharmacological", "Outcome_Other", "Participant_Condition", "Outcome_Physical", "Intervention_Control", "Participant_Sample-size" ]
HPC1 is a Gene
3_task0
Sentence: Combined analysis of hereditary prostate cancer linkage to 1q24-25: results from 772 hereditary prostate cancer families from the International Consortium for Prostate Cancer Genetics. A previous linkage study provided evidence for a prostate cancer-susceptibility locus at 1q24-25. Subsequent reports in additional collections of families have yielded conflicting results. In addition, evidence for locus heterogeneity has been provided by the identification of other putative hereditary prostate cancer loci on Xq27-28, 1q42-43, and 1p36. The present study describes a combined analysis for six markers in the 1q24-25 region in 772 families affected by hereditary prostate cancer and ascertained by the members of the International Consortium for Prostate Cancer Genetics (ICPCG) from North America, Australia, Finland, Norway, Sweden, and the United Kingdom. Overall, there was some evidence for linkage, with a peak parametric multipoint LOD score assuming heterogeneity (HLOD) of 1.40 (P=.01) at D1S212. The estimated proportion of families (alpha) linked to the locus was.06 (1-LOD support interval.01-.12). This evidence was not observed by a nonparametric approach, presumably because of the extensive heterogeneity. Further parametric analysis revealed a significant effect of the presence of male-to-male disease transmission within the families. In the subset of 491 such families, the peak HLOD was 2.56 (P=.0006) and alpha =.11 (1-LOD support interval.04-.19), compared with HLODs of 0 in the remaining 281 families. Within the families with male-to-male disease transmission, alpha increased with the early mean age at diagnosis (<65 years, alpha =.19, with 1-LOD support interval.06-.34) and the number of affected family members (five or more family members, alpha =.15, with 1-LOD support interval.04-.28). The highest value of alpha was observed for the 48 families that met all three criteria (peak HLOD = 2.25, P=.001, alpha=.29, with 1-LOD support interval.08-.53). These results support the finding of a prostate cancer-susceptibility gene linked to 1q24-25, albeit in a defined subset of prostate cancer families. Although HPC1 accounts for only a small proportion of all families affected by hereditary prostate cancer, it appears to play a more prominent role in the subset of families with several members affected at an early age and with male-to-male disease transmission. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Gene
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Combined analysis of hereditary prostate cancer linkage to 1q24-25: results from 772 hereditary prostate cancer families from the International Consortium for Prostate Cancer Genetics. A previous linkage study provided evidence for a prostate cancer-susceptibility locus at 1q24-25. Subsequent reports in additional collections of families have yielded conflicting results. In addition, evidence for locus heterogeneity has been provided by the identification of other putative hereditary prostate cancer loci on Xq27-28, 1q42-43, and 1p36. The present study describes a combined analysis for six markers in the 1q24-25 region in 772 families affected by hereditary prostate cancer and ascertained by the members of the International Consortium for Prostate Cancer Genetics (ICPCG) from North America, Australia, Finland, Norway, Sweden, and the United Kingdom. Overall, there was some evidence for linkage, with a peak parametric multipoint LOD score assuming heterogeneity (HLOD) of 1.40 (P=.01) at D1S212. The estimated proportion of families (alpha) linked to the locus was.06 (1-LOD support interval.01-.12). This evidence was not observed by a nonparametric approach, presumably because of the extensive heterogeneity. Further parametric analysis revealed a significant effect of the presence of male-to-male disease transmission within the families. In the subset of 491 such families, the peak HLOD was 2.56 (P=.0006) and alpha =.11 (1-LOD support interval.04-.19), compared with HLODs of 0 in the remaining 281 families. Within the families with male-to-male disease transmission, alpha increased with the early mean age at diagnosis (<65 years, alpha =.19, with 1-LOD support interval.06-.34) and the number of affected family members (five or more family members, alpha =.15, with 1-LOD support interval.04-.28). The highest value of alpha was observed for the 48 families that met all three criteria (peak HLOD = 2.25, P=.001, alpha=.29, with 1-LOD support interval.08-.53). These results support the finding of a prostate cancer-susceptibility gene linked to 1q24-25, albeit in a defined subset of prostate cancer families. Although HPC1 accounts for only a small proportion of all families affected by hereditary prostate cancer, it appears to play a more prominent role in the subset of families with several members affected at an early age and with male-to-male disease transmission.
[ "Combined", "analysis", "of", "hereditary", "prostate", "cancer", "linkage", "to", "1q24", "-", "25", ":", "results", "from", "772", "hereditary", "prostate", "cancer", "families", "from", "the", "International", "Consortium", "for", "Prostate", "Cancer", "Genetics", ".", "A", "previous", "linkage", "study", "provided", "evidence", "for", "a", "prostate", "cancer", "-", "susceptibility", "locus", "at", "1q24", "-", "25", ".", "Subsequent", "reports", "in", "additional", "collections", "of", "families", "have", "yielded", "conflicting", "results", ".", "In", "addition", ",", "evidence", "for", "locus", "heterogeneity", "has", "been", "provided", "by", "the", "identification", "of", "other", "putative", "hereditary", "prostate", "cancer", "loci", "on", "Xq27", "-", "28", ",", "1q42", "-", "43", ",", "and", "1p36", ".", "The", "present", "study", "describes", "a", "combined", "analysis", "for", "six", "markers", "in", "the", "1q24", "-", "25", "region", "in", "772", "families", "affected", "by", "hereditary", "prostate", "cancer", "and", "ascertained", "by", "the", "members", "of", "the", "International", "Consortium", "for", "Prostate", "Cancer", "Genetics", "(", "ICPCG", ")", "from", "North", "America", ",", "Australia", ",", "Finland", ",", "Norway", ",", "Sweden", ",", "and", "the", "United", "Kingdom", ".", "Overall", ",", "there", "was", "some", "evidence", "for", "linkage", ",", "with", "a", "peak", "parametric", "multipoint", "LOD", "score", "assuming", "heterogeneity", "(", "HLOD", ")", "of", "1.40", "(", "P=.01", ")", "at", "D1S212", ".", "The", "estimated", "proportion", "of", "families", "(", "alpha", ")", "linked", "to", "the", "locus", "was.06", "(", "1-LOD", "support", "interval.01-.12", ")", ".", "This", "evidence", "was", "not", "observed", "by", "a", "nonparametric", "approach", ",", "presumably", "because", "of", "the", "extensive", "heterogeneity", ".", "Further", "parametric", "analysis", "revealed", "a", "significant", "effect", "of", "the", "presence", "of", "male", "-", "to", "-", "male", "disease", "transmission", "within", "the", "families", ".", "In", "the", "subset", "of", "491", "such", "families", ",", "the", "peak", "HLOD", "was", "2.56", "(", "P=.0006", ")", "and", "alpha", "=", ".11", "(", "1-LOD", "support", "interval.04-.19", ")", ",", "compared", "with", "HLODs", "of", "0", "in", "the", "remaining", "281", "families", ".", "Within", "the", "families", "with", "male", "-", "to", "-", "male", "disease", "transmission", ",", "alpha", "increased", "with", "the", "early", "mean", "age", "at", "diagnosis", "(", "<", "65", "years", ",", "alpha", "=", ".19", ",", "with", "1-LOD", "support", "interval.06-.34", ")", "and", "the", "number", "of", "affected", "family", "members", "(", "five", "or", "more", "family", "members", ",", "alpha", "=", ".15", ",", "with", "1-LOD", "support", "interval.04-.28", ")", ".", "The", "highest", "value", "of", "alpha", "was", "observed", "for", "the", "48", "families", "that", "met", "all", "three", "criteria", "(", "peak", "HLOD", "=", "2.25", ",", "P=.001", ",", "alpha=.29", ",", "with", "1-LOD", "support", "interval.08-.53", ")", ".", "These", "results", "support", "the", "finding", "of", "a", "prostate", "cancer", "-", "susceptibility", "gene", "linked", "to", "1q24", "-", "25", ",", "albeit", "in", "a", "defined", "subset", "of", "prostate", "cancer", "families", ".", "Although", "HPC1", "accounts", "for", "only", "a", "small", "proportion", "of", "all", "families", "affected", "by", "hereditary", "prostate", "cancer", ",", "it", "appears", "to", "play", "a", "more", "prominent", "role", "in", "the", "subset", "of", "families", "with", "several", "members", "affected", "at", "an", "early", "age", "and", "with", "male", "-", "to", "-", "male", "disease", "transmission", ".", "\n" ]
[ "Gene" ]
HPC1 is a Gene
3_task1
Sentence: Combined analysis of hereditary prostate cancer linkage to 1q24-25: results from 772 hereditary prostate cancer families from the International Consortium for Prostate Cancer Genetics. A previous linkage study provided evidence for a prostate cancer-susceptibility locus at 1q24-25. Subsequent reports in additional collections of families have yielded conflicting results. In addition, evidence for locus heterogeneity has been provided by the identification of other putative hereditary prostate cancer loci on Xq27-28, 1q42-43, and 1p36. The present study describes a combined analysis for six markers in the 1q24-25 region in 772 families affected by hereditary prostate cancer and ascertained by the members of the International Consortium for Prostate Cancer Genetics (ICPCG) from North America, Australia, Finland, Norway, Sweden, and the United Kingdom. Overall, there was some evidence for linkage, with a peak parametric multipoint LOD score assuming heterogeneity (HLOD) of 1.40 (P=.01) at D1S212. The estimated proportion of families (alpha) linked to the locus was.06 (1-LOD support interval.01-.12). This evidence was not observed by a nonparametric approach, presumably because of the extensive heterogeneity. Further parametric analysis revealed a significant effect of the presence of male-to-male disease transmission within the families. In the subset of 491 such families, the peak HLOD was 2.56 (P=.0006) and alpha =.11 (1-LOD support interval.04-.19), compared with HLODs of 0 in the remaining 281 families. Within the families with male-to-male disease transmission, alpha increased with the early mean age at diagnosis (<65 years, alpha =.19, with 1-LOD support interval.06-.34) and the number of affected family members (five or more family members, alpha =.15, with 1-LOD support interval.04-.28). The highest value of alpha was observed for the 48 families that met all three criteria (peak HLOD = 2.25, P=.001, alpha=.29, with 1-LOD support interval.08-.53). These results support the finding of a prostate cancer-susceptibility gene linked to 1q24-25, albeit in a defined subset of prostate cancer families. Although HPC1 accounts for only a small proportion of all families affected by hereditary prostate cancer, it appears to play a more prominent role in the subset of families with several members affected at an early age and with male-to-male disease transmission. Instructions: please typing these entity words according to sentence: HPC1 Options: Gene
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Combined analysis of hereditary prostate cancer linkage to 1q24-25: results from 772 hereditary prostate cancer families from the International Consortium for Prostate Cancer Genetics. A previous linkage study provided evidence for a prostate cancer-susceptibility locus at 1q24-25. Subsequent reports in additional collections of families have yielded conflicting results. In addition, evidence for locus heterogeneity has been provided by the identification of other putative hereditary prostate cancer loci on Xq27-28, 1q42-43, and 1p36. The present study describes a combined analysis for six markers in the 1q24-25 region in 772 families affected by hereditary prostate cancer and ascertained by the members of the International Consortium for Prostate Cancer Genetics (ICPCG) from North America, Australia, Finland, Norway, Sweden, and the United Kingdom. Overall, there was some evidence for linkage, with a peak parametric multipoint LOD score assuming heterogeneity (HLOD) of 1.40 (P=.01) at D1S212. The estimated proportion of families (alpha) linked to the locus was.06 (1-LOD support interval.01-.12). This evidence was not observed by a nonparametric approach, presumably because of the extensive heterogeneity. Further parametric analysis revealed a significant effect of the presence of male-to-male disease transmission within the families. In the subset of 491 such families, the peak HLOD was 2.56 (P=.0006) and alpha =.11 (1-LOD support interval.04-.19), compared with HLODs of 0 in the remaining 281 families. Within the families with male-to-male disease transmission, alpha increased with the early mean age at diagnosis (<65 years, alpha =.19, with 1-LOD support interval.06-.34) and the number of affected family members (five or more family members, alpha =.15, with 1-LOD support interval.04-.28). The highest value of alpha was observed for the 48 families that met all three criteria (peak HLOD = 2.25, P=.001, alpha=.29, with 1-LOD support interval.08-.53). These results support the finding of a prostate cancer-susceptibility gene linked to 1q24-25, albeit in a defined subset of prostate cancer families. Although HPC1 accounts for only a small proportion of all families affected by hereditary prostate cancer, it appears to play a more prominent role in the subset of families with several members affected at an early age and with male-to-male disease transmission.
[ "Combined", "analysis", "of", "hereditary", "prostate", "cancer", "linkage", "to", "1q24", "-", "25", ":", "results", "from", "772", "hereditary", "prostate", "cancer", "families", "from", "the", "International", "Consortium", "for", "Prostate", "Cancer", "Genetics", ".", "A", "previous", "linkage", "study", "provided", "evidence", "for", "a", "prostate", "cancer", "-", "susceptibility", "locus", "at", "1q24", "-", "25", ".", "Subsequent", "reports", "in", "additional", "collections", "of", "families", "have", "yielded", "conflicting", "results", ".", "In", "addition", ",", "evidence", "for", "locus", "heterogeneity", "has", "been", "provided", "by", "the", "identification", "of", "other", "putative", "hereditary", "prostate", "cancer", "loci", "on", "Xq27", "-", "28", ",", "1q42", "-", "43", ",", "and", "1p36", ".", "The", "present", "study", "describes", "a", "combined", "analysis", "for", "six", "markers", "in", "the", "1q24", "-", "25", "region", "in", "772", "families", "affected", "by", "hereditary", "prostate", "cancer", "and", "ascertained", "by", "the", "members", "of", "the", "International", "Consortium", "for", "Prostate", "Cancer", "Genetics", "(", "ICPCG", ")", "from", "North", "America", ",", "Australia", ",", "Finland", ",", "Norway", ",", "Sweden", ",", "and", "the", "United", "Kingdom", ".", "Overall", ",", "there", "was", "some", "evidence", "for", "linkage", ",", "with", "a", "peak", "parametric", "multipoint", "LOD", "score", "assuming", "heterogeneity", "(", "HLOD", ")", "of", "1.40", "(", "P=.01", ")", "at", "D1S212", ".", "The", "estimated", "proportion", "of", "families", "(", "alpha", ")", "linked", "to", "the", "locus", "was.06", "(", "1-LOD", "support", "interval.01-.12", ")", ".", "This", "evidence", "was", "not", "observed", "by", "a", "nonparametric", "approach", ",", "presumably", "because", "of", "the", "extensive", "heterogeneity", ".", "Further", "parametric", "analysis", "revealed", "a", "significant", "effect", "of", "the", "presence", "of", "male", "-", "to", "-", "male", "disease", "transmission", "within", "the", "families", ".", "In", "the", "subset", "of", "491", "such", "families", ",", "the", "peak", "HLOD", "was", "2.56", "(", "P=.0006", ")", "and", "alpha", "=", ".11", "(", "1-LOD", "support", "interval.04-.19", ")", ",", "compared", "with", "HLODs", "of", "0", "in", "the", "remaining", "281", "families", ".", "Within", "the", "families", "with", "male", "-", "to", "-", "male", "disease", "transmission", ",", "alpha", "increased", "with", "the", "early", "mean", "age", "at", "diagnosis", "(", "<", "65", "years", ",", "alpha", "=", ".19", ",", "with", "1-LOD", "support", "interval.06-.34", ")", "and", "the", "number", "of", "affected", "family", "members", "(", "five", "or", "more", "family", "members", ",", "alpha", "=", ".15", ",", "with", "1-LOD", "support", "interval.04-.28", ")", ".", "The", "highest", "value", "of", "alpha", "was", "observed", "for", "the", "48", "families", "that", "met", "all", "three", "criteria", "(", "peak", "HLOD", "=", "2.25", ",", "P=.001", ",", "alpha=.29", ",", "with", "1-LOD", "support", "interval.08-.53", ")", ".", "These", "results", "support", "the", "finding", "of", "a", "prostate", "cancer", "-", "susceptibility", "gene", "linked", "to", "1q24", "-", "25", ",", "albeit", "in", "a", "defined", "subset", "of", "prostate", "cancer", "families", ".", "Although", "HPC1", "accounts", "for", "only", "a", "small", "proportion", "of", "all", "families", "affected", "by", "hereditary", "prostate", "cancer", ",", "it", "appears", "to", "play", "a", "more", "prominent", "role", "in", "the", "subset", "of", "families", "with", "several", "members", "affected", "at", "an", "early", "age", "and", "with", "male", "-", "to", "-", "male", "disease", "transmission", ".", "\n" ]
[ "Gene" ]
HPC1
3_task2
Sentence: Combined analysis of hereditary prostate cancer linkage to 1q24-25: results from 772 hereditary prostate cancer families from the International Consortium for Prostate Cancer Genetics. A previous linkage study provided evidence for a prostate cancer-susceptibility locus at 1q24-25. Subsequent reports in additional collections of families have yielded conflicting results. In addition, evidence for locus heterogeneity has been provided by the identification of other putative hereditary prostate cancer loci on Xq27-28, 1q42-43, and 1p36. The present study describes a combined analysis for six markers in the 1q24-25 region in 772 families affected by hereditary prostate cancer and ascertained by the members of the International Consortium for Prostate Cancer Genetics (ICPCG) from North America, Australia, Finland, Norway, Sweden, and the United Kingdom. Overall, there was some evidence for linkage, with a peak parametric multipoint LOD score assuming heterogeneity (HLOD) of 1.40 (P=.01) at D1S212. The estimated proportion of families (alpha) linked to the locus was.06 (1-LOD support interval.01-.12). This evidence was not observed by a nonparametric approach, presumably because of the extensive heterogeneity. Further parametric analysis revealed a significant effect of the presence of male-to-male disease transmission within the families. In the subset of 491 such families, the peak HLOD was 2.56 (P=.0006) and alpha =.11 (1-LOD support interval.04-.19), compared with HLODs of 0 in the remaining 281 families. Within the families with male-to-male disease transmission, alpha increased with the early mean age at diagnosis (<65 years, alpha =.19, with 1-LOD support interval.06-.34) and the number of affected family members (five or more family members, alpha =.15, with 1-LOD support interval.04-.28). The highest value of alpha was observed for the 48 families that met all three criteria (peak HLOD = 2.25, P=.001, alpha=.29, with 1-LOD support interval.08-.53). These results support the finding of a prostate cancer-susceptibility gene linked to 1q24-25, albeit in a defined subset of prostate cancer families. Although HPC1 accounts for only a small proportion of all families affected by hereditary prostate cancer, it appears to play a more prominent role in the subset of families with several members affected at an early age and with male-to-male disease transmission. Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Combined analysis of hereditary prostate cancer linkage to 1q24-25: results from 772 hereditary prostate cancer families from the International Consortium for Prostate Cancer Genetics. A previous linkage study provided evidence for a prostate cancer-susceptibility locus at 1q24-25. Subsequent reports in additional collections of families have yielded conflicting results. In addition, evidence for locus heterogeneity has been provided by the identification of other putative hereditary prostate cancer loci on Xq27-28, 1q42-43, and 1p36. The present study describes a combined analysis for six markers in the 1q24-25 region in 772 families affected by hereditary prostate cancer and ascertained by the members of the International Consortium for Prostate Cancer Genetics (ICPCG) from North America, Australia, Finland, Norway, Sweden, and the United Kingdom. Overall, there was some evidence for linkage, with a peak parametric multipoint LOD score assuming heterogeneity (HLOD) of 1.40 (P=.01) at D1S212. The estimated proportion of families (alpha) linked to the locus was.06 (1-LOD support interval.01-.12). This evidence was not observed by a nonparametric approach, presumably because of the extensive heterogeneity. Further parametric analysis revealed a significant effect of the presence of male-to-male disease transmission within the families. In the subset of 491 such families, the peak HLOD was 2.56 (P=.0006) and alpha =.11 (1-LOD support interval.04-.19), compared with HLODs of 0 in the remaining 281 families. Within the families with male-to-male disease transmission, alpha increased with the early mean age at diagnosis (<65 years, alpha =.19, with 1-LOD support interval.06-.34) and the number of affected family members (five or more family members, alpha =.15, with 1-LOD support interval.04-.28). The highest value of alpha was observed for the 48 families that met all three criteria (peak HLOD = 2.25, P=.001, alpha=.29, with 1-LOD support interval.08-.53). These results support the finding of a prostate cancer-susceptibility gene linked to 1q24-25, albeit in a defined subset of prostate cancer families. Although HPC1 accounts for only a small proportion of all families affected by hereditary prostate cancer, it appears to play a more prominent role in the subset of families with several members affected at an early age and with male-to-male disease transmission.
[ "Combined", "analysis", "of", "hereditary", "prostate", "cancer", "linkage", "to", "1q24", "-", "25", ":", "results", "from", "772", "hereditary", "prostate", "cancer", "families", "from", "the", "International", "Consortium", "for", "Prostate", "Cancer", "Genetics", ".", "A", "previous", "linkage", "study", "provided", "evidence", "for", "a", "prostate", "cancer", "-", "susceptibility", "locus", "at", "1q24", "-", "25", ".", "Subsequent", "reports", "in", "additional", "collections", "of", "families", "have", "yielded", "conflicting", "results", ".", "In", "addition", ",", "evidence", "for", "locus", "heterogeneity", "has", "been", "provided", "by", "the", "identification", "of", "other", "putative", "hereditary", "prostate", "cancer", "loci", "on", "Xq27", "-", "28", ",", "1q42", "-", "43", ",", "and", "1p36", ".", "The", "present", "study", "describes", "a", "combined", "analysis", "for", "six", "markers", "in", "the", "1q24", "-", "25", "region", "in", "772", "families", "affected", "by", "hereditary", "prostate", "cancer", "and", "ascertained", "by", "the", "members", "of", "the", "International", "Consortium", "for", "Prostate", "Cancer", "Genetics", "(", "ICPCG", ")", "from", "North", "America", ",", "Australia", ",", "Finland", ",", "Norway", ",", "Sweden", ",", "and", "the", "United", "Kingdom", ".", "Overall", ",", "there", "was", "some", "evidence", "for", "linkage", ",", "with", "a", "peak", "parametric", "multipoint", "LOD", "score", "assuming", "heterogeneity", "(", "HLOD", ")", "of", "1.40", "(", "P=.01", ")", "at", "D1S212", ".", "The", "estimated", "proportion", "of", "families", "(", "alpha", ")", "linked", "to", "the", "locus", "was.06", "(", "1-LOD", "support", "interval.01-.12", ")", ".", "This", "evidence", "was", "not", "observed", "by", "a", "nonparametric", "approach", ",", "presumably", "because", "of", "the", "extensive", "heterogeneity", ".", "Further", "parametric", "analysis", "revealed", "a", "significant", "effect", "of", "the", "presence", "of", "male", "-", "to", "-", "male", "disease", "transmission", "within", "the", "families", ".", "In", "the", "subset", "of", "491", "such", "families", ",", "the", "peak", "HLOD", "was", "2.56", "(", "P=.0006", ")", "and", "alpha", "=", ".11", "(", "1-LOD", "support", "interval.04-.19", ")", ",", "compared", "with", "HLODs", "of", "0", "in", "the", "remaining", "281", "families", ".", "Within", "the", "families", "with", "male", "-", "to", "-", "male", "disease", "transmission", ",", "alpha", "increased", "with", "the", "early", "mean", "age", "at", "diagnosis", "(", "<", "65", "years", ",", "alpha", "=", ".19", ",", "with", "1-LOD", "support", "interval.06-.34", ")", "and", "the", "number", "of", "affected", "family", "members", "(", "five", "or", "more", "family", "members", ",", "alpha", "=", ".15", ",", "with", "1-LOD", "support", "interval.04-.28", ")", ".", "The", "highest", "value", "of", "alpha", "was", "observed", "for", "the", "48", "families", "that", "met", "all", "three", "criteria", "(", "peak", "HLOD", "=", "2.25", ",", "P=.001", ",", "alpha=.29", ",", "with", "1-LOD", "support", "interval.08-.53", ")", ".", "These", "results", "support", "the", "finding", "of", "a", "prostate", "cancer", "-", "susceptibility", "gene", "linked", "to", "1q24", "-", "25", ",", "albeit", "in", "a", "defined", "subset", "of", "prostate", "cancer", "families", ".", "Although", "HPC1", "accounts", "for", "only", "a", "small", "proportion", "of", "all", "families", "affected", "by", "hereditary", "prostate", "cancer", ",", "it", "appears", "to", "play", "a", "more", "prominent", "role", "in", "the", "subset", "of", "families", "with", "several", "members", "affected", "at", "an", "early", "age", "and", "with", "male", "-", "to", "-", "male", "disease", "transmission", ".", "\n" ]
[ "Gene" ]
Granulocyte - macrophage colony - stimulating factor is a protein_molecule, 94-kD STAT5A is a protein_molecule, 80-kD STAT5A isoform is a protein_molecule
25853_task0
Sentence: Granulocyte-macrophage colony-stimulating factor preferentially activates the 94-kD STAT5A and an 80-kD STAT5A isoform in human peripheral blood monocytes. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: protein_molecule
[ "B-protein_molecule", "I-protein_molecule", "I-protein_molecule", "I-protein_molecule", "I-protein_molecule", "I-protein_molecule", "I-protein_molecule", "O", "O", "O", "B-protein_molecule", "I-protein_molecule", "O", "O", "B-protein_molecule", "I-protein_molecule", "I-protein_molecule", "O", "O", "O", "O", "O", "O" ]
Granulocyte-macrophage colony-stimulating factor preferentially activates the 94-kD STAT5A and an 80-kD STAT5A isoform in human peripheral blood monocytes.
[ "Granulocyte", "-", "macrophage", "colony", "-", "stimulating", "factor", "preferentially", "activates", "the", "94-kD", "STAT5A", "and", "an", "80-kD", "STAT5A", "isoform", "in", "human", "peripheral", "blood", "monocytes", "." ]
[ "protein_molecule", "other_name", "protein_complex", "protein_family_or_group", "DNA_domain_or_region", "cell_type" ]
Granulocyte - macrophage colony - stimulating factor is a protein_molecule, 94-kD STAT5A is a protein_molecule, 80-kD STAT5A isoform is a protein_molecule
25853_task1
Sentence: Granulocyte-macrophage colony-stimulating factor preferentially activates the 94-kD STAT5A and an 80-kD STAT5A isoform in human peripheral blood monocytes. Instructions: please typing these entity words according to sentence: Granulocyte - macrophage colony - stimulating factor, 94-kD STAT5A, 80-kD STAT5A isoform Options: protein_molecule
[ "B-protein_molecule", "I-protein_molecule", "I-protein_molecule", "I-protein_molecule", "I-protein_molecule", "I-protein_molecule", "I-protein_molecule", "O", "O", "O", "B-protein_molecule", "I-protein_molecule", "O", "O", "B-protein_molecule", "I-protein_molecule", "I-protein_molecule", "O", "O", "O", "O", "O", "O" ]
Granulocyte-macrophage colony-stimulating factor preferentially activates the 94-kD STAT5A and an 80-kD STAT5A isoform in human peripheral blood monocytes.
[ "Granulocyte", "-", "macrophage", "colony", "-", "stimulating", "factor", "preferentially", "activates", "the", "94-kD", "STAT5A", "and", "an", "80-kD", "STAT5A", "isoform", "in", "human", "peripheral", "blood", "monocytes", "." ]
[ "protein_molecule", "other_name", "protein_complex", "protein_family_or_group", "DNA_domain_or_region", "cell_type" ]
Granulocyte - macrophage colony - stimulating factor, 94-kD STAT5A, 80-kD STAT5A isoform
25853_task2
Sentence: Granulocyte-macrophage colony-stimulating factor preferentially activates the 94-kD STAT5A and an 80-kD STAT5A isoform in human peripheral blood monocytes. Instructions: please extract entity words from the input sentence
[ "B-protein_molecule", "I-protein_molecule", "I-protein_molecule", "I-protein_molecule", "I-protein_molecule", "I-protein_molecule", "I-protein_molecule", "O", "O", "O", "B-protein_molecule", "I-protein_molecule", "O", "O", "B-protein_molecule", "I-protein_molecule", "I-protein_molecule", "O", "O", "O", "O", "O", "O" ]
Granulocyte-macrophage colony-stimulating factor preferentially activates the 94-kD STAT5A and an 80-kD STAT5A isoform in human peripheral blood monocytes.
[ "Granulocyte", "-", "macrophage", "colony", "-", "stimulating", "factor", "preferentially", "activates", "the", "94-kD", "STAT5A", "and", "an", "80-kD", "STAT5A", "isoform", "in", "human", "peripheral", "blood", "monocytes", "." ]
[ "protein_molecule", "other_name", "protein_complex", "protein_family_or_group", "DNA_domain_or_region", "cell_type" ]
RBP4 is a protein, glucose is a compound, insulin is a protein
DS.d200_task0
Sentence: Decreased hepatic RBP4 secretion is correlated with reduced hepatic glucose production but is not associated with insulin resistance in patients with liver cirrhosis. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: compound, protein
[ "O", "O", "B-protein", "O", "O", "O", "O", "O", "O", "B-compound", "O", "O", "O", "O", "O", "O", "B-protein", "O", "O", "O", "O", "O", "O", "O" ]
Decreased hepatic RBP4 secretion is correlated with reduced hepatic glucose production but is not associated with insulin resistance in patients with liver cirrhosis.
[ "Decreased", "hepatic", "RBP4", "secretion", "is", "correlated", "with", "reduced", "hepatic", "glucose", "production", "but", "is", "not", "associated", "with", "insulin", "resistance", "in", "patients", "with", "liver", "cirrhosis", "." ]
[ "compound", "protein" ]
RBP4 is a protein, glucose is a compound, insulin is a protein
DS.d200_task1
Sentence: Decreased hepatic RBP4 secretion is correlated with reduced hepatic glucose production but is not associated with insulin resistance in patients with liver cirrhosis. Instructions: please typing these entity words according to sentence: RBP4, glucose, insulin Options: compound, protein
[ "O", "O", "B-protein", "O", "O", "O", "O", "O", "O", "B-compound", "O", "O", "O", "O", "O", "O", "B-protein", "O", "O", "O", "O", "O", "O", "O" ]
Decreased hepatic RBP4 secretion is correlated with reduced hepatic glucose production but is not associated with insulin resistance in patients with liver cirrhosis.
[ "Decreased", "hepatic", "RBP4", "secretion", "is", "correlated", "with", "reduced", "hepatic", "glucose", "production", "but", "is", "not", "associated", "with", "insulin", "resistance", "in", "patients", "with", "liver", "cirrhosis", "." ]
[ "compound", "protein" ]
RBP4, glucose, insulin
DS.d200_task2
Sentence: Decreased hepatic RBP4 secretion is correlated with reduced hepatic glucose production but is not associated with insulin resistance in patients with liver cirrhosis. Instructions: please extract entity words from the input sentence
[ "O", "O", "B-protein", "O", "O", "O", "O", "O", "O", "B-compound", "O", "O", "O", "O", "O", "O", "B-protein", "O", "O", "O", "O", "O", "O", "O" ]
Decreased hepatic RBP4 secretion is correlated with reduced hepatic glucose production but is not associated with insulin resistance in patients with liver cirrhosis.
[ "Decreased", "hepatic", "RBP4", "secretion", "is", "correlated", "with", "reduced", "hepatic", "glucose", "production", "but", "is", "not", "associated", "with", "insulin", "resistance", "in", "patients", "with", "liver", "cirrhosis", "." ]
[ "compound", "protein" ]
judgment is an umlsterm, clinical medicine is an umlsterm, diagnostic is an umlsterm, therapeutic process is an umlsterm, systematic is an umlsterm, documentation is an umlsterm, standard is an umlsterm, nomenclature is an umlsterm, classification is an umlsterm, instruments is an umlsterm, outcome measure is an umlsterm, documentation is an umlsterm, standards is an umlsterm, goal is an umlsterm, set is an umlsterm, orthopedic surgery is an umlsterm, information system is an umlsterm, data pool is an umlsterm, patient care is an umlsterm, research is an umlsterm
DerOrthopaede.90280191.eng.abstr_task0
Sentence: For the judgment of the quality of medical services and for the progress of clinical medicine the comparison of data and informations of the diagnostic and therapeutic process is demanded . Therefore a systematic and concrete system of documentation should be implemented in every clinic , which consists of standard nomenclature , classification , instruments of outcome measure and documentation standards . There are a group of problems and barriers which stand in the way of this goal . It is useful to build a minimum basis data set which includes core criterias of clinical dokumentation in orthopedic surgery and include this in an information system so that all of these parts are considered and that a central and comparable data pool is offered for patient care , quality management and research . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm
[ "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O" ]
For the judgment of the quality of medical services and for the progress of clinical medicine the comparison of data and informations of the diagnostic and therapeutic process is demanded . Therefore a systematic and concrete system of documentation should be implemented in every clinic , which consists of standard nomenclature , classification , instruments of outcome measure and documentation standards . There are a group of problems and barriers which stand in the way of this goal . It is useful to build a minimum basis data set which includes core criterias of clinical dokumentation in orthopedic surgery and include this in an information system so that all of these parts are considered and that a central and comparable data pool is offered for patient care , quality management and research .
[ "For", "the", "judgment", "of", "the", "quality", "of", "medical", "services", "and", "for", "the", "progress", "of", "clinical", "medicine", "the", "comparison", "of", "data", "and", "informations", "of", "the", "diagnostic", "and", "therapeutic", "process", "is", "demanded", ".", "Therefore", "a", "systematic", "and", "concrete", "system", "of", "documentation", "should", "be", "implemented", "in", "every", "clinic", ",", "which", "consists", "of", "standard", "nomenclature", ",", "classification", ",", "instruments", "of", "outcome", "measure", "and", "documentation", "standards", ".", "There", "are", "a", "group", "of", "problems", "and", "barriers", "which", "stand", "in", "the", "way", "of", "this", "goal", ".", "It", "is", "useful", "to", "build", "a", "minimum", "basis", "data", "set", "which", "includes", "core", "criterias", "of", "clinical", "dokumentation", "in", "orthopedic", "surgery", "and", "include", "this", "in", "an", "information", "system", "so", "that", "all", "of", "these", "parts", "are", "considered", "and", "that", "a", "central", "and", "comparable", "data", "pool", "is", "offered", "for", "patient", "care", ",", "quality", "management", "and", "research", "." ]
[ "umlsterm" ]
judgment is an umlsterm, clinical medicine is an umlsterm, diagnostic is an umlsterm, therapeutic process is an umlsterm, systematic is an umlsterm, documentation is an umlsterm, standard is an umlsterm, nomenclature is an umlsterm, classification is an umlsterm, instruments is an umlsterm, outcome measure is an umlsterm, documentation is an umlsterm, standards is an umlsterm, goal is an umlsterm, set is an umlsterm, orthopedic surgery is an umlsterm, information system is an umlsterm, data pool is an umlsterm, patient care is an umlsterm, research is an umlsterm
DerOrthopaede.90280191.eng.abstr_task1
Sentence: For the judgment of the quality of medical services and for the progress of clinical medicine the comparison of data and informations of the diagnostic and therapeutic process is demanded . Therefore a systematic and concrete system of documentation should be implemented in every clinic , which consists of standard nomenclature , classification , instruments of outcome measure and documentation standards . There are a group of problems and barriers which stand in the way of this goal . It is useful to build a minimum basis data set which includes core criterias of clinical dokumentation in orthopedic surgery and include this in an information system so that all of these parts are considered and that a central and comparable data pool is offered for patient care , quality management and research . Instructions: please typing these entity words according to sentence: judgment, clinical medicine, diagnostic, therapeutic process, systematic, documentation, standard, nomenclature, classification, instruments, outcome measure, documentation, standards, goal, set, orthopedic surgery, information system, data pool, patient care, research Options: umlsterm
[ "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O" ]
For the judgment of the quality of medical services and for the progress of clinical medicine the comparison of data and informations of the diagnostic and therapeutic process is demanded . Therefore a systematic and concrete system of documentation should be implemented in every clinic , which consists of standard nomenclature , classification , instruments of outcome measure and documentation standards . There are a group of problems and barriers which stand in the way of this goal . It is useful to build a minimum basis data set which includes core criterias of clinical dokumentation in orthopedic surgery and include this in an information system so that all of these parts are considered and that a central and comparable data pool is offered for patient care , quality management and research .
[ "For", "the", "judgment", "of", "the", "quality", "of", "medical", "services", "and", "for", "the", "progress", "of", "clinical", "medicine", "the", "comparison", "of", "data", "and", "informations", "of", "the", "diagnostic", "and", "therapeutic", "process", "is", "demanded", ".", "Therefore", "a", "systematic", "and", "concrete", "system", "of", "documentation", "should", "be", "implemented", "in", "every", "clinic", ",", "which", "consists", "of", "standard", "nomenclature", ",", "classification", ",", "instruments", "of", "outcome", "measure", "and", "documentation", "standards", ".", "There", "are", "a", "group", "of", "problems", "and", "barriers", "which", "stand", "in", "the", "way", "of", "this", "goal", ".", "It", "is", "useful", "to", "build", "a", "minimum", "basis", "data", "set", "which", "includes", "core", "criterias", "of", "clinical", "dokumentation", "in", "orthopedic", "surgery", "and", "include", "this", "in", "an", "information", "system", "so", "that", "all", "of", "these", "parts", "are", "considered", "and", "that", "a", "central", "and", "comparable", "data", "pool", "is", "offered", "for", "patient", "care", ",", "quality", "management", "and", "research", "." ]
[ "umlsterm" ]
judgment, clinical medicine, diagnostic, therapeutic process, systematic, documentation, standard, nomenclature, classification, instruments, outcome measure, documentation, standards, goal, set, orthopedic surgery, information system, data pool, patient care, research
DerOrthopaede.90280191.eng.abstr_task2
Sentence: For the judgment of the quality of medical services and for the progress of clinical medicine the comparison of data and informations of the diagnostic and therapeutic process is demanded . Therefore a systematic and concrete system of documentation should be implemented in every clinic , which consists of standard nomenclature , classification , instruments of outcome measure and documentation standards . There are a group of problems and barriers which stand in the way of this goal . It is useful to build a minimum basis data set which includes core criterias of clinical dokumentation in orthopedic surgery and include this in an information system so that all of these parts are considered and that a central and comparable data pool is offered for patient care , quality management and research . Instructions: please extract entity words from the input sentence
[ "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O" ]
For the judgment of the quality of medical services and for the progress of clinical medicine the comparison of data and informations of the diagnostic and therapeutic process is demanded . Therefore a systematic and concrete system of documentation should be implemented in every clinic , which consists of standard nomenclature , classification , instruments of outcome measure and documentation standards . There are a group of problems and barriers which stand in the way of this goal . It is useful to build a minimum basis data set which includes core criterias of clinical dokumentation in orthopedic surgery and include this in an information system so that all of these parts are considered and that a central and comparable data pool is offered for patient care , quality management and research .
[ "For", "the", "judgment", "of", "the", "quality", "of", "medical", "services", "and", "for", "the", "progress", "of", "clinical", "medicine", "the", "comparison", "of", "data", "and", "informations", "of", "the", "diagnostic", "and", "therapeutic", "process", "is", "demanded", ".", "Therefore", "a", "systematic", "and", "concrete", "system", "of", "documentation", "should", "be", "implemented", "in", "every", "clinic", ",", "which", "consists", "of", "standard", "nomenclature", ",", "classification", ",", "instruments", "of", "outcome", "measure", "and", "documentation", "standards", ".", "There", "are", "a", "group", "of", "problems", "and", "barriers", "which", "stand", "in", "the", "way", "of", "this", "goal", ".", "It", "is", "useful", "to", "build", "a", "minimum", "basis", "data", "set", "which", "includes", "core", "criterias", "of", "clinical", "dokumentation", "in", "orthopedic", "surgery", "and", "include", "this", "in", "an", "information", "system", "so", "that", "all", "of", "these", "parts", "are", "considered", "and", "that", "a", "central", "and", "comparable", "data", "pool", "is", "offered", "for", "patient", "care", ",", "quality", "management", "and", "research", "." ]
[ "umlsterm" ]
Eprosartan is a DRUG, digoxin is a DRUG, warfarin is a DRUG, glyburide is a DRUG, eprosartan is a DRUG, ketoconazole is a DRUG, fluconazole is a DRUG, eprosartan is a DRUG, Ranitidine is a DRUG, eprosartan is a DRUG, Eprosartan is a DRUG, thiazide diuretic is a GROUP, hydrochlorothiazide is a DRUG, Eprosartan is a DRUG, calcium channel blockers is a GROUP, nifedipine is a DRUG
Eprosartan_ddi_task0
Sentence: Eprosartan has been shown to have no effect on the pharmacokinetics of digoxin and the pharmacodynamics of warfarin and glyburide. Thus no dosing adjustments are necessary during concomitant use with these agents. Because eprosartan is not metabolized by the cytochrome P450 system, inhibitors of CYP450 enzyme would not be expected to affect its metabolism, and ketoconazole and fluconazole, potent inhibitors of CYP3A and 2C9, respectively, have been shown to have no effect on eprosartan pharmacokinetics. Ranitidine also has no effect on eprosartan pharmacokinetics. Eprosartan (up to 400 mg b.i.d. or 800 mg q.d.) doses have been safely used concomitantly with a thiazide diuretic (hydrochlorothiazide). Eprosartan doses of up to 300 mg b.i.d. have been safely used concomitantly with sustained-release calcium channel blockers (sustained-release nifedipine) with no clinically significant adverse interactions. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: GROUP, DRUG
[ "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "I-GROUP", "O", "B-DRUG", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "I-GROUP", "I-GROUP", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O" ]
Eprosartan has been shown to have no effect on the pharmacokinetics of digoxin and the pharmacodynamics of warfarin and glyburide. Thus no dosing adjustments are necessary during concomitant use with these agents. Because eprosartan is not metabolized by the cytochrome P450 system, inhibitors of CYP450 enzyme would not be expected to affect its metabolism, and ketoconazole and fluconazole, potent inhibitors of CYP3A and 2C9, respectively, have been shown to have no effect on eprosartan pharmacokinetics. Ranitidine also has no effect on eprosartan pharmacokinetics. Eprosartan (up to 400 mg b.i.d. or 800 mg q.d.) doses have been safely used concomitantly with a thiazide diuretic (hydrochlorothiazide). Eprosartan doses of up to 300 mg b.i.d. have been safely used concomitantly with sustained-release calcium channel blockers (sustained-release nifedipine) with no clinically significant adverse interactions.
[ "Eprosartan", "has", "been", "shown", "to", "have", "no", "effect", "on", "the", "pharmacokinetics", "of", "digoxin", "and", "the", "pharmacodynamics", "of", "warfarin", "and", "glyburide", ".", "Thus", "no", "dosing", "adjustments", "are", "necessary", "during", "concomitant", "use", "with", "these", "agents", ".", "Because", "eprosartan", "is", "not", "metabolized", "by", "the", "cytochrome", "P450", "system", ",", "inhibitors", "of", "CYP450", "enzyme", "would", "not", "be", "expected", "to", "affect", "its", "metabolism", ",", "and", "ketoconazole", "and", "fluconazole", ",", "potent", "inhibitors", "of", "CYP3A", "and", "2C9", ",", "respectively", ",", "have", "been", "shown", "to", "have", "no", "effect", "on", "eprosartan", "pharmacokinetics", ".", "Ranitidine", "also", "has", "no", "effect", "on", "eprosartan", "pharmacokinetics", ".", "Eprosartan", "(", "up", "to", "400", "mg", "b.i.d", ".", "or", "800", "mg", "q.d", ".", ")", "doses", "have", "been", "safely", "used", "concomitantly", "with", "a", "thiazide", "diuretic", "(", "hydrochlorothiazide", ")", ".", "Eprosartan", "doses", "of", "up", "to", "300", "mg", "b.i.d", ".", "have", "been", "safely", "used", "concomitantly", "with", "sustained", "-", "release", "calcium", "channel", "blockers", "(", "sustained", "-", "release", "nifedipine", ")", "with", "no", "clinically", "significant", "adverse", "interactions", "." ]
[ "GROUP", "DRUG" ]
Eprosartan is a DRUG, digoxin is a DRUG, warfarin is a DRUG, glyburide is a DRUG, eprosartan is a DRUG, ketoconazole is a DRUG, fluconazole is a DRUG, eprosartan is a DRUG, Ranitidine is a DRUG, eprosartan is a DRUG, Eprosartan is a DRUG, thiazide diuretic is a GROUP, hydrochlorothiazide is a DRUG, Eprosartan is a DRUG, calcium channel blockers is a GROUP, nifedipine is a DRUG
Eprosartan_ddi_task1
Sentence: Eprosartan has been shown to have no effect on the pharmacokinetics of digoxin and the pharmacodynamics of warfarin and glyburide. Thus no dosing adjustments are necessary during concomitant use with these agents. Because eprosartan is not metabolized by the cytochrome P450 system, inhibitors of CYP450 enzyme would not be expected to affect its metabolism, and ketoconazole and fluconazole, potent inhibitors of CYP3A and 2C9, respectively, have been shown to have no effect on eprosartan pharmacokinetics. Ranitidine also has no effect on eprosartan pharmacokinetics. Eprosartan (up to 400 mg b.i.d. or 800 mg q.d.) doses have been safely used concomitantly with a thiazide diuretic (hydrochlorothiazide). Eprosartan doses of up to 300 mg b.i.d. have been safely used concomitantly with sustained-release calcium channel blockers (sustained-release nifedipine) with no clinically significant adverse interactions. Instructions: please typing these entity words according to sentence: Eprosartan, digoxin, warfarin, glyburide, eprosartan, ketoconazole, fluconazole, eprosartan, Ranitidine, eprosartan, Eprosartan, thiazide diuretic, hydrochlorothiazide, Eprosartan, calcium channel blockers, nifedipine Options: GROUP, DRUG
[ "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "I-GROUP", "O", "B-DRUG", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "I-GROUP", "I-GROUP", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O" ]
Eprosartan has been shown to have no effect on the pharmacokinetics of digoxin and the pharmacodynamics of warfarin and glyburide. Thus no dosing adjustments are necessary during concomitant use with these agents. Because eprosartan is not metabolized by the cytochrome P450 system, inhibitors of CYP450 enzyme would not be expected to affect its metabolism, and ketoconazole and fluconazole, potent inhibitors of CYP3A and 2C9, respectively, have been shown to have no effect on eprosartan pharmacokinetics. Ranitidine also has no effect on eprosartan pharmacokinetics. Eprosartan (up to 400 mg b.i.d. or 800 mg q.d.) doses have been safely used concomitantly with a thiazide diuretic (hydrochlorothiazide). Eprosartan doses of up to 300 mg b.i.d. have been safely used concomitantly with sustained-release calcium channel blockers (sustained-release nifedipine) with no clinically significant adverse interactions.
[ "Eprosartan", "has", "been", "shown", "to", "have", "no", "effect", "on", "the", "pharmacokinetics", "of", "digoxin", "and", "the", "pharmacodynamics", "of", "warfarin", "and", "glyburide", ".", "Thus", "no", "dosing", "adjustments", "are", "necessary", "during", "concomitant", "use", "with", "these", "agents", ".", "Because", "eprosartan", "is", "not", "metabolized", "by", "the", "cytochrome", "P450", "system", ",", "inhibitors", "of", "CYP450", "enzyme", "would", "not", "be", "expected", "to", "affect", "its", "metabolism", ",", "and", "ketoconazole", "and", "fluconazole", ",", "potent", "inhibitors", "of", "CYP3A", "and", "2C9", ",", "respectively", ",", "have", "been", "shown", "to", "have", "no", "effect", "on", "eprosartan", "pharmacokinetics", ".", "Ranitidine", "also", "has", "no", "effect", "on", "eprosartan", "pharmacokinetics", ".", "Eprosartan", "(", "up", "to", "400", "mg", "b.i.d", ".", "or", "800", "mg", "q.d", ".", ")", "doses", "have", "been", "safely", "used", "concomitantly", "with", "a", "thiazide", "diuretic", "(", "hydrochlorothiazide", ")", ".", "Eprosartan", "doses", "of", "up", "to", "300", "mg", "b.i.d", ".", "have", "been", "safely", "used", "concomitantly", "with", "sustained", "-", "release", "calcium", "channel", "blockers", "(", "sustained", "-", "release", "nifedipine", ")", "with", "no", "clinically", "significant", "adverse", "interactions", "." ]
[ "GROUP", "DRUG" ]
Eprosartan, digoxin, warfarin, glyburide, eprosartan, ketoconazole, fluconazole, eprosartan, Ranitidine, eprosartan, Eprosartan, thiazide diuretic, hydrochlorothiazide, Eprosartan, calcium channel blockers, nifedipine
Eprosartan_ddi_task2
Sentence: Eprosartan has been shown to have no effect on the pharmacokinetics of digoxin and the pharmacodynamics of warfarin and glyburide. Thus no dosing adjustments are necessary during concomitant use with these agents. Because eprosartan is not metabolized by the cytochrome P450 system, inhibitors of CYP450 enzyme would not be expected to affect its metabolism, and ketoconazole and fluconazole, potent inhibitors of CYP3A and 2C9, respectively, have been shown to have no effect on eprosartan pharmacokinetics. Ranitidine also has no effect on eprosartan pharmacokinetics. Eprosartan (up to 400 mg b.i.d. or 800 mg q.d.) doses have been safely used concomitantly with a thiazide diuretic (hydrochlorothiazide). Eprosartan doses of up to 300 mg b.i.d. have been safely used concomitantly with sustained-release calcium channel blockers (sustained-release nifedipine) with no clinically significant adverse interactions. Instructions: please extract entity words from the input sentence
[ "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "I-GROUP", "O", "B-DRUG", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "I-GROUP", "I-GROUP", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O" ]
Eprosartan has been shown to have no effect on the pharmacokinetics of digoxin and the pharmacodynamics of warfarin and glyburide. Thus no dosing adjustments are necessary during concomitant use with these agents. Because eprosartan is not metabolized by the cytochrome P450 system, inhibitors of CYP450 enzyme would not be expected to affect its metabolism, and ketoconazole and fluconazole, potent inhibitors of CYP3A and 2C9, respectively, have been shown to have no effect on eprosartan pharmacokinetics. Ranitidine also has no effect on eprosartan pharmacokinetics. Eprosartan (up to 400 mg b.i.d. or 800 mg q.d.) doses have been safely used concomitantly with a thiazide diuretic (hydrochlorothiazide). Eprosartan doses of up to 300 mg b.i.d. have been safely used concomitantly with sustained-release calcium channel blockers (sustained-release nifedipine) with no clinically significant adverse interactions.
[ "Eprosartan", "has", "been", "shown", "to", "have", "no", "effect", "on", "the", "pharmacokinetics", "of", "digoxin", "and", "the", "pharmacodynamics", "of", "warfarin", "and", "glyburide", ".", "Thus", "no", "dosing", "adjustments", "are", "necessary", "during", "concomitant", "use", "with", "these", "agents", ".", "Because", "eprosartan", "is", "not", "metabolized", "by", "the", "cytochrome", "P450", "system", ",", "inhibitors", "of", "CYP450", "enzyme", "would", "not", "be", "expected", "to", "affect", "its", "metabolism", ",", "and", "ketoconazole", "and", "fluconazole", ",", "potent", "inhibitors", "of", "CYP3A", "and", "2C9", ",", "respectively", ",", "have", "been", "shown", "to", "have", "no", "effect", "on", "eprosartan", "pharmacokinetics", ".", "Ranitidine", "also", "has", "no", "effect", "on", "eprosartan", "pharmacokinetics", ".", "Eprosartan", "(", "up", "to", "400", "mg", "b.i.d", ".", "or", "800", "mg", "q.d", ".", ")", "doses", "have", "been", "safely", "used", "concomitantly", "with", "a", "thiazide", "diuretic", "(", "hydrochlorothiazide", ")", ".", "Eprosartan", "doses", "of", "up", "to", "300", "mg", "b.i.d", ".", "have", "been", "safely", "used", "concomitantly", "with", "sustained", "-", "release", "calcium", "channel", "blockers", "(", "sustained", "-", "release", "nifedipine", ")", "with", "no", "clinically", "significant", "adverse", "interactions", "." ]
[ "GROUP", "DRUG" ]
KC cells is a Cell, cell - line is a Cell, KC cells is a Cell, BHK cells is a Cell, cells is a Cell
PMID-21423801_task0
Sentence: Saliva proteins of vector Culicoides modify structure and infectivity of bluetongue virus particles. Bluetongue virus (BTV) and epizootic haemorrhagic disease virus (EHDV) are related orbiviruses, transmitted between their ruminant hosts primarily by certain haematophagous midge vectors (Culicoides spp.). The larger of the BTV outer-capsid proteins, 'VP2', can be cleaved by proteases (including trypsin or chymotrypsin), forming infectious subviral particles (ISVP) which have enhanced infectivity for adult Culicoides, or KC cells (a cell-line derived from C. sonorensis). We demonstrate that VP2 present on purified virus particles from 3 different BTV strains can also be cleaved by treatment with saliva from adult Culicoides. The saliva proteins from C. sonorensis (a competent BTV vector), cleaved BTV-VP2 more efficiently than those from C. nubeculosus (a less competent/non-vector species). Electrophoresis and mass spectrometry identified a trypsin-like protease in C. sonorensis saliva, which was significantly reduced or absent from C. nubeculosus saliva. Incubating purified BTV-1 with C. sonorensis saliva proteins also increased their infectivity for KC cells ~10 fold, while infectivity for BHK cells was reduced by 2-6 fold. Treatment of an 'eastern' strain of EHDV-2 with saliva proteins of either C. sonorensis or C. nubeculosus cleaved VP2, but a 'western' strain of EHDV-2 remained unmodified. These results indicate that temperature, strain of virus and protein composition of Culicoides saliva (particularly its protease content which is dependent upon vector species), can all play a significant role in the efficiency of VP2 cleavage, influencing virus infectivity. Saliva of several other arthropod species has previously been shown to increase transmission, infectivity and virulence of certain arboviruses, by modulating and/or suppressing the mammalian immune response. The findings presented here, however, demonstrate a novel mechanism by which proteases in Culicoides saliva can also directly modify the orbivirus particle structure, leading to increased infectivity specifically for Culicoides cells and, in turn, efficiency of transmission to the insect vector. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Cell
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "I-Cell", "O", "O", "B-Cell", "I-Cell", "I-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "I-Cell", "O", "O", "O", "O", "O", "O", "B-Cell", "I-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Saliva proteins of vector Culicoides modify structure and infectivity of bluetongue virus particles. Bluetongue virus (BTV) and epizootic haemorrhagic disease virus (EHDV) are related orbiviruses, transmitted between their ruminant hosts primarily by certain haematophagous midge vectors (Culicoides spp.). The larger of the BTV outer-capsid proteins, 'VP2', can be cleaved by proteases (including trypsin or chymotrypsin), forming infectious subviral particles (ISVP) which have enhanced infectivity for adult Culicoides, or KC cells (a cell-line derived from C. sonorensis). We demonstrate that VP2 present on purified virus particles from 3 different BTV strains can also be cleaved by treatment with saliva from adult Culicoides. The saliva proteins from C. sonorensis (a competent BTV vector), cleaved BTV-VP2 more efficiently than those from C. nubeculosus (a less competent/non-vector species). Electrophoresis and mass spectrometry identified a trypsin-like protease in C. sonorensis saliva, which was significantly reduced or absent from C. nubeculosus saliva. Incubating purified BTV-1 with C. sonorensis saliva proteins also increased their infectivity for KC cells ~10 fold, while infectivity for BHK cells was reduced by 2-6 fold. Treatment of an 'eastern' strain of EHDV-2 with saliva proteins of either C. sonorensis or C. nubeculosus cleaved VP2, but a 'western' strain of EHDV-2 remained unmodified. These results indicate that temperature, strain of virus and protein composition of Culicoides saliva (particularly its protease content which is dependent upon vector species), can all play a significant role in the efficiency of VP2 cleavage, influencing virus infectivity. Saliva of several other arthropod species has previously been shown to increase transmission, infectivity and virulence of certain arboviruses, by modulating and/or suppressing the mammalian immune response. The findings presented here, however, demonstrate a novel mechanism by which proteases in Culicoides saliva can also directly modify the orbivirus particle structure, leading to increased infectivity specifically for Culicoides cells and, in turn, efficiency of transmission to the insect vector.
[ "Saliva", "proteins", "of", "vector", "Culicoides", "modify", "structure", "and", "infectivity", "of", "bluetongue", "virus", "particles", ".", "\n", "Bluetongue", "virus", "(", "BTV", ")", "and", "epizootic", "haemorrhagic", "disease", "virus", "(", "EHDV", ")", "are", "related", "orbiviruses", ",", "transmitted", "between", "their", "ruminant", "hosts", "primarily", "by", "certain", "haematophagous", "midge", "vectors", "(", "Culicoides", "spp", ".", ")", ".", "The", "larger", "of", "the", "BTV", "outer", "-", "capsid", "proteins", ",", "'", "VP2", "'", ",", "can", "be", "cleaved", "by", "proteases", "(", "including", "trypsin", "or", "chymotrypsin", ")", ",", "forming", "infectious", "subviral", "particles", "(", "ISVP", ")", "which", "have", "enhanced", "infectivity", "for", "adult", "Culicoides", ",", "or", "KC", "cells", "(", "a", "cell", "-", "line", "derived", "from", "C.", "sonorensis", ")", ".", "We", "demonstrate", "that", "VP2", "present", "on", "purified", "virus", "particles", "from", "3", "different", "BTV", "strains", "can", "also", "be", "cleaved", "by", "treatment", "with", "saliva", "from", "adult", "Culicoides", ".", "The", "saliva", "proteins", "from", "C.", "sonorensis", "(", "a", "competent", "BTV", "vector", ")", ",", "cleaved", "BTV", "-", "VP2", "more", "efficiently", "than", "those", "from", "C.", "nubeculosus", "(", "a", "less", "competent", "/", "non", "-", "vector", "species", ")", ".", "Electrophoresis", "and", "mass", "spectrometry", "identified", "a", "trypsin", "-", "like", "protease", "in", "C.", "sonorensis", "saliva", ",", "which", "was", "significantly", "reduced", "or", "absent", "from", "C.", "nubeculosus", "saliva", ".", "Incubating", "purified", "BTV-1", "with", "C.", "sonorensis", "saliva", "proteins", "also", "increased", "their", "infectivity", "for", "KC", "cells", "~10", "fold", ",", "while", "infectivity", "for", "BHK", "cells", "was", "reduced", "by", "2", "-", "6", "fold", ".", "Treatment", "of", "an", "'", "eastern", "'", "strain", "of", "EHDV-2", "with", "saliva", "proteins", "of", "either", "C.", "sonorensis", "or", "C.", "nubeculosus", "cleaved", "VP2", ",", "but", "a", "'", "western", "'", "strain", "of", "EHDV-2", "remained", "unmodified", ".", "These", "results", "indicate", "that", "temperature", ",", "strain", "of", "virus", "and", "protein", "composition", "of", "Culicoides", "saliva", "(", "particularly", "its", "protease", "content", "which", "is", "dependent", "upon", "vector", "species", ")", ",", "can", "all", "play", "a", "significant", "role", "in", "the", "efficiency", "of", "VP2", "cleavage", ",", "influencing", "virus", "infectivity", ".", "Saliva", "of", "several", "other", "arthropod", "species", "has", "previously", "been", "shown", "to", "increase", "transmission", ",", "infectivity", "and", "virulence", "of", "certain", "arboviruses", ",", "by", "modulating", "and", "/", "or", "suppressing", "the", "mammalian", "immune", "response", ".", "The", "findings", "presented", "here", ",", "however", ",", "demonstrate", "a", "novel", "mechanism", "by", "which", "proteases", "in", "Culicoides", "saliva", "can", "also", "directly", "modify", "the", "orbivirus", "particle", "structure", ",", "leading", "to", "increased", "infectivity", "specifically", "for", "Culicoides", "cells", "and", ",", "in", "turn", ",", "efficiency", "of", "transmission", "to", "the", "insect", "vector", ".", "\n" ]
[ "Cell" ]
KC cells is a Cell, cell - line is a Cell, KC cells is a Cell, BHK cells is a Cell, cells is a Cell
PMID-21423801_task1
Sentence: Saliva proteins of vector Culicoides modify structure and infectivity of bluetongue virus particles. Bluetongue virus (BTV) and epizootic haemorrhagic disease virus (EHDV) are related orbiviruses, transmitted between their ruminant hosts primarily by certain haematophagous midge vectors (Culicoides spp.). The larger of the BTV outer-capsid proteins, 'VP2', can be cleaved by proteases (including trypsin or chymotrypsin), forming infectious subviral particles (ISVP) which have enhanced infectivity for adult Culicoides, or KC cells (a cell-line derived from C. sonorensis). We demonstrate that VP2 present on purified virus particles from 3 different BTV strains can also be cleaved by treatment with saliva from adult Culicoides. The saliva proteins from C. sonorensis (a competent BTV vector), cleaved BTV-VP2 more efficiently than those from C. nubeculosus (a less competent/non-vector species). Electrophoresis and mass spectrometry identified a trypsin-like protease in C. sonorensis saliva, which was significantly reduced or absent from C. nubeculosus saliva. Incubating purified BTV-1 with C. sonorensis saliva proteins also increased their infectivity for KC cells ~10 fold, while infectivity for BHK cells was reduced by 2-6 fold. Treatment of an 'eastern' strain of EHDV-2 with saliva proteins of either C. sonorensis or C. nubeculosus cleaved VP2, but a 'western' strain of EHDV-2 remained unmodified. These results indicate that temperature, strain of virus and protein composition of Culicoides saliva (particularly its protease content which is dependent upon vector species), can all play a significant role in the efficiency of VP2 cleavage, influencing virus infectivity. Saliva of several other arthropod species has previously been shown to increase transmission, infectivity and virulence of certain arboviruses, by modulating and/or suppressing the mammalian immune response. The findings presented here, however, demonstrate a novel mechanism by which proteases in Culicoides saliva can also directly modify the orbivirus particle structure, leading to increased infectivity specifically for Culicoides cells and, in turn, efficiency of transmission to the insect vector. Instructions: please typing these entity words according to sentence: KC cells, cell - line, KC cells, BHK cells, cells Options: Cell
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "I-Cell", "O", "O", "B-Cell", "I-Cell", "I-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "I-Cell", "O", "O", "O", "O", "O", "O", "B-Cell", "I-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Saliva proteins of vector Culicoides modify structure and infectivity of bluetongue virus particles. Bluetongue virus (BTV) and epizootic haemorrhagic disease virus (EHDV) are related orbiviruses, transmitted between their ruminant hosts primarily by certain haematophagous midge vectors (Culicoides spp.). The larger of the BTV outer-capsid proteins, 'VP2', can be cleaved by proteases (including trypsin or chymotrypsin), forming infectious subviral particles (ISVP) which have enhanced infectivity for adult Culicoides, or KC cells (a cell-line derived from C. sonorensis). We demonstrate that VP2 present on purified virus particles from 3 different BTV strains can also be cleaved by treatment with saliva from adult Culicoides. The saliva proteins from C. sonorensis (a competent BTV vector), cleaved BTV-VP2 more efficiently than those from C. nubeculosus (a less competent/non-vector species). Electrophoresis and mass spectrometry identified a trypsin-like protease in C. sonorensis saliva, which was significantly reduced or absent from C. nubeculosus saliva. Incubating purified BTV-1 with C. sonorensis saliva proteins also increased their infectivity for KC cells ~10 fold, while infectivity for BHK cells was reduced by 2-6 fold. Treatment of an 'eastern' strain of EHDV-2 with saliva proteins of either C. sonorensis or C. nubeculosus cleaved VP2, but a 'western' strain of EHDV-2 remained unmodified. These results indicate that temperature, strain of virus and protein composition of Culicoides saliva (particularly its protease content which is dependent upon vector species), can all play a significant role in the efficiency of VP2 cleavage, influencing virus infectivity. Saliva of several other arthropod species has previously been shown to increase transmission, infectivity and virulence of certain arboviruses, by modulating and/or suppressing the mammalian immune response. The findings presented here, however, demonstrate a novel mechanism by which proteases in Culicoides saliva can also directly modify the orbivirus particle structure, leading to increased infectivity specifically for Culicoides cells and, in turn, efficiency of transmission to the insect vector.
[ "Saliva", "proteins", "of", "vector", "Culicoides", "modify", "structure", "and", "infectivity", "of", "bluetongue", "virus", "particles", ".", "\n", "Bluetongue", "virus", "(", "BTV", ")", "and", "epizootic", "haemorrhagic", "disease", "virus", "(", "EHDV", ")", "are", "related", "orbiviruses", ",", "transmitted", "between", "their", "ruminant", "hosts", "primarily", "by", "certain", "haematophagous", "midge", "vectors", "(", "Culicoides", "spp", ".", ")", ".", "The", "larger", "of", "the", "BTV", "outer", "-", "capsid", "proteins", ",", "'", "VP2", "'", ",", "can", "be", "cleaved", "by", "proteases", "(", "including", "trypsin", "or", "chymotrypsin", ")", ",", "forming", "infectious", "subviral", "particles", "(", "ISVP", ")", "which", "have", "enhanced", "infectivity", "for", "adult", "Culicoides", ",", "or", "KC", "cells", "(", "a", "cell", "-", "line", "derived", "from", "C.", "sonorensis", ")", ".", "We", "demonstrate", "that", "VP2", "present", "on", "purified", "virus", "particles", "from", "3", "different", "BTV", "strains", "can", "also", "be", "cleaved", "by", "treatment", "with", "saliva", "from", "adult", "Culicoides", ".", "The", "saliva", "proteins", "from", "C.", "sonorensis", "(", "a", "competent", "BTV", "vector", ")", ",", "cleaved", "BTV", "-", "VP2", "more", "efficiently", "than", "those", "from", "C.", "nubeculosus", "(", "a", "less", "competent", "/", "non", "-", "vector", "species", ")", ".", "Electrophoresis", "and", "mass", "spectrometry", "identified", "a", "trypsin", "-", "like", "protease", "in", "C.", "sonorensis", "saliva", ",", "which", "was", "significantly", "reduced", "or", "absent", "from", "C.", "nubeculosus", "saliva", ".", "Incubating", "purified", "BTV-1", "with", "C.", "sonorensis", "saliva", "proteins", "also", "increased", "their", "infectivity", "for", "KC", "cells", "~10", "fold", ",", "while", "infectivity", "for", "BHK", "cells", "was", "reduced", "by", "2", "-", "6", "fold", ".", "Treatment", "of", "an", "'", "eastern", "'", "strain", "of", "EHDV-2", "with", "saliva", "proteins", "of", "either", "C.", "sonorensis", "or", "C.", "nubeculosus", "cleaved", "VP2", ",", "but", "a", "'", "western", "'", "strain", "of", "EHDV-2", "remained", "unmodified", ".", "These", "results", "indicate", "that", "temperature", ",", "strain", "of", "virus", "and", "protein", "composition", "of", "Culicoides", "saliva", "(", "particularly", "its", "protease", "content", "which", "is", "dependent", "upon", "vector", "species", ")", ",", "can", "all", "play", "a", "significant", "role", "in", "the", "efficiency", "of", "VP2", "cleavage", ",", "influencing", "virus", "infectivity", ".", "Saliva", "of", "several", "other", "arthropod", "species", "has", "previously", "been", "shown", "to", "increase", "transmission", ",", "infectivity", "and", "virulence", "of", "certain", "arboviruses", ",", "by", "modulating", "and", "/", "or", "suppressing", "the", "mammalian", "immune", "response", ".", "The", "findings", "presented", "here", ",", "however", ",", "demonstrate", "a", "novel", "mechanism", "by", "which", "proteases", "in", "Culicoides", "saliva", "can", "also", "directly", "modify", "the", "orbivirus", "particle", "structure", ",", "leading", "to", "increased", "infectivity", "specifically", "for", "Culicoides", "cells", "and", ",", "in", "turn", ",", "efficiency", "of", "transmission", "to", "the", "insect", "vector", ".", "\n" ]
[ "Cell" ]
KC cells, cell - line, KC cells, BHK cells, cells
PMID-21423801_task2
Sentence: Saliva proteins of vector Culicoides modify structure and infectivity of bluetongue virus particles. Bluetongue virus (BTV) and epizootic haemorrhagic disease virus (EHDV) are related orbiviruses, transmitted between their ruminant hosts primarily by certain haematophagous midge vectors (Culicoides spp.). The larger of the BTV outer-capsid proteins, 'VP2', can be cleaved by proteases (including trypsin or chymotrypsin), forming infectious subviral particles (ISVP) which have enhanced infectivity for adult Culicoides, or KC cells (a cell-line derived from C. sonorensis). We demonstrate that VP2 present on purified virus particles from 3 different BTV strains can also be cleaved by treatment with saliva from adult Culicoides. The saliva proteins from C. sonorensis (a competent BTV vector), cleaved BTV-VP2 more efficiently than those from C. nubeculosus (a less competent/non-vector species). Electrophoresis and mass spectrometry identified a trypsin-like protease in C. sonorensis saliva, which was significantly reduced or absent from C. nubeculosus saliva. Incubating purified BTV-1 with C. sonorensis saliva proteins also increased their infectivity for KC cells ~10 fold, while infectivity for BHK cells was reduced by 2-6 fold. Treatment of an 'eastern' strain of EHDV-2 with saliva proteins of either C. sonorensis or C. nubeculosus cleaved VP2, but a 'western' strain of EHDV-2 remained unmodified. These results indicate that temperature, strain of virus and protein composition of Culicoides saliva (particularly its protease content which is dependent upon vector species), can all play a significant role in the efficiency of VP2 cleavage, influencing virus infectivity. Saliva of several other arthropod species has previously been shown to increase transmission, infectivity and virulence of certain arboviruses, by modulating and/or suppressing the mammalian immune response. The findings presented here, however, demonstrate a novel mechanism by which proteases in Culicoides saliva can also directly modify the orbivirus particle structure, leading to increased infectivity specifically for Culicoides cells and, in turn, efficiency of transmission to the insect vector. Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "I-Cell", "O", "O", "B-Cell", "I-Cell", "I-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "I-Cell", "O", "O", "O", "O", "O", "O", "B-Cell", "I-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Saliva proteins of vector Culicoides modify structure and infectivity of bluetongue virus particles. Bluetongue virus (BTV) and epizootic haemorrhagic disease virus (EHDV) are related orbiviruses, transmitted between their ruminant hosts primarily by certain haematophagous midge vectors (Culicoides spp.). The larger of the BTV outer-capsid proteins, 'VP2', can be cleaved by proteases (including trypsin or chymotrypsin), forming infectious subviral particles (ISVP) which have enhanced infectivity for adult Culicoides, or KC cells (a cell-line derived from C. sonorensis). We demonstrate that VP2 present on purified virus particles from 3 different BTV strains can also be cleaved by treatment with saliva from adult Culicoides. The saliva proteins from C. sonorensis (a competent BTV vector), cleaved BTV-VP2 more efficiently than those from C. nubeculosus (a less competent/non-vector species). Electrophoresis and mass spectrometry identified a trypsin-like protease in C. sonorensis saliva, which was significantly reduced or absent from C. nubeculosus saliva. Incubating purified BTV-1 with C. sonorensis saliva proteins also increased their infectivity for KC cells ~10 fold, while infectivity for BHK cells was reduced by 2-6 fold. Treatment of an 'eastern' strain of EHDV-2 with saliva proteins of either C. sonorensis or C. nubeculosus cleaved VP2, but a 'western' strain of EHDV-2 remained unmodified. These results indicate that temperature, strain of virus and protein composition of Culicoides saliva (particularly its protease content which is dependent upon vector species), can all play a significant role in the efficiency of VP2 cleavage, influencing virus infectivity. Saliva of several other arthropod species has previously been shown to increase transmission, infectivity and virulence of certain arboviruses, by modulating and/or suppressing the mammalian immune response. The findings presented here, however, demonstrate a novel mechanism by which proteases in Culicoides saliva can also directly modify the orbivirus particle structure, leading to increased infectivity specifically for Culicoides cells and, in turn, efficiency of transmission to the insect vector.
[ "Saliva", "proteins", "of", "vector", "Culicoides", "modify", "structure", "and", "infectivity", "of", "bluetongue", "virus", "particles", ".", "\n", "Bluetongue", "virus", "(", "BTV", ")", "and", "epizootic", "haemorrhagic", "disease", "virus", "(", "EHDV", ")", "are", "related", "orbiviruses", ",", "transmitted", "between", "their", "ruminant", "hosts", "primarily", "by", "certain", "haematophagous", "midge", "vectors", "(", "Culicoides", "spp", ".", ")", ".", "The", "larger", "of", "the", "BTV", "outer", "-", "capsid", "proteins", ",", "'", "VP2", "'", ",", "can", "be", "cleaved", "by", "proteases", "(", "including", "trypsin", "or", "chymotrypsin", ")", ",", "forming", "infectious", "subviral", "particles", "(", "ISVP", ")", "which", "have", "enhanced", "infectivity", "for", "adult", "Culicoides", ",", "or", "KC", "cells", "(", "a", "cell", "-", "line", "derived", "from", "C.", "sonorensis", ")", ".", "We", "demonstrate", "that", "VP2", "present", "on", "purified", "virus", "particles", "from", "3", "different", "BTV", "strains", "can", "also", "be", "cleaved", "by", "treatment", "with", "saliva", "from", "adult", "Culicoides", ".", "The", "saliva", "proteins", "from", "C.", "sonorensis", "(", "a", "competent", "BTV", "vector", ")", ",", "cleaved", "BTV", "-", "VP2", "more", "efficiently", "than", "those", "from", "C.", "nubeculosus", "(", "a", "less", "competent", "/", "non", "-", "vector", "species", ")", ".", "Electrophoresis", "and", "mass", "spectrometry", "identified", "a", "trypsin", "-", "like", "protease", "in", "C.", "sonorensis", "saliva", ",", "which", "was", "significantly", "reduced", "or", "absent", "from", "C.", "nubeculosus", "saliva", ".", "Incubating", "purified", "BTV-1", "with", "C.", "sonorensis", "saliva", "proteins", "also", "increased", "their", "infectivity", "for", "KC", "cells", "~10", "fold", ",", "while", "infectivity", "for", "BHK", "cells", "was", "reduced", "by", "2", "-", "6", "fold", ".", "Treatment", "of", "an", "'", "eastern", "'", "strain", "of", "EHDV-2", "with", "saliva", "proteins", "of", "either", "C.", "sonorensis", "or", "C.", "nubeculosus", "cleaved", "VP2", ",", "but", "a", "'", "western", "'", "strain", "of", "EHDV-2", "remained", "unmodified", ".", "These", "results", "indicate", "that", "temperature", ",", "strain", "of", "virus", "and", "protein", "composition", "of", "Culicoides", "saliva", "(", "particularly", "its", "protease", "content", "which", "is", "dependent", "upon", "vector", "species", ")", ",", "can", "all", "play", "a", "significant", "role", "in", "the", "efficiency", "of", "VP2", "cleavage", ",", "influencing", "virus", "infectivity", ".", "Saliva", "of", "several", "other", "arthropod", "species", "has", "previously", "been", "shown", "to", "increase", "transmission", ",", "infectivity", "and", "virulence", "of", "certain", "arboviruses", ",", "by", "modulating", "and", "/", "or", "suppressing", "the", "mammalian", "immune", "response", ".", "The", "findings", "presented", "here", ",", "however", ",", "demonstrate", "a", "novel", "mechanism", "by", "which", "proteases", "in", "Culicoides", "saliva", "can", "also", "directly", "modify", "the", "orbivirus", "particle", "structure", ",", "leading", "to", "increased", "infectivity", "specifically", "for", "Culicoides", "cells", "and", ",", "in", "turn", ",", "efficiency", "of", "transmission", "to", "the", "insect", "vector", ".", "\n" ]
[ "Cell" ]
FE200486 is a TRIVIALVAR, degarelix is a TRIVIAL, degarelix is a TRIVIAL, [ N(beta)-(2-pyridyl - methyl)d - Dap(3)]degarelix is a IUPAC, [ Pra(7)]degarelix is a TRIVIAL, [ N(delta)-(IGly)Orn(8)]degarelix is a IUPAC, [ N(alpha)-methyl - Leu(7)]degarelix is a IUPAC, degarelix is a TRIVIAL, [ N(epsilon)-cyclohexyl - Lys(8)]degarelix is a IUPAC, [ N(beta)-(IbetaAla)Dap(8)]degarelix is a IUPAC, azaline B is a TRIVIAL, [ N(gamma)-(IGly)Dab(8)]degarelix is a IUPAC, [ IOrn(8)]degarelix is a IUPAC, azaline B is a TRIVIAL, degarelix is a TRIVIAL
example-17_task0
Sentence: Degarelix (FE200486, Ac-d-2Nal(1)-d-4Cpa(2)-d-3Pal(3)-Ser(4)-4Aph(l-Hor)(5)-d-4Aph(Cbm)(6)-Leu(7)-ILys(8)-Pro(9)-d-Ala( )-NH(2)) is a potent and very long acting antagonist of gonadotropin-releasing hormone (GnRH) after subcutaneous administration in mammals including humans. Analogues of degarelix were synthesized, characterized, and screened for the antagonism of GnRH-induced response in a reporter gene assay in HEK-293 cells expressing the human GnRH receptor. The duration of action was also determined in the castrated male rat assay to measure the extent (efficacy and duration of action) of inhibition of luteinizing hormone (LH) release. Structurally, this series of analogues has novel substitutions at positions 3, 7, and 8 and N(alpha)-methylation at positions 6, 7, and 8 in the structure of degarelix. These substitutions were designed to probe the spatial limitations of the receptor's cavity and to map the steric and ionic boundaries. Some functional groups were introduced that were hypothesized to influence the phamacokinetic properties of the analogues such as bioavailability, solubility, intra- or intermolecular hydrogen bond forming capacity, and ability to bind carrier proteins. Substitutions at positions 3 ([N(beta)-(2-pyridyl-methyl)d-Dap(3)]degarelix, IC( ) = 2.71 nM) (5), 7 ([Pra(7)]degarelix, IC( ) = 2.11 nM) (16), and 8 ([N(delta)-(IGly)Orn(8)]degarelix, IC( ) = 1.38 nM) ( ) and N-methylation ([N(alpha)-methyl-Leu(7)]degarelix, IC( ) = 1.47 nM) (32) yielded analogues that were equipotent to degarelix (2) in vitro (IC( ) = 1.64 nM) but shorter acting in vivo. Out of the 33 novel analogues tested for the duration of action in this series, two analogues ([N(epsilon)-cyclohexyl-Lys(8)]degarelix, IC( ) = 1.50 nM) (23) and ([N(beta)-(IbetaAla)Dap(8)]degarelix, IC( ) = 1.98 nM) (26) had antagonist potencies and duration of action similar to that of azaline B {inhibited LH (&gt; ) release for &gt;72 h after sc injection to castrated male rats at a standard dose of mug/rat in 5% mannitol}. Under similar conditions analogues ([N(gamma)-(IGly)Dab(8)]degarelix, IC( ) = 1.56 nM) (21) and ([IOrn(8)]degarelix, IC( ) = 1.72 nM) (18) had a longer duration of action {inhibited LH (&gt;96 h) release} than azaline B; however they were shorter acting than degarelix. Hydrophilicity of these analogues, a potential measure of their ability to be formulated for sustained release, was determined using RP-HPLC at neutral pH yielding analogues with shorter as well as longer retention times. No correlation was found between retention times and antagonist potency or duration of action. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: , TRIVIAL, IUPAC, TRIVIALVAR
[ "O", "O", "B-TRIVIALVAR", "O", "B-", "I-", "I-", "I-", "I-", "I-", "I-", "I-", "I-", "I-", "I-", "I-", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-TRIVIAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-TRIVIAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-IUPAC", "I-IUPAC", "I-IUPAC", "I-IUPAC", "I-IUPAC", "I-IUPAC", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-TRIVIAL", "I-TRIVIAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-IUPAC", "I-IUPAC", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-IUPAC", "I-IUPAC", "I-IUPAC", "I-IUPAC", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-TRIVIAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-IUPAC", "I-IUPAC", "I-IUPAC", "I-IUPAC", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-IUPAC", "I-IUPAC", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-TRIVIAL", "I-TRIVIAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-IUPAC", "I-IUPAC", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-IUPAC", "I-IUPAC", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-TRIVIAL", "I-TRIVIAL", "O", "O", "O", "O", "O", "O", "O", "B-TRIVIAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Degarelix (FE200486, Ac-d-2Nal(1)-d-4Cpa(2)-d-3Pal(3)-Ser(4)-4Aph(l-Hor)(5)-d-4Aph(Cbm)(6)-Leu(7)-ILys(8)-Pro(9)-d-Ala( )-NH(2)) is a potent and very long acting antagonist of gonadotropin-releasing hormone (GnRH) after subcutaneous administration in mammals including humans. Analogues of degarelix were synthesized, characterized, and screened for the antagonism of GnRH-induced response in a reporter gene assay in HEK-293 cells expressing the human GnRH receptor. The duration of action was also determined in the castrated male rat assay to measure the extent (efficacy and duration of action) of inhibition of luteinizing hormone (LH) release. Structurally, this series of analogues has novel substitutions at positions 3, 7, and 8 and N(alpha)-methylation at positions 6, 7, and 8 in the structure of degarelix. These substitutions were designed to probe the spatial limitations of the receptor's cavity and to map the steric and ionic boundaries. Some functional groups were introduced that were hypothesized to influence the phamacokinetic properties of the analogues such as bioavailability, solubility, intra- or intermolecular hydrogen bond forming capacity, and ability to bind carrier proteins. Substitutions at positions 3 ([N(beta)-(2-pyridyl-methyl)d-Dap(3)]degarelix, IC( ) = 2.71 nM) (5), 7 ([Pra(7)]degarelix, IC( ) = 2.11 nM) (16), and 8 ([N(delta)-(IGly)Orn(8)]degarelix, IC( ) = 1.38 nM) ( ) and N-methylation ([N(alpha)-methyl-Leu(7)]degarelix, IC( ) = 1.47 nM) (32) yielded analogues that were equipotent to degarelix (2) in vitro (IC( ) = 1.64 nM) but shorter acting in vivo. Out of the 33 novel analogues tested for the duration of action in this series, two analogues ([N(epsilon)-cyclohexyl-Lys(8)]degarelix, IC( ) = 1.50 nM) (23) and ([N(beta)-(IbetaAla)Dap(8)]degarelix, IC( ) = 1.98 nM) (26) had antagonist potencies and duration of action similar to that of azaline B {inhibited LH (&gt; ) release for &gt;72 h after sc injection to castrated male rats at a standard dose of mug/rat in 5% mannitol}. Under similar conditions analogues ([N(gamma)-(IGly)Dab(8)]degarelix, IC( ) = 1.56 nM) (21) and ([IOrn(8)]degarelix, IC( ) = 1.72 nM) (18) had a longer duration of action {inhibited LH (&gt;96 h) release} than azaline B; however they were shorter acting than degarelix. Hydrophilicity of these analogues, a potential measure of their ability to be formulated for sustained release, was determined using RP-HPLC at neutral pH yielding analogues with shorter as well as longer retention times. No correlation was found between retention times and antagonist potency or duration of action.
[ "Degarelix", "(", "FE200486", ",", "Ac", "-", "d-2Nal(1)-d-4Cpa(2)-d-3Pal(3)-Ser(4)-4Aph(l", "-", "Hor)(5)-d-4Aph(Cbm)(6)-Leu(7)-ILys(8)-Pro(9)-d", "-", "Ala", "(", " ", ")", "-NH(2", ")", ")", "is", "a", "potent", "and", "very", "long", "acting", "antagonist", "of", "gonadotropin", "-", "releasing", "hormone", "(", "GnRH", ")", "after", "subcutaneous", "administration", "in", "mammals", "including", "humans", ".", "Analogues", "of", "degarelix", "were", "synthesized", ",", "characterized", ",", "and", "screened", "for", "the", "antagonism", "of", "GnRH", "-", "induced", "response", "in", "a", "reporter", "gene", "assay", "in", "HEK-293", "cells", "expressing", "the", "human", "GnRH", "receptor", ".", "The", "duration", "of", "action", "was", "also", "determined", "in", "the", "castrated", "male", "rat", "assay", "to", "measure", "the", "extent", "(", "efficacy", "and", "duration", "of", "action", ")", "of", "inhibition", "of", "luteinizing", "hormone", "(", "LH", ")", "release", ".", "Structurally", ",", "this", "series", "of", "analogues", "has", "novel", "substitutions", "at", "positions", "3", ",", "7", ",", "and", "8", "and", "N(alpha)-methylation", "at", "positions", "6", ",", "7", ",", "and", "8", "in", "the", "structure", "of", "degarelix", ".", "These", "substitutions", "were", "designed", "to", "probe", "the", "spatial", "limitations", "of", "the", "receptor", "'s", "cavity", "and", "to", "map", "the", "steric", "and", "ionic", "boundaries", ".", "Some", "functional", "groups", "were", "introduced", "that", "were", "hypothesized", "to", "influence", "the", "phamacokinetic", "properties", "of", "the", "analogues", "such", "as", "bioavailability", ",", "solubility", ",", "intra-", "or", "intermolecular", "hydrogen", "bond", "forming", "capacity", ",", "and", "ability", "to", "bind", "carrier", "proteins", ".", "Substitutions", "at", "positions", "3", "(", "[", "N(beta)-(2-pyridyl", "-", "methyl)d", "-", "Dap(3)]degarelix", ",", "IC", "(", " ", ")", "=", "2.71", "nM", ")", "(", "5", ")", ",", "7", "(", "[", "Pra(7)]degarelix", ",", "IC", "(", " ", ")", "=", "2.11", "nM", ")", "(", "16", ")", ",", "and", "8", "(", "[", "N(delta)-(IGly)Orn(8)]degarelix", ",", "IC", "(", " ", ")", "=", "1.38", "nM", ")", "(", " ", ")", "and", "N", "-", "methylation", "(", "[", "N(alpha)-methyl", "-", "Leu(7)]degarelix", ",", "IC", "(", " ", ")", "=", "1.47", "nM", ")", "(", "32", ")", "yielded", "analogues", "that", "were", "equipotent", "to", "degarelix", "(", "2", ")", "in", "vitro", "(", "IC", "(", " ", ")", "=", "1.64", "nM", ")", "but", "shorter", "acting", "in", "vivo", ".", "Out", "of", "the", "33", "novel", "analogues", "tested", "for", "the", "duration", "of", "action", "in", "this", "series", ",", "two", "analogues", "(", "[", "N(epsilon)-cyclohexyl", "-", "Lys(8)]degarelix", ",", "IC", "(", " ", ")", "=", "1.50", "nM", ")", "(", "23", ")", "and", "(", "[", "N(beta)-(IbetaAla)Dap(8)]degarelix", ",", "IC", "(", " ", ")", "=", "1.98", "nM", ")", "(", "26", ")", "had", "antagonist", "potencies", "and", "duration", "of", "action", "similar", "to", "that", "of", "azaline", "B", "{", "inhibited", "LH", "(", "&", "gt", ";", " ", ")", "release", "for", "&", "gt;72", "h", "after", "sc", "injection", "to", "castrated", "male", "rats", "at", "a", "standard", "dose", "of", " ", "mug", "/", "rat", "in", "5", "%", "mannitol", "}", ".", "Under", "similar", "conditions", "analogues", "(", "[", "N(gamma)-(IGly)Dab(8)]degarelix", ",", "IC", "(", " ", ")", "=", "1.56", "nM", ")", "(", "21", ")", "and", "(", "[", "IOrn(8)]degarelix", ",", "IC", "(", " ", ")", "=", "1.72", "nM", ")", "(", "18", ")", "had", "a", "longer", "duration", "of", "action", "{", "inhibited", "LH", "(", "&", "gt;96", "h", ")", "release", "}", "than", "azaline", "B", ";", "however", "they", "were", "shorter", "acting", "than", "degarelix", ".", "Hydrophilicity", "of", "these", "analogues", ",", "a", "potential", "measure", "of", "their", "ability", "to", "be", "formulated", "for", "sustained", "release", ",", "was", "determined", "using", "RP", "-", "HPLC", "at", "neutral", "pH", "yielding", "analogues", "with", "shorter", "as", "well", "as", "longer", "retention", "times", ".", "No", "correlation", "was", "found", "between", "retention", "times", "and", "antagonist", "potency", "or", "duration", "of", "action", "." ]
[ "", "IUPAC", "TRIVIAL", "TRIVIALVAR" ]
FE200486 is a TRIVIALVAR, degarelix is a TRIVIAL, degarelix is a TRIVIAL, [ N(beta)-(2-pyridyl - methyl)d - Dap(3)]degarelix is a IUPAC, [ Pra(7)]degarelix is a TRIVIAL, [ N(delta)-(IGly)Orn(8)]degarelix is a IUPAC, [ N(alpha)-methyl - Leu(7)]degarelix is a IUPAC, degarelix is a TRIVIAL, [ N(epsilon)-cyclohexyl - Lys(8)]degarelix is a IUPAC, [ N(beta)-(IbetaAla)Dap(8)]degarelix is a IUPAC, azaline B is a TRIVIAL, [ N(gamma)-(IGly)Dab(8)]degarelix is a IUPAC, [ IOrn(8)]degarelix is a IUPAC, azaline B is a TRIVIAL, degarelix is a TRIVIAL
example-17_task1
Sentence: Degarelix (FE200486, Ac-d-2Nal(1)-d-4Cpa(2)-d-3Pal(3)-Ser(4)-4Aph(l-Hor)(5)-d-4Aph(Cbm)(6)-Leu(7)-ILys(8)-Pro(9)-d-Ala( )-NH(2)) is a potent and very long acting antagonist of gonadotropin-releasing hormone (GnRH) after subcutaneous administration in mammals including humans. Analogues of degarelix were synthesized, characterized, and screened for the antagonism of GnRH-induced response in a reporter gene assay in HEK-293 cells expressing the human GnRH receptor. The duration of action was also determined in the castrated male rat assay to measure the extent (efficacy and duration of action) of inhibition of luteinizing hormone (LH) release. Structurally, this series of analogues has novel substitutions at positions 3, 7, and 8 and N(alpha)-methylation at positions 6, 7, and 8 in the structure of degarelix. These substitutions were designed to probe the spatial limitations of the receptor's cavity and to map the steric and ionic boundaries. Some functional groups were introduced that were hypothesized to influence the phamacokinetic properties of the analogues such as bioavailability, solubility, intra- or intermolecular hydrogen bond forming capacity, and ability to bind carrier proteins. Substitutions at positions 3 ([N(beta)-(2-pyridyl-methyl)d-Dap(3)]degarelix, IC( ) = 2.71 nM) (5), 7 ([Pra(7)]degarelix, IC( ) = 2.11 nM) (16), and 8 ([N(delta)-(IGly)Orn(8)]degarelix, IC( ) = 1.38 nM) ( ) and N-methylation ([N(alpha)-methyl-Leu(7)]degarelix, IC( ) = 1.47 nM) (32) yielded analogues that were equipotent to degarelix (2) in vitro (IC( ) = 1.64 nM) but shorter acting in vivo. Out of the 33 novel analogues tested for the duration of action in this series, two analogues ([N(epsilon)-cyclohexyl-Lys(8)]degarelix, IC( ) = 1.50 nM) (23) and ([N(beta)-(IbetaAla)Dap(8)]degarelix, IC( ) = 1.98 nM) (26) had antagonist potencies and duration of action similar to that of azaline B {inhibited LH (&gt; ) release for &gt;72 h after sc injection to castrated male rats at a standard dose of mug/rat in 5% mannitol}. Under similar conditions analogues ([N(gamma)-(IGly)Dab(8)]degarelix, IC( ) = 1.56 nM) (21) and ([IOrn(8)]degarelix, IC( ) = 1.72 nM) (18) had a longer duration of action {inhibited LH (&gt;96 h) release} than azaline B; however they were shorter acting than degarelix. Hydrophilicity of these analogues, a potential measure of their ability to be formulated for sustained release, was determined using RP-HPLC at neutral pH yielding analogues with shorter as well as longer retention times. No correlation was found between retention times and antagonist potency or duration of action. Instructions: please typing these entity words according to sentence: FE200486, Ac - d-2Nal(1)-d-4Cpa(2)-d-3Pal(3)-Ser(4)-4Aph(l - Hor)(5)-d-4Aph(Cbm)(6)-Leu(7)-ILys(8)-Pro(9)-d - Ala ( ) -NH(2 ), degarelix, degarelix, [ N(beta)-(2-pyridyl - methyl)d - Dap(3)]degarelix, [ Pra(7)]degarelix, [ N(delta)-(IGly)Orn(8)]degarelix, [ N(alpha)-methyl - Leu(7)]degarelix, degarelix, [ N(epsilon)-cyclohexyl - Lys(8)]degarelix, [ N(beta)-(IbetaAla)Dap(8)]degarelix, azaline B, [ N(gamma)-(IGly)Dab(8)]degarelix, [ IOrn(8)]degarelix, azaline B, degarelix Options: , TRIVIAL, IUPAC, TRIVIALVAR
[ "O", "O", "B-TRIVIALVAR", "O", "B-", "I-", "I-", "I-", "I-", "I-", "I-", "I-", "I-", "I-", "I-", "I-", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-TRIVIAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-TRIVIAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-IUPAC", "I-IUPAC", "I-IUPAC", "I-IUPAC", "I-IUPAC", "I-IUPAC", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-TRIVIAL", "I-TRIVIAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-IUPAC", "I-IUPAC", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-IUPAC", "I-IUPAC", "I-IUPAC", "I-IUPAC", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-TRIVIAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-IUPAC", "I-IUPAC", "I-IUPAC", "I-IUPAC", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-IUPAC", "I-IUPAC", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-TRIVIAL", "I-TRIVIAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-IUPAC", "I-IUPAC", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-IUPAC", "I-IUPAC", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-TRIVIAL", "I-TRIVIAL", "O", "O", "O", "O", "O", "O", "O", "B-TRIVIAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Degarelix (FE200486, Ac-d-2Nal(1)-d-4Cpa(2)-d-3Pal(3)-Ser(4)-4Aph(l-Hor)(5)-d-4Aph(Cbm)(6)-Leu(7)-ILys(8)-Pro(9)-d-Ala( )-NH(2)) is a potent and very long acting antagonist of gonadotropin-releasing hormone (GnRH) after subcutaneous administration in mammals including humans. Analogues of degarelix were synthesized, characterized, and screened for the antagonism of GnRH-induced response in a reporter gene assay in HEK-293 cells expressing the human GnRH receptor. The duration of action was also determined in the castrated male rat assay to measure the extent (efficacy and duration of action) of inhibition of luteinizing hormone (LH) release. Structurally, this series of analogues has novel substitutions at positions 3, 7, and 8 and N(alpha)-methylation at positions 6, 7, and 8 in the structure of degarelix. These substitutions were designed to probe the spatial limitations of the receptor's cavity and to map the steric and ionic boundaries. Some functional groups were introduced that were hypothesized to influence the phamacokinetic properties of the analogues such as bioavailability, solubility, intra- or intermolecular hydrogen bond forming capacity, and ability to bind carrier proteins. Substitutions at positions 3 ([N(beta)-(2-pyridyl-methyl)d-Dap(3)]degarelix, IC( ) = 2.71 nM) (5), 7 ([Pra(7)]degarelix, IC( ) = 2.11 nM) (16), and 8 ([N(delta)-(IGly)Orn(8)]degarelix, IC( ) = 1.38 nM) ( ) and N-methylation ([N(alpha)-methyl-Leu(7)]degarelix, IC( ) = 1.47 nM) (32) yielded analogues that were equipotent to degarelix (2) in vitro (IC( ) = 1.64 nM) but shorter acting in vivo. Out of the 33 novel analogues tested for the duration of action in this series, two analogues ([N(epsilon)-cyclohexyl-Lys(8)]degarelix, IC( ) = 1.50 nM) (23) and ([N(beta)-(IbetaAla)Dap(8)]degarelix, IC( ) = 1.98 nM) (26) had antagonist potencies and duration of action similar to that of azaline B {inhibited LH (&gt; ) release for &gt;72 h after sc injection to castrated male rats at a standard dose of mug/rat in 5% mannitol}. Under similar conditions analogues ([N(gamma)-(IGly)Dab(8)]degarelix, IC( ) = 1.56 nM) (21) and ([IOrn(8)]degarelix, IC( ) = 1.72 nM) (18) had a longer duration of action {inhibited LH (&gt;96 h) release} than azaline B; however they were shorter acting than degarelix. Hydrophilicity of these analogues, a potential measure of their ability to be formulated for sustained release, was determined using RP-HPLC at neutral pH yielding analogues with shorter as well as longer retention times. No correlation was found between retention times and antagonist potency or duration of action.
[ "Degarelix", "(", "FE200486", ",", "Ac", "-", "d-2Nal(1)-d-4Cpa(2)-d-3Pal(3)-Ser(4)-4Aph(l", "-", "Hor)(5)-d-4Aph(Cbm)(6)-Leu(7)-ILys(8)-Pro(9)-d", "-", "Ala", "(", " ", ")", "-NH(2", ")", ")", "is", "a", "potent", "and", "very", "long", "acting", "antagonist", "of", "gonadotropin", "-", "releasing", "hormone", "(", "GnRH", ")", "after", "subcutaneous", "administration", "in", "mammals", "including", "humans", ".", "Analogues", "of", "degarelix", "were", "synthesized", ",", "characterized", ",", "and", "screened", "for", "the", "antagonism", "of", "GnRH", "-", "induced", "response", "in", "a", "reporter", "gene", "assay", "in", "HEK-293", "cells", "expressing", "the", "human", "GnRH", "receptor", ".", "The", "duration", "of", "action", "was", "also", "determined", "in", "the", "castrated", "male", "rat", "assay", "to", "measure", "the", "extent", "(", "efficacy", "and", "duration", "of", "action", ")", "of", "inhibition", "of", "luteinizing", "hormone", "(", "LH", ")", "release", ".", "Structurally", ",", "this", "series", "of", "analogues", "has", "novel", "substitutions", "at", "positions", "3", ",", "7", ",", "and", "8", "and", "N(alpha)-methylation", "at", "positions", "6", ",", "7", ",", "and", "8", "in", "the", "structure", "of", "degarelix", ".", "These", "substitutions", "were", "designed", "to", "probe", "the", "spatial", "limitations", "of", "the", "receptor", "'s", "cavity", "and", "to", "map", "the", "steric", "and", "ionic", "boundaries", ".", "Some", "functional", "groups", "were", "introduced", "that", "were", "hypothesized", "to", "influence", "the", "phamacokinetic", "properties", "of", "the", "analogues", "such", "as", "bioavailability", ",", "solubility", ",", "intra-", "or", "intermolecular", "hydrogen", "bond", "forming", "capacity", ",", "and", "ability", "to", "bind", "carrier", "proteins", ".", "Substitutions", "at", "positions", "3", "(", "[", "N(beta)-(2-pyridyl", "-", "methyl)d", "-", "Dap(3)]degarelix", ",", "IC", "(", " ", ")", "=", "2.71", "nM", ")", "(", "5", ")", ",", "7", "(", "[", "Pra(7)]degarelix", ",", "IC", "(", " ", ")", "=", "2.11", "nM", ")", "(", "16", ")", ",", "and", "8", "(", "[", "N(delta)-(IGly)Orn(8)]degarelix", ",", "IC", "(", " ", ")", "=", "1.38", "nM", ")", "(", " ", ")", "and", "N", "-", "methylation", "(", "[", "N(alpha)-methyl", "-", "Leu(7)]degarelix", ",", "IC", "(", " ", ")", "=", "1.47", "nM", ")", "(", "32", ")", "yielded", "analogues", "that", "were", "equipotent", "to", "degarelix", "(", "2", ")", "in", "vitro", "(", "IC", "(", " ", ")", "=", "1.64", "nM", ")", "but", "shorter", "acting", "in", "vivo", ".", "Out", "of", "the", "33", "novel", "analogues", "tested", "for", "the", "duration", "of", "action", "in", "this", "series", ",", "two", "analogues", "(", "[", "N(epsilon)-cyclohexyl", "-", "Lys(8)]degarelix", ",", "IC", "(", " ", ")", "=", "1.50", "nM", ")", "(", "23", ")", "and", "(", "[", "N(beta)-(IbetaAla)Dap(8)]degarelix", ",", "IC", "(", " ", ")", "=", "1.98", "nM", ")", "(", "26", ")", "had", "antagonist", "potencies", "and", "duration", "of", "action", "similar", "to", "that", "of", "azaline", "B", "{", "inhibited", "LH", "(", "&", "gt", ";", " ", ")", "release", "for", "&", "gt;72", "h", "after", "sc", "injection", "to", "castrated", "male", "rats", "at", "a", "standard", "dose", "of", " ", "mug", "/", "rat", "in", "5", "%", "mannitol", "}", ".", "Under", "similar", "conditions", "analogues", "(", "[", "N(gamma)-(IGly)Dab(8)]degarelix", ",", "IC", "(", " ", ")", "=", "1.56", "nM", ")", "(", "21", ")", "and", "(", "[", "IOrn(8)]degarelix", ",", "IC", "(", " ", ")", "=", "1.72", "nM", ")", "(", "18", ")", "had", "a", "longer", "duration", "of", "action", "{", "inhibited", "LH", "(", "&", "gt;96", "h", ")", "release", "}", "than", "azaline", "B", ";", "however", "they", "were", "shorter", "acting", "than", "degarelix", ".", "Hydrophilicity", "of", "these", "analogues", ",", "a", "potential", "measure", "of", "their", "ability", "to", "be", "formulated", "for", "sustained", "release", ",", "was", "determined", "using", "RP", "-", "HPLC", "at", "neutral", "pH", "yielding", "analogues", "with", "shorter", "as", "well", "as", "longer", "retention", "times", ".", "No", "correlation", "was", "found", "between", "retention", "times", "and", "antagonist", "potency", "or", "duration", "of", "action", "." ]
[ "", "IUPAC", "TRIVIAL", "TRIVIALVAR" ]
FE200486, Ac - d-2Nal(1)-d-4Cpa(2)-d-3Pal(3)-Ser(4)-4Aph(l - Hor)(5)-d-4Aph(Cbm)(6)-Leu(7)-ILys(8)-Pro(9)-d - Ala ( ) -NH(2 ), degarelix, degarelix, [ N(beta)-(2-pyridyl - methyl)d - Dap(3)]degarelix, [ Pra(7)]degarelix, [ N(delta)-(IGly)Orn(8)]degarelix, [ N(alpha)-methyl - Leu(7)]degarelix, degarelix, [ N(epsilon)-cyclohexyl - Lys(8)]degarelix, [ N(beta)-(IbetaAla)Dap(8)]degarelix, azaline B, [ N(gamma)-(IGly)Dab(8)]degarelix, [ IOrn(8)]degarelix, azaline B, degarelix
example-17_task2
Sentence: Degarelix (FE200486, Ac-d-2Nal(1)-d-4Cpa(2)-d-3Pal(3)-Ser(4)-4Aph(l-Hor)(5)-d-4Aph(Cbm)(6)-Leu(7)-ILys(8)-Pro(9)-d-Ala( )-NH(2)) is a potent and very long acting antagonist of gonadotropin-releasing hormone (GnRH) after subcutaneous administration in mammals including humans. Analogues of degarelix were synthesized, characterized, and screened for the antagonism of GnRH-induced response in a reporter gene assay in HEK-293 cells expressing the human GnRH receptor. The duration of action was also determined in the castrated male rat assay to measure the extent (efficacy and duration of action) of inhibition of luteinizing hormone (LH) release. Structurally, this series of analogues has novel substitutions at positions 3, 7, and 8 and N(alpha)-methylation at positions 6, 7, and 8 in the structure of degarelix. These substitutions were designed to probe the spatial limitations of the receptor's cavity and to map the steric and ionic boundaries. Some functional groups were introduced that were hypothesized to influence the phamacokinetic properties of the analogues such as bioavailability, solubility, intra- or intermolecular hydrogen bond forming capacity, and ability to bind carrier proteins. Substitutions at positions 3 ([N(beta)-(2-pyridyl-methyl)d-Dap(3)]degarelix, IC( ) = 2.71 nM) (5), 7 ([Pra(7)]degarelix, IC( ) = 2.11 nM) (16), and 8 ([N(delta)-(IGly)Orn(8)]degarelix, IC( ) = 1.38 nM) ( ) and N-methylation ([N(alpha)-methyl-Leu(7)]degarelix, IC( ) = 1.47 nM) (32) yielded analogues that were equipotent to degarelix (2) in vitro (IC( ) = 1.64 nM) but shorter acting in vivo. Out of the 33 novel analogues tested for the duration of action in this series, two analogues ([N(epsilon)-cyclohexyl-Lys(8)]degarelix, IC( ) = 1.50 nM) (23) and ([N(beta)-(IbetaAla)Dap(8)]degarelix, IC( ) = 1.98 nM) (26) had antagonist potencies and duration of action similar to that of azaline B {inhibited LH (&gt; ) release for &gt;72 h after sc injection to castrated male rats at a standard dose of mug/rat in 5% mannitol}. Under similar conditions analogues ([N(gamma)-(IGly)Dab(8)]degarelix, IC( ) = 1.56 nM) (21) and ([IOrn(8)]degarelix, IC( ) = 1.72 nM) (18) had a longer duration of action {inhibited LH (&gt;96 h) release} than azaline B; however they were shorter acting than degarelix. Hydrophilicity of these analogues, a potential measure of their ability to be formulated for sustained release, was determined using RP-HPLC at neutral pH yielding analogues with shorter as well as longer retention times. No correlation was found between retention times and antagonist potency or duration of action. Instructions: please extract entity words from the input sentence
[ "O", "O", "B-TRIVIALVAR", "O", "B-", "I-", "I-", "I-", "I-", "I-", "I-", "I-", "I-", "I-", "I-", "I-", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-TRIVIAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-TRIVIAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-IUPAC", "I-IUPAC", "I-IUPAC", "I-IUPAC", "I-IUPAC", "I-IUPAC", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-TRIVIAL", "I-TRIVIAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-IUPAC", "I-IUPAC", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-IUPAC", "I-IUPAC", "I-IUPAC", "I-IUPAC", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-TRIVIAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-IUPAC", "I-IUPAC", "I-IUPAC", "I-IUPAC", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-IUPAC", "I-IUPAC", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-TRIVIAL", "I-TRIVIAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-IUPAC", "I-IUPAC", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-IUPAC", "I-IUPAC", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-TRIVIAL", "I-TRIVIAL", "O", "O", "O", "O", "O", "O", "O", "B-TRIVIAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Degarelix (FE200486, Ac-d-2Nal(1)-d-4Cpa(2)-d-3Pal(3)-Ser(4)-4Aph(l-Hor)(5)-d-4Aph(Cbm)(6)-Leu(7)-ILys(8)-Pro(9)-d-Ala( )-NH(2)) is a potent and very long acting antagonist of gonadotropin-releasing hormone (GnRH) after subcutaneous administration in mammals including humans. Analogues of degarelix were synthesized, characterized, and screened for the antagonism of GnRH-induced response in a reporter gene assay in HEK-293 cells expressing the human GnRH receptor. The duration of action was also determined in the castrated male rat assay to measure the extent (efficacy and duration of action) of inhibition of luteinizing hormone (LH) release. Structurally, this series of analogues has novel substitutions at positions 3, 7, and 8 and N(alpha)-methylation at positions 6, 7, and 8 in the structure of degarelix. These substitutions were designed to probe the spatial limitations of the receptor's cavity and to map the steric and ionic boundaries. Some functional groups were introduced that were hypothesized to influence the phamacokinetic properties of the analogues such as bioavailability, solubility, intra- or intermolecular hydrogen bond forming capacity, and ability to bind carrier proteins. Substitutions at positions 3 ([N(beta)-(2-pyridyl-methyl)d-Dap(3)]degarelix, IC( ) = 2.71 nM) (5), 7 ([Pra(7)]degarelix, IC( ) = 2.11 nM) (16), and 8 ([N(delta)-(IGly)Orn(8)]degarelix, IC( ) = 1.38 nM) ( ) and N-methylation ([N(alpha)-methyl-Leu(7)]degarelix, IC( ) = 1.47 nM) (32) yielded analogues that were equipotent to degarelix (2) in vitro (IC( ) = 1.64 nM) but shorter acting in vivo. Out of the 33 novel analogues tested for the duration of action in this series, two analogues ([N(epsilon)-cyclohexyl-Lys(8)]degarelix, IC( ) = 1.50 nM) (23) and ([N(beta)-(IbetaAla)Dap(8)]degarelix, IC( ) = 1.98 nM) (26) had antagonist potencies and duration of action similar to that of azaline B {inhibited LH (&gt; ) release for &gt;72 h after sc injection to castrated male rats at a standard dose of mug/rat in 5% mannitol}. Under similar conditions analogues ([N(gamma)-(IGly)Dab(8)]degarelix, IC( ) = 1.56 nM) (21) and ([IOrn(8)]degarelix, IC( ) = 1.72 nM) (18) had a longer duration of action {inhibited LH (&gt;96 h) release} than azaline B; however they were shorter acting than degarelix. Hydrophilicity of these analogues, a potential measure of their ability to be formulated for sustained release, was determined using RP-HPLC at neutral pH yielding analogues with shorter as well as longer retention times. No correlation was found between retention times and antagonist potency or duration of action.
[ "Degarelix", "(", "FE200486", ",", "Ac", "-", "d-2Nal(1)-d-4Cpa(2)-d-3Pal(3)-Ser(4)-4Aph(l", "-", "Hor)(5)-d-4Aph(Cbm)(6)-Leu(7)-ILys(8)-Pro(9)-d", "-", "Ala", "(", " ", ")", "-NH(2", ")", ")", "is", "a", "potent", "and", "very", "long", "acting", "antagonist", "of", "gonadotropin", "-", "releasing", "hormone", "(", "GnRH", ")", "after", "subcutaneous", "administration", "in", "mammals", "including", "humans", ".", "Analogues", "of", "degarelix", "were", "synthesized", ",", "characterized", ",", "and", "screened", "for", "the", "antagonism", "of", "GnRH", "-", "induced", "response", "in", "a", "reporter", "gene", "assay", "in", "HEK-293", "cells", "expressing", "the", "human", "GnRH", "receptor", ".", "The", "duration", "of", "action", "was", "also", "determined", "in", "the", "castrated", "male", "rat", "assay", "to", "measure", "the", "extent", "(", "efficacy", "and", "duration", "of", "action", ")", "of", "inhibition", "of", "luteinizing", "hormone", "(", "LH", ")", "release", ".", "Structurally", ",", "this", "series", "of", "analogues", "has", "novel", "substitutions", "at", "positions", "3", ",", "7", ",", "and", "8", "and", "N(alpha)-methylation", "at", "positions", "6", ",", "7", ",", "and", "8", "in", "the", "structure", "of", "degarelix", ".", "These", "substitutions", "were", "designed", "to", "probe", "the", "spatial", "limitations", "of", "the", "receptor", "'s", "cavity", "and", "to", "map", "the", "steric", "and", "ionic", "boundaries", ".", "Some", "functional", "groups", "were", "introduced", "that", "were", "hypothesized", "to", "influence", "the", "phamacokinetic", "properties", "of", "the", "analogues", "such", "as", "bioavailability", ",", "solubility", ",", "intra-", "or", "intermolecular", "hydrogen", "bond", "forming", "capacity", ",", "and", "ability", "to", "bind", "carrier", "proteins", ".", "Substitutions", "at", "positions", "3", "(", "[", "N(beta)-(2-pyridyl", "-", "methyl)d", "-", "Dap(3)]degarelix", ",", "IC", "(", " ", ")", "=", "2.71", "nM", ")", "(", "5", ")", ",", "7", "(", "[", "Pra(7)]degarelix", ",", "IC", "(", " ", ")", "=", "2.11", "nM", ")", "(", "16", ")", ",", "and", "8", "(", "[", "N(delta)-(IGly)Orn(8)]degarelix", ",", "IC", "(", " ", ")", "=", "1.38", "nM", ")", "(", " ", ")", "and", "N", "-", "methylation", "(", "[", "N(alpha)-methyl", "-", "Leu(7)]degarelix", ",", "IC", "(", " ", ")", "=", "1.47", "nM", ")", "(", "32", ")", "yielded", "analogues", "that", "were", "equipotent", "to", "degarelix", "(", "2", ")", "in", "vitro", "(", "IC", "(", " ", ")", "=", "1.64", "nM", ")", "but", "shorter", "acting", "in", "vivo", ".", "Out", "of", "the", "33", "novel", "analogues", "tested", "for", "the", "duration", "of", "action", "in", "this", "series", ",", "two", "analogues", "(", "[", "N(epsilon)-cyclohexyl", "-", "Lys(8)]degarelix", ",", "IC", "(", " ", ")", "=", "1.50", "nM", ")", "(", "23", ")", "and", "(", "[", "N(beta)-(IbetaAla)Dap(8)]degarelix", ",", "IC", "(", " ", ")", "=", "1.98", "nM", ")", "(", "26", ")", "had", "antagonist", "potencies", "and", "duration", "of", "action", "similar", "to", "that", "of", "azaline", "B", "{", "inhibited", "LH", "(", "&", "gt", ";", " ", ")", "release", "for", "&", "gt;72", "h", "after", "sc", "injection", "to", "castrated", "male", "rats", "at", "a", "standard", "dose", "of", " ", "mug", "/", "rat", "in", "5", "%", "mannitol", "}", ".", "Under", "similar", "conditions", "analogues", "(", "[", "N(gamma)-(IGly)Dab(8)]degarelix", ",", "IC", "(", " ", ")", "=", "1.56", "nM", ")", "(", "21", ")", "and", "(", "[", "IOrn(8)]degarelix", ",", "IC", "(", " ", ")", "=", "1.72", "nM", ")", "(", "18", ")", "had", "a", "longer", "duration", "of", "action", "{", "inhibited", "LH", "(", "&", "gt;96", "h", ")", "release", "}", "than", "azaline", "B", ";", "however", "they", "were", "shorter", "acting", "than", "degarelix", ".", "Hydrophilicity", "of", "these", "analogues", ",", "a", "potential", "measure", "of", "their", "ability", "to", "be", "formulated", "for", "sustained", "release", ",", "was", "determined", "using", "RP", "-", "HPLC", "at", "neutral", "pH", "yielding", "analogues", "with", "shorter", "as", "well", "as", "longer", "retention", "times", ".", "No", "correlation", "was", "found", "between", "retention", "times", "and", "antagonist", "potency", "or", "duration", "of", "action", "." ]
[ "", "IUPAC", "TRIVIAL", "TRIVIALVAR" ]
Paxillin is a protein, GST is an experiment-tag, SH2 is a protein-domain, Grb2 is a protein, SH2 is a protein-domain
1.0alpha7.train.59_task0
Sentence: Paxillin failed to bind GST alone or the SH2 domain of Grb2 that belongs to the family of SH2/SH3-containing signaling molecules. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: experiment-tag, protein-domain, protein
[ "B-protein", "O", "O", "O", "B-experiment-tag", "O", "O", "O", "B-protein-domain", "O", "O", "B-protein", "O", "O", "O", "O", "O", "O", "B-protein-domain", "O", "O", "O", "O", "O" ]
Paxillin failed to bind GST alone or the SH2 domain of Grb2 that belongs to the family of SH2/SH3-containing signaling molecules.
[ "Paxillin", "failed", "to", "bind", "GST", "alone", "or", "the", "SH2", "domain", "of", "Grb2", "that", "belongs", "to", "the", "family", "of", "SH2", "/", "SH3-containing", "signaling", "molecules", "." ]
[ "protein", "protein-domain", "experiment-tag" ]
Paxillin is a protein, GST is an experiment-tag, SH2 is a protein-domain, Grb2 is a protein, SH2 is a protein-domain
1.0alpha7.train.59_task1
Sentence: Paxillin failed to bind GST alone or the SH2 domain of Grb2 that belongs to the family of SH2/SH3-containing signaling molecules. Instructions: please typing these entity words according to sentence: Paxillin, GST, SH2, Grb2, SH2 Options: experiment-tag, protein-domain, protein
[ "B-protein", "O", "O", "O", "B-experiment-tag", "O", "O", "O", "B-protein-domain", "O", "O", "B-protein", "O", "O", "O", "O", "O", "O", "B-protein-domain", "O", "O", "O", "O", "O" ]
Paxillin failed to bind GST alone or the SH2 domain of Grb2 that belongs to the family of SH2/SH3-containing signaling molecules.
[ "Paxillin", "failed", "to", "bind", "GST", "alone", "or", "the", "SH2", "domain", "of", "Grb2", "that", "belongs", "to", "the", "family", "of", "SH2", "/", "SH3-containing", "signaling", "molecules", "." ]
[ "protein", "protein-domain", "experiment-tag" ]